Regulation of the transcription factor nuclear factor kappa B in the neuroendocrine response to stress by Mehet, Devinder Kaur & Mehet, Devinder Kaur
University of London 
Regulation of the Transcription Factor 
Nuclear Factor kappa B in the 
Neuroendocrine Response to Stress 
Devinder Kaur Mehet 
Department of Cellular & Molecular Neurosciences 
Imperial College London, Technology & Medicine 
Hammersmith Hospital 
London 
A thesis submitted to the Faculty of Medicine, University of London, for the 
degree of Doctor of Philosophy 
Declaration 
I hereby declare that the work presented in this thesis is my own. I have 
acknowledged the help and contribution of others (page 31). 
-OvItOthc 
Devinder Mehet 
2 
Abstract 
Lipopolysaccharide (LPS) activates the hypothalamo-pituitary adrenal (HPA) axis, 
possibly by acting on the anterior pituitary gland. Whilst the mechanisms governing 
this response are unclear, LPS induces many of its effects via the glucocorticoid 
sensitive pro-inflammatory transcription factor, nuclear factor kappa B (NFKB). The 
present study tested the hypothesis that LPS promotes adrenocorticotrophin (ACTH) 
release via an NFKB-dependent mechanism and may be a target for the negative 
feedback actions of glucocorticoids. Two murine pituitary cell lines, which were found 
to express an intact LPS signalling system, were utilised alone and in co-culture to 
model folliculostellate (TtT/GF cells) and corticotroph (AtT20 D16:16 cells) inter-
communication. TtT/GF cell-derived interleukin 6 (IL-6) release was induced by LPS 
via an NR(B-dependent mechanism and inhibited by dexamethasone. Although LPS 
did not directly affect basal ACTH secretion from the AtT20 D16:16 cells, 
recombinant IL-6 potentiated the stimulatory effect of CRH, supporting the premise 
that LPS increases ACTH release via actions of folliculostellate cell-derived IL-6. In 
contrast, LPS-induced NFKB activity in the AtT20 D16:16 cells inhibited CRH-induced 
ACTH release. In the co-culture studies, CRH increased ACTH secretion directly and 
indirectly by stimulating IL-6 release from the TtT/GF cells, possibly via actions of 
AtT20 D16:16 cell-derived mediator(s). These findings support the hypothesis that 
NFKB signalling in folliculostellate cells promotes ACTH secretion and is sensitive to 
the inhibitory effects of glucocorticoids, whilst corticotroph NFKB signalling inhibits 
CRH-induced ACTH secretion. 
Whilst NFKB inhibitors show potential as therapeutic agents for anti-inflammatory 
disorders, the in vitro studies suggest such compounds may impair the HPA 
response to stress. We therefore examined the effects of a novel NFKB inhibitor, 
PHA781535E, upon the HPA responses to immunological (LPS) and psychological 
(restraint) stress in rats. In the LPS model, PHA781535E treatment attenuated the 
stress-induced rises in plasma ACTH, IL-6 and tumour necrosis factor alpha (TNFa), 
but not corticosterone. In parallel, increased NFKB activity in the anterior pituitary 
gland was also reduced, supporting the premise that, in addition to the stimulatory 
actions of circulating NFKB-dependent pro-inflammatory cytokines, NFKB signalling 
in the anterior pituitary gland is important in mediating the ACTH response to LPS. 
Furthermore, it was shown for the first time that restraint stress activates NFKB in the 
anterior pituitary gland and that impairment of NFKB signalling reduces restraint 
stress-induced ACTH and corticosterone release. The study has identified, for the 
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first time, an important role for NFKB in mediating the HPA responses to 
immunological and psychological stress. Together, these findings suggest that, whilst 
NFKB inhibitors may be beneficial for treating chronic inflammatory disorders, such 
treatment may be compromised by impaired stress-induced HPA activity. 
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1 Introduction 
1.1 The stress response 
In response to an imbalance in, or a threat to, homeostasis in an individual, a general 
alarm is initiated followed by a series of co-ordinated adaptations aimed at restoring 
homeostasis. These co-ordinated responses, collectively known as the stress 
response, are composed of alterations in behaviour, autonomic function and the 
secretion of multiple hormones, including adrenocorticotrophin (ACTH), cortisol/ 
corticosterone and adrenal catecholamines (adrenaline and noradrenaline), to enable 
the individual to cope with the situation (Chrousos 1988; Van De Kar & Blair 1999). 
The autonomic responses alter the physiological state of the individual, through 
changes in respiratory rate and intermediate metabolism (e.g. gluconeogenesis and 
lipolysis), elevations in core temperature, enhancement of cardiac output, the 
redirection of blood flow to provide highest perfusion to the brain and skeletal 
muscles and shunting oxygen and nutrients to the central nervous system, skeletal 
muscles and the stressed body site(s). These changes occur primarily to promote 
both the availability of vital substrates and redirect energy to enable the individual to 
cope with the stress, whilst detoxification functions to rid the individual of 
unnecessary metabolic products (Chrousos 1988; Gold et aL 1988b; Gold et aL 
1988a). The behavioural changes depend on the nature of the stressor and the 
previous experience of the individual, and include aggression, increased alertness 
and arousal, improved cognition, immobility, appetite suppression as well as 
euphoria or dysphoria. The neuroendocrine changes include alterations of the 
hypothalamo-pituitary adrenal (HPA) axis (section 1.2). Activation of the HPA axis 
involves the release of corticotrophin releasing hormone (CRH) from the 
hypothalamus which in turn acts on the anterior pituitary gland to stimulate ACTH 
secretion. The principal target of ACTH is the adrenal cortex, which releases 
glucocorticoids that act in a negative feedback manner to restore homeostasis. The 
stress response is therefore an essential physiological response and although in 
itself it is no threat to the individual, if sustained and the individual fails to cope, the 
response may lead to illness. 
The stress response is subserved by both the central nervous system (CNS) and the 
periphery, and the CNS receives and integrates a diversity of neurosensory (i.e. 
higher cortical, limbic, visual, auditory, olfactory, gustatory, somatosensory, 
nociceptive and visceral) and blood borne signals (i.e. hormones, prostaglandins, 
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cytokines and other mediators) that arrive via distinct pathways to converge on the 
hypothalamus (Chrousos & Gold 1992). The hypothalamus and the brainstem are 
important regions of the stress system. They include neurones of the paraventricular 
nuclei (PVN) of the hypothalamus and neurones of the paragigantocellular and 
parabrachial nuclei of the medulla as well as the locus coeruleus (LC) and other 
noradrenergic (NE) cell groups of the medulla and pons (Chrousos & Gold 1992). 
The peripheral limbs of the stress system include the pituitary and adrenal glands, 
together with the efferent sympathetic/adrenomedullary system, and components of 
the parasympathetic nervous system. 
1.2 The Hypothalamo-pituitary adrenal axis 
The HPA axis serves as the primary effector of the stress response, influencing 
virtually every cell in the body in response to a stressor. Following exposure to 
stress, cells of the PVN secrete CRH into the hypophyseal blood supply, which in 
turn act on the anterior pituitary gland to stimulate the synthesis of 
proopiomelanocortin (POMC) and the release of ACTH, a product of POMC, into the 
bloodstream. Arginine vasopressin (AVP) is also released from the PVN and acts 
synergistically with CRH to stimulate ACTH release, but not POMC synthesis (Gillies 
et a/. 1982; Antoni 1993). ACTH primarily targets the adrenal glands to stimulate the 
synthesis and release of glucocorticoids (cortisol in humans, corticosterone in 
rodents). The HPA axis is self-regulated to prevent its over-activation, which could be 
detrimental to the individual. This is achieved through the actions of the released 
glucocorticoids, which feed back on to the pituitary gland, the hypothalamus and the 
higher centres of the brain (long feedback actions) which are activated by stress and 
send projections which converge onto the hypothalamus (see section 1.2.1), and also 
by suppression of the generation of mediators of the immune response (see section 
1.3.1). Together, these actions down-regulate the HPA axis (figure 1.1) and thus 
restore homeostasis in the individual (Habib et al. 2001). 
Basal HPA activity is influenced by the circadian timing system and therefore exhibits 
pronounced daily rhythmicity. Its activity is also regulated by the negative feedback 
actions of glucocorticoids, which is facilitated by the binding of glucocorticoids to 
glucocorticoid receptors (GRs; see section 1.3.2) in the hypothalamus, pituitary, and 
extra-hypothalamic regions (e.g. hippocampus). As a result, glucocorticoid levels 
show a robust diurnal rhythm that is in phase opposition with CRH under normal 
conditions (i.e. in humans peaking around the time of awakening and dropping to 
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their lowest levels in the evening whereas the opposite is true for CRH (Suemaru et 
al. 1995; Lightman et al. 2000; Wong et al. 2000). 
1.2.1 Ultra short feedback loops in the regulation of CRH and ACTH release 
In addition to the long feedback actions of glucocorticoids, short and ultrashort 
feedback loops also exist between the hypothalamus and the pituitary gland which 
serve to regulate CRH and ACTH release (figure 1.1). CRH is able to augment its 
own secretion during stress through an ultrashort positive feedback loop (Ono et al. 
1985a; Ono et al. 1985b). The site of action for the stimulatory effect of CRH on its 
own release is not clear, but may involve cross-talk between the PVN and the locus 
coeruleus-noradrenergic (LC-NE) system as projections of CRH-secreting neurones 
from the lateral PVN to the central sympathetic systems in the brain stem stimulates 
the secretion of noradrenaline through its specific receptors, which in turn stimulates 
CRH secretion primarily through al-adrenergic receptors (Calogero et al. 1988b; 
Chrousos & Gold 1992; Chrousos 1995). Autoregulatory, ultrashort negative 
feedback loops are also present in these neurones, with CRH and noradrenaline 
collateral fibres acting in an inhibitory fashion on pre-synaptic CRH and a2-
adrenoreceptors, respectively. The CRH, AVP, and noradrenaline neurones receive 
stimulatory input from the serotonergic, cholinergic, and histaminergic systems and 
inhibitory input from the gamma-aminobutyric acid and opioid peptide neuronal 
systems of the brain. 
Animal studies have also provided evidence that circulating ACTH acts to restrain its 
own secretion (Motta et al. 1965; Vernikos-Danellis & Trigg 1967). Whether this 
postulated ACTH autoregulation takes place directly at the pituitary level as an 
ultrashort negative feedback loop or is mediated via inhibition of CRH secretion from 
the hypothalamus, thus participating as a short negative feedback loop, remains 
uncertain. Direct self inhibition by pituitary ACTH has been suggested by in vitro 
studies using mouse pituitary tumour cells producing ACTH (Richardson 1978), and 
in clinical studies (Boscaro et al. 1988) and short-loop negative feedback effects of 
the short POMC derived peptides, ACTH, a/pha-melanocyte stimulating hormone (a-
MSH) and corticotrophin-like intermediate lobe peptide (CLIP) on CRH secretion has 
been demonstrated in vitro (Motta et al. 1965; Suda et al. 1986; Suda et al. 1987; 
Calogero et al. 1988b), although the source of POMC gene-derived peptides involved 
in this short negative feedback loop in vivo has not been fully elucidated. Pituitary 
ACTH, which is unable to cross the blood-brain barrier (BBB) (Allen et al. 1974) may 
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suppress hypothalamic CRH secretion by acting at the median eminence (ME), one 
of five brain structures not protected by the BBB (Moore 1986). However, the 
concentrations of POMC peptides in the hypophysial portal blood of adult monkeys 
are not affected by hypophysectomy (Newman et al. 1984), suggesting that the most 
likely source of these peptides is the brain (Smith et al. 1982). 
1.2.2 Adrenal glands 
The adrenal glands are paired glands, situated close to the anterior part of the 
kidney. Each gland comprises a central medulla and a surrounding cortex, which 
have different functions and embryonic origins. The adrenal cortex comprises three 
layers, the zona glomerulosa, which secretes mineralocorticoids (aldosterone) (Gill 
1979) the zona fasciculata, and the zona reticularis, which release glucocorticoids 
(cortisol or corticosterone) and androgens respectively (Gill 1979). The cortex 
contains low levels of stored glucocorticoids and efficiently synthesises hormone 
when required. The primary stimulus for the synthesis and release of glucocorticoids 
is ACTH (Gill 1979) which triggers the production of pregnenolone from cholesterol in 
the mitochondria (Simpson & Waterman 1988). Pregnenolone is then further 
converted to glucocorticoids by a series of distinct P450 enzymes (Simpson & 
Waterman 1988). ACTH binds to its specific receptor, the ACTH receptor (ACTH-R; 
also know as melanocortin receptor 2) which is a seven transmembrane domain 
receptor belonging to the G-protein coupled receptor (GPCR) super-family and is 
expressed in all three zones of the adrenal cortex (Mountjoy et al. 1992). The binding 
of ACTH to ACTH-R leads to the activation of adenylate cyclase and causes an 
increase in cyclic adenosine 3',5'-monophosphate (cAMP) levels and the activation of 
cAMP dependent protein kinases (Buckley & Ramachandran 1981; Beuschlein et al. 
2001), subsequently resulting in the synthesis of glucocorticoids, the final product of 
the HPA axis. 
1.2.2.1 	Functions of glucocorticoids 
Glucocorticoids exert powerful regulatory actions over a wide range of physiological 
functions. One of the first identified of these was the regulation of intermediary 
metabolism, through the up-regulation of gluconeogenesis in the liver, kidney and 
skeletal muscle and the elevation of blood glucose levels. Other roles of 
glucocorticoids include modulating fat, protein and glutamine metabolism and bone 
turnover. They are also essential for the regulation of several homeostatic 
mechanisms in the body, including the cardiovascular system, maintaining metabolic 
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homeostasis and modulating the host defence system. Glucocorticoids also have 
diverse effects on CNS functions including memory, cognition and attention and their 
control over the behaviour of the individual is aimed to limit homeostatic disturbance, 
an example of this being the synchronisation and co-ordination of circadian events 
such as food intake and sleep. The primary role of glucocorticoids in the 
physiological stress response is to prepare the body to respond to stress and 
facilitate the recovery of homeostasis after stress. This is achieved by altering 
several parameters including maintaining blood glucose levels, acting as powerful 
immunosuppressive/anti-inflammatory agents and restoring homeostasis. However, 
in situations where the levels of glucocorticoids are exacerbated, many components 
of the immune system, such as pro-inflammatory mediator expression and leukocyte 
migration, are inhibited (Vincent et al. 1977; Keller et al. 1981; Zhang et al. 1998; 
Elenkov & Chrousos 1999; Bauer et al. 2001) which can result in suppression of the 
immune system. The consequences of immuno-suppression include increased 
susceptibility and frequency of disease, prolonged healing times, and a greater 
incidence of secondary health complications associated with infection (Bailey et al. 
2003). 
1.2.3 Pituitary gland 
The pituitary gland, which is highly vascularised, is comprised of two distinctive parts 
termed the posterior lobe (neurohypophysis) and the anterior lobe 
(adenohypophysis). In many mammals, there is also an intermediate lobe which lies 
between the anterior and posterior pituitary but is nearly indistinguishable from the 
anterior lobe. The pituitary gland is located immediately below the ME of the 
hypothalamus to which it is connected via the pituitary stalk. The hypophyseal portal 
vein system transports hormones secreted by the neurones terminating in the ME to 
the anterior pituitary gland. The pituitary stalk contains both efferent fibres from the 
hypothalamus which project to the cells of the posterior lobe and the portal 
vasculature connecting the ME and the anterior pituitary gland. The anterior pituitary 
is the largest and most important functional part of the pituitary gland. At least five 
distinct endocrine cell types exist in the adenohypophysis. These endocrine cells are 
corticotrophs, which produce ACTH and comprise of approximately 5% of the total 
cell population, gonadotrophs (10% of cell population) which release follicle-
stimulating hormone (FSH) and lutenizing hormone (LH), lactotrophs (15-25%) which 
produce prolactin (PRL), somatotrophs (50%) which are growth hormone (GH) 
releasing cells and thyrotrophs (5%) which produce thyroid-stimulating hormone 
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(TSH). These subtypes can easily be identified by classical histological methods 
[reviewed in (Pelletier 1991)]. The remaining cell types include endothelial and 
folliculostellate cells (see section 1.7.2.1). 
Stressful Stimuli 
Pathogenic Stimuli 
Figure 1.1 	The auto-regulation of the HPA axis by glucocorticoid negative 
feedback following exposure to stress and its interactions with the immune 
system. The diagram depicts the major mediators involved in communication 
between the hypothalamus, anterior pituitary gland and adrenal cortex to regulate the 
stress response and the interactions between pro-inflammatory mediators released 
by immune/inflammatory cells and the HPA axis. Solid black lines represent 
interaction of the immune system with the HPA axis, solid red lines represent 
stimulatory pathways within the HPA axis and solid blue lines represent negative 
feedback effects of cortisol/corticosterone. Pink and blue dashed lines represent 
short and ultra-short feedback loops involved in the regulation of ACTH and CRH 
release. ACTH, adrenocorticotrophic hormone; AVP, arginine vasopressin; CRH, 
corticotrophin releasing hormone; +, stimulatory effect; -, inhibitory effect. 
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Activation of the HPA axis results in the increased release of ACTH from the anterior 
pituitary gland. ACTH is initially synthesised as an inactive precursor, POMC, which 
is processed post-translationally by a family of subtilisin/kexin-like endoproteases 
generally known as proprotein convertases (SPCs), of which seven distinct 
proprotease convertase genes have been identified to date [reviewed by (Bergeron 
et a/. 2000)]. In the pituitary, gene expression of SPC1 (Day et al. 1993), SPC2, 
SPC3 (Day et al. 1992), SPC4 and SPC6 (Dong et al. 1995) has been detected. 
POMC is cleaved by SPC2, which is abundantly expressed in the intermediate lobe 
of the pituitary gland (Benjannet et al. 1991; Bloomquist et al. 1991; Seidah et al. 
1991), to produce f3-endorphin and a-MSH or by SPC3, which is expressed in the 
anterior pituitary gland (Dong & Day 2002), to generate pro-ACTH and [3-lipotrophin 
(Benjannet et aL 1991; Thomas et al. 1991). Pro-ACTH is then cleaved in two places 
to produce ACTH and N-terminal POMC (N-POMC), as well as a joining peptide 
between the two and [3-lipocortin is further cleaved to produce (3-endorphin and y-
lipotrophin. Several isoforms of N-POMC have been identified, of which the major 
circulating N-POMC peptide is pro-y-MSH (human 1-76 POMC). The biological 
activity of each of these peptides is distinct as also are the biological responses they 
induce (Estivariz et aL 1980; Estivariz et al. 1982; Lu et al. 2002; Coll et al. 2006), 
and the concentrations of these circulating ACTH precursors can be as high as that 
of ACTH (White & Gibson 1998). 
Removal of endogenous glucocorticoids by adrenalectomy results in an increase in 
SPC3 mRNA expression in corticotrophs, an effect which is attenuated with the 
administration of the synthetic glucocorticoid dexamethasone (Dong & Day 2002). 
These findings may present a mechanism by which glucocorticoids regulate POMC 
processing. Furthermore, studies in adrenalectomised rats revealed a time-
dependent increase in the nuclear transportation of mature POMC mRNA to the 
cytoplasm, an effect which was inhibited by dexamethasone administration 
(Autelitano et al. 1989), suggesting glucocorticoids also regulate POMC gene 
expression at the post-transcriptional level. 
1.2.3.1 	Pituitary folliculostellate cells 
The pituitary cell population includes a number of non-endocrine cell types such as 
resident macrophages, endothelial cells and folliculostellate cells. Of particular 
interest for the regulation of pituitary function are the folliculostellate cells which were 
previously designated either follicular cells or folliculostellate cells (Ishikawa et al. 
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1983; Girod et al. 1985). The first description of follicular cells was made by Farquhar 
in 1957, who identified a population of cells that form small follicles and are 
distributed throughout the anterior pituitary gland (Farquhar 1957 414). Due to their 
star-shaped morphology (Bergland & Torack 1969) and long cellular processes that 
project to neighbouring endocrine and endothelial cells, these cells were renamed 
folliculostellate cells (Ishikawa et al. 1983). 
Folliculostellate cells comprise up to 10% of the anterior pituitary cell population 
(Matsumoto et al. 1993) and, since their discovery, efforts have been made to assign 
their origin and their function in the pituitary gland. The population of folliculostellate 
cells does not consist of a uniform cell-type, but comprises subpopulations of 
different immuno-phenotypes. To date, five sub-types of folliculostellate cells have 
been identified in the anterior pituitary, and they have been categorised by the 
different markers they express. A proportion of cells have been found to co-express 
S-100 and glial fibrillary acid protein (GFAP) (Velasco et al. 1982) both of which are 
markers of neuroectodermal origin. Another subset express both S-100 and keratin 
(Tachibana & Yamashima 1988) and the third group co-express vimentin and S-100 
or GFAP (Nakajima et al. 1980; Velasco et al. 1982; Hofler et al. 1984). The fourth 
subset, described by Yamashita et al., show expression of keratin and weak 
expression of S-100 (Yamashita et al. 2005). The final subset co-expresses S100 
and MHC-class II determinants (an immune marker) and may thus be derived from a 
monocyte/dendritic cell/macrophage lineage (Allaerts et al. 1991; Allaerts et al. 1993; 
Allaerts et al. 1996). This subset has both IL-6 secretory and T-cell stimulatory 
capacities, further supporting their similarities to lymphoid dendritic cells (Allaerts et 
a/. 1997). However, further studies are required to ascertain whether these subsets 
represent distinct cell types or populations at different stages of development and/or 
activation. 
The origin of the folliculostellate cells has been the subject of debate since the 
discovery that they are immunoreactive for the S-100 protein (Cocchia & Miani 1980; 
Nakajima et aL 1980; Allaerts & Vankelecom 2005). As dendritic cells in lymphoid 
and non-lymphoid tissues also express S-100 (Zeid & Muller 1993), it has been 
suggested that S-100 positive folliculostellate cells are of myeloid origin (Allaerts et 
al. 1996; Hoek et al. 1997; Herkenham 2005). Others have proposed that the 
folliculostellate cells may be part of a renewal or stem cell system in the anterior 
pituitary gland (Horvath & Kovacs 2002; Inoue et al. 2002). While it has been 
suggested that stem cells are required for the replenishment of endocrine cells 
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(Carbajo-Perez & Watanabe 1990; Taniguchi et al. 2002) no stem cells have been 
identified in the pituitary gland to date. These observations have led to the 
suggestion that folliculostellate cells may differentiate into other pituitary cell types, 
although evidence for such a phenotypical change is still required. 
In contrast to endocrine cells, folliculostellate cells are multifunctional, providing 
structural support within the anterior pituitary gland, and are involved in intra-pituitary 
cell-to-cell communication, modulating the response of endocrine cells to 
neuroendocrine and immunological stimuli through gap junction connections to these 
hormone-producing cells (Mira-Moser 1975; Morand et al. 1996). Folliculostellate 
cells do not secrete classical pituitary hormones but provide a source of growth 
factors and cytokines such as vascular endothelial growth factor (VEGF) (Ferrara & 
Henzel 1989; Gospodarowicz & Lau 1989), follistatin (Gospodarowicz & Lau 1989), 
basic fibroblast growth factor (bFGF) (Ferrara et al. 1987; Amano et al. 1993), NO 
(Ceccatelli et al. 1993), macrophage inhibitory factor (MIF) (Tierney et al. 2005), LIF 
(Ferrara et al. 1992) and IL-6 (Vankelecom et a/. 1989; Renner et al. 1998). 
Folliculostellate cell derived IL-6 acts in an autocrine/paracrine manner to stimulate 
PRL, GH, LH and FSH release from primary pituitary cultures (Arzt et al. 1999; 
Gloddek et a/. 2001). Studies have focused on elucidating the mechanism by which 
folliculostellate cells communicate with each other and endocrine cells over long 
distances and it has been proposed that this communication occurs through the 
electro-coupling of folliculostellate cells via calcium waves which are then propagated 
through gap junctions within the folliculostellate cell and endocrine cell network 
(Fauquier et al. 2001). 
Functional studies examining folliculostellate cell subpopulations have been possible 
with the establishment of immortalised cell lines, in particular, the TtT/GF cell line, 
which was established from a murine thyrotropic pituitary tumour (Inoue et al. 1992). 
The TtT/GF cell line exhibits many characteristics assigned to folliculostellate cells 
including the production of IL-6 and the positive expression of S-100 and GFAP after 
repeated passages (Inoue et al. 1992). It is likely that the TtT/GF cell line represents 
a sub-population of folliculostellate cells of the anterior pituitary as approximately 
30% of folliculostellate cells co-express S-100 and GFAP (Tachibana & Yamashima 
1988). 
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1.2.4 Hypothalamus 
The hypothalamus plays a vital role in the maintenance of homeostasis, forming 
extensive links with other brain areas to control bodily processes important for both 
autonomic and behavioural functions. These bodily functions include blood pressure, 
body temperature, fluid balance and metabolism and are maintained by the 
hypothalamus either through neural signals to the autonomic nervous system or via 
neuroendocrine signals to the pituitary gland. The hypothalamus is located below the 
thalamus on either side of the third ventricle and contains neurosecretory cells which 
are arranged in discrete nuclei. Some of these cells have projections which lead to a 
specialised region on the floor of the third ventricle, known as the ME, and it is from 
here that various hypothalamic factors [which include CRH, AVP, LH releasing 
hormone, FSH releasing factor, dopamine, y-aminobutyric acid (GABA) and 
somatostain] produced by the neurosecretory cells are stored and released into the 
hypophyseal-portal blood system via a distinct group of capillary loops (hypophyseal-
portal blood vessels) that leave the brain and descend along the pituitary stalk to 
terminate at the pituitary (Pelletier 1991; Marubayashi et a/. 1999; Kiss et al. 2006). 
The main hypothalamic nuclei involved in the neuroendocrine axis are the arcuate 
nucleus (ArcN), medial preoptic area (mPOA), periventricular nucleus (PeN), 
ventromedial nucleus (VMN) and the paraventricular nucleus (PVN) (figure 1.2). The 
PVN contains both magnocellular and parvocellular cells; the magnocellular PVN 
cells project to, and release hormones from, the posterior pituitary, whereas the 
parvocellular cells of the PVN release hormones which target the anterior pituitary in 
response to stressful stimuli (Antoni 1986; Aguilera 1994). 
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Figure 1.2 	Diagrammatic representation of the locations of key 
hypothalamic nuclei from corona! sections of the rat hypothalamus. (A) Rostral 
section of the hypothalamus positioned at -1.4mm with respect to bregma and (B) 
caudal section of the hypothalamus positioned at -2.1mm with respect to bregma. 3V, 
third ventricle; ArcN, arcuate nucleus; ME, median eminence; mPOA, medial preoptic 
area; OC, optic chiasm; PeN, periventricular nucleus; PVN, paraventricular nucleus; 
VMN, ventromedial nucleus [taken from (Paxinos 1986)]. 
1.2.4.1 	Arginine vasopressin 
The synthesis and release of AVP by magnocellular neurones are stimulated in 
response to stressors such as haemorrhage, hypotension and hypoglycaemia (Baylis 
1987; Laszlo et al. 1991) and the peptide released has an important role in 
osmoregulation and modulating blood volume and pressure via its anti-diuretic and 
vasoconstrictor actions. AVP was initially believed to be the principal factor involved 
in hypothalamic control of ACTH secretion (McCann & Brobeck 1954). However, 
following the discovery of CRH (Vale et al. 1981), which was found to stimulate the 
release of ACTH and (3-endorphin in vitro (Vale et al. 1983) and in vivo (Rivier et al. 
1982; Donald et al. 1983), AVP was shown to act primarily by potentiating the actions 
of CRH (Gillies et al. 1982). The regulatory effects of AVP occur through interactions 
of the peptide with specific plasma membrane receptors of which there are three 
subtypes; Via, V2 and Vib (also known as V3). Via receptors are widely distributed on 
blood vessels and have been detected in the CNS (Ostrowski et al. 1994), and the V2 
subtype is predominantly expressed by cells of the renal collecting system (De Wied 
et al. 1991). The third subtype, Vib (V3), is predominantly expressed by pituitary 
corticotrophs (Jard et al. 1986; Rene et al. 2000) as well as in multiple brain regions 
and a number of peripheral tissues including kidney, heart, lung and breast (Lolait et 
al. 1995). 
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	1.2.4.2 	Corticotrophin releasing hormone 
CRH is a 41 amino acid peptide found in both the brain and peripheral organs such 
as the adrenal gland (Thompson et al. 1987; Valentino et al. 1995) and ovaries 
(Mastorakos et aL 1993b; Mastorakos et al. 1994). In addition to its role in activating 
the HPA axis, CRH also participates in the inflammatory response as a locally 
expressed pro-inflammatory factor (Karalis et aL 1991; Van Tol et al. 1996; Webster 
et al. 1998). CRH exerts its actions via its receptors CRH-R1 and CRH-R2, which are 
expressed in the anterior pituitary, throughout the brain and in various peripheral 
organs such as the adrenal medulla, prostate, gut and spleen (Habib et al. 2001). In 
the pituitary however, CRH predominantly exerts its effects through CRH-R1 
[reviewed by (Aguilera et al. 2004)]. The binding of CRH to CRH-R1 causes an 
increase in cAMP levels, a rapid release of pre-existing ACTH into the circulation and 
an increase in POMC mRNA levels (Kalin et aL 1983; Suda et al. 1988). 
In addition to the stimulatory effect of CRH upon ACTH synthesis and release, CRH 
also acts through the CNS to mediate both behavioural and autonomic responses to 
stress (Fisher 1989; Cole & G.F. 1991; Davis 1992). The autonomic changes induced 
by CRH include increased blood pressure, heart rate, plasma catecholamine levels 
and glucose levels (Brown et aL 1982; Fisher et a/. 1983; Brown & Fisher 1985; 
Kurosawa et a/. 1986; Bakke et al. 1990; Diamant & De Wied 1991; Korte et al. 1993) 
and behavioural changes include changes in locomotor activity, rearing, grooming 
and feeding (Sutton et al. 1982; Koob et a/. 1984; Brown & Hayden 1985; Sherman & 
Kalin 1987; Dunn & Berridge 1990; Cole & G.F. 1991; Diamant & De Wied 1991; 
Glowa & Gold 1991; Bray 1992; Korte et al. 1993; Wiersma et al. 1995). The 
structures involved in the effects of CRH upon such behavioural and autonomic 
changes include the LC, the PVN, the hippocampus, the central nucleus of the 
amygdala and the bed nucleus of the stria terminalis (Lee & Davis 1997; Koob & 
Heinrichs 1999; Nijsen et al. 2001). 
1.2.4.3 	Implications of CRH and AVP in depression 
AVP has only weak ACTH secretagogue activity alone (Lamberts et a/. 1984) but 
acts synergistically with CRH to potentiate ACTH release in comparison with levels 
achieved following CRH administration alone (Gillies et al. 1982; Rivier & Vale 1983; 
Lamberts et a/. 1984; Murakami et aL 1984; Antoni 1986). However, AVP does not 
affect POMC gene transcription, peptide synthesis or storage (Scott & Dinan 1998). 
Despite its weak stimulatory effects upon ACTH release during acute/novel stressor 
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exposure, recent work suggests that HPA axis dysregulation in chronic stress 
paradigms and depression may be associated with a shift towards increased 
vasopressinergic control of the axis (Kiss et al. 1984; Sawchenko et al. 1984; De 
Goeij et al. 1991; De Goeij et al. 1992a; De Goeij et al. 1992b; De Goeij et a/. 1992c; 
Holsboer & Barden 1996; Dinan et al. 1999). 
Recent studies utilising models of both chronic psychosocial and immobilisation 
stressors have shown alterations in AVP and CRH mRNA expression (Hauger et al. 
1987; Whitnall et al. 1987), namely an increase in AVP synthesis in CRH-producing 
neurones of the PVN, and in AVP storage in the CRH-containing nerve terminals in 
the external zone of the ME (De Goeij et al. 1991; Bartanusz et al. 1993; Bartanusz 
et al. 1994). In contrast, CRH production was decreased, with an associated down-
regulation of the CRH receptor and the upregulation of the Vib receptor. Such 
findings suggest that HPA axis dysregulation in chronic stress paradigms and 
depression is associated with a shift from CRH to AVP controlled pituitary-adrenal 
activation (Kiss et aL 1984; Sawchenko et al. 1984; Hauger et aL 1987; Tilders 1989; 
De Goeij et al. 1991; De Goeij et al. 1992a; De Goeij et al. 1992b; De Goeij et al. 
1992c; Holsboer & Barden 1996; Dinan et al. 1999). 
1.2.5 Higher control of the HPA axis in response to cognitive and non-
cognitive stress 
The release of CRH and AVP from the hypothalamus is controlled by ascending 
pathways from the brainstem and descending pathways from the higher centres that 
converge onto the hypothalamus. These higher centres include limbic-associated 
structures which are also targeted by the negative feedback actions of 
glucocorticoids. The brain circuits that initiate and maintain the stress response are 
illustrated in figure 1.3. The main limbic structures include the hippocampus, the 
medial prefrontal cortex and the amygdala but these structures do not regulate the 
HPA axis in response to stressors which lack a cognitive component, such as 
immunological challenge (e.g. endotoxin exposure) or physical trauma (e.g. 
haemorrhage) (Chrousos 1988). Direct input from these limbic-associated structures 
influences the stress responsive CRH and/or AVP neurones of the PVN. The 
hippocampus exerts a tonic inhibitory effect on CRH and AVP mRNA expression as 
shown by rodent hippocampal lesion studies (Herman et aL 1989; Sapolsky et al. 
1989; Herman et al. 1992; Herman et al. 1995b). The hippocampus is also involved 
in terminating the stress response, whereby hippocampal lesioning in the rodent 
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resulted in prolonged release of corticosterone and/or ACTH following exposure to a 
number of psychological stressors (Sapolsky et al. 1989; Herman et al. 1995b). This 
inhibition may be mediated via neurones in the ventral subiculum, which is the 
principal source of hippocampal efferents (Herman et al. 1995b). 
The medial prefrontal cortex is also involved in modulating HPA axis activation, as 
bilateral lesions of the anterior cingulate or pre-limbic components of the medial 
prefrontal cortex resulted in an enhanced ACTH and corticosterone response to 
restraint stress (Diorio et al. 1993; Brake et al. 2000). Such findings support the 
premise that dorsal subregions of the medial prefrontal cortex selectively inhibit HPA 
axis responses to anticipatory stressors. However, unlike the hippocampus, dorsal 
and ventral medial prefrontal cortex lesions do not affect the morning or evening 
basal levels of ACTH or corticosterone, indicating the prefrontal cortex is involved in 
selective modulation of stress-induced HPA axis activity (Diorio et al. 1993; 
Figueiredo et al. 2003). 
In contrast to the hippocampus and prefrontal cortex, the amygdala is involved in 
activating the HPA axis, with amygdala lesions resulting in a decrease in both ACTH 
and corticosterone plasma levels following restraint stress (Beaulieu etal. 1986). The 
amygdala has little direct contact with the PVN, which is limited to scattered fibres 
present in pre-autonomic cell groups (Gray et aL 1989; Marcilhac & Siaud 1997). Its 
actions occur via its rich connections to the brain stem structures, including the bed 
nucleus of the stria terminalis, which in turn innervate the PVN (Schwaber et aL 
1982; Van Der Kooy et al. 1984). 
Non-cognitive stressors, such as immune challenge, changes in blood pressure 
(hypotension and hypertension), pain, cold, heat or trauma also increase CRH/AVP 
secretion from the PVN by signalling through brain stem nuclei (Berkenbosch et al. 
1987; Sapolsky et aL 1987; Uehara et al. 1987; Rivest & Rivier 1991). In response to 
such stressors, there is afferent input by sensory neurones to the brain stem that 
activates the LC, leading to CRH and probably AVP release (McCann et al. 2000a). 
Studies have provided evidence for the involvement of at least two brain stem nuclei, 
the nucleus tractus solitarius (NTS) and ventrolateral medulla (VLM), in signalling to 
the PVN through reciprocal connections following systemic immune challenge 
(Swanson & Kuypers 1980; Sawchenko & Swanson 1982; Schwanzel-Fukuda et al. 
1984; Van Der Kooy et al. 1984; Luiten et a/. 1985; Ericsson et al. 1994; Portillo et a/. 
1998; Shafton et al. 1998; Pyner & Coote 1999; Toth et al. 1999; Buller et al. 2001; 
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Hardy 2001; Buller et aL 2003). The VLM is important in the tonic and reflex control 
of arterial blood pressure (Pyner & Coote 1999), with bilateral lesions in the VLM 
reducing blood pressure (Guertzenstein & Silver 1974), whilst injection of excitatory 
amino acids increase blood pressure (Dampney et al. 1982; Dampney 1994). 
Regulation of blood pressure by the VLM involves signalling input from the NTS 
(Krukoff et al. 1995; Masubuchi et al. 2004) and it has been suggested that an 
imbalance of activity between the two nuclei can lead to hypertension (Johnson et al. 
1996; Masubuchi et al. 2004). From these findings, it is likely that the activation of the 
HPA axis in response to hypertension involves reciprocal communication between 
the NTS, the VLM and the PVN (Guertzenstein & Silver 1974; Coote 1995; Pyner & 
Coote 1999). In conditions of hypotensive haemorrhage, Fos immunoreactive 
neurones have been visualized in autonomic regions of the brain stem, including the 
NTS, VLM, lateral parabrachial nucleus and LC (Chan & Sawchenko 1994), in the 
hypothalamic supraoptic nucleus, and in magnocellular and parvocellular neurones 
of the PVN (Badoer et al. 1993; Petrov et al. 1995), a region which is known to 
contain neurones which project to brainstem autonomic regions and spinal cord 
sympathetic preganglion neurones (Badoer et al. 1993; Blair et al. 1996). 
Furthermore, the ACTH response to blood loss is prevented by lesions in the NTS 
(Darlington et al. 1986) and the LC (Lefcort et al. 1984) suggesting that PVN CRH 
neurones receive cardiovascular afferent information conveyed from multiple 
brainstem sites (Chan & Sawchenko 1994; Van De Kar & Blair 1999). 
These findings support the premise that the CNS responses to non-cognitive stress 
involve complex reciprocal connections between the PVN and the brainstem, 
whereby brainstem cell populations could essentially act as integratory sites for 
descending and ascending signals. 
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Figure 1.3 	A simplified representation of the central and peripheral 
components of the stress system with their functional interactions to other 
central pathways involved in the stress response. A.Ch., acetylcholine; ACTH, 
adrenocorticotrophic hormone; ArcN, arcuate nucleus; AVP, arginine vasopressin; 
CRH, corticotrophic releasing hormone; GABA, y-aminobutyric acid; LC/NE Symp. 
Syst., locus coeruleus/adrenaline-sympathetic system; NPY, neuropeptide Y; POMC, 
proopiomelanocortin; SP, substance P. Activation is represented by solid blue lines, 
and inhibition is represented by dashed red lines [Adapted from (Habib et al. 2001)]. 
1.3 Glucocorticoids 
1.3.1 Negative feedback actions of glucocorticoids 
Hypersecretion of glucocorticoids is prevented by a complex network of negative 
feedback systems through which the steroids act at multiple sites to suppress the 
release of ACTH and its hypothalamic releasing factors (figure 1.1). There are three 
phases of glucocorticoid feedback; (1) rapid, (2) early delayed and (3) late delayed 
feedback. These phases are the consequence of at least three separate molecular 
mechanisms of glucocorticoid action at feedback-sensitive sites. The fast phase of 
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glucocorticoid feedback occurs in the first few minutes of the stress response and 
does not involve protein synthesis and thus does not occur through genomic actions 
(Jones et aL 1972). This phase involves inhibition of the release of preformed ACTH 
and CRH/AVP stored in granules in the corticotrophs and in the terminals of 
CRH/AVP neurones respectively (Keller-Wood & Dallman 1984). These 'early' 
inhibitory effects play a crucial role in the regulation of basal plasma ACTH levels 
(Windle et al. 1997), and in determining the magnitude and duration of the stress 
response (Engeland et aL 1977). 
The early delayed feedback phase emerges approximately thirty minutes after a rise 
in glucocorticoids and is usually maximal at approximately two hours. However, this 
phase can persist for up to twenty four hours (Jones & Stockham 1966; Hodges & 
Sadow 1967) and is believed to be dependent upon the actions of second 
messengers such as the glucocorticoid-inducible protein annexin 1 (ANXA1) which 
acts to inhibit the release, but not the synthesis of, ACTH and its hypothalamic 
releasing factors (Buckingham 1992). The late phase of feedback is apparent after 
several hours of exposure to glucocorticoids and during this phase, glucocorticoids 
inhibit the synthesis and release of both hypothalamic CRH/AVP and pituitary ACTH 
(Jingami et al. 1985; Herman et al. 1995a; Young etal. 1995; Keller-Wood & Dallman 
1984). Hence early feedback occurs through a non-genomic mechanism and is 
primarily involved in the inhibition of pre-formed hormone, whilst a genomic 
mechanism is predominantly responsible for the inhibition of both pre-formed 
hormone release and its synthesis during the late delayed feedback phase. 
1.3.2 Genomic effects of glucocorticoids 
Glucocorticoids exert many of their effects through the GR, a member of the type I 
nuclear hormone receptor super-family, which, following hormone activation, acts as 
a transcription factor. The nuclear receptors contain five domains designated A to E. 
Domain C is the DNA binding site and contains 8 cysteine residues arranged in two 
groups of four. These groups facilitate the binding of two zinc atoms, which result in 
the formation of two zinc fingers that protrude from the molecule and interact with 
DNA. The C-terminus (domain E) contains a ligand binding site and also acts as the 
homodimerisation site. There are two forms of GR; GRa and GRP and they are both 
produced from the same gene by alternate splicing (Hollenberg et al. 1985). 
Expression of GRP is located in the liver, lungs and thymus and GRa is expressed in 
every tissue in the body and to a greater extent than GRI3. The GRa variant of GR is 
48 
the predominantly biologically active form and in the absence of glucocorticoid 
hormone, GRa resides in the cytoplasm in an inactive state. Ligand binding facilitates 
translocation of the GR-complex to the nucleus, which can then interact with 
glucocorticoid response elements (GRE) within the DNA to activate appropriate 
glucocorticoid responsive genes. This results in increased transcription of genes 
coding for anti-inflammatory proteins, e.g. ANXA1, IL-10 and IL-1 receptor antagonist 
(IL-1ra), and the down-regulation of pro-inflammatory genes e.g. IL-8, IL-6 and TNFa 
(Nyhlen et al. 2000; Li et al. 2001), the enzymes responsible for their biosynthesis 
and regulation (e.g. nitric oxide synthase 2; NOS-2) (Barnes 1998), and for 
hypothalamic (e.g. AVP and CRH) and pituitary-derived (e.g. POMC) hormones. 
However, not all these pro-inflammatory cytokines contain GREs and the down 
regulation of these cytokines can occur through GR-mediated inhibition of pro-
inflammatory transcription factors responsible for cytokine transcription. Such 
transcription factors include activating protein 1 (AP-1) (Karin & Chang 2001) and 
nuclear factor kappa B (NFKB) (Scheinman et al. 1995b). In addition, glucocorticoids 
inhibit pro-inflammatory cytokine synthesis by altering the stability of mRNA and thus 
the translation rate of several glucocorticoid responsive proteins (Ing 2005). They 
also influence the secretion rates of specific proteins and alter the electrical potential 
of neuronal cells through unelucidated mechanisms (Ing 2005). Glucocorticoids are 
also able to mediate their effects through their binding to another member of the 
nuclear receptor family, the mineralocorticoid receptor (MR). Glucocorticoids display 
a ten-fold higher affinity for MR binding compared to GR binding and the mechanism 
of glucocorticoid-MR interaction is similar to that of glucocorticoid-GR binding 
(Marver et al. 1974; Arriza et al. 1987; Beato et al. 1995; Reul et al. 2000). 
Access of glucocorticoids to their receptors is regulated by the enzyme 116-
hydroxysteroid dehydrogenase (113-HSD), of which there are two isoforms - 116-
HSD1 and 1113-HSD2. 116-HSD catalyses the inter-conversion of hormonally active 
glucocorticoid (cortisol, corticosterone) and its inactivate form (cortisone, 11-
dehydrocorticosterone) (Stewart & Krozowski 1999). In human tissues, 116-HSD1 
converts cortisone to the active form cortisol and 116-HSD2 converts cortisol to the 
inactive form, cortisone. 116-HSD1 is widely distributed, but found most abundantly 
in the pituitary gland, the liver and in adipose tissue whereas 116-HSD2 is 
predominantly expressed in mineralocorticoid target tissues and the kidney and 
colon, where it serves to protect MR from excess binding of glucocorticoids 
(Korbonits et al. 2001; Quinkler & Stewart 2003). MR can also bind to GREs leading 
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to speculation over the extent of functional specificity of glucocorticoid and 
mineralocorticoid action (Beato et al. 1995). Unlike GR, MR is expressed in a specific 
pattern, located in the distal colon, kidney, hippocampus and CNS (Fuller & Verity 
1990; Funder 1996; Zennaro et al. 1997; Watzka et al. 2000). 
1.3.3 Non-genomic effects of glucocorticoids 
The actions of glucocorticoids do not solely occur through intra-cellular receptor-
mediated alterations in gene transcription. There are a multitude of rapid, 
glucocorticoid-mediated effects that cannot be explained via a genomic mechanism. 
With respect to the feedback actions of glucocorticoids within the HPA axis, non-
genomic actions have been associated principally with the initial rapid phase of 
feedback (Jones et aL 1972). The speed of action of glucocorticoids during this 
phase is less than ten minutes, which is too early to account for a genomic action. 
Inhibition of DNA and protein synthesis utilizing the DNA-dependent RNA synthesis 
inhibitor, actinomycin D and the protein synthesis inhibitor, cyclohexamide had no 
effect upon this initial feedback response in vivo (Liu et al. 1995). The non-genomic 
actions of glucocorticoids are likely to involve specific membrane receptors, yet to be 
identified, which in turn modulate the protein kinase C (PKC) and the protein kinase 
A (PKA) signalling pathways that result in a reduction in intracellular Ca2+ 
concentration in neural-glial cells and pituitary cells respectively (Chen & Qiu 1999). 
Di et aL recently identified a non-genomic mechanism of rapid glucocorticoid 
feedback inhibition at the level of hypothalamic neurones. This mechanism involves 
glucocorticoid-activated release of a retrograde endocannabinoid messenger from 
CRH neurones via the activation of a postsynaptic G-protein coupled membrane 
receptor. These cannabinoids were able to decrease the excitatory synaptic drive to 
parvocellular neuroendocrine cells of the PVN (including CRH expressing cells), by 
acting locally on pre-synaptic type I cannabinoid receptors expressed on afferent 
glutamergic axon terminals (Di et al. 2003). 
Glucocorticoids also exert rapid inhibitory effects on neurohypophysial oxytocin and 
AVP secretion from hypothalamic magnocellular neurones of the supraoptic nucleus 
and PVN via a similar mechanism to the parvocellular cells (Di et al. 2005). These 
findings provide an appropriate mechanism for the rapid phase feedback actions of 
glucocorticoids on the activity of CRH neurones and similar mechanisms may occur 
elsewhere in the brain, such as the hindbrain, midbrain and limbic sites, which have 
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been implicated as sites of action for the rapid effects of glucocorticoids. Endogenous 
cannabinoids also exert robust effects on hormone secretion from the pituitary, 
leading to the suppression of pituitary hormone release (e.g. TSH, gonadotropin, GH 
and PRL) (Hillard et al. 1984; Murphy et al. 1998; Wenger & Moldrich 2002). In 
addition to the ability of cannabinoids to inhibit pituitary-derived hormone release via 
the hypothalamus, cannabinoids may also exert their inhibitory effects directly at the 
level of the pituitary. Conversely, exogenous cannabinoids are able to stimulate the 
HPA axis (Puder et al. 1982; Weidenfeld et al. 1994; Brown & Dobs 2002; Patel et al. 
2004). A possible explanation for the opposing effects of endogenous versus 
exogenous cannabinoids in the PVN is that the stimulatory effects of 
exocannabinoids occur upstream from the hypothalamus and are relayed 
synaptically to the CRH neurones in the PVN (Tasker 2004). However, the 
receptor(s) and second messengers(s) involved in this mechanism still need to be 
identified. 
At the level of the pituitary, glucocorticoids have been shown to up-regulate the 
expression of the second messenger ANXA1 (Buckingham & Flower 1997), which 
has been shown to inhibit both CRH and ACTH release both in vitro and in vivo 
(Loxley et al. 1993; Taylor et al. 1993; Sudlow et al. 1996). 
1.3.3.1 	An nexi n 1 
ANXA1 is a 37kDa protein of the annexin family of phospholipid and Ca2+ binding 
proteins and contributes to the anti-inflammatory effects of glucocorticoids (Flower & 
Rothwell 1994). Within the HPA axis, ANXA1 expression is confined to discrete cell 
types. In the hypothalamus, ANXA1 is localised in the ependymal lining of the third 
ventricle and in microglia (Woods et al. 1990; Smith et al. 1993; McKanna & Zhang 
1997) and inhibits the release of hypothalamic CRH (Loxley et al. 1993; Sudlow et a/. 
1996; Pompeo et a/. 1997). In the anterior pituitary gland, ANXA1 is expressed 
mainly in the non-endocrine folliculostellate cells, particularly in projections that lie in 
close proximity with endocrine cells (Traverso et al. 1999; Chapman et al. 2002), and 
suppresses the release of ACTH and other pituitary hormones (Taylor et al. 1993). 
ANXA1 also acts as a mediator of the anti-inflammatory effects of glucocorticoids 
both peripherally and locally at sites of inflammation (Taylor et al. 1993; Green et al. 
1998). The inhibitory actions of glucocorticoid-induced ANXA1 upon ACTH release is 
involved in the non-genomic actions of glucocorticoids (Taylor et al. 1993; 
Buckingham et al. 2003). Studies conducted by our laboratory have shown that the 
51 
steroid-induced exportation of ANXA1, from folliculostellate cells, occurs via a non-
classical GR-dependent mechanism that requires mitogen-activated protein kinase 
(MAPK), phosphatidylinositiol 3-kinase, and Ca2+-dependent PKC pathways (John & 
Buckingham 2003; Solito et al. 2003). However, the externalisation of ANXA1 does 
not occur by the classical regulated secretory pathway (Comera & Russo-Marie 
1995; Philip et al. 1998) as ANXA1 lacks a cleavable signal sequence at its N-
terminal (Wallner et al. 1986). A likely mechanism for ANXA1 externalisation in 
folliculostellate cells has recently been shown to involve a member of the ATP-
binding cassette (ABC) transporter family of proteins A, ABCA1 (Chapman et al. 
2003; Omer et al. 2006). 
1.4 Stressors activating the HPA axis 
The pathways involved in the activation of the HPA axis depend largely on the nature 
of the stressor. Some of the most potent activators of the HPA axis and the 
autonomic nervous system are psychological in nature, with consequent increments 
in plasma glucocorticoids (Keim & Sigg 1976) and catecholamines (Kvetnansky et al. 
1971). Intrinsic to psychological stress is a cognitive assessment of the stimulus, and 
common forms of psychological stress include loss of control of an individual's 
environment, threats to self-esteem and perceived confinement. A well-established 
model of mild psychological stress is the restraint technique (Pare & Glavin 1986; 
Glavin et al. 1994). This model is widely used for the elucidation of drug effects, 
where the effects of various agents can be examined on restraint stress-induced 
pathology and the HPA axis. 
As outlined earlier (see section 1.2.5.2), the HPA axis is also sensitive to non-
cognitive stimuli such as hypotension, hypoglycaemia and immunological challenge 
(e.g. endotoxin exposure). In the case of immune insults, the primary driving force for 
glucocorticoid release is pro-inflammatory mediators released by activated immune 
and inflammatory cells (e.g. eicosanoids and cytokines). These mediators are 
capable of acting directly at all levels of the HPA axis, or indirectly, by acting at the 
site of inflammation to stimulate nociceptive afferents which in turn stimulates the 
HPA axis via central pathways (see figure 1.1). 
1.4.1 Psychological stress 
Emotions are processed in the limbic system and frontal cortex which is composed of 
nuclei including the sensory thalamic nuclei, the basolateral and central amygdala, 
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the nucleus accumbens, the LC, the hippocampus and associated cortical areas 
such as the medial prefrontal cortex (Glavin et al. 1983; Chrousos & Gold 1992). 
Projections from these higher centres converge on the hypothalamus, both directly 
and indirectly [e.g. PVN CRH neurones receive input from the central amygdala both 
directly and through the bed nucleus of the stria terminalis (Gray et aL 1989; Cullinan 
et aL 1993; Gray et al. 1993)] to stimulate the release of CRH, and are activated in 
response to restraint stress (Sheng & Greenberg 1990; Schreiber et al. 1991; Arnold 
et al. 1992; Kononen et al. 1992; Chowdhury et al. 2000). 
Exposure to chronic restraint has been associated with a variety of central and 
peripheral changes including hypothermia (Murakami et al. 1985), atrophy of the 
thymus and spleen and adrenal hypertrophy (Seyle 1936). Chronic stress increases 
both AVP mRNA expression in the PVN, to a greater degree than CRH mRNA, and 
POMC mRNA expression in the anterior pituitary gland (Harbuz & Lightman 1989; 
Bartanusz et al. 1993), which is associated with elevated plasma levels of ACTH and 
corticosterone (Pare & Glavin 1986). 
Restraint stress is also associated with increased plasma levels of the pro-
inflammatory cytokines IL-1 and IL-6 (Zhou et al. 1993; Merlot et al. 2002), although 
this effect appears to be dependent on the severity and length of the stressor (Li et 
al. 2000). Interestingly, non-immune induced elevation of these cytokines occurs 
independently of endotoxaemia, tissue damage or inflammation (Lemay et aL 1990; 
Takaki et al. 1994; Besedovsky & Del Rey 1996). Studies have shown that 
psychological stress induces gut permeability, resulting in the release of intestinal 
endotoxins, which may stimulate the production of cytokines (Hart & Kamm 2002). 
Similarly, restraint stress causes an increase in the production of glucocorticoids, 
which, in turn, adversely affects cutaneous permeability (Denda et al. 2000; Kao et 
al. 2003). 
1.4.2 Immunological stress 
Endotoxin is also a potent activator of the HPA axis (Van Amersfoort et al. 2003). In 
animals, lipopolysaccharide (LPS), a component of the outer wall of gram negative 
bacteria, stimulates the release of ACTH and corticosterone (Butler et aL 1989; 
Feuerstein et aL 1990; Ramachandra et al. 1992; Schotanus et aL 1994; Tilders et al. 
1994). In addition, many cytokines produced during an immune/inflammatory 
response e.g. IL-6, interleukin 1 beta (IL-1p) and TNFa are also capable of provoking 
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widespread pathological effects, which are perceived as stressful and can therefore 
stimulate the HPA axis (Buckingham et al. 1996). Activation of the HPA axis by 
inflammatory mediators is not exclusive to cytokines, but is also induced by other 
products of the immune system including platelet activating factor, epidermal growth 
factor and prostaglandin E2 (PGE2). PGE2 is synthesised by the inducible enzyme 
cyclooxygenase 2 (COX-2; which converts arachidonic acid into prostaglandins) 
(Ribot et al. 2003), an enzyme which is activated by nitric oxide (NO) (Mohn et al. 
2005; Mollace et al. 2005) and these products all exhibit strong CRH releasing 
properties (Calogero et al. 1988a; McCoy et aL 1994; Rivier 1998; Uribe et al. 1999; 
Bugajski et al. 2003; Ribot et al. 2003; Gadek-Michalska & Bugajski 2004; Cragnolini 
et al. 2006). The importance of prostaglandins in activating the HPA axis following 
LPS treatment was shown by Gadek-Michalska et al., whereby inhibition of COX-2 
caused a significant reduction in LPS-induced ACTH and corticosterone levels 
(Gadek-Michalska & Bugajski 2004). However, in contrast to the stimulatory effects 
of phospholipase A2 (PLA2; a key enzyme involved in the release of arachidonic acid 
from the cell membrane) and its metabolites arachidonic acid and PGE2 on ACTH 
release (Cowell et al. 1991; Brooks 1992), incubation of primary pituitary cultures 
with prostaglandin D2 (PGD2) and prostaglandin F2 alpha (PGF2a) attenuated CRH-
stimulated, but not tonic, ACTH release, indicating differential roles of PLA2 and 
eicosanoids in the regulation of ACTH release (Vlaskovska et al. 1984; Cowell et aL 
1991). 
1.4.3 Cytokine activation of the HPA axis 
The most notable immune-derived mediators which activate the HPA axis are pro-
inflammatory cytokines (e.g. TNFa, IL-1(3 and IL-6). Cytokines are large polypeptides 
which do not cross the BBB readily. Therefore, the mechanisms through which 
inflammatory cytokines access the central AVP and CRH secretory neurones are not 
clear. However, several structures, such as the axon terminals of the PVN neurones 
that project into the ME and the posterior pituitary gland, are exposed to circulating 
cytokines in the blood stream. Furthermore, the circumventricular organs (CVOs) 
also lack a BBB and are exposed to the chemical environment of the systemic 
circulation (Krisch et al. 1978), in particular the choroid plexus, the vascular organ of 
the lamina terminalis and the subfornical organ (Harre et aL 2002). The expression of 
immune cytokines has also been detected in these structures. For example, an 
increase in IL-113 and IL-6 mRNA has been observed in response to LPS stimulation, 
suggesting that cytokines may contribute to HPA axis activation through pathways 
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originating in the CVOs (Grinevich et al. 2001). Cytokines are also synthesised in the 
brain and it is possible that during stress, brain derived cytokines may augment 
peripheral cytokine expression (De Simoni et al. 1990). In addition, the pituitary and 
adrenal glands are also capable of producing IL-6 (Vankelecom et al. 1989; 
Spangelo et al. 1990a; Spangelo et al. 1990c; Tatsuno et al. 1991; Judd 1998) and 
ACTH has been shown to stimulate the release of IL-6 from cultured zona 
glomerulosa cells (Judd & Macleod 1992). 
In addition, cytokines are capable of initiating a cascade of paracrine and autocrine 
events which results in the sequential secretion of pro-inflammatory mediators by 
non-fenestrated endothelial cells, glial cells and cytokine responsive neurones which 
are able to act on AVP and CRH secreting neurones. Alternatively, LPS may act 
directly on the endothelium of the blood brain vessels, which express the LPS 
signalling receptor, toll-like receptor 4 (TIr4) and the co-receptor, CD14, to trigger a 
series of signalling events leading to the development of an inflammatory response in 
the brain (Singh & Jiang 2004). The pro-inflammatory cytokines produced in 
response to LPS signalling also up-regulate CD14 and TIr4 expression and may act 
in a paracrine manner to activate adjacent cells within the brain. Indeed, Rivest et al. 
showed that intracerebroventricular TNFa injection cause a robust and rapid 
production of CD14 mRNA in the rat brain (Rivest et al. 2000). 
Several studies have provided evidence that peripherally produced cytokines, 
including 1L-1p and IL-6, may cross the BBB at sites of increased permeability in 
response to bacterial infection, to stimulate AVP/CRH secreting neurones (Banks et 
al. 1994; Gutierrez et al. 1994; Boje 1995; De Vries et al. 1996; Banks et al. 2001). 
However, other laboratories have found LPS does not alter the permeability of the 
BBB (Bickel et al. 1998), or has only a modest effect to allow permeability to smaller 
molecular weight compounds (Singh & Jiang 2004). Singh et al. demonstrated 
peripherally administrated LPS does not cross the BBB, but accumulates in brain 
endothelial cells which express receptors for LPS signalling (Singh & Jiang 2004). 
The binding of LPS to CD14 may trigger a series of signalling events leading to the 
release of eicosanoids and pro-inflammatory mediators, including NO and IL-1p 
(Lacroix et al. 1998). In particular, NO production has been demonstrated in the PVN 
following LPS challenge (Uribe et al. 1999) and NO is a likely candidate for 
modulating ACTH release, both at the hypothalamic and pituitary level. 
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Cytokines are also able to indirectly activate the HPA axis through the stimulation of 
central noradrenergic pathways, or by acting at the sites of inflammation to stimulate 
peripheral nociceptive, somatosensory and visceral afferent fibres leading to 
activation of the LC/NE and PVN CRH neuronal systems via ascending spinal 
pathways [reviewed in (Chrousos 1995)]. However, not all signals from the immune 
system are stimulatory to the stress system; for example, transforming growth factor 
13 (TG93) exerts negative effects on HPA axis activity (Raber et al. 1997). 
Immune cytokines are also expressed in the hippocampus, the hypothalamus and 
the pituitary gland (Ray & Melmed 1997; Vitkovic et al. 2000) and increased 
expression of these cytokines in response to insult influences the release of 
hormones from endocrine tissue. For example, IL-1 receptor (IL-1R) expression has 
been detected in the murine AtT20 pituitary corticotroph-like cell line (Bristulf et al. 
1991) and is up-regulated by CRH treatment, as well as by other cAMP inducers 
including forskolin and isoprenaline (Ray & Melmed 1997). 
1.4.4 Effects of nitric oxide on the HPA axis 
NO is synthesised from L-arginine by a family of enzymes called NO synthases 
(NOS). The biochemical pathways leading to NO formation involves three distinct 
NOS isoenzymes: neuronal NOS (NOS-1), inducible NOS (NOS-2) and endothelial 
NOS (NOS-3) (Knowles & Moncada 1994; Nathan & Xie 1994; Dawson & Dawson 
1996). NOS-1 and NOS-3, which are constitutively expressed in neurones, 
endothelial cells and astrocytes, produce NO in a rapid and Ca2+ -dependent manner 
(Lamas et al. 1992; Knowles & Moncada 1994; Nelson et aL 1997). NOS-2, which 
was first described in cells of the immune system (Xie et al. 1992), is a Ca2+ -
independent isoform and is expressed in the brain by cell types including glial cells 
and microvascular endothelial cells (Nelson et aL 1997). 
The expression of NOS has been localised to the anterior pituitary (Ceccatelli et al. 
1993) and hypothalamic regions controlling hypophyseal secretions (Bredt et al. 
1990; Siaud et al. 1994; Uribe et al. 1999) and in the immediate proximity of 
neuroendocrine nerve terminals to the external zone of the ME (Prevot et al. 2000). 
Studies have shown that LPS induced NOS activity increases the expression of CRH 
and AVP mRNA expression in the PVN and the release of ACTH, an effect which is 
reversed by NOS inhibition (Lee et al. 1999; Uribe et al. 1999; Akasaka et al. 2006). 
LPS also increases PVN NOS-2 expression, but this effect was only evident several 
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hours after the peak in ACTH secretion, implying that this isoform is not involved in 
the acute ACTH response, but may play a role in sustaining ACTH levels (Wong et 
al. 1996b). The stimulatory effects of NO upon hypothalamic peptide synthesis and 
release may represent a mechanism by which peripheral LPS stimulates ACTH 
release, without directly crossing the BBB (Van Dam et al. 1998; Uribe et al. 1999; 
Rivest et al. 2000) 
Conversely, NO localised to corticotrophs (Ohta et al. 1993) and folliculostellate cells 
(Ceccatelli et al. 1993), has been shown to inhibit ACTH release (Vankelecom et aL 
1992; McCann et aL 2000b), as well as the release of other pituitary hormones, 
including PRL, GH and LH (Vankelecom et al. 1990; Kato 1992; Ceccatelli et al. 
1993). The inhibitory role of NO in the pituitary is further supported by studies which 
have shown that IFNy increases folliculostellate derived NOS-2 expression in both 
primary pituitary monolayer and aggregate cultures, resulting in the attenuation of 
ACTH release (Vankelecom et al. 1990; Vankelecom et al. 1997). The opposing 
effect of NO in the pituitary, compared to at the hypothalamic level, may reflect a 
pathway by which folliculostellate cells regulate ACTH secretion in response to 
immunological stimulation. 
1.5 Innate immunity and inflammation 
1.5.1 The inflammatory response 
In response to viral or bacterial infection or injury, a cascade of events is initiated by 
the host, termed the inflammatory response. This response can lead to inflammation 
at the local site of injection/injury as wells as systemic inflammation, fever, 
leukocytosis and activation of the HPA axis. 
The inflammatory response is a protective response and functions as part of a 
normal host surveillance mechanism to destroy or quarantine both harmful agents 
and damaged tissue. Following insult, components of the immune system are 
recruited to initiate the production of pro-inflammatory mediators, including cytokines 
synthesised by activated macrophages. The immediate and sequential release of 
these mediators causes vasodilatation, increased blood flow and raises vascular 
permeability (Laroux 2004; Rankin 2004). This results in an increase in leukocyte 
trafficking to the inflammatory site due to the induction of endothelial and leukocyte 
cell adhesion molecule expression and chemoattractant production (Carlos & Harlan 
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1994; Springer 1994). During this stage of the response, there is a predominance of 
polymorphonuclear leukocytes at the inflamed site, which like monocytes and tissue 
macrophages, are phagocytic cells that engulf and eliminate foreign micro-organisms 
(Robbins S. 1989). 
Following the removal of the infectious agent, the inflammatory response progresses 
to the resolution (tealing') phase, which involves restoration of tissue function and 
repair of any damage caused. Removal of the causative agent leads to the clearing 
of inflammatory cells by apoptosis and lymphatic drainage (Savill 2001) and anti-
inflammatory mediators involved in the repair process are produced until the insult is 
resolved (Spector & Willoughby 1968). 
1.5.2 Glucocorticoids as anti-inflammatory agents 
Glucocorticoids are powerful anti-inflammatory agents, which act to inhibit pro-
inflammatory cell recruitment, down-regulate the production of both pro-inflammatory 
cytokines and prostanoids, and up-regulate the production of anti-inflammatory 
mediators (Van Der Burg & Van Der Saag 1996; Chivers et al. 2004; Schramm & 
Thorlacius 2004; Yeager et al. 2004). An important mechanism by which 
glucocorticoids exert their anti-inflammatory effects is through the inhibition of NFKB 
and AP-1. In the nucleus, activated GRs modulate transcriptional events by directly 
associating with DNA elements compatible with the GREs. The binding of GR to its 
response element allows inhibition of the activity of pro-inflammatory transcription 
factors (Almawi & Melemedjian 2002). Glucocorticoids also mediate gene 
transcription through the up-regulation of ANXA1 (Flower & Rothwell 1994). ANXA1 
inhibits the expression and activity of pro-inflammatory enzymes such as NOS-2 in 
macrophages (Wu et al. 1995) and COX-2 in microglia (Minghetti et al. 1999), and is 
also involved in the inhibition of neutrophil and macrophage migration at local sites of 
inflammation (Walther et al. 2000; Oliani et a/. 2001). 
1.5.3 The LPS signalling pathway 
Bacterial lipopolysaccharides, the major outer surface membrane components 
present in almost all gram-negative bacteria, act as potent stimulators of innate or 
natural immunity. LPS consist of a poly- or oligosaccharide region that is anchored in 
the outer bacterial membrane by a specific carbohydrate lipid moiety termed lipid A, 
which is the primary immuno-stimulatory centre of LPS. With respect to immuno-
activation in mammals, the classical group of strongly agonistic forms of LPS has 
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been shown to be comprised of a similar set of lipid A types [reviewed by (Seydel et 
al. 2003)]. These agonistic forms of LPS trigger numerous physiological immuno-
stimulatory effects in mammalian organisms, but exposure to higher doses can also 
lead to pathological reactions such as the induction of septic shock. 
The LPS signalling pathway involves the recognition of LPS by the host, which is 
initiated by binding of LPS and its binding protein (LBP) to either the membrane-
bound or the soluble form of the co-receptor CD14 (Schumann et al. 1990; Wright et 
aL 1990; Hailman et al. 1994). Extracellular toll-like receptor 4 (TIr4) acts as a 
heterodimer with the accessory protein myeloid differentiation 2 (MD-2), which goes 
on to interact with the LPS/LBP/CD14 complex [reviewed in (Beutler 2000) and 
(Anderson 2000)]. When engaged by LPS, the complex transduces a signal detected 
by the adaptor molecule myeloid differentiation primary-response protein 88 
(MyD88), which is then recruited and facilitates the association of interleukin-1-
receptor-associated kinase 4 (IRAK4) (Muzio et al. 1998; Kawai et al. 1999). The 
binding of MyD88 to IRAK4 leads to IRAK4-mediated phosphorylation of IRAK1 and 
the binding of tumour necrosis factor receptor-associated factor 6 (TRAF6) to this 
complex. The IRAK1-TRAF6 complex disengages from the receptor and interacts at 
the plasma membrane with another preformed complex consisting of TAK1 (a 
member of the mitogen-activated protein kinase kinase kinase family; MAPKKK) and 
the TAK1 binding proteins, TAB1 (activator protein) and TAB2 (adaptor protein) or 
TABS (He et al. 2003). The formation of this complex results in the phosphorylation of 
TAB2/3 and TAK1 which translocate to the cytoplasm where TAK1 is activated. This 
leads to the activation of the inhibitor of kappa B (11(13) kinases (IKKs) and the 
phosphorylation and degradation of IKB for subsequent release of NFKB (Akira & 
Takeda 2004) (figure 1.4). 
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Figure 1.4 	The LPS signalling pathway. CD14, cluster of differentiation factor 
14; DD, death domain; IKB, inhibitor of kappa B; IKK, IKB kinase; IRAK1, interleukin-
1-receptor-associated kinase 1; LPS, lipopolysaccharide; LBP, LPS-binding protein; 
mCD14, membrane bound CD14; MD-2, myeloid differentiation 2; MyD88, myeloid 
differentiation primary response protein 88; NFKB, nuclear factor kappa B; sCD14, 
soluble CD14; TIR, toll/interleukin-1 receptor; TIRAP, TIR-domain-containing adaptor 
protein; TIr4, Toll-like receptor 4; TNF-receptor-associated factor 6; TRAF6. 
1.5.4 The Toll-like receptor family 
The innate immune system includes a family of trans-membrane receptors that 
mediate the recognition of conserved microbial structures to activate the host 
immune response, known as the toll-like receptor (TIr) family. Signalling through the 
TIr family was originally identified in Drosophilla as part of the embryonic dorso-
ventral patterning system (Belvin & Anderson 1996) and subsequently found to 
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mediate the innate immune response against fungal infection (Lemaitre et al. 1996). 
Homologues of Toll have been found and eleven members of the Tlr family have 
been identified in mammals to date. The Toll receptor structure is similar to that of 
type I transmembrane receptors, with an ectodomain containing leucine-rich repeats 
and a conserved intracellular region and the Toll/interleukin-1 receptor (TIR) domain 
that is required for downstream signal transduction (Slack et al. 2000). 
The various members of the TIr family are activated by different ligands leading to the 
activation of NFKB and the release of pro-inflammatory mediators (Akira & Takeda 
2004). The TIr4 receptor is required for mediating a pro-inflammatory response to the 
bacterial endotoxin LPS, a potent activator of host cells such as monocytes, 
macrophages and neutrophils (Chow et al. 1999; Shimazu et al. 1999). In addition to 
LPS signalling through TIr4, gram-positive bacteria (which do not contain LPS, but 
carry surface teichoic acids, lipoteichoic acids and peptidoglycan instead) also trigger 
the release of pro-inflammatory cytokines, although subsequent signalling occurs 
through TIr2 rather than TIr4 (Akira 2000). The TIr2 receptor is also expressed in both 
mouse and human adrenal glands under basal conditions and is involved in 
mediating the adrenal stress response (Bornstein et al. 2004b). The absence of TIr2 
has been associated with an enlargement of the adrenal gland and reduction of 
corticosterone levels and impairment of the HPA axis (Bornstein et al. 2004b). 
1.6 	Nuclear factor kappa B 
1.6.1 NFKB signalling 
NFKB is a ubiquitous dimeric transcription factor comprising members of the Rel 
protein family. To date, the Rel family members identified include the mammalian 
proteins p65 (also known as Rel A), Rel B, c-Rel, p50/p105 and p100/p52. The 
p50/p52 subunits are proteolytic cleavage products of precursor proteins that 
possess both a Rel region and an lx13-like region. Rel proteins possess a highly 
conserved region of approximately 300 amino acids known as the Rel homology 
domain. Contained within this domain are DNA recognition/binding sites involved in 
the dimerisation and nuclear localisation functions of NFx13. These Rel proteins have 
the ability to homodimerise or heterodimerise with other Rel proteins to form DNA 
binding-competent NFxB factors with different sequence specificities. Although not all 
combinations of NFx13 dimers have been shown to form or to have relevant 
physiological actions, several transcriptionally active NFKB dimers have been 
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identified, including Rel B/p52, p65/p50, p65/p65 and p50/p50. The composition of 
NFKB dimers determines their DNA sequence specificity by combining different DNA 
recognition loops in the Rel homology domains of different subunits, for example p65 
homodimers preferentially bind DNA enhancer motifs that are not well recognised by 
p65/50 heterodimers or p50/p50 homodimers. The variety of dimerisation may 
contribute to the cell type specificity of the NFKB response. The prototypical and 
most extensively studied NFKB dimer is the p65/p50 heterodimer and is considered 
the "classical NFKB" (Karin 1999). 
In resting cells, NFKB is found in an inactive form in the cytoplasm bound to an 
inhibitor protein of the IKB family (Baeuerle & Baltimore 1988), which conceals the 
nuclear localisation sequence and thus prevents NFKB from translocating to the 
nucleus. The most extensively studied protein in this family is IKBa. Pro-inflammatory 
stimuli activate the inhibitor of kappa B kinase (IKK) complex (IKKC), which contains 
two catalytic subunits (IKK-a and IKK-(3) and one regulatory subunit (IKK-7). 
Activation of IKKC signals the ubiquitination, phosphorylation and degradation of the 
IKBa protein in the proteosome, exposing the nuclear translocation signal of NFKB. 
This causes the release of the active NFKB dimer, allowing its translocation to the 
nucleus. In the nucleus, NFKB binds with a consensus sequence (5'-GGGACTTTCC-
3') in the promoter region of various genes and activates their transcription (Karin & 
Delhase 2000). The phosphorylation activity of IKKs are greater when IKBa is bound 
to NFKB, explaining how free IxBa can accumulate in cells in which IKK is still active, 
thus contributing to the termination of NFKB activation (Zandi et al. 1998). 
The classical pro-inflammatory pathway involves IKBa complexed to p65/p50 NFKB 
and activation of the IKKC, in particular IKK13, allowing 'free' NFKB to transcribe 
genes encoding proteins including the cytokines IL-8 and IL-6, intercellular adhesion 
molecule 1 and the inducible enzymes NOS-2 and COX-2. A key component of the 
resolution phase of the inflammatory response is the inhibition of NFKB activity, and 
hence a down-regulation of inflammatory mediators. This action is an important 
target for glucocorticoids in their anti-inflammatory role. 
1.6.2 Immunological stress activation of NFKB 
NFKB was identified more than a decade ago by Sen and Baltimore as an enhancer- 
binding protein controlling immunoglobulin kappa light chain (Igic) gene expression in 
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B cells. Despite being initially perceived as a tissue-restricted transcription factor, 
NFKB was later found to be expressed in other immune cells as an inactive protein 
sequestered in the cytoplasm and to be activated in response to pro-inflammatory 
stimuli such as LPS or TNFa. Its role is of particular importance to immune cells, 
where it has been shown to regulate a wide variety of genes involved in mammalian 
immune and inflammatory responses [reviewed in (Liou 2002)]. NFKB is 
characteristically activated by cellular factors including oxidative stress, cytokines 
and growth factors, which induce nuclear translocation of NFKB in endothelial and 
smooth muscle cells, monocytes and macrophages, and the renal epithelium 
(Hofmann et al. 1999; Valen et al. 2001; Wardle 2001). Upon nuclear translocation, 
NFKB is able to up-regulate the expression of target genes including adhesion 
molecules and pro-inflammatory cytokines. These cytokines are also able to further 
stimulate NFKB activation (Zhou et al. 1993; Shintani et al. 1995; Merlot et al. 2002). 
NFKB also controls the gene expression of all known anti-apoptotic genes and is 
therefore important in promoting cell survival as well as modulating inflammatory 
responses (Collins & Cybulsky 2001). In addition to their roles in immune and 
inflammatory responses, NFKB family members are also crucial regulators of cell 
development, proliferation and differentiation (Guttridge et al. 1999; Weih & 
Caamano 2003), apoptosis (Grimm et al. 1996; Chen et al. 2000) and oncogenesis 
(Cavin et al. 2004). Along with its previously described function in neurological 
disorders and apoptotic processes within the brain, NFKB also has a confirmed role 
in normal physiological function of the CNS at both cellular and behavioural levels, 
for example, studies have shown that the inhibition of NFKB results in an impairment 
of long term memory (Merlo et al. 2002; Meffert & Baltimore 2005). NFKB signalling 
in the brain is clearly very important but more research is required to fully understand 
its multi-functional roles. For example, little work has been done in elucidating the 
signal transduction mechanisms leading to NFKB activation in neuronal or glial cells 
and it is important to investigate the potential roles of the NFKB family members in 
the development of the CNS. 
1.6.3 Psychological stress-induced activation of NFKB 
The activation of NFKB was primarily believed to occur in response to immunological 
stress. However, psychological stressors have also been associated with an increase 
in cellular activation and cytokine release. Although no clear mechanism has yet 
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been elucidated to account for the interaction between psychological stress and 
immune activation, NFKB is a likely candidate. 
Studies have found that psychosocial stress induces the activation of NFKB in 
peripheral blood mononuclear cells (PBMCs) through the interaction of noradrenaline 
with ar and p-adrenergic receptors, which results in activation of the MAPK pathway 
and subsequent NFKB nuclear translocation (Bierhaus et al. 2003). Removal of the 
stressor resulted in the expression of nuclear NFKB protein returning to basal levels, 
although the time frame for restoration of basal levels varied between the subjects, 
implying that the individual's perception of stressful situations modulates the extent 
and duration of NFicB activation (Bierhaus et al. 2003). Restraint stress is also 
associated with NFKB activation, whereby nuclear translocation of NFKB is detected 
in the cerebral cortex after four hours of stressor exposure (Garcia-Bueno et al. 
2005). NFKB is an important regulator of NOS-2 and COX-2, which are both involved 
in the production of reactive oxygen species (ROS), and their expression has been 
detected in the brain following restraint stress (Olivenza et al. 2000; Madrigal et al. 
2002; Garcia-Bueno et al. 2005). ROS are potent stimulators of NFKB and indirect 
activation of NFKB by restraint induced NOS-2 and COX-2 production may present a 
feedback loop for increasing NFKB activation and pro-inflammatory cytokine release. 
The stimulation of receptors for the neurotransmitter glutamate also leads to NFKB 
activation in neurones (Guerrini et aL 1995; Kaltschmidt et aL 1995; Madrigal et al. 
2002), and glutamate released following restraint stress may also trigger nuclear 
translocation of NFKB. 
Although it is clear that NFKB is activated in response to psychological stressors, 
such as restraint stress, further studies are required to ascertain the importance of 
NFKB signalling in modulating the HPA axis response to restraint stress. 
1.7 Interactions between the CNS and the immune system 
The immune system and the CNS system mount a variety of essential, coordinated 
responses to danger and they communicate with each other through three types of 
systems. In the first, the CNS system acts reciprocally with the immune system, in 
the second, the CNS drives immunity through both neuroendocrine and neuronal 
pathways and in the third, the immune system regulates the CNS through neuronal 
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and humoral routes, via immune mediators, cytokines and their respective receptors. 
Thus, these two systems, which are involved in both sensing danger and mounting a 
counterattack to these threats, are inextricably linked. 
1.7.1 Cytokine activation of the HPA axis 
Immune cytokines are a large and diverse group of pleiotropic and redundant 
polypeptides. They are rapidly induced in response to tissue injury, infection and 
inflammation. In addition to acting locally at sites of injury/infection, cytokines also act 
in the brain to regulate the HPA axis, through several mechanisms as outlined in 
section 1.3.3. The most extensively studied cytokine in regard to regulation of the 
HPA axis is IL-6, particularly in respect to hormone secretion from the pituitary 
(Bethin et al. 2000). IL-6 is a member of the IL-6-family of cytokines, comprising of IL-
11, leukaemia inhibitory factor (LIF), oncostatin M, ciliary neurotrophic factor and 
cardiotrophin 1. Members of this family all share a common signal-transducing 
mechanism and thus elicit similar, overlapping physiological responses. IL-6 
signalling involves association of IL-6 with its membrane-bound receptor, IL-6Ra (the 
alpha subunit of the functional receptor), which induces the association of IL-6Ra 
with gp130 (Arzt 2001). The IL-6Ra may also occur in a soluble form through 
proteolytic cleavage of the membrane form or as a result of alternative mRNA 
splicing, resulting in a transcript encoding only the extracellular domain portion and a 
modified C-terminal sequence. These modified forms of IL-6Ra retain the same 
binding affinity for IL-6 and the ability to complex with the membrane-bound gp130 
receptor (Montero-Julian 2001). The soluble form of gp130 acts as an antagonist for 
the IL-6/1L-6Ra complex as it is able to bind to the complex, but it is unable to fulfil its 
role as initiator of the downstream signalling pathway (Montero-Julian 2001). The 
binding of IL-6/IL-6Ra to gp130 leads to the rapid homodimerisation of gp130. This 
homodimerisation is necessary for signal transduction through the IL-6Ra complex 
and also for other related complexes involving the other receptor a subunits such as 
for LIF. Signalling with LIF is similar to that of IL-6, but involves binding of LIF to its 
LIF receptor a subunit (LIF-Ra), which results in induction of the heterodimer 
LIFR/gp130 (Jones et al. 1994). Signalling through gp130 is mediated by tyrosine 
kinases of the Janus-activated kinase (JAK) family and transcription factors of the 
signal transducers and activator of transcription (STAT) family. 
Activation of the JAK/STAT pathway is initiated following homo/heterodimerisation of 
gp130. Thereafter, JAKs (JAK1, JAK2 and Tyk2) are activated and in turn, 
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phosphorylate gp130 at several residues, providing docking sites for SH2 domain 
containing molecules such as the STAT1 or STAT3 members of the STAT family. 
Upon phosphorylation, the STATs are translocated as dimers to the nucleus and bind 
to promoter regions of their specific response genes (Arzt 2001). In order to prevent 
excessive hyperactivation of the HPA axis in terms of ACTH release, a tightly 
regulated mechanism is in place in pituitary corticotrophs, in addition to the negative 
feedback actions of circulating glucocorticoids. This mechanism involves the 
inhibitory actions of suppressor of cytokine signalling (SOC). SOC-3 is an early 
response gene which is induced in response to a variety of cytokines including IL-6 
and gp130 in the pituitary (Starr et al. 1997; Auernhammer et al. 1999). SOC-3 
inhibits corticotroph JAK/STAT signalling, rendering the cell resistant to further 
stimulation by gp130 cytokines and thus inhibits cytokine-mediated POMC synthesis 
and ACTH release (Starr et al. 1997; Auernhammer et al. 2000; Nicholson et al. 
2000). 
1.7.2 Interleukin 6 
Originally, IL-6 was identified as a factor which induces immunoglobulin synthesis in 
B cells, promotes B-cell hybridoma and plasmacytoma growth, stimulates acute-
phase protein synthesis in hepatocytes and plays a role in haematopoiesis and 
cytotoxic T-cell differentiation (Van Snick 1990). Progressively, the biological role of 
IL-6 has expanded to its involvement in inflammation (Hirano 1992), viral infection 
(Akira & Kishimoto 1992), autoimmunity (Kishimoto 1992) and development (Lee 
1992). IL-6 is upregulated in response to a variety of stimuli such as restraint stress 
(Zhou et al. 1993; Takaki et al. 1994; Li et al. 2000; Merlot et al. 2002), 
proinflammatory cytokines (Ammit et al. 2002), prostaglandins (Denizot et al. 1998) 
and LPS (Spangelo et al. 1990b; Schobitz et al. 1993), and is inhibited by anti-
inflammatory agents including IL-10 (De Waal Malefyt et al. 1991) and 
glucocorticoids (Ray et al. 1990; Carmeliet et al. 1991). 
Research into the role of IL-6 in modulating the HPA axis has developed substantially 
over the last few years. Receptors for IL-6 have been detected at all levels of the 
HPA axis, particularly in the pituitary and adrenal glands (Path et al. 1997; Vallieres & 
Rivest 1997; Kurotani et al. 2001) and IL-6 has been shown to stimulate the release 
of CRH (Navarra et al. 1991; Vallieres & Rivest 1999) and promote glucocorticoid 
release both in vitro and in vivo (Tominaga et a/. 1991; Mastorakos et al. 1993a; 
Franchimont et aL 2000). It is during the later phase of endotoxaemia that IL-6 
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appears to be required, to prolong the activation of neural cells throughout the brain 
and maintain CRH expression in the PVN neurones (Vallieres & Rivest 1999). This is 
consistent with studies that have examined the temporal profile of cytokine release 
and HPA axis responsiveness in LPS stimulated rodents, wherein both PVN and 
plasma levels of IL-6 increased after maximal levels of ACTH and corticosterone had 
been reached (Givelois et al. 1994; Kakizaki et al. 1999). IL-6 also stimulates the 
release of ACTH through a CRH-independent mechanism, to promote glucocorticoid 
synthesis and release (Naitoh et al. 1988; Fukata et al. 1989; Mastorakos et al. 
1993a; Bethin et al. 2000). The later increase in IL-6 is likely to contribute to the 
continued release of ACTH after LPS exposure, thus maintaining glucocorticoid 
levels. This is further supported by studies which demonstrated IL-6 deficient mice 
did not have an altered response to LPS after one hour exposure, but levels of 
circulating glucocorticoid were significantly lower in the knockout animals compared 
to their wild type counterparts thereafter (Fattori et aL 1994; Turnbull et al. 2003). 
IL-6 is also synthesised in the brain following endotoxin exposure and is likely to act 
as a long-term regulator of plasma ACTH and glucocorticoid levels by acting directly 
at the level of the anterior pituitary gland (Muramami et al. 1993). The primary source 
of IL-6 has been located to the folliculostellate cells of the pituitary (Vankelecom et al. 
1989; Vankelecom et a/. 1993), a site which is sensitive to the negative feedback 
actions of glucocorticoids (Carmeliet et aL 1991; Grosset et al. 1999; Lohrer et aL 
2000). IL-6, synthesised and released by folliculostellate cells, is able to act in an 
autocrine and paracrine manner to further stimulate its production and to promote the 
release of ACTH from corticotrophs, which express the IL-6R/gp130 receptors and 
are up-regulated in response to LPS (Bethin et al. 2000; Kurotani et aL 2001; 
Gautron et al. 2003). Regulation of IL-6 gene expression is controlled by the binding 
of several transcription factors to known consensus sequences within the promoter 
region. These include cis-acting binding elements for GR, AP-1, cAMP response 
element binding protein (CREB), CCAAT enhancer-binding protein-f3 (C/EBP-(3), 
nuclear factor IL-6 (NF-IL6) and NFKB (Ray et al. 1988; Tanabe et al. 1988; Akira et 
al. 1990; Libermann & Baltimore 1990). Binding of IL-6 to its receptor and activation 
of the JAK/STAT pathway leads to translocation of the activated STAT-3 complex to 
the nucleus and binding to its response element on the POMC promoter, with 
subsequent transcription of POMC and, ultimately, ACTH release (Bousquet et al. 
1997; Bousquet et aL 2000). 
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1.7.3 Modulation of NFxB signalling in the pituitary gland by cytokines 
Utilising macrophage, monocytic, osteoblastic, fibrosacroma and uterine cell lines, 
stimulators such as LPS, IL-1 and TNFa have been shown to critically require intact 
NF-IL6 and NFxB binding sites within the IL-6 promoter in order to stimulate IL-6 
release (Matsusaka et aL 1993; Galien et al. 1996; Deshpande et aL 1997; Ray et aL 
1997; Vanden Berghe et al. 1998). Concurrent with these findings, Lohrer et al. found 
that LPS directly stimulated NFxB activation, which was associated with an increase 
in IL-6 release from TtT/GF cells and primary murine folliculostellate cell cultures and 
involved the p38alpha (p38a) MAPK pathway (Lohrer et al. 2000). However, the 
involvement of NFxB activation in pituitary-derived IL-6 release appears to be 
dependent on the stimulus as demonstrated by Nagashima et al. whereby TtT/GF 
cells exposed to pituitary adenylate cyclase-activating peptide (PACAP) released IL-6 
independently of NF-IL6 and NFKB, and required AP-1 and CREB (Nagashima et al. 
2003). 
Recent studies support the premise that LPS stimulated IL-6, and possible LIF, 
requires an intact NFxB signalling pathway (figure 1.5). Such evidence includes the 
demonstration of NFxB DNA binding activity in murine pituitary tissue in response to 
LPS stimulation (Parnet et al. 2003) and the subsequent release of IL-6 which was 
inhibited with a specific p38 MAPK inhibitor (Lohrer et al. 2000). The activation of 
NFxB in the pituitary and the subsequent production of pro-inflammatory mediators 
may present an additional pathway by which ACTH synthesis and release occurs. 
1.7.4 Glucocorticoid and NFKB interactions 
The yeast two-hybrid system has allowed investigators to study the interactions 
between transcription factors and has led to the identification of a variety of enhancer 
binding transcription factors that interact with a wide range of nuclear proteins. These 
nuclear proteins act as transcriptional co-factors that repress or enhance the activity 
of transcription factors. The interaction between GR and NFKB provides an example 
of this, both having opposite functions in the regulation of immune and inflammatory 
responses. The activity of NFKB is involved in up-regulating the transcription of pro-
inflammatory cytokines involved in immunity and inflammation, whereas GR inhibits 
the expression of many of these cytokines. The absence of GREs on these NFKB 
inducible genes initially made it difficult to ascertain the mechanism through which 
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glucocorticoids repressed these genes. It is now understood that these transcription 
factors can physically interact with one another to function as mutual transcriptional 
antagonists. One mechanism by which glucocorticoids inhibit NFKB has been shown 
to be through the direct interaction of GR with the p65 subunit of NFKB, thus 
preventing p65 from binding to its target gene sequences (Ray & Prefontaine 1994; 
Scheinman et al. 1995b; De Bosscher et al. 1997). Additionally, glucocorticoid 
mediated inhibition of NFKB can also occur indirectly, by inducing the expression of 
IKBa protein, which inactivates the transcriptional activity of NFKB by sequestering it 
in the cytoplasm (Auphan et aL 1995, Scheinman, 1995 #113). These genomic 
mechanisms of NFKB inhibition may contribute to the early delayed and late delayed 
phases of glucocorticoid feedback but not to the rapid phase of feedback, which 
occurs through non-genomic pathways. The anti-inflammatory ANXA1 protein is 
constitutively expressed in the hypothalamus (Loxley et al. 1993; Taylor et al. 1993; 
Buckingham & Flower 1997) and the pituitary gland (Traverso et al. 1999) and is 
induced by glucocorticoids. The induction of this protein may present a non-genomic 
glucocorticoid pathway through which NFKB activity is inhibited (Solito et al. 2003; 
John et al. 2004). 
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Figure 1.5 	Paracrine communications in the anterior pituitary gland. 
Diagrammatic representation illustrating the proposed mechanisms by which LPS 
acts on folliculostellate cells in the anterior pituitary gland to trigger the cytokine-
dependent synthesis and release of ACTH. Red arrows indicate pathways leading to 
increased ACTH synthesis and release; blue lines indicate glucocorticoid-dependent 
inhibition of NFKB activation and the subsequent synthesis and release of ACTH. 
ACTH, adrenocorticotrophic hormone; CD14, cluster of differentiation 14; CRH, 
corticotrophin releasing hormone; CRH-R1, corticotrophin-releasing hormone 
receptor 1; GC, glucocorticoid; GR, glucocorticoid receptor; IL-6, interleukin 6; IL-
6Ra, interleukin-6 receptor alpha; Jak/STAT, janus activated kinase/signal 
transducer and activator of transcription; Jnk, Janus N kinase; LIF, leukaemia 
inhibitory factor; LIFR, leukaemia inhibitory factor receptor; LPS, lipopolysaccharide; 
MAPK, mitogen activated protein kinase; MD-2, myeloid differentiation factor 2; 
MyD88, myeloid differentiation primary response protein 88; NFKB, nuclear factor 
kappa B; PKA, protein kinase A; POMC, proopiomelanocortin; TIr4, Toll-like receptor 
4. 
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1.8 Hypothesis 
The activation of the HPA axis during inflammation is an important protective 
mechanism for the host as the neuroendocrine stress response, and resultant 
induction of glucocorticoids, suppresses the immune reaction to prevent its over-
activation, and assists in progression to the resolution phase. The pituitary derived 
pro-inflammatory cytokine IL-6 has been shown to sustain activation of the HPA axis 
in response to stressors such as bacterial infection, and understanding both the 
importance of intra-pituitary-derived IL-6 in mediating ACTH, and the pathways 
involved in its synthesis, are of great interest for the treatment of inflammatory 
disorders and impaired glucocorticoid function. 
As part of the classical neuroendocrine response to stress, we hypothesise that the 
production of ACTH and subsequent glucocorticoid release is dependent, in part, on 
an NFKB signalling pathway, involving pituitary folliculostellate cells. The 
transcriptional activity of NFKB is likely to be of particular importance in mediating the 
HPA axis response to immune insults and possibly psychological stress. Signalling 
through NFKB is therefore a potentially significant component of a co-ordinated multi-
factorial process, which facilitates an optimal neuroendocrine response to 
immune/inflammatory insults and other stressors. 
NFKB signalling in the folliculostellate cells of the pituitary following stress stimulation 
is responsible for mediating the synthesis and release of IL-6, which in turn 
stimulates the release of ACTH. We propose that pituitary NFKB signalling may be 
sensitive to the actions of glucocorticoids, and that it is through the inhibition of NFKB 
that glucocorticoids mediate part of their negative feedback effects upon the HPA 
axis. 
NFKB is an important target for the treatment of inflammatory diseases such as 
rheumatoid arthritis. Yet little is known about the importance of NFKB signalling in the 
HPA axis, and hence the possible side effects that may arise following its inhibition. 
Therefore, the aim of this thesis is to investigate the role of NFKB in the activation of 
the HPA axis following both physiological (bacterial invasion) and psychological 
(restraint) stress and whether compounds inhibiting NFKB activity will impair HPA 
axis function. 
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1.9 Aims and objectives 
Whilst previous studies support the premise that bacterial endotoxin (LPS) can act 
directly at the anterior pituitary level to induce ACTH release, little is understood 
about the mechanisms involved in this response. Evidence suggests that the 
stimulatory effects of LPS occur through the release of pro-inflammatory cytokines 
(e.g. IL-6) from anterior pituitary folliculostellate cells which in turn act in a paracrine 
manner on neighbouring corticotrophs to stimulate the synthesis and release of 
ACTH. NFKB is an important modulator of IL-6 gene expression in immune cells (e.g. 
macrophages) and it is likely that this transcription factor is involved in LPS-
stimulated IL-6 release from folliculostellate cells. Although normal corticotrophs 
express LPS signalling receptors, to our knowledge, no effect of LPS upon ACTH 
release from corticotrophs has been reported and it is unclear whether LPS-induced 
NFKB activity in corticotrophs affects CRH-stimulated ACTH secretion. Furthermore, 
whilst CRH is a potent stimulator of ACTH release, this peptide does not affect the 
release of folliculostellate cell-derived IL-6. 
Thus, the first aim of this thesis is to investigate the mechanisms involved in LPS and 
CRH-induced ACTH release utilising transformed cell lines of folliculostellate cells 
and corticotrophs. The effects of LPS and CRH stimulation upon IL-6 (folliculostellate 
cells) and ACTH release (corticotrophs) will be examined and the effects of inhibiting 
NFKB on the release of these factors will be investigated. The second aim of the 
thesis is to investigate whether the responses of these cell-types are altered when 
they are co-cultured together. These studies will provide information as to whether 
endotoxin-induced ACTH release is dependent upon interactions between 
folliculostellate cells and corticotrophs. The third aim is to extend the in vitro findings 
to in vivo models to examine whether HPA responses to immunological and 
psychological stress are affected by NFKB inhibition. The in vivo studies will use rats 
treated with LPS as the immunological stressor and rats subjected to restraint stress 
as the psychological stressor. The HPA responses will be assessed by measuring 
plasma ACTH and corticosterone release, and NFKB activity in the anterior pituitary 
gland. 
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2 Methods 
2.1 Animals 
All experiments were carried out in accordance with the United Kingdom Animals 
(Scientific Procedures) Act 1986 under project licence PPL 70/5593. 
2.1.1 Rats 
Male Sprague-Dawley rats were obtained from a commercial supplier (Harlan Olac, 
Oxfordshire, UK) and maintained in standard, wire-top cages in the Comparative 
Biology Unit at Hammersmith Hospital (Faculty of Medicine, Imperial College 
London), in conditions of controlled lighting (lights were on between 08.00h and 
20.00h), temperature (21°C-23°C) and humidity (60-65%) with standard rat chow and 
water provided ad libitum. On arrival, the rats were acclimatised to their new 
environment for 48-72 hours and they were housed in groups of five per cage. The 
experiments were always started between 09.00h and 11.00h to minimise 
complications associated with the circadian rhythm. For one week prior to the stress 
experiments, rats were gently handled between 09:00 and 12:00 daily. 
2.2 Cell Lines 
2.2.1 TtT/GF cell line 
The TtT/GF cell line (a gift from Dr C McArdle, University of Bristol, UK) was used as 
a model of murine folliculo-stellate cells of the anterior pituitary. The cell line was 
established from a murine pituitary thyrotrophic tumour and possesses 
characteristics similar to those of folliculostellate cells, i.e. the presence of many 
lysosomes and numerous intermediate filaments in the cytoplasm, phagocytic 
activity, follicle formation, and stains positively for GFAP and S-100 protein (Inoue et 
al. 1992). 
2.2.2 PDFS cell line 
The PDFS cell line (a gift from Dr A Klibansky and Dr D Danila, Harvard Medical 
School, Massachusetts, USA) was used as a model of human folliculostellate cells of 
the anterior pituitary. This cell line spontaneously developed from a clinically non-
functioning pituitary macroadenoma and possesses characteristics similar to those of 
folliculo-stellate cells, i.e. the cells exhibit an epithelial morphology with long 
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cytoplasmic projections and frequent intercellular junctions including desmosomes. 
These cells express vimentin, S-100 protein, follistatin and activin A, all of which are 
characteristic of folliculo-stellate cells (Danila et al. 2000). 
2.2.3 AtT20 (D1 and D16:16) cell lines 
The AtT20 cell line was used as a model of corticotroph cells due to its ability to 
secrete ACTH. These cells also synthesise and secrete the ACTH/p-lipotrophin 
family of peptides, including p-endorphin, which are derived from POMC. The D1 
subclone (a gift from Dr S Guild, University of St Andrews, Fife, UK) is a non-
adherent cell line that was first cloned by Buonassisi et al. and established after 
alternate passage of mouse pituitary tumour cells as tumours in animals and in cell 
culture (Buonassisi et al. 1962). The pituitary tumours were originally removed from 
LAF1 mice by Gadsden et al (Gadsden & Furth 1953). The D16:16 (a gift from Dr S 
Guild, UK) cell line is a subclone of the D16v cell line (Yasumura 1968), a clonal 
variant of the original D1 clone and grows as an adherent monolayer with spindle-
shaped morphology. The AtT20 D16:16 cells are responsive to CRH and sensitive to 
the inhibitory effects of glucocorticoid treatment (Woods et a/. 1992; Tierney et a/. 
2003). 
2.2.4 RAW 264.7 cell line 
The RAW 264.7 cell line (purchased from American Type Culture Collection, 
Manassas, VA, via LGC Promochem, Middlesex, UK) was used as a model of murine 
macrophage cells. This cell line was established from the ascites of a tumour induced 
in a male mouse by the intraperitoneal injection of Abelson leukaemia virus (A-MuLV) 
(Ralph & Nakoinz 1977). These cells are phagocytic and express receptors for both 
complement and immunoglobulin. 
2.2.5 Maintenance of cell lines 
All cell lines were grown in 75m1 ventilated flasks (T75; Costar, New York, USA) at 
37°C and 5% CO2 (Heraeus Incubator; Kendro Laboratory Products, Hertfordshire, 
UK) in Dulbecco's Modified Eagle Media (DMEM) containing 44mM NaHCO3, 111µM 
sodium pyruvate and 4mM L-alanyl-L-glutamine (Invitrogen Ltd, Paisley, UK), 100µM 
L-alanine, 98µM L-asparagine, 8.80 L-aspartic acid, 101AM L-glutamic acid, 1µM 
glycine, 10mM L-proline and 100 L-serine; Invitrogen Ltd, UK) and supplemented 
with 10% heat inactivated fetal calf serum (FCS; PAA Laboratories Ltd, Yeovil, UK) 
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and 105µM gentamicin (Sigma, Poole, UK). For the TtT/GF and AtT20 (D16:16) cell 
lines, the medium was further supplemented with 5mg/I insulin, 5mg/I transferrin, 
116µM sodium selenite (Invitrogen Ltd, UK) and 30pM tri-iodo-L-thyronine sodium 
salt (T3; Sigma, UK). The PDFS cells are a non-adherent cell line, therefore, the 
flasks were pre-coated with poly-L lysine (prepared as 0.1% (w/v) in distilled water; 
Sigma, UK), which is an effective adhesive reagent due its ability to interact with the 
anionic sites of both tissue and cells. The PDFS cells were cultured in the same 
supplemented medium as the TtT/GF and AtT20 (D16:16) cell lines, but without T3. 
2.2.6 Passage of cells 
Once the TtT/GF cells, PDFS cells and AtT20 (D16:16) cells reached approximately 
90% confluency, they were washed with Dulbecco's phosphate-buffered saline (PBS) 
containing 2.7mM KCI, 1.5mM KH2PO4, 137mM NaCI and 6.5mM Na2HPO4  
(Invitrogen Ltd, UK) and incubated with 0.5g/I trypsin (Invitrogen Ltd, UK) and 684µM 
tetrasodium ethylenediaminetetraacetate (EDTA; Invitrogen Ltd, UK) for 2 minutes at 
37°C to detach them from the flask wall. The cells were plated at 1.5x106 cells per 
T75 flask in DMEM, supplemented as previously mentioned (see section 2.2.5). For 
the passage of the suspension AtT20 (D1) cell line, the medium containing the cells 
was centrifuged at 200g for 5 minutes. The cell pellet was washed in PBS, 
resuspended in fresh medium and plated at 3x106 cells per T75 flask. Once the RAW 
264.7 cells reached approximately 90% confluency, they were washed in PBS, 
detached by gentle scraping with a rubber scraper (Costar, USA) and seeded at 
3x106 cells per T75 flask. The cell lines used did not exceed a passage number of 
30. 
2.3 In vitro experiments 
2.3.1 Single cell cultures 
2.3.1.1 	Experimental conditions for determining NFKB activation 
For the detection of NFKB activation, the cells were plated in their respective culture 
medium (section 2.2.5) for 24 hours prior to stimulation at a density of: 2.5x105 
(TtT/GF), 6x105 (RAW 264.7), or 6x105 (AtT20 D16:16) cells per cm2. For stimulation, 
the cells were transferred to fresh medium containing the appropriate drugs and 
incubated for periods ranging from 0 to 24 hours. They were collected by gentle 
scraping with a rubber scraper (Costar, USA) and subjected to nuclear and cytosolic 
75 
protein extraction (section 2.5.3). The cytosolic and nuclear extracts were prepared 
for detection of p65 and IKBa protein expression by western blot analysis (section 
2.5.4) and the nuclear extracts were prepared for the detection of NFKB DNA-binding 
activity by electrophoretic mobility shift assay (EMSA; section 2.5.5) and/or p65 
TransAMTM assay (section 2.5.7). 
	
2.3.1.2 	Experimental conditions for measuring IL-6 release 
For the measurement of IL-6, the cells were plated in their respective culture medium 
(section 2.2.5) [at a density of 1.3x105 cells per cm2] for 24 hours prior to stimulation. 
Cells were then transferred to fresh medium containing appropriate drugs and 
incubated for periods ranging from 0 to 24 hours. Following incubation, the medium 
was collected, concentrated (section 2.5.8) and assayed for IL-6 by enzyme linked 
immunosorbant assay (ELISA; section 2.5.9) 
2.3.1.3 	Experimental conditions for measuring ACTH release 
For the measurement of ACTH, the cells were incubated in their respective culture 
medium (section 2.2.5) [at a density of 1.3x105 cells per cm2] for 24 hours prior to 
stimulation. Cells were then transferred to fresh medium containing appropriate drugs 
and incubated for periods ranging from 0 to 24 hours. Following incubation, the 
medium was collected and assayed for ACTH release by radioimmunoassay (RIA; 
section 2.5.11). 
2.3.1.4 	Experimental conditions for stimulation with LPS and CRH 
Within the anterior pituitary gland, folliculostellate cells provide an exclusive source of 
IL-6 (Vankelecom et aL 1989; Renner et al. 1998) and LPS injection increases intra-
pituitary IL-6 production in vivo (Grinevich et al. 2001). Therefore, the cell lines 
utilised in the current in vitro studies were incubated with 10Ong/nnl LPS, a 
concentration previously shown to stimulate IL-6 release from folliculostellate cells 
(Lohrer et al. 2000; Tierney et al. 2005). The cells were stimulated with LPS 
(10Ong/m1; Escherichia coli serotype 011:64; Sigma, UK) and/or graded 
concentrations of CRH (1-100nM; Tocris Biosciences, Avonmouth, UK) over a 24 
hour period to determine the optimal time point for NFKB activation and IL-6 and 
ACTH release by ELISA and RIA (sections 2.5.9 and 2.5.11 respectively). From 
these experiments, the optimal time for NFKB activation following LPS and/or CRH 
stimulation was 30 minutes for the TtT/GF cells and 1 and 7 hours for the AtT20 
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D16:16 cells. The optimal time point for IL-6 release from the TtT/GF cells following 
LPS stimulation was 16 hours and for the AtT20 D16:16 cells, the optimal ACTH 
response was 7 hours following CRH stimulation (see chapter 3). 
	
2.3.1.5 	Experimental conditions for stimulation of AtT20 D16:16 cells with 
murine recombinant IL-6 
The AtT20 D16:16 cells were stimulated with murine recombinant IL-6 (1nM; R&D 
systems, Abingdon, UK) in the presence and absence of graded concentrations of 
CRH (1-100nM; Tocris Biosciences, Avonmouth, UK). The medium was collected 
and the concentration of ACTH was determined by RIA (section 2.5.11). 
2.3.2 NFKB inhibition studies 
For the NFKB inhibition studies, the following compounds were utilised: 1) the 
proteosome inhibitor Mg132 [dissolved in 2mM ethanol; Tocris Biosciences, UK; 
(Chen et al. 1997)], 2) the synthetic glucocorticoid dexamethasone [dexamethasone 
21-phosphate disodium salt, dissolved in culture medium; Sigma, UK; (Jeon et a/. 
2000)] or 3) the specific IKK13 inhibitor SC514 [dissolved in 0.1% DMSO; Pfizer Ltd, 
Kent, UK; (Kishore et al. 2003)]. 
2.3.2.1 	Experimental conditions for the treatment of TtT/GF cells with Mg132 
The TtT/GF cells were pre-treated for 1 hour with Mg132 (1-10011M) prior to the 
addition of LPS (10Ong/m1; Sigma, UK). The cells were collected for cytosolic and 
nuclear extraction (section 2.5.3) and the nuclear extracts were subjected to NFKB 
EMSA (section 2.5.5). For the measurement of IL-6, the cells were pre-treated with 
Mg132 for 1 hour prior to the addition of LPS (10Ong/m1; Sigma, UK). The medium 
was collected, concentrated (section 2.5.8) and assayed for IL-6 (section 2.5.9). 
2.3.2.2 	Experimental conditions for the treatment of TtT/GF cells with 
dexamethasone 
The TtT/GF cells were incubated concomitantly with dexamethasone (1-100nM; 
Sigma, UK) and LPS (10Ong/m1; Sigma, UK). Following incubation, the cytosolic and 
nuclear fractions were extracted from the cells (section 2.5.4) for the detection of 
NFKB activity by EMSA (section 2.5.5) and hcBa protein expression by western blot 
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(section 2.5.4). The medium was collected, concentrated (section 2.5.8) and assayed 
for IL-6 (section 2.5.9). 
	
2.3.2.3 	Experimental conditions for the treatment of TtT/GF and AtT20 
D16:16 cells with the IKKL3 inhibitor SC-514 
The TtT/GF and D16:16 cells were incubated for 1 hour with SC-514 (50-30041) 
prior to the addition of LPS (10Ong/m1; Sigma, UK) and/or graded concentrations of 
CRH (1-100nM; Tocris Biosciences, UK). The medium from the TtT/GF cells was 
collected following incubation, concentrated (section 2.5.8) and assayed for IL-6 
(section 2.5.9) and the medium from the AtT20 D16:16 cells was collected and 
assayed for ACTH release (section 2.5.11). For the detection of NFKB activity, the 
cytosolic and nuclear fractions were extracted from the cells (section 2.5.3) and 
subjected to either NFKB EMSA (TtT/GF cells; section 2.5.5) or p65 TransAMTM  
assay (AtT20 D16:16 cells; section 2.5.7). 
2.3.3 Co-cultures of TtT/GF and AtT20 D16:16 cells 
To investigate further the effects of LPS and CRH stimulation upon IL-6 and ACTH 
release from the TtT/GF and AtT20 D16:16 cells respectively, when these two cell 
types are in contact with one another, a co-culture model was utilised. 
2.3.3.1 	Monolayer co-cultures 
For mono-layer co-cultures of the TtT/GF and AtT20 D16:16 cells, the cells were 
plated at a 1:4 ratio of ItT/GF:AtT20 D16:16 cells (see chapter 3) and left for 24 
hours to adhere. The following day, the medium was changed and the cells for left for 
a further 24 hours. On the third day, the cells were stimulated, in new medium. 
2.3.3.1.1 Estimation of cell numbers 
To determine the number of TtT/GF and AtT20 D16:16 cells in the monolayer co-
cultures, the cells were plated at a ratio of 1:4 (TtT/GF:AtT20 D16:16 cells) and 
incubated in culture medium (see section 2.2.5). On the third day, the cells were 
incubated with 0.5g/I trypsin (Invitrogen Ltd, UK) and 684µM tetrasodium 
ethylenediaminetetraacetate (EDTA; Invitrogen Ltd, UK) for 2 minutes at 37°C to 
detach them from the plate. The cells were then counted under a light microscope 
using a haemocytometer. The shape of the detached TtT/GF cells was distinct from 
the AtT20 D16:16 cells, thus enabling the two cells types to be easily distinguished. 
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	2.3.3.2 	Aggregate co-cultures 
For aggregate co-cultures, the cells were plated at ratio of 1:4 (TtT/GF:AtT20 D16:16 
cells) in non-adherent 24-well culture plates and placed over night on a rocking 
platform under the conditions outlined in section 3.2.5, to allow clusters of the TtT/GF 
and AtT20 D16:16 cells to form. The following day, the medium was changed and the 
cells were incubated for a further 24 hours on the rocking platform prior to treatment. 
2.3.3.3 	Experimental conditions for measuring IL-6 and ACTH release 
For the measurement of IL-6 and ACTH release, the cells were plated at a density of 
3.3x104 (TtT/GF cells) and 1.3x105 (D16:16 cells) per cm2. The cultures were 
stimulated with LPS (10Ong/m1; Sigma, UK) in the presence and absence of graded 
concentrations of CRH (1-100nM; Tocris Biosciences, UK) and the medium was 
collected and either concentrated (section 2.5.8) and assayed for IL-6 release 
(section 2.5.9) or stored for the measurement of ACTH (section 2.5.11). 
2.3.3.4 	Experimental conditions for the inhibition of NFKB 
For the NFKB inhibition studies, the co-cultures were pre-treated for 1 hour with SC-
514 (100µM; Pfizer Ltd, UK) prior to the addition of LPS (10Ong/m1; Sigma, UK) 
and/or CRH (1-100nM; Tocris Biosciences, UK). The medium was collected following 
incubation and either concentrated (section 2.5.8) for IL-6 determination (section 
2.5.9) or stored for ACTH measurement (section 2.5.11). 
2.4 In vivo experiments 
These experiments were undertaken to explore the role of NFKB in mediating the 
HPA responses to psychological (restraint) or immunological (LPS) stress. 
2.4.1 Application of restraint stress 
Adult male rats (section 2.1.1), weighing approximately 200-250g, were placed into 
cylindrical Broome rodent restrainers that allowed for a close fit (barrel internal 
diameter 50.8mm; Harvard Apparatus Ltd, Kent, UK) for 15 or 30 minutes. Control 
animals were not subjected to stress. Animals were either killed by decapitation 
immediately following restraint stress (15 and 30 minutes) or, returned to their 
housing cages for a 30 minute or 1 hour period of recovery and then killed by 
decapitation. The brains were quickly removed, frozen in liquid nitrogen and stored at 
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-80°C. The trunk blood was collected into EDTA-coated tubes, allowed to clot on ice 
prior to centrifugation at 3130g for 15 minutes and the plasma was stored at -80°C 
until required for detection of ACTH (section 2.5.12), corticosterone (section 2.5.13), 
IL-6 (section 2.5.9) and TNFa (section 2.5.10). The anterior pituitary, thymus and 
adrenal glands were quickly removed and subjected to cytosolic and nuclear 
extraction (section 2.5.3) for the detection of NFKB activation by EMSA (section 
2.5.5). 
2.4.2 Pre-treatment with the IKKI3 inhibitor, PHA781535E, prior to restraint 
stress 
Two hours prior to the onset of restraint stress (duration of 15 minutes) adult males 
rats were treated with the NFKB inhibitor, PHA718535E (a kind gift from Pfizer Ltd, 
Kent, UK), orally in a volume of 400µI, at a dose of 25 or 50mg/kg, or an equivalent 
volume of vehicle (4000, methycellulose-tween-saline). The dose and 
pharmacokinetic parameters of PHA718535E were established by Pfizer Ltd 
(unpublished observations, confidential). The animals were killed by decapitation and 
the trunk blood, brain, anterior pituitary, thymus and adrenal glands were collected 
and processed as described in section 2.4.1. 
2.4.3 Treatment with LPS 
Adult male rats (see section 2.1.1) weighing approximately 200-250g were injected 
intraperitoneally (i.p.) with either vehicle (400µI, sterile physiological saline; Baxter 
International Inc., Glasgow, UK) or LPS (dissolved in sterile physiological saline; 
Escherichia coli; serotype 055:B5; Sigma, UK) in a volume of 4000 (5mg/kg). The 
dose of LPS was selected based on previous studies examining the release of pro-
inflammatory cytokine release and ACTH and corticosterone release in rats receiving 
LPS i.p. (Kakizaki et al. 1999; Hannibal et al. 1999). Control animals were not 
subjected to vehicle or LPS administration. Animals were killed by decapitation either 
2 or 4 hours after LPS administration. Trunk blood, brain, anterior pituitary, thymus 
and adrenal glands were collected and processed as described in section 2.4.1. 
2.4.4 Pre-treatment with the IKKO inhibitor, PHA781535E, prior to LPS 
treatment 
Two hours prior to the administration of LPS (i.p., 4000, 50mg/kg; Sigma, UK), adult 
males rats were treated with the NFKB inhibitor, PHA718535E (Pfizer Ltd, Kent, UK), 
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orally in a volume of 400W, at a dose of 25 or 50mg/kg, or an equivalent volume of 
vehicle (400µ1, methycellulose-tween-saline). Two hours after LPS injection, the 
animals were killed by decapitation and the trunk blood, brain, anterior pituitary, 
thymus and adrenal glands were collected and processed as described in section 
2.4.1. 
2.5 Analytical techniques 
2.5.1 RNA extraction 
The RNA was extracted from the TtT/GF, RAW 264.7, PDFS and AtT20 (D1 and 
D16:16) cells for reverse transcriptase polymerase chain reaction (RT-PCR) analysis 
(section 2.5.2). The adherent cells (approximately 5x108 cells) were removed from 
the flask wall either by trypsinisation (PDFS, D16:16 and TtT/GF cells; see section 
2.2.6) or by scraping (RAW 264.7 cells; see section 2.2.6). The D1 cells, which grow 
in suspension, were collected in their medium and centrifuged at 200g for 5 minutes. 
The cells were washed twice in PBS and the RNA was extracted immediately using 
the Qiagen RNeasy kit (Qiagen, West Sussex, UK) as described below. 
Tissue and cell pellets were resuspended in 350111 RLT® buffer (as provided in the 
Qiagen RNeasy kit, RLT is the given name of the buffer by the company) containing 
100mM13-mercaptoethanol, transferred to a Qiagen shredder column and centrifuged 
at 15000g for 2 minutes at 4°C. Following the addition of 35% ethanol (VWR 
International Ltd, Poole, UK), the lysate was transferred to an RNeasy column and 
centrifuged at 8500g for 1 minute at 4°C. The column was washed with RW1® buffer 
(as provided in the Qiagen RNeasy kit, RW1 is the given name of the buffer by the 
company) and centrifuged at 8500g for 1 minute at 4°C. The column was washed 
through with RPE® buffer (as provided in the Qiagen RNeasy kit, RPE is the given 
name of the buffer by the company) and centrifuged at 8500g for 1 minute at 4°C. 
The column was washed again with RPE buffer and centrifuged at 8500g for 2 
minutes at 4°C. To elute the RNA, the column was transferred to a collection tube 
and 30111 RNase-free water (Ambion Incorporation, Texas, USA) was added directly 
onto the RNeasy silica-gel membrane. The column was centrifuged for at 8500g for 1 
minute at 4°C. This step was repeated to ensure all the RNA was eluted from the 
membrane. The RNA extracts were then diluted 1:50 in RNase-free water and the 
optical density (OD) was measured at 260nm and 280nm using a spectrophotometer 
(Jenway 6305 UVNisual Spectrum; Jencon PLS, Forest Row, East Sussex, UK). The 
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reading at 260nm allows the calculation of the concentration of nucleic acid in the 
sample. An OD of 1 corresponds to approximately 40µg/m1 for single stranded RNA 
(Davis et al. 1986). The ratio between the readings at 260nm and 280nm 
(0D260/0D280) provides an estimate of the purity of the nucleic acid (Davis et al. 
1986). Pure preparations of RNA have OD260/0D280 values between 1.8 and 2.0 
(Davis etal. 1986). 
2.5.2 Detection of mRNAs by reverse transcriptase polymerase chain reaction 
	
2.5.2.1 	Preparation of cDNA by reverse transcription 
The RNA extracted from the TtT/GF, RAW 264.7, PDFS and AtT20 (D1 and D16:16) 
cells (see section 2.5.1) was reverse transcribed (RT) by avian myeloblastosis virus 
reverse transcriptase (AMV RT; Promega Ltd, UK) and the resulting cDNA was 
amplified by polymerase chain reaction (PCR; section 2.5.2.2). 
Reverse transcription was performed on RNA samples (3µg) incubated with 
0.05µg/µloligo (dT)15Primer (Promega Ltd, Southampton, UK) and made up to a final 
volume of 28111 with RNase-free water. The RNA was denatured for 5 minutes at 
65°C on a thermal cycler (Omnigene; Thermo Electron Co., UK) and chilled on ice for 
2 minutes. Reverse transcriptase solution containing a dNTP mix (0.6mM dATP, 
0.6mM dCTP, 0.6mM dGTP and 0.6mM dTTP; Promega Ltd, UK), 1U/m1 
rRNasin®Ribonuclease inhibitor (Promega Ltd, UK), 5U/ml AMV RT (Promega Ltd, 
UK) and 5U/ml Moloney murine leukaemia virus (M-MLV) buffer [57mM Tris-HCI, pH 
8.3, 85mM KCI, 3mM MgCl2, 11mM dithiothreitol (DTT); Promega Ltd, UK] was 
added to 12111 of denatured RNA and incubated for 2 hours at 42°C. The cDNA was 
stored at —20°C. 
2.5.2.2 	Polymerase chain reaction 
Polymerase chain reaction (PCR; Techne TC-312; Jencons PLS, UK) was performed 
on the complementary DNA (cDNA) generated by reverse transcription (section 
3.5.2.1) with specific primers for the genes of interest (Table 2.1). The PCR mixture 
was composed of PCR buffer (50mM KCI, 10mM Tris-HCI, pH 9.0 at 25°C, 
0.1%Tritoex-100; Promega Ltd, UK), 0.2mM dNTP mix (Promega Ltd, UK), 1.5mM 
MgCl2 (Promega Ltd, UK), 0.05U/µI Taq DNA polymerase (Promega Ltd, UK) and 
forward and reverse primers (Applied Biosystems, North Warrington, UK) specific for 
each reaction. Table 2.2 shows the optimal concentrations used for each PCR 
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reaction, determined by preliminary studies in which graded concentrations of 
primers were used (10µM, 2511M and 50µM). To the PCR mixture, 5µI cDNA was 
added and the final volume was made up to 50111 with RNase-free water. The cycling 
parameters consisted of a denaturing step for 5 minutes at 95°C followed by 35 PCR 
cycles (the optimal PCR cycle number was determined from preliminary experiments 
using a series of cycle numbers — 15, 25, 30 and 35 cycles) of denaturation for 1 
minute at 95°C, annealing of primers at specific temperatures (Table 2.2) for 1 
minute and an extension step for 1 minute at 72°C. The PCR products were 
subjected to a final extension step of 72°C for 15 minutes following completion of the 
cycles and were stored at 4°C. For the detection of amplified cDNA, 5µI of PCR 
product and 5p,I of PCR marker (Promega Ltd, UK; molecular weight bands 
corresponded to 1000, 750, 500, 300, 150 and 50 base pairs) were mixed with 1µI 6x 
loading dye each (Promega Ltd, UK) and were loaded into separate wells of a 2% 
agarose gel (Gibco-BRL, Paisely, UK) stained with 0.02% ethidium bromide (Sigma, 
UK). The gel was subjected to electrophoresis for 30 minutes at 100V in EDTA buffer 
(TAE; Invitrogen, UK). Analysis of the RT-PCR product was performed under 
ultraviolet light with camera image analysis (Herolab GmBH Laborgerte, Germany) 
and Multi-Genius Bio-lmaging System software (Syngene, Cambridge, UK). The 
amplification of the correct sequences was confirmed by the product length. 
2.5.3 Extraction of nuclear and cytoplasmic protein 
For preparation of nuclear and cellular extracts, tissue or cell samples were 
resuspended in 200µI buffer A (containing 10mM HEPES (Sigma, UK), 10mM KCI 
(Sigma, UK), 0.1mM EDTA (Invitrogen, UK), 0.1mM EGTA (Sigma, UK), 1mM DTT 
(Sigma, UK), 0.5mM phenylmethylsulfonyl fluoride (PMSF; Sigma, UK), 1mM Na3VO4  
(Sigma, UK), 1mM NaF (Sigma, UK), 1µg/mlaprotinin (Sigma, UK), 1µg/ml pepstatin 
and 1µg/m1 leupeptin (Sigma, UK), pH 7.4 at 4°C). The primary tissue samples were 
gently sonicated in 200111 buffer A and all samples (cell lines and tissue) were 
allowed to swell on ice for 15 minutes prior to the addition of 0.4% NP-40 (Sigma, 
UK). Samples were vortexed for 10 seconds and centrifuged for 5 minutes at 8500g 
at 4°C. The supernatant containing the cytoplasmic fraction was collected and the 
concentration was measured using the Bio-Rad protein assay system (Bio-Rad 
Laboratories, California, USA; section 2.5.4.1). The nuclear pellet was resuspended 
in 100µ1 cold buffer C (20mM HEPES, 0.4mM NaCI (Sigma, UK), 1mM EDTA, 1mM 
EGTA, 1mM DTT, 1mM PMSF, 1mM Na3VO4, 1mM NaF, 1µg/m1 aprotinin, 1µg/ml 
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pepstatin and 1µg/m1 leupeptin, pH 7.4 at 4°C) and vigorously agitated at 4°C for 15 
minutes. The samples were centrifuged at 8500g for 5 minutes at 4°C and the 
supernatant containing the nuclear fraction was collected. The concentration of the 
nuclear extracts was measured by the Bio-Rad protein assay system (section 
2.5.4.1). The cytoplasmic and nuclear extracts were stored at —80°C until required for 
western blotting (section 2.5.4), EMSA (section 2.5.5) or p65 TransAMTM assay 
(section 2.5.7). 
Table 2.1 	Primer sequences. CD14, cluster of differentiation 14; MD-2, myeloid 
of differentiation factor 2; TIr2, Toll-like receptor 2; TIr4, toll-like receptor 4. 
Target 	 Primer Sequence* 
CD14 (mouse) 	 5' ATGGAGCGTGTGCTTGGCTTGTTGCTGTTG 
3' GCGGCTTAAACAAAGAGGCGATCTCCTAGG 
TIr2 (mouse) 	 5' GCGGCGGAACACTTTTCATCCGATGCCCG 
3' GCGGCAGCCTGGTGACATTCCAAGACGGA 
TIr4 (mouse) 	 5' GCGGCGGGTCAAGGAACAGAAGCAG 
3' GCGGCGCTCATTTCTCACCCAGTCC 
MD-2 (mouse) 	 5' CTGAATCTGAGAAGCAACAGTGG 
3' CAGTCTCTCCTTTCAGAGCTCTGC 
CD14 (human/mouse) 	5' GCCCTGCGTGTGCT 
3' CAGGATTGTCAGACAGG 
TIr2 (human) 	 5' GGCTTCTCTGTCTTGTGACC 
3' GGGCTTGAACCAGGAAGACG 
TIr4 (human) 	 5' TTGTATTCAAGGTCTGGCTGG 
3' GCAACCTTTGAAACTCAAGCC 
MD-2 (human) 	 5' CTGCAACTCATCCGATGCAAG 
3' CAGTCTCTCCTTTCAGAGCTCTGC 
GAPDH (human/mouse) 	5' AAGGTGAAGGTCGGAGTCAACG 
3' GGCAGAGATGATGACCCTTTTGGC 
*Gene sequences were identified through GenBank® and primer sequences were calculated 
using the BioMath Primer3 programme (httb://fodo.wi.mit.edu/cgi-bin/primer3/brimer3.ccii/). 
Sequences that matched the gene of interest with 95°/0 identity were chosen. Accession 
numbers of gene sequences are: mCD14, NM_009841; mTlr2, NM_011905; mTlr4, 
NM067272; mMD-2, AB018550; mGAPDH, NM_008084; hCD14, NM_000591; hTlr2, 
U88878; hTlr4, U88880; hMD2, AB018549; hGAPDH, M33197. 
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Table 2.2 	RT-PCR conditions for mRNA detection of TIr2, TIr4, MD-2 & 
CD14. CD14, cluster of differentiation 14; MD-2, myeloid of 
differentiation factor 2; TIr2, Toll-like receptor 2; TIr4, toll-like receptor 
4. 
Target Concentration of primers 
(pmol/p.1) 
Annealing temperature 
(°C) * 
TIr2 (mouse) 50 47 
TIr4 (mouse) 50 30 
MD2 (mouse) 50 56 
CD14 (mouse) 25 50 
TIr2 (human) 50 54 
TIr4 (human) 50 50 
MD2 (human) 50 56 
CD14 (human/mouse) 50 47 
*Annealing temperatures recommended by Applied Biosystems, UK 
2.5.4 Sodium dodecyl sulphate western blot analysis 
2.5.4.1 	Protein concentration determination (Bradford assay) 
The binding of Coomassie blue to tyrosine residues causes a shift in the absorption 
maximum of the dye from 465nm to 595nm. The increase in the absorption maximum 
is measured at 595nm against a standard curve ranging from 0-1mg/m1 BSA. The 
lysed cell samples (section 2.5.3) were diluted to ensure they fell within the linear 
portion of the standard curve. The samples and the standards were added in 
duplicate into a 96-well microtitre plate (10µ1/well) followed by the addition of Bio-Rad 
protein assay reagent (100111/well; stock solution diluted 1:5 with distilled water; Bio-
Rad, USA). After 1 minute colour equilibration, the plate was read on an Anthos htll 
plate reader (Anthos Labtec Instruments GmbH, Austria) at 595nm. The sample 
protein concentrations were calculated by linear regression from the standard curve 
(figure 2.1). 
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Figure 2.1 	Typical standard curve for protein estimation 
2.5.4.2 	Electrophoretic separation of proteins 
Proteins were separated by sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE) using acrylamide gels [10% v/v acrylamide, (Bio-Rad 
Laboratories, California, USA), 377mM Tris-HCI (Sigma, UK), 1mM sodium dodecyl 
sulfate (SDS; Sigma, UK), 0.5mM N,N,N',N'-tetramethylethylenediamine (TEMED; 
Sigma, UK) and 0.5mM ammonium persulfate (Sigma, UK), pH 8.8]. The stacking gel 
consisted of 25mM acrylamide/bis solution, 132mM Tris-HCI, 1mM SDS, 1mM 
TEMED and 5.2mM ammonium persulfate at pH 6.8. The cytoplasmic and nuclear 
protein extracts (section 2.5.3) were resuspended in triple concentrate sample buffer 
(192mM Tris-base, 150mM 2-mercaptoethanol, 300mM glycerol, 60mM sodium 
dodecyl sulfate and 0.03mM bromophenol) and heated to 100°C for 2 minutes. The 
samples and molecular weight marker (Santa Cruz Biotechnology Inc., California, 
USA; consisting of molecular weights of 132, 90, 55, 43, 34 and 23 kDa) were loaded 
in individual wells. The proteins were resolved in non-denaturing conditions (running 
buffer: 100mM Tris/Bicine and 1mM SDS at pH 8.3) at 100V for 180 minutes. 
2.5.4.3 	Western blot with chemiluminescent detection 
The separated proteins were transferred onto a nitrocellulose membrane (Hybond-C; 
Amersham Biosciences Ltd, Chalfont St Giles, UK), which was pre-soaked in transfer 
buffer (25mM Tris-HCI (Sigma, UK), 200mM glycine (Sigma, UK) and 200mM ethanol 
(BDH Chemicals Ltd, Poole, UK) at pH 8.3), by electrophoresis at 50mA (per blot; 
2117 MULTIFOR II, Pharmacia LKB, Bromma, Sweden) for 120 minutes. The 
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nitrocellulose membrane was washed for 10 minutes in 50mM Tris-buffered saline 
(TBS; 50mM Tris-HCL, 150mM NaCI at pH 7.0), containing 1% Tween (TTBS), and 
incubated in TTBS supplemented with 5% non-fat milk powder (Marvel, Knighton 
Edbaston, Stafford, UK) for 2 hours at room temperature on a rocking platform. The 
membrane was washed 4 times for 15 minutes in TTBS and incubated at 4°C 
overnight under agitation with either goat anti-rabbit p65 polyclonal antibody (Santa 
Cruz Biotechnology Inc., USA) or goat anti-rabbit licBa polyclonal antibody (Santa 
Cruz Biotechnology Inc., USA) at a 1:1000 dilution in TTBS containing 5% non-fat 
milk powder and 1% BSA. The membrane was washed a further 4 times (15 minutes 
each) with TTBS and incubated with horseradish peroxidase (HRP) conjugated rabbit 
anti-goat IgG antibody (Santa Cruz Biotechnology Inc., USA) at 1:2000 in TTBS 
containing 5% milk powder and 1% BSA for 1 hour at room temperature under 
agitation. 
The membrane was washed for a further hour (4 x 15 minute washes) and antibody 
binding was visualised by enzymatic chemiluminescense (ECL) according to 
manufacturer's instructions (ECL Plus; Amersham Biosciences Ltd, UK). To ensure 
equal amounts of protein were loaded, the membrane was then washed again and 
incubated in TTBS supplemented with 5% non-fat milk powder for 1 hour at room 
temperature on a rocking platform. The membranes were washed and incubated with 
mouse monoclonal anti-mouse 13-actin antibody (Abcam Ltd, Cambridge, UK) at 
1:5000 in TTBS containing 5% milk powder for 1 hour at room temperature. The 
membrane was washed again and incubated with HRP-conjugated rabbit anti-mouse 
IgG antibody (Sigma, UK) at 1:1000 in TTBS containing 5% milk powder for 1 hour at 
room temperature on a rocking platform. The membrane was washed and the bands 
were visualised by ECL Plus detection (Amersham Biosciences Ltd, UK). 
The proteins were visualised by exposure to X-ray film (Amersham Biosciences Ltd, 
UK) for up to 5 minutes, for a permanent record using an automatic developer 
(Konica medical film processor, model: SRX — 101A, Konica UK Ltd, UK) and the 
developed blots were scanned onto a PC (HP Scanjet 5200C with Adobe 
Photodeluxe Business Edition version 1.1). Because comparisons between separate 
gels can not be made, the experiments were repeated at least two times to ensure 
reproducibility and densitometric analysis of the bands on the same gel were 
performed using Scion Image (version Beta 4.02, Frederick, Maryland, USA). The 
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data were presented as a percentage of control (per gel) to show changes in protein 
expression more clearly (non-quantitative). 
2.5.4.4 	Determination of NFKB DNA binding activity by electrophoretic 
mobility shift assay 
The nuclear proteins extracted from the tissue samples and cell lines (section 2.5.3) 
were analysed for NFKB DNA binding activity by electrophoretic mobility shift assay 
(EMSA). NFKB consensus oligonucleotides (3.5pmol; 5'-AGT TGA GGG GAC TTT CCC 
AGG C-3', 5'-CCT GGG AAA GTC CCC TCA ACT-3'; Promega Ltd, UK) were end labelled 
with [y-32P]ATP (0.19MBq; Amersham Biosciences Ltd, UK) using T4 polynucleotide 
kinase (10-20U) in commercially supplied T4 polynucleotide kinase buffer (Promega 
Ltd, UK). The mixture was incubated at 37°C for 10 minutes before the reaction was 
halted by addition of 0.5M EDTA and made up to a final volume of 100111 with 
diethylpyrocarbonate (DEPC) pre-treated distilled water. Unincorporated nucleotides 
were removed from the DNA probe by passage through a G-25 Sephadex® column 
containing 10mM Tris-base, 1mM EDTA, 100mM NaCI (pH 8.0; Boehringer 
Mannheim, Ingelheim, Germany). The activity of the labelled DNA was measured 
using a liquid scintillation counter (model WALLAC 1409B; LKB WALLAC, Sweden) 
with probes of activities between 2x105 and 4 x105 counts per minute being used. 
Nuclear protein extract (5-10µg) was incubated with labelled probe in commercially 
supplied binding buffer (containing 5mM Tris-HCI, 0.5mM MgC12, 0.25mM EDTA, 
0.25mM DTT, 25mM NaCI, 0.025µg/µ1 poly(dl-dC), 2% glycerol, at pH 7.5; Promega 
Ltd, UK) for 30 minutes at room temperature. In control reactions, unlabelled 
consensus NFKB (1.75pmol; specific competitor) or AP-1 non-specific competitor 
(1.75pmol; 5'-CGC TTG ATG AGT CAG CCG GAA-3', 5'-TTC CGG CTG ACT CAT CAA GCG-3'; 
Promega Ltd, UK) oligonucleotides were added to the nuclear extracts in buffer and 
incubated for 10 minutes on ice. To the control and sample reactions, [y-32P]ATP-
labelled double-stranded probe was added and the reactions were incubated for 30 
minutes at room temperature. 
All extracts were resolved on a 4% non-denaturing polyacrylamide gel containing 5% 
v/v Tris-Borate-EDTA (TBE; consisting of 100mM Tris base, 100mM boric acid and 
2mM EDTA at pH 8.3; Promega Ltd, UK) buffer, 15% v/v acrylamide/bisacrylamide 
(Bis-2®; Amresco, Ohio, USA), 3.5% v/v acrylamide (Acryl-40®; Amresco, USA), 3.5% 
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v/v glycerol at 200V in 0.5x TBE buffer. The gel was fixed in 10% v/v methanol (VWR 
International, Leicestershire, UK), 10% v/v acetic acid (VWR International, UK) for 10 
minutes before being transferred to Whatman filter paper (Whatman®, Maidstone, 
UK) and dried using a Scie-Plas gel dryer system (Model GD5040; Warwickshire, 
UK). The gel was then exposed to X-ray film for 1-2 days (Kodak Biomax MR film; 
Anachem, Luton, UK) for a permanent record and the films were scanned onto a PC 
(HP Scanjet 5200 with Adobe Photodeluxe Business Edition version 1.1) and 
subsequently, densitometric analysis of the bands on each gel were performed using 
Scion Image (version Beta 4.02, Frederick, Maryland, USA). As direct comparisons 
between separate gels could not be made, the experiments were repeated at least 
two times to ensure reproducibility and the data were presented as the mean 
percentage of control to show changes in NFKB DNA-binding activity more clearly 
(non-quantitative). Where possible, three or more samples from the same treatment 
group were loaded on the same gel and following densitometric analysis, non-
parametric (semi-quantitative) statistical analysis was performed (see section 2.5.13). 
2.5.5 Determination of p50 and p65 subunits of NFKB by supershift assay 
For the identification of the NFKB DNA-binding complexes containing the 
transcriptionally active p65 subunit, supershift assays were performed on LPS 
(10Ong/m1) stimulated TtT/GF cells (figure 2.2), AtT20 D16:16 cells (figure 2.3) and 
pituitary and adrenal tissue extracted from LPS (5mg/kg, i.p.) treated rats (figure 2.4). 
The nuclear extracts of the AtT20 D16:16 cells (101.tg) were pre-incubated with 
antibody directed against p65 (0.51.1g, goat anti-rabbit p65 polyclonal antibody; Santa 
Cruz Biotechnology Inc., USA) and nuclear extracts of the TtT/GF cells (104) and 
anterior pituitary and adrenal tissues (51.1g) were pre-incubated with either an 
antibody directed against p65 (0.514; Santa Cruz Biotechnology Inc., USA) or 
antibody directed against p50 (0.5n; goat anti-rabbit p50 polyclonal antibody; Santa 
Cruz Biotechnology Inc., USA) for 10 minutes on ice prior to the addition of 
radioactive label and followed by EMSA (section 2.5.5). A supershift or a decrease in 
the intensity of the NFKB band in the presence of the antibodies was considered to 
be indicative of the presence of that protein in the DNA-binding complex. 
Densitometry analysis (see section 2.5.5) was performed on bands identified as the 
p65/p50 heterodimer by supershift in the cells/tissues (figure 2.2 - 2.4). 
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Figure 2.2 	Identification of NFKB binding proteins in TtT/GF cells stimulated 
with LPS (10Ongml, 30 minutes — 4 hours) by antibody supershift 
electrophoretic mobility shift assay (EMSA). The heavy line identifies the DNA 
binding complexes super-shifted by p65 antibody and the dotted and fine lines 
indicate specific NFkB binding complexes. A reduction in the bands labelled with a 
dotted line in the presence of p65 and p50 antibodies indicate the NFKB DNA-binding 
complex is the p65/p50 heterodimer. Competitive reactions were included with 100 
fold molar excess of the NFKB oligonucleotide (s, specific) and AP-1 oligonucleotide 
(AP-1; ns, non-specific). LPS, lipopolysaccharide; NFKB, nuclear factor kappa B. 
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Figure 2.3 	Identification of NFKB binding proteins in AtT20 D16:16 cells 
stimulated with LPS (10Ongml, 15 minutes — 24 hours) by antibody supershift 
electrophoretic mobility shift assay (EMSA). The heavy lines identify the DNA 
binding complexes super-shifted by the p65 antibody and the dotted and fine lines 
indicate specific NFKB binding complexes. A reduction in the bands labelled with a 
dotted line in the presence of p65 antibody indicates p65 containing NFKB DNA-
binding complexes. (1) and (2) indicate non-specific binding due to the continued 
presence of these bands in the competitive reaction containing 100 molar excess of 
the NFKB oligonucleotide (s, specific). Ab, antibody; LPS, lipopolysaccharide; NFKB, 
nuclear factor kappa B. 
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Figure 2.4 	Identification of NFiB binding proteins in anterior pituitary and 
adrenal tissue extracted from LPS (5mg/kg, 2 hours) treated rats by antibody 
supershift electrophoretic mobility shift assay (EMSA). The heavy line identifies 
the DNA binding complexes super-shifted by p65 antibody and the dotted and fine 
lines indicate specific NFkB binding complexes. A reduction in the bands labelled 
with the dotted line in the presence of p65 and p50 antibodies indicate the NFKB 
DNA-binding complex is the p65/p50 heterodimer. Competitive reactions were 
included with 100 fold molar excess of the NFKB oligonucleotide (s, specific) and AP-
1 oligonucleotide (AP-1; ns, non-specific). AD, adrenal tissue; LPS, 
lipopolysaccharide; NFKB, nuclear factor kappa B; PIT, anterior pituitary tissue; 
2.5.6 Determination of NFKB DNA binding activity by TransAMTM  
The prepared AtT20 D16:16 nuclear extracts (section 2.5.3) were analysed for NFKB 
DNA binding activity by a TransAMTM kit (Active Motif, Rixensart, Belgium). The 
assay was carried out according to the manufacturer's specifications and all reagents 
were supplied by the manufacturer. Nuclear protein extract (2.5µg; diluted in lysis 
buffer containing 5mM DTT and 10p1 protease inhibitor cocktail; as provided in the 
kit) was added to a 96-well plate coated with an immobiiised oligonucleotide 
containing the NFKB consensus site (5'-GG ACT TTc-3') for 1 hour, at room 
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temperature, under gentle agitation (100rpm on a rocking platform), in the presence 
of 30p1 commercially supplied binding buffer (as provided in the kit; containing 2mM 
DTT and 1Ong/p1 Herring sperm DNA). In control reactions, 30p1 of binding buffer 
containing either wild-type (20pmol; specific competitor; provided in the kit) or 
mutated (20pmol; non-specific competitor; provided in the kit) consensus 
oligonucleotides were added to the nuclear extracts prior to incubation. 
Following incubation, the wells were washed three times with wash buffer 
(200pl/well; provided in the kit). The samples were incubated for 1 hour at room 
temperature with p65 primary antibody (details of antibody not specified by the 
manufacturer, 100pl/well; antibody was diluted 1:100 in antibody binding buffer as 
provided in the kit). The wells were washed three times with wash buffer and 100p1 of 
anti-rabbit HRP-conjugated IgG secondary antibody (details of antibody not specified 
by the manufacturer) was added to each well (diluted 1:100 in antibody binding buffer 
as provided in the kit) and incubated for 1 hour at room temperature. To each well, 
100p1 of developing solution (as provided in the kit) was added and incubated for 2-
10 minutes in the dark, until the colour of the samples had developed from a range of 
medium to dark blue. To stop the reaction, 100p1 of stop solution (as provided by the 
kit) was added to each well and the optical density was measured at 450nm and 
655nm. The values obtained from the 655nm reading were subtracted from the 
450nm readings to correct for optical imperfections in the plate. As separate assays 
were not standardised to each other, direct comparsions could not be made. 
Therefore, where possible, the assay was repeated twice (using sampes taken from 
repeated experiments) to ensure the results were reproducible. The mean optical 
density detected each treatment group was expressed as a percentage of control to 
show changes in NFKB DNA-binding activity more clearly (non-quantitative). The 
assay specifically detects bound NFKB p65 in human, mouse and rat extracts and 
the detection limit of the assay was 0.5pg. 
2.5.7 Concentration of culture medium 
The supernatant collected from incubated cell lines was concentrated by micon 
centrifugal filter devices (according to manufacturer's instructions; Millipore, USA) 
with a 10kDa cut-off point for the measurement of IL-6 by ELISA (section 2.5.9). 
The medium was applied to the concentrator columns and centrifuged at 6000g at 
10°C for 1 hour. The filters were placed into 2m1 collection tubes and centrifuged for 
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a further 5 minutes at 8500g to collect the retained medium. Equal volumes of 
retained medium were collected following concentration (6001.11) and stored at -80°C 
until required. 
2.5.8 Measurement of IL-6 by enzyme-linked immunosorbant assay 
The rat plasma (section 2.4) and the concentrated media (section 3.5.8) collected 
from incubated cell lines were subjected to an enzyme-linked immunosorbant assay 
(ELISA) to measure the concentration of (i) mouse IL-6 released from TtT/GF, AtT20 
(D16:16 subclone) and RAW 264.7 cells, (ii) human IL-6 released from PDFS cells 
and (iii) rat plasma IL-6. Specific DuoSet ELISA development kits were obtained from 
R&D Systems (Abingdon, UK) and each ELISA was performed according to the 
manufacturer's specifications. 
A 96 well titre plate was coated with 100111 of capture antibody per well (for mouse 
specific IL-6 ELISA, the capture antibody was rat anti-mouse IL-6 (2µg/m1); human —
mouse anti-human IL-6 (2µg/ml); rat - mouse anti-rat IL-6 (4µg/ml)) and sealed and 
incubated overnight at room temperature. The capture antibody was aspirated and 
the plate was washed four times with Tween washing buffer (0.05% Tween-20 in 
PBS, pH 7.2 — 7.4) and drained. Any remaining buffer was removed by blotting the 
plate against a paper towel. To reduce non-specific binding, 300µI of block buffer for 
the mouse ELISA (1% BSA, 5% sucrose, 0.05% NaN3 in PBS, pH 7.2 — 7.4) or 3000 
of Reagent Diluent for the human and rat ELISA (1% BSA in PBS, pH 7.2 - 7.4; as 
provided by IL-6 ELISA kit) was added and incubated for 1 hour at room temperature, 
after which the plate was washed four times as previously described. In duplicate, 
100µ.1 of sample or recombinant mouse IL-6 standard for the mouse ELISA 
(concentrations ranging from 3.9 to 1000pg/m1 in Reagent Diluent), 1000 of sample 
or recombinant human IL-6 standard for the human ELISA (concentrations ranging 
from 9.3 to 600pg/ml in Reagent Diluent) or 100111 of sample or recombinant rat IL-6 
standard for the rat ELISA (concentrations ranging from 31.25 to 8000pg/ml in 
Reagent Diluent) was added to each well and incubated at room temperature for 2 
hours. Two wells containing 100p1 of Reagent Diluent were added for reference and 
an intra-assay standard (mouse - 100pg/m1; human — 75pg/ml; rat — 500pg/ml) was 
also included for each assay. 
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Following the incubation period, the plate was washed four times and any remaining 
buffer was removed. To each well, 1000 biotinylated IL-6 detection antibody 
(200ng/ml goat anti-mouse in Reagent Diluent for mouse ELISA; 200ng/mIgoat anti-
human for human ELISA; 10Ong/m1 goat anti-rat for rat ELISA) was added and the 
plate was incubated for 2 hours at room temperature. The plate was washed four 
times and 100µI streptavidin conjugated to horse radish peroxidase (as provided by 
IL-6 ELISA kit, R&D systems, UK) was added to each well (and incubated for 20 
minutes at room temperature in the dark. The plate was washed a further four times 
and 100µ1 substrate solution (1:1 mixture of colour reagent A; H202 and colour 
reagent B; tetramethylbenzidine, as provided by IL-6 ELISA kit, R&D systems, UK) 
was added to each well. To stop the enzymatic reaction, 50µI of 2M H2SO4 was 
added to each well and the plate was tapped gently to ensure thorough mixing. The 
optical density was measured at 450nm and 570nm. The values obtained from the 
570nm reading were subtracted from the 450nm readings to correct for optical 
imperfections in the plate. The concentration of IL-6 was calculated by linear 
regression from the standard curve (a representative graph is illustrated in figure 
2.5). The inter-assay and intra-assay coefficients of variation for the mouse ELISA 
were 5.7% and 3.9% respectively, 6.2% and 7.8% for the human ELISA and 9.8% 
and 14% for the rat ELISA. The detection limit for the mouse ELISA was 7.8pg/ml, 
9.2pg/ml for the human ELISA and 31.25pg/mlfor the rat ELISA. 
10 
I 	I 	I 	1 1 1 1 1 
1 	 10 	100 	1000 
Concentration (pglml) 
Figure 2.5 	Typical standard curve for IL-6 ELISA. ELISA, enzyme-linked 
immunosorbant assay; IL-6, interleukin 6. 
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2.5.9 Measurement of TNFa by enzyme-linked immunosorbant assay 
The plasma collected from the rats (see section 2.4.1 and 2.4.3) was subjected to an 
ELISA for the measurement of TNFa. Specific DuoSet ELISA development kits were 
obtained from R&D Systems (Abingdon, UK) and each ELISA was performed 
according to the manufacturer's specifications. 
The TNFa ELISA was conducted as outlined in section 2.5.8, with the following 
changes: 1000 of capture antibody (mouse anti-rat TNFa; 4µg/m1) was added to a 
96-well microtitre plate and incubated overnight at room temperature. The plate was 
washed with wash buffer (see section 2.5.8) and 300111 of Reagent Diluent (1% BSA 
in PBS, pH 7.2 - 7.4; as provided by TNFa ELISA) was added to each well and 
incubated for 1 hour at room temperature, after which the plate was washed four 
times as previously described. In duplicate, 10011.1 of sample or recombinant 
TNFa standard (concentrations ranging from 31.25 to 4000pg/ml in Reagent Diluent) 
was added to each well and incubated at room temperature for 2 hours. Two wells 
containing 100111 of Reagent Diluent were added for reference and an intra-assay 
standard (500pg/ml) was also included for each assay. 
Following the incubation period, the plate was washed four times and 1000 
biotinylated TNFa detection antibody (10Ong/m1 goat anti-rat TNFa in Reagent 
Diluent) was added to each well for 2 hours at room temperature. The plate was then 
developed with streptavidin conjugated to horse radish peroxidase (100111/well; as 
provided by TNFa ELISA kit) and substrate solution (1000; 1:1 mixture of colour 
reagent A; H202 and colour reagent B; tetramethylbenzidine, as provided by TNFa 
ELISA kit) under the conditions detailed in section 2.5.8 and the optical density was 
measured at 450nm and 570nm. The values obtained from the 570nm reading were 
subtracted from the 450nm readings to correct for optical imperfections in the plate. 
The concentration of TNFa was calculated by linear regression from the standard 
curve (a representative graph is illustrated in figure 2.6). The inter-assay and intra-
assay coefficients of variation for the assay were 4.7% and 2.8% respectively. 
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Figure 2.6 	Typical standard curve for TNFa ELISA. ELISA, enzyme-linked 
immunosorbant assay; TNFa, tumour necrosis factor alpha. 
2.5.10 Measurement of ACTH release by radioimmunoassay 
The release of ACTH into the medium of incubated cell lines was determined in 
duplicate by RIA using reagents supplied by the National Institute of Diabetes and 
Digestive and Kidney Disease (NIDDK, California, USA). The primary ACTH antibody 
was raised in rabbit against human ACTH1_39 (code: AFP6328031 National Hormone 
and Pituitary Program, California, USA) and provided in 2% normal rabbit serum in 
phosphate buffered saline (PBS), lyophilized and reconstituted in 1m1 distilled water. 
The antibody was directed against the 1-39 region of the peptide and did not cross-
react with corticotrophin-like intermediate lobe peptide (CLIP), a-melanocyte-
stimulating hormone (a-MSH), LH or prolactin (PRL). The reference preparation was 
synthetic human ACTH1_39 (NIDDK, USA) and provided in 1% BSA in PBS. Standard 
solutions of this peptide were prepared in triplicate by serial dilution of a stock 
solution (1 µg/m1 in 0.1M HCI) containing 10mM ascorbic acid, to produce solutions 
ranging from 19.5 to 10, 000pg/ml. The assay buffer used contained 12.7mM EDTA 
68.2mM Na2HPO4, 3mM sodium azide, 2mM DTT, 0.1% v/v Triton X-100 and 
0.033% w/v BSA in distilled water at pH 7.4 (Sigma, UK). Tubes containing 100µI test 
solution and 2091.1.1 ACTH antibody (diluted 1:48 000) were prepared in duplicate. 
97 
0 
1 
0 
10000 10 	1000 
ancentration (pg/ml) 
3000 - 
2500 
2000 - 
1500 - 
1000 - 
500 - 
C
ou
nt
s  
pe
r  m
in
u t
e  
(c
pm
)  
Tubes containing 300µI assay buffer were used to determine non-specific binding 
and tubes containing 100111 assay buffer and 200111 ACTH antibody were used to 
determine specific binding. To each tube, 1000 of 1251-labelled human ACTH 
(NIDDK, USA), which had been diluted in assay buffer to give approximately 10 000 
counts per minute, was added. To determine the total number of counts, tubes 
containing only WOO of 1251-labelled ACTH were included. The tubes were then 
vortexed and incubated at 4°C for 4 days. On the fourth day, the bound and free 
peptides were separated by the addition of 1001_11 of goat anti-rabbit decanting 
suspension (Pharmacia Upjohn, Buckinghamshire, UK) to each tube, except for the 
total counts tubes, and incubated for 2 hours at room temperature. To each tube, 
500111 of 0.1% triton X-100 in PBS and 5001.11 of 30% PEG in 0.05M phosphate buffer 
was added (excluding the total counts tubes) and centrifuged at 1760g for 1 hour. 
The supernatant fluid was aspirated and the bound fraction counted on an automatic 
gamma counter (Perkin-Elmer LAS (UK) Ltd., Beaconsfield, UK) using a 2 minute 
count time. The concentration of ACTH was calculated from the standard curve (a 
representative graph is shown in figure 2.7). The inter-assay and intra-assay 
variations were 11.1% and 10.7% respectively. The detection limit of the assay was 
40pg/ml. 
Figure 2.7 	Typical standard curve for ACTH RIA. ACTH, adrenocorticotrophin; 
RIA, radioimmunoassay. 
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2.5.11 Measurement of plasma rat ACTH by a two-site solid phase 
immunoradiometric assay 
Plasma levels of ACTH in rat was determined in duplicate by an IRMA kit supplied 
EURO-Diagnostica AB (Malmo, Sweden), The IRMA method has high accuracy and 
specificity and is a useful and convenient system for quantifying plasma ACTH. The 
assay involved the use of two polyclonal antibodies in excess. These antibodies 
recognise different binding sites on the antigen. The first antibody (lyophilised and 
reconstituted in 12.5m1 distilled water) is a highly purified monospecific radioionated 
sheep IgG and recognises the N-terminus of the ACTH molecule. The second 
antibody reacts non-competitively with the C-terminal region of the ACTH molecule 
and is immobilised and coupled to primary sheep anti-rabbit coated tubes. 
Standard solutions containing lyophilised ACTH were provided in the kit and stored in 
human plasma matrix with preservative and stabiliser. Each standard was 
reconstituted in 1m1 of distilled water and prepared in duplicate in C-terminal anti-
ACTH, coupled to sheep anti-rabbit, coated tubes. The range of standards provided 
was 0 — 1250pg/ml. 
Tubes containing 200µI standard and test plasma were prepared in coated tubes, in 
duplicate. Non-coated tubes containing 4041 standard A (Opg/mI) were used to 
determine non-specific binding and coated tubes containing 200111 standard A were 
used to determine specific binding. To each tube, 200µ1 1251 ACTH antibody was 
added. To determine the total number of counts, non-coated tubes containing only 
200µI 1251 ACTH antibody were included. The tubes were vortexed gently and 
incubated overnight at room temperature. During this incubation step, both antibodies 
react with the ACTH in the sample. A sandwich-type complex is formed, which binds 
to the tube wall. 
The remaining excess of tracer (1251 Sheep-anti-human ACTH) was removed from 
each tube (except for the total counts tubes) by washing the coated tubes twice with 
2m1 of wash buffer (as provided in the kit; reconstituted with 300m1 distilled water) 
and the liquid was aspirated completely. The radioactivity in the tube was counted on 
an automatic gamma counter (Perkin-Elmer LAS (UK) Ltd., Beaconsfield, UK) using 
a 2 minute count time. The concentration of ACTH in the plasma was calculated from 
the standard curve (a representative graph is shown in figure 2.8). The inter-assay 
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and intra-assay variations were 3.6% and 3.4% respectively. The detection limit of 
the assay was 3pg/ml. 
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Figure 2.8 Typical standard curve for IRMA ACTH assay. ACTH, 
adrenocorticotrophin; IRMA, two-site solid phase immunoradiometric assay. 
2.5.12 Measurement of plasma rat corticosterone by radioimmunoassay 
Plasma concentrations of corticosterone were determined in duplicate using a double 
antibody RIA kit provided by Immunodiagnostic Systems Ltd (Tyne and Wear, U.K). 
A polyclonal rabbit anti-corticosterone antiserum was used as the primary antibody in 
this assay and provided in assay buffer (PBS containing gelatine and a preservative 
supplied by the manufacturer). Corticosterone standard solutions were prepared in 
duplicate by serial dilution of a stock solution (1000ng/ml, provided in assay buffer), 
to produce concentrations ranging from 0.5 — 62.5ng/ml. Tubes containing 50µI of 
standards and test (plasma) solution, in duplicate, were incubated with 50µI 
corticosterone antiserum. Tubes containing 100µI assay buffer were used to 
determine non-specific binding and tubes containing 500 assay buffer and 50µI 
corticosterone antiserum were used to determine specific binding. To each tube, 50µI 
of 125l-labelled corticosterone was added. To determine the total number of counts, 
tubes containing only 50111 of 125l-corticosterone ACTH were included. The tubes 
were then vortexed and incubated at 4°C for 16-24 hours. Following the incubation 
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period, 50µI secondary antibody (goat anti-rabbit gamma globulin in assay buffer) 
was added to all the tubes, except the total counts tube, and incubated for 1 hour at 
room temperature. To all the tubes (except total counts), 500µI of saline was added 
and the tubes were centrifuged at 1760g for 15 minutes. The supernatant fluid was 
aspirated and the bound fraction counted on an automatic gamma counter (Perkin-
Elmer LAS (UK) Ltd., Beaconsfield, UK) using a 2 minute count time. The 
concentration of corticosterone in the plasma was calculated from the standard curve 
(figure 2.9). The inter-assay and intra-assay variations were 2.0% and 2.3% 
respectively. The detection limit of the assay was 0.39ng/ml. 
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Figure 2.9 	Typical standard curve for corticosterone RIA. RIA, 
radioimmunoassay. 
2.5.13 Statistical analysis 
All data are expressed as the mean ± standard error of the mean (SEM). All 
statistical analyses were carried out using Jandel SigmaStat 3.0 software (Jandal 
Corporation, San Ramon, CA). Preliminary analysis was undertaken to show that 
data were normally distributed (Kolmogorov-Smirnov test) and that variances were 
equal (Levene's median test). Statistical analysis was carried out using one-way 
ANOVA, two-way ANOVA or three-way ANOVA (as appropriate), with post hoc 
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analysis performed using Bonferroni's corrected Student's t-test. For statistical 
analysis of densitometric results from EMSA gels (chapter 5), the comparison of two 
groups (n=5, restraint vs control) was performed by the non-parametric Mann-
Whitney rank sum test and the comparison of three groups (n=4, untreated control, 
saline vehicle control and LPS) was performed by Kruskal-Wallis one-way ANOVA 
followed by the Student-Newman-Keul method. In all cases, differences were 
considered to be significant at p<0.05. 
2.5.14 Drugs and reagents 
Table 2.3 	Drugs and reagents. The following drugs and reagents were used: 
Gentamicin Sigma, Poole, UK 
Thyronine sodium salt (T3) Sigma, Poole, UK 
Oligo (dT)15Primer Promega Ltd, Southampton, UK 
rRNasin®Ribonuclease inhibitor Promega Ltd, Southampton, UK 
AMV reverse transcriptase Promega Ltd, Southampton, UK 
Taq DNA polymerase Promega Ltd, Southampton, UK 
Aprotinin Sigma, Poole, UK 
Leupeptin Sigma, Poole, UK 
Goat anti-rabbit p65 polyclonal antibody Santa Cruz Biotechnology, California, 
USA 
Goat 	anti-rabbit 	IKBa 	polyclonal 
antibody 
Santa Cruz Biotechnology, California, 
USA 
Goat anti-rabbit IgG antibody Santa Cruz Biotechnology, California, 
USA 
Mouse monoclonal anti-mouse 13-actin 
antibody 
Abcam Ltd, Cambridge, UK 
Rabbit anti-mouse IgG antibody Sigma, Poole, UK 
Aprotonin Bayer UK Ltd, Berkshire, UK 
NFKB consensus oligonucleotide Promega Ltd, Southampton, UK 
AP-1 consensus oligonucleotide Promega Ltd, Southampton, UK 
[y-32P]ATP Amersham Biosciences Ltd, Chalfont St 
Giles, UK 
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T4 polynucleotide kinase Promega Ltd, Southampton, UK 
Rat anti-mouse IL-6 antibody R&D Systems, Abingdon, UK 
Biotinylated goat anti-mouse antibody R&D Systems, Abingdon, UK 
Recombinant mouse IL-6 standard R&D Systems, Abingdon, UK 
Rabbit anti-human ACTI-11_39 peptide National Hormone and Pituitary Program, 
California, USA 
Synthetic human ACTH1_39 peptide National Hormone and Pituitary Program, 
California, USA 
1251-labelled human ACTH National Hormone and Pituitary Program, 
California, USA 
LPS (Escherichia coil 0111:64) Sigma, Poole, UK 
LPS (Escherichia coil 055:65) Sigma, Poole, UK 
Dexamethasone 21-disodium 
phosphate 
Sigma, Poole, UK 
SC-514 Provided by Pfizer Ltd, Kent, UK 
Mg132 Tocris Bioscience, Avonmouth, UK 
PHA718535E Provided by Pfizer Ltd, Kent, UK 
Recombinant mouse IL-6 Tocris Biosciences, Avonmouth, UK 
Recombinant human CRH R&D Systems, Abingdon, UK 
Corticosterone 21-acetate Sigma, Poole, UK 
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3 LPS signalling in pituitary-derived cell lines 
Immunological challenge with LPS potently activates the HPA axis, causing a release 
of ACTH from the corticotrophs in the anterior pituitary gland (Butler et al. 1989; 
Feuerstein et al. 1990; Ramachandra et al. 1992; Schotanus et al. 1994; Tilders et al. 
1994). This activation occurs, in part, through the upregulation of systemically 
produced IL-6, which has been shown to induce ACTH secretion independently of 
CRH (Bethin et aL 2000). Intra-pituitary IL-6 released from folliculostellate cells 
(Vankelecom et aL 1989; Renner et al. 1998) may also act directly on corticotrophs to 
influence ACTH secretion (Gloddek et al. 2001). Glucocorticoids, which are the end 
products of the activated HPA axis, may therefore target folliculostellate cell derived 
IL-6 as part of their negative feedback actions, resulting in the inhibition of ACTH 
synthesis and release (see section 1.7.2). 
The aim of this study was to characterise the LPS signalling pathway(s) in the 
anterior pituitary gland utilising in vitro models of folliculostellate cells (murine TtT/GF 
and human PDFS cell lines) and corticotrophs (murine AtT20 D1 and D16:16 
subclones). Further work involved analysis of the functional consequence of LPS 
signalling by detecting NFKB activation (by western blot analysis, EMSA and p65 
TransAMTM assay; see sections 2.5.4.3, 2.5.5 and 2.5.7 respectively), IL-6 (by 
ELISA; section 2.5.9) and ACTH release (by RIA; see section 2.5.11), and 
investigating the possible modulatory role of glucocorticoids upon this system (using 
the synthetic glucocorticoid, dexamethasone). 
3.1 	Detection of LPS signalling components in cell lines by RT-PCR 
To ensure the cell lines used in these studies were appropriate for examining LPS 
signalling, expression of mRNAs for the major components necessary for a cellular 
response to LPS (TIr4, CD14 and MD-2) were investigated by reverse transcriptase 
polymerase chain reaction (RT-PCR; see section 3.5.2). The expression of TIr2, the 
receptor involved in the recognition of gram-positive bacteria and fungal stimuli, was 
also explored as signalling through this receptor, as with TIr4, occurs via CD14 and 
leads to NFKB activation. The LPS signalling pathway has been well established in 
the macrophage-like RAW 264.7 cell line and therefore this cell line was included as 
a positive control (Du et aL 1999). 
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The detection of mRNA for the housekeeping gene GAPDH in the cell lines was also 
included in the RT-PCR studies, using the same cDNA for each reaction, to verify 
that equal amounts of mRNAs were used (a representative PCR gel is shown in 
figure 3.1E). 
3.1.1 TtT/GF cells 
In the TtT/GF cells, a band at 1100bp, which corresponds to the expression of CD14 
mRNA, was detected (figure 3.1A). The TtT/GF cells also expressed mRNAs for MD-
2 and TIr4, as indicated by bands of 293bp (figure 3.1B) and 300bp (figure 3.1c) 
respectively. In addition, TIr2 mRNA was detected in these cells (490bp; figure 3.1o). 
3.1.2 PDFS cells 
The human derived folliculostellate PDFS cell line expressed mRNAs for CD14 
(detected at 300bp; figure 3.1A) and TIr2 (294bp; figure 3.1D). However, mRNAs for 
MD-2 (389bp; figure 3.1B) or TIr4 (438bp; figure 3.1c) were not detected, indicating 
that the PDFS cells do not possess an intact LPS signalling system and thus do not 
exhibit all the characteristics assigned previously to folliculostellate cells (Danila et al. 
2000). 
3.1.3 AtT20 D1 and D16:16 subclones 
The expression of CD14 mRNA was detected in the D16:16 subclone (1100bp), but 
not in the D1 subclone (figure 3.1A). However, both subclones expressed mRNAs for 
MD-2, TIr4 and TIr2 (figures 3.1B, C and D respectively). 
3.1.4 RAW 264.7 cells 
The RAW 264.7 cell line, which was included in the RT-PCR studies as a positive 
control, expressed mRNAs for CD14, MD-2, TIr4 and TIr2 (figures 3.1A, B, c and D). 
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Figure 3.1 	Detection of mRNA for the LPS signalling components (A) CD14, 
(B) MD-2, (c) Tir4 and (D) Tir2 in folliculostellate (TtT/GF and PDFS), 
corticotroph (AtT20 D1 and D16:16 subciones) and macrophage (RAW 264.7) 
cell lines by reverse transcriptase-polymerase chain reaction (RT-PCR). 
Representative PCR gel for GAPDH mRNA expression is shown in (E). Data are 
representative of 3 separate PCR reactions. bp, base pair; h, human; m, murine; MW 
marker, molecular weight marker; TIr, Toll-like receptor. 
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3.2 Examination of the functional effects of LPS stimulation in the 
TtT/GF, PDFS, AtT20 (D1 and D16:16) and RAW 264.7 cell lines — IL-
6 release 
Following the confirmation of the presence of mRNAs for the important LPS 
signalling components in the TtT/GF cell line, the functional relevance of LPS 
signalling was examined. LPS is a potent stimulator of NFKB-mediated IL-6 release 
(Tanabe et al. 1988; Akira et al. 1990; Libermann & Baltimore 1990; Schobitz et al. 
1993), which is characteristically produced by folliculostellate cells (Vankelecom et al. 
1989; Vankelecom et al. 1993). Therefore, both NFKB activation and IL-6 release 
were examined in the TtT/GF cell line following LPS stimulation. Previous studies 
have shown that 10Ong/m1 LPS (in the presence of 10% fetal calf serum) induces a 
sub-maximal IL-6 response in TtT/GF cells (Lohrer et al. 2000) and this was 
confirmed in our laboratory (Tierney et al. 2005). The PDFS cell line was also 
included in the study to examine whether these cells would respond to LPS despite 
not expressing TIr4 or MD-2 mRNAs. Although previous reports have found that 
corticotrophs do not release IL-6, the presence of the LPS signalling components in 
the AtT20 subclones prompted further investigation as to whether these corticotroph-
like cell lines produced IL-6. For a positive comparison, the profile of NFKB activation 
and IL-6 release in LPS-stimulated RAW 264.7 cells was also examined. 
3.2.1 TtT/GF cells 
The stimulation of the TtT/GF cells with LPS (10Ong/m1) resulted in a significant time-
dependent increase in IL-6 release, with the effect being first evident after 4 hours 
contact (p<0.001 vs unstimulated control) and maximal at 16 and 24 hours (p<0.01 
vs unstimulated control and preceding LPS stimulated time point; figure 3.2A). 
3.2.2 RAW 264.7 cells 
The RAW 264.7 cells readily responded to LPS stimulation with an increase in IL-6 
release. Elevated amounts of IL-6 were measured in the medium after 4 hours of 
LPS exposure (p<0.001 vs unstimulated control) being maximal after 16 hours 
(p<0.001 vs unstimulated control and preceding LPS stimulated time point; figure 
3.2B). The concentration of LPS-stimulated IL-6 release in the medium of the RAW 
264.7 cells was significantly higher than that measured in the medium of the TtT/GF 
cells from 4 hours up to 24 hours post stimulation (p<0.001), with the maximal IL-6 
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concentrations from the RAW 264.7 cells (figure 3.2B) being 50 times greater than 
that of TtT/GF cells (figure 3.2A). 
3.2.3 PDFS cells 
The effects of LPS (10Ong/ml, 0-24 hours) stimulation on IL-6 release from the PDFS 
cells were investigated. Unlike the TtT/GF cells, the PDFS cells did not produce 
detectable amounts of IL-6 at any of the time points investigated (Table 3.1), 
confirming our suggestion that this cell line will not respond to LPS due to the 
absence of the TIr4 receptor, a requisite for LPS signalling. 
3.2.4 AtT20 D1 and D16:16 subclones 
The AtT20 D1 and D16:16 subclones also failed to produce detectable amounts of 
IL-6 (AtT20 Dl; Table 3.2 and AtT20 D16:16; Table 3.3), despite expressing TIr4, 
MD-2 and CD14 mRNA (figure 3.1A, B and c), further supporting their similarity to 
primary corticotrophs, which do not release IL-6 (Yeung et al. 2006). 
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Figure 3.2 	Time-dependent effects of LPS (10Ong/ml, 30 minutes - 24 hours) 
on IL-6 release from (A) TtT/GF and (B) RAW 264.7 cells. Each value is a mean ± 
SEM of four samples. The data are representative of three separate experiments. 
+++p<0.01 vs unstimulated control, **p<0.01, ***p<0.001 vs preceding time points. 
Analysis was performed by two-way ANOVA with post hoc comparison using 
Bonferroni's West. IL-6, interleukin 6; LPS, lipopolysaccharide. 
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Table 3.1 	Time-dependent effect of LPS (10Ong/ml, 30 minutes - 24 hours) 
stimulation on IL-6 release from PDFS cells. The detection limit of the human IL-6 
ELISA assay was 4.6pg/ml. ELISA, enzyme linked immunosorbant assay; IL-6, 
interleukin 6; LPS, lipopolysaccharide. 
Time (h) 
IL-6 release (pg/ml) 
Unstimulated LPS (10Ong/m1) 
0.5 undetectable undetectable 
2 undetectable undetectable 
4 undetectable undetectable 
7 undetectable undetectable 
16 undetectable undetectable 
24 undetectable undetectable 
Known 
standard 
(100pg/m1) 
103.6 ± 3.8 - 
Table 3.2 	Time-dependent effect of LPS (10Ong/ml, 30 minutes - 24 hours) 
stimulation on IL-6 release from AtT20 D1 cells. The detection limit of the mouse 
IL-6 ELISA was 3.9pg/ml. ELISA, enzyme linked immunosorbant assay; IL-6, 
interleukin 6; LPS, lipopolysaccharide. 
Time (h) 
IL-6 release (pg/ml) 
Unstimulated LPS (10Ong/m1) 
0.5 undetectable undetectable 
2 undetectable undetectable 
4 undetectable undetectable 
7 undetectable undetectable 
16 undetectable undetectable 
24 undetectable undetectable 
Known 
standard 
(100pg/m1) 
64.7± 2.9 - 
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Table 3.3 	Time-dependent effect of LPS (10Ong/ml, 30 minutes - 24 hours) 
stimulation on IL-6 release from AtT20 D16:16 cells. The detection limit of the 
mouse IL-6 ELISA was 3.9pg/ml. ELISA, enzyme linked immunosorbant assay; IL-6, 
interleukin 6; LPS, lipopolysaccharide. 
Time (h) 
IL-6 release (pg/mI) 
Unstimulated LPS (10Ong/m1) 
0.5 undetectable undetectable 
2 undetectable undetectable 
4 undetectable undetectable 
7 undetectable undetectable 
16 undetectable undetectable 
24 undetectable undetectable 
Known 
standard 
(100pg/m1) 
85.41± 1.9 - 
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3.3 Effects of LPS stimulation upon NFKB activity in TtT/GF and RAW 
264.7 cells 
The nuclear translocation of the functionally active p65 subunit of NFKB was 
examined by western blot analysis in the TtT/GF and RAW 264.7 cells, following LPS 
challenge (10Ong/ml, 0-24 hours). The expression of the cytosolic inhibitory protein 
IKBa was also examined, as NFKB activation is associated with hcBa degradation. In 
parallel, the functional activation of NFKB (p65/p50) was investigated, by assessing 
the DNA binding activity of the transcription factor to its consensus DNA sequence by 
EMSA. 
3.3.1 Nuclear translocation of p65 and IKBa protein degradation in LPS 
stimulated TtT/GF cells 
The p65 subunit of NFKB was readily detected in cytoplasmic extracts of TtT/GF cells 
(figure 3.3). The intensity of the band corresponding to p65 was reduced by exposure 
of the cells to LPS (10Ong/m1) for 30 minutes and 2 hours. Within 4 hours, 
cytoplasmic p65 protein expression had increased to above control levels (figure 
3.3A). The decrease in cytoplasmic p65 protein was paralleled by an increase in p65 
protein expression in the nuclear extracts compared to unstimulated cells, where p65 
expression was barely detectable in the nucleus (figure 3.3B). A further decrease in 
cytoplasmic p65 was evident in the cells after 16 hours stimulation with LPS, but with 
levels higher than control at 24 hours (figure 3.3A). However, the nuclear levels of 
p65 expression remained unchanged at 16 and 24 hours (figure 3.3B). 
IKBa protein expression was readily detected by western blot analysis in cytosolic 
fractions of TtT/GF cells. The degradation of cytosolic IKBa was evident after 30 
minutes exposure to LPS and thereafter returned to control levels (figure 3.4). The 
time frame of IKBa degradation correlated with the increased levels of nuclear p65 
expression (figure 3.3B). 
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Figure 3.3 	Time-dependent effects of LPS (10Ong/ml, 0-24 hours) on p65 
protein expression in (A) cytosolic (20gg) and (B) nuclear extracts (20µg) of 
ItT/GF cells, detected by western blot analysis. The data are representative of 
three separate experiments and the histogram represents the mean optical density of 
the bands, expressed as a percentage of control (0 hours). The points on the 
histogram represent the range values. LPS, lipopolysaccharide; OD, optical density. 
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Figure 3.4 	Time-dependent effects of LPS (10Ong/ml, 0-24 hours) on IKBa 
protein expression in cytosolic (20µg) extracts of TtT/GF cells, detected by 
western blot analysis. The data are representative of three separate experiments 
and the histogram represents the mean optical density of the bands, expressed as a 
percentage of control (0 hours). The points on the histogram represent the range 
values. IKBa, inhibitor of kappa B alpha; LPS, iipopolysaccharide; OD, optical 
density. 
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3.3.2 Detection of NFKB DNA binding activity in LPS stimulated TtT/GF cells 
by EMSA 
To verify the activation of NFKB by LPS (10Ong/m1; 0-24 hours) stimulation, the DNA 
binding activity of NFKB was assessed in nuclear extracts of TtT/GF cells by EMSA 
(section 4.4.12). Two bands were detected, the higher band (1, figure 3.5A) 
representing the larger p65/p50 heterodimer and the lower band representing the 
p50/p50 homodimer (2, figure 3.5A; see section 2.5.6 in methods). The DNA-binding 
activity of the p65/p50 heterodimer, detected by EMSA (figure 3.5B), corresponded 
with the profile of nuclear p65 protein expression detected by western blot analysis 
(figure 3.3). NFKB (p65/p50) DNA binding was increased following 30 minutes and 2 
hours LPS stimulation in the TtT/GF cell line, further confirming our findings that 
NFKB activation in the TtT/GF cell line is a rapid response (figure 3.5). 
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Figure 3.5 	Time-dependent effects of LPS (10Ong/ml, 0-24 hours) on 
NFKB DNA binding activity in nuclear extracts (1014) of TtT/GF cells, detected 
by (A) electrophoretic mobility shift assay (EMSA). To confirm NFKB binding, a 
competitive binding reaction was performed with 100 fold molar excess of unlabelled 
NFKB consensus oligonucleotides (lane s). Upper band (1) represents p65/p50 
heterodimer and lower band (2) represents p50/p50 homodimer. Bands labelled as 
(3) represent non-specific binding. (B) The data are representative of two separate 
experiments and the histogram represents the mean optical density of the p65/p50 
bands, expressed as a percentage of control (0 hours). The points on the histogram 
represent the range values. LPS, lipopolysaccharide; NFKB, nuclear factor kappa B; 
OD, optical density; s, competitive NFKB specific binding. 
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3.3.3 Effects of LPS stimulation on the p65 nuclear translocation and licBa 
protein degradation in LPS stimulated RAW 264.7 cells 
In contrast to the profile of NFKB (p65/p50) activity seen in the TIT/GF cells, the RAW 
264.7 cells exhibited a prolonged activation of NFKB in response to LPS stimulation. 
A decrease in cytoplasmic p65 protein expression was evident with 30 minutes of 
LPS stimulation compared to control levels (figure 3.6A). The levels declined 
progressively with time, such that the protein was barely detectable at 24 hours 
(figure 3.6A). The decrease in cytoplasmic p65 was associated with an increase in 
nuclear p65 protein expression, which persisted for 7 hours, with p65 expression 
returning to levels comparable to those of the unstimulated control at 16 hours and 
24 hours (figure 3.6B). The LPS-induced increase in nuclear p65 protein in the RAW 
264.7 cells was accompanied by a decrease in cytoplasmic 11(13a protein, which 
persisted for 24 hours (figure 3.7). 
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Figure 3.6 	Time-dependent effects of LPS (10Ong/ml, 0-24 hours) stimulation 
on protein expression of p65 in (A) cytosolic (2011g) and (B) nuclear (20iig) 
extracts of RAW 264.7 cells, detected by western blot analysis. The data are 
representative of two separate experiments and the histogram represents the mean 
optical density of the bands, expressed as a percentage of control (0 hours). The 
points on the histogram represent the range values. LPS, lipopolysaccharide; OD, 
optical density. 
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Figure 3.7 	Time-dependent effects of LPS (10Ong/ml, 0-24 hours) stimulation 
on protein expression of licBic in cytosolic (20µg) extracts of RAW 264.7 cells, 
detected by western blot analysis. The data are representative of two separate 
experiments and the histogram represents the mean optical density of the bands, 
expressed as a percentage of control (0 hours). The points on the histogram 
represent the range values. I K Ba, inhibitor of kappa B alpha; LPS, 
lipopolysaccharide; OD, optical density. 
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3.3.4 Detection of NFKB DNA binding activity in LPS stimulated RAW 264.7 
cells by EMSA 
The time-dependent changes in the DNA binding activity of the p65/p50 heterodimer 
detected by EMSA (1, figure 3.6A) in the LPS (10Ong/m1; 0-24 hours) stimulated 
RAW 264.7 cells correlated with the profile of nuclear p65 protein expression 
detected by western blot analysis (figure 3.6B), with increased NFKB (p65/p50) 
activity observed at all the time points examined over the 7 hour stimulation period 
(figure 3.8B). This activity was reduced at 24 hours, but still higher than the control 
(figure 3.8B). 
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Figure 3.8 	Time-dependent effects of LPS (10Ong/ml, 0-24 hours) on 
NFiB DNA binding activity in nuclear extracts (10pg) of RAW 264.7 cells, 
detected by (A) electrophoretic mobility shift assay (EMSA). To confirm NFKB 
binding, a competitive binding reaction was performed with 100 fold molar excess of 
unlabelled NFKB consensus oligonucleotides (lane s). Upper band (1) represents 
p65/p50 heterodimer and lower band (2) represents p50/p50 homodimer. Bands 
labelled as (3) represent non-specific binding. (B) The data are representative of two 
separate experiments and the histogram represents the mean optical density of the 
p65/p50 bands, expressed as a percentage of control (0 hours). The points on the 
histogram represent the range values. LPS, lipopolysaccharide; NFKB, nuclear factor 
kappa B; OD, optical density; s, competitive NFKB specific binding. 
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3.4 Effects of NFKB inhibition upon LPS stimulated IL-6 release from 
TtT/GF cells 
Whilst the IL-6 promoter is known to be regulated by multiple transcription factors 
(see section 1.5.2.3), the relative importance of each of these varies, depending on 
the cell type (Akira et al. 1990; Matsusaka et al. 1993; Galien et al. 1996; Deshpande 
et al. 1997; Ray et a/. 1997). To examine whether IL-6 transcription is regulated by 
NFKB in the TtT/GF cell line, the effect of inhibition of NFKB activity upon the release 
of LPS-stimulated IL-6 was investigated, using the specific IKKf3 inhibitor SC-514 and 
the proteosome inhibitor Mg132. To examine whether IL-6 release and NFKB 
activation in the TtT/GF cells are sensitive to glucocorticoid action, the synthetic 
glucocorticoid dexamethasone was included in the medium. 
Our previous studies have shown LPS induces a time-dependent increase in IL-6 
from TtT/GF cells (figure 3.2A), with optimal concentrations measured after 16 hours 
incubation. Therefore, we used this time point to investigate the effects of including 
SC-514 (50-30011M), Mg132 (1-100µM) or dexamethasone (1-100nM) in the medium 
of TtT/GF cells on the release of IL-6 induced by LPS (10Ong/ml, 16 hours). As an 
increase in NFKB (p65/p50) activity was detected after 30 minutes LPS challenge in 
the TtT/GF cells, (figure 3.3 and 3.5), the effect of these compounds on LPS 
stimulated NFKB (p65/p50) activity was investigated at this time point. 
3.4.1 Effect of SC-514 treatment on NFKB activity and IL-6 release from LPS 
stimulated TtT/GF cells 
Incubation of the TtT/GF cells with either SC-514 (25-100µM, 30 minutes) or the 
vehicle solution (0.2% DMSO, 30 minutes) did not alter basal NFKB (p65/p50) DNA-
binding activity compared to unstimulated control samples (1, figure 3.9A and B). 
NFKB (p65/p50) activation induced by LPS stimulation was not affected by the 
presence of DMSO, thus any effects seen with SC-514 were due to the compound 
and not the DMSO vehicle (figure 3.9A and B). As shown by densitometric analysis, 
LPS stimulated NFKB (p65/p50) activation was attenuated by SC-514 treatment in a 
concentration-dependent manner (figure 3.9B). 
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Figure 3.9 	Effect of the IKK13 inhibitor, SC-514 (25-100µM, 90 minutes), on 
LPS (10Ong/ml, 30 minutes) stimulated NFic13 activity in nuclear extracts (10pg) 
of TtT/GF cells, detected by (A) electrophoretic mobility shift assay (EMSA). 
Bands labelled (1) represent p65/p50 heterodimer, (2) p50/p50 homodimer and (3) 
non-specific binding. Cells were treated with SC-514 for 1 hour prior to LPS 
stimulation and the drug was kept in the medium throughout the 30 minute incubation 
period with LPS. (B) The data are representative of three separate experiments and 
the histogram represents the mean optical density of the p65/p50 bands, expressed 
as a percentage of control (untreated control). The points on the histogram represent 
the range values. Competitive reactions were included with 100 fold molar excess of 
the NFKB oligonucleotide (s, specific) and AP-1 oligonucleotide (AP-1; ns, non-
specific). DMSO, dimethylsulfoxide; LPS, lipopolysaccharide; NFKB, nuclear factor 
kappa B; OD, optical density. 
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The vehicle solution, (0.2% DMSO, 16 hours) did not affect basal (p=1.00) or LPS 
(10Ong/ml, 16 hours) stimulated (p=0.512) IL-6 release from the TtT/GF cells (figure 
3.10). Treatment with SC-514 (50-300[M, 16 hours) alone did not affect IL-6 release 
(p=1.00; figure 3.10), but incubation of the cells with 50 and 100µM SC-514 resulted 
in an attenuation of LPS-stimulated IL-6 release (p<0.01 vs LPS; figure 3.10). In 
contrast, the higher concentration of SC-514 (300µM) was without effect (p=0.229; 
figure 3.10). 
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Figure 3.10 Effect of the IKK13 inhibitor, SC-514 (50-300µM, 17 hours), on LPS 
(10Ong/ml, 16 hours) stimulated IL-6 release from TtT/GF cells. The cells were 
incubated with SC-514 or vehicle (0.2% DMSO) for 1 hour prior to the addition of 
LPS and the drug was kept in the medium throughout the 16 hour incubation period 
with LPS. Control and treated groups are the mean of six samples ± SEM. The data 
are representative of three separate experiments. "p<0.01 vs unstimulated control 
(Con), "p<0.01 vs LPS alone. Analysis was performed by two-way ANOVA with post 
hoc comparison using Bonferroni's t-test. IL-6, interleukin 6; LPS, lipopolysaccharide. 
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3.4.2 Effects of the proteosome inhibitor Mg132 on LPS stimulated NFKB 
activity and IL-6 release from TtT/GF cells 
The effects of the proteosome inhibitor Mg132 (1-50µM, 90 minutes) on LPS 
(10Ong/ml, 30 minutes) induced NFKB activity in the TtT/GF cells were examined by 
EMSA (figure 3.11A and B). Several bands representing NFKB DNA-binding 
complexes were detected by EMSA (figure 3.11A). The lower two bands (labelled as 
3 and 4) are likely to represent non-specific binding as they were still highly 
expressed in the competitive reaction (lanes s; figure 3.11A) compared to the non-
competitive reaction (lane ns; figure 3.11A). The higher two bands, labelled (1) and 
(2) represent the different dimer compositions of NFKB, with the higher of the two 
being the p65/50 heterodimer (1) and the lower being p50/p50 (2) (figure 3.11A; see 
section in 2.5.6). 
Basal levels of NFKB (p65/p50) activity were increased in the TtT/GF cells following 
90 minutes incubation with a low (1µM) concentration of Mg132 but higher 
concentrations (10 and 50µM) were without effect (figure 3.11B). The vehicle 
(ethanol, 2mM) did not affect resting levels of NFKB (p65/p50) but it caused a small 
increase in LPS induced NFKB activity (figure 3.11B). Mg132 (1 and 10µM) 
decreased LPS-stimulated NFKB activation, but this effect was more pronounced 
when the concentration was raised to 50µM (figure 3.11B). 
125 
A 	 s ns 
LPS (10Ong/m1) 
EtOH (2mM) 	 + 	+ + + + + 	+ + 
Mg132 (µM) 1 	10 50 	1 10 	50 	- 
%
 c
on
tr
o
l (
O
D
)  
300 
250 
200 
150 - 
100 
50 - 
0 	 
 
O 
  
  
O 
    
LPS (10Ong/m1) 
EtOH (2mM) 	 + 	+ + + 	+ + + + 
Mg132 (p.M) 1 10 50 1 	10 50 
Figure 3.11 Effect of the proteosome inhibitor, Mg132 (1-50µM, 90 minutes), 
on LPS (10Ong/ml, 30 minutes) stimulated NFiB activation in TtT/GF cells, 
detected by (A) electrophoretic mobility shift assay (EMSA). The cells were 
incubated with Mg132 for 1 hour prior to the addition of LPS and the drug remained 
in the medium in the presence of LPS. Bands labelled (1) represent the p65/p50 
heterodimer; (2), p50/p50 homodimer and (3) and (4) represent non-specific binding. 
(B) The data are representative of two separate experiments and the histogram 
represents the mean optical density of the p65/p50 bands, expressed as a 
percentage of control (untreated control). The points on the histogram represent the 
range values. Competitive reactions were included with 100 fold molar excess of the 
NFKB oligonucleotide (s, specific) and AP-1 oligonucleotide (AP-1; ns, non-specific). 
EtOH, ethanol; LPS, lipopolysaccharide; NFKB, nuclear factor kappa B; OD, optical 
density. 
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Treatment with Mg132 (25µM, p=0.183) did not affect basal IL-6 release and the 
vehicle (2mM EtOH, p=1.00) did not influence the stimulatory effect of LPS (figure 
3.12). However, treatment with 50µM Mg132 alone potentiated basal IL-6 release 
(p<0.05 vs control). Mg132 treatment (25µM) significantly reduced LPS-stimulated IL-
6 release (p<0.001 vs LPS), with a 2-fold higher concentration being less potent 
(50µM; p<0.01 vs 25µM Mg132 + LPS; figure 3.12). 
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Figure 3.12 Effect of proteosome inhibitor, Mg132 (25 and 50µM), on LPS 
(10Ong/ml, 16 hours) stimulated IL-6 release from TtT/GF cells. The cells were 
incubated with Mg132 or vehicle (2mM ethanol) for 1 hour prior to the addition of 
LPS. Control and treated groups are the mean of six samples ± SEM. The data are 
representative of three separate experiments. +++p<0.001 vs unstimulated control 
(Con), **p<0.01, ***p<0.001 vs LPS alone. Analysis was performed by two-way 
ANOVA with post hoc comparison using Bonferroni's t-test. EtOH, ethanol; IL-6, 
interleukin 6; LPS, lipopolysaccharide. 
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3.4.3 Effects of dexamethasone upon LPS stimulated NFKB activity and IL-6 
release from TtT/GF cells 
The treatment of the TtT/GF cells with dexamethasone alone (1-100nM) did not alter 
the basal level of NFKB (p65/p50) activity (labelled at 1; figure 3.13A), but it reduced 
the stimulatory effect of LPS (10Ong/ml, 30 minutes) in a concentration-dependent 
manner (figure 3.13A and B). The inhibitory effects of glucocorticoids upon NFKB 
activity have been shown to occur, at least in part, through the upregulation of 
IKBa (Auphan et al. 1995, Scheinman, 1995 #112). To investigate whether 
dexamethasone increased the expression of IKBa in the TtT/GF cells, the protein 
levels of cytosolic IKBa were detected by western blot analysis in samples that had 
been treated with dexamethasone (10nM, 30 minutes) in the presence and absence 
of LPS (10Ongml, 30 minutes; figure 3.14A). LPS stimulation decreased the protein 
expression of IKBa compared to control levels (figure 3.14A and B). In contrast, 
dexamethasone treatment alone and with LPS increased IKBa protein expression 
compared to the control and LPS stimulated samples (figure 3.14A and B). 
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Figure 3.13 Effect of the synthetic glucocorticoid, dexamethasone (1-100nM, 
30 minutes), in the presence and absence of LPS (10Ong/ml, 30 minutes), on 
NFic13 activity in nuclear (10pg) TtT/GF cells, detected by (A) electrophoretic 
mobility shift assay (EMSA). (1) p65/p50 heterodimer; (2) p50/p50 homodimer and 
(3) non-specific binding. (B) The data are representative of two separate experiments 
and the histogram represents the mean optical density of the p65/p50 bands, 
expressed as a percentage of control (untreated control). The points on the 
histogram represent the range values. Competitive reactions were included with 100 
fold molar excess of the NFKB oligonucleotide (s, specific) and AP-1 oligonucleotide 
(AP-1; ns, non-specific). LPS, lipopolysaccharide; NFKB, nuclear factor kappa B; OD, 
optical density. 
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Figure 3.14 Effect of the synthetic glucocorticoid, dexamethasone (10nM, 30 
minutes), on cytosolic hcBa (20p.g) protein expression in LPS (10Ong/ml, 30 
minutes) stimulated TtT/GF cells. IKBa protein expression was detected by (A) 
western blot analysis and (B) densitometric analysis of IKBa protein expression 
(expressed as percentage of control). The data are representative of two separate 
experiments and the histogram represents the mean optical density of the bands, 
expressed as a percentage of control (untreated). The points on the histogram 
represent the range values. Con; unstimulated control, DEX, dexamethasone, IKBa; 
inhibitor of kappa B alpha; LPS; lipopolysaccharide, OD; optical density. 
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IL-6 was undetectable in the medium of both unstimulated and dexamethasone 
treated (1-100nM, 16 hours) cells (figure 3.15). Inclusion of LPS (10Ong/m1) for 16 
hours induced a robust increase in IL-6 release (p<0.001 vs control; figure 3.15). 
Dexamethasone attenuated the stimulatory effect of LPS in a concentration 
dependent manner (10 and 100nM; p<0.001 vs LPS), with the lowest concentration 
used having no effect (1nM; p=0.058; figure 3.15). 
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Figure 3.15 Effect of the synthetic glucocorticoid, dexamethasone (1-100nM, 
16 hours), on LPS (10Ong/ml, 16 hours) stimulated IL-6 release from TtT/GF 
cells. The concentrations of IL-6 in the medium of the unstimulated control and 
dexamethasone (1, 10 and 10nM) alone treated cells were undetectable (the 
detection limit of the IL-6 ELISA was 3.9pg/ml). Control and treated groups are the 
mean of six samples ± SEM. The data are representative of three separate 
experiments. +++p<0.001 vs unstimulated control (Con), ***p<0.001 vs LPS-stimulated 
group. Analysis was performed by two-way ANOVA with post hoc comparison using 
Bonferroni's t-test. Con, control; IL-6, interleukin 6; LPS, lipopolysaccharide; ND, not 
detected. 
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3.4.4 Modulation of IL-6 release from LPS stimulated TtT/GF cells by CRH 
Hypothalamic CRH is a potent stimulator of ACTH release from corticotrophs. 
However, the influence of CRH upon IL-6 release from folliculostellate cells has not 
been previously examined to our knowledge. Therefore, the effects of CRH (1 and 
10nM; 16 hours) stimulation on the release of IL-6 from the TtT/GF cells, in the 
presence and absence of LPS (10Ong/ml, 16 hours), were examined (section 
2.3.1.2). 
The release of IL-6 from the TtT/GF cells was significantly increased in the presence 
of LPS, compared to unstimulated controls (p<0.001 vs control; figure 3.16). 
Treatment with the vehicle solution (10}tM ascorbic acid) did not affect basal levels of 
IL-6 (p=1.00) or interfere with the stimulatory effect of LPS on IL-6 release (p=1.00; 
figure 3.16). Incubation of the cells with CRH (1 and 10nM) did not affect basal or 
LPS stimulated IL-6 release 1nM, p=1.00; 10nM, p=0.195; figure 3.16). 
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Figure 3.16 Effect of CRH upon LPS stimulated IL-6 release from TtT/GF 
cells. The release of IL-6 was measured from cells stimulated with CRH (1 and 
10nM) and/or LPS (10Ong/m1) for 16 hours. Control (vehicle only - 1011M AA) and 
treated groups are the mean of six samples ± SEM. The data are representative of 
three separate experiments. "p<0.01 vs vehicle (AA). Analysis was performed by 
two-way ANOVA with post hoc comparison using Bonferroni's t-test. AA, ascorbic 
acid; CRH, corticotrophin releasing hormone; IL-6, interleukin 6; LPS, 
lipopolysaccharide. 
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3.5 LPS signalling in AtT20 D16:16 cells 
The effects of LPS stimulation upon corticotroph-derived ACTH release were 
compared to those induced by CRH, a potent stimulator of ACTH secretion. For 
these studies, the AtT20 D16:16 cell line was used as the model of corticotrophs as 
previous studies have shown that this AtT20 subclone responds more readily to CRH 
stimulation compared to the AtT20 D1 subclone (Woods et al. 1992). Additionally, the 
AT20 D16:16 cells are ideal for co-culture studies (section 3.6) due to their adherent 
nature, rather than the AtT20 D1 suspension cell line. In parallel the DNA-binding 
activity of NFKB in these cells, following either LPS or CRH stimulation, was 
examined by EMSA (section 2.5.4.4) and p65 TransAMTm assay (section 2.5.6). 
Further work entailed examining the interactions between CRH and LPS upon both 
ACTH release and NFiB activity and the consequence of inhibiting NFKB (using SC-
514) upon these parameters. 
3.5.1 Effects of CRH on ACTH release from AtT20 D16:16 cells 
The AtT20 D16:16 cells released ACTH spontaneously and a time-dependent 
accumulation of ACTH into the medium was observed over 24 hours, with significant 
increases measured 16 hours after the addition of new medium (p<0.01 vs 7 hours; 
figure 3.17). Stimulation with 10nM CRH resulted in a marked increase in ACTH 
release after 7 hours exposure compared to basal levels (p<0.01 vs 7 hours control), 
whilst 1nM CRH did not affect the basal accumulation of ACTH into the medium 
(p=1.00 vs respective control time point; figure 3.17). 
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Figure 3.17 Time-dependent effect of CRH (1-10nM, 30 minutes - 24 hours) 
upon ACTH release from AtT20 D16:16 cells. Control (vehicle - 10p,M ascorbic 
acid) stimulated groups are the mean of six samples ± SEM. All samples contained 
vehicle. The data are representative of three separate experiments. ++p<0.01, 
+++p<0.001 vs respective time point of unstimulated control, **p<0.01, ***p<0.001 vs 
respective time point of 1nM CRH, Itp<0.01 vs preceding time point. Analysis was 
performed by two-way ANOVA with post hoc comparison using Bonferroni's t-test. 
ACTH, adrenocorticotrophin; CRH, corticotrophin releasing hormone; LPS, 
lipopolysaccharide. 
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3.5.2 Effects of CRH on NFIcB activity in AtT20 D16:16 cells 
NFKB (p65/p50) activity in the AtT20 D16:16 cells following CRH (10nM) stimulation 
was increased after 30 minutes challenge (figure 3.18A and B) and the activity was 
reduced after 2 hours to levels comparable to control (2 hour unstimulated control; 
figure 3.18A and B). A later increase in activity was observed from 4 hours up to 16 
hours post-stimulation (figure 3.18A and B). 
Because the constitutive activity of NFKB in the AtT20 D16:16 cells were high, in 
comparison to the TtT/GF cells (figure 3.5), changes in activity in the AtT20 D16:16 
cells after stimulation with CRH were difficult to detect by EMSA (figure 3.18A). NFKB 
activity was thus also measured using the more sensitive p65 TransAMTM assay (see 
section 2.5.6). In concurrence with the EMSA results, an increase in NFKB (p65) 
activity was detected 30 minutes after the onset of stimulation with CRH and activity 
was reduced at 2 hours (10nM; figure 3.19). However, although an increase in 
activity was still observed at 4 hours by EMSA (figure 3.18A), data from the p65 
TransAMTM assay showed a reduction in NFKB activity at 4 hours CRH challenge, 
and was comparable to control at 7 hours (figure 3.19). The differences in the 
findings from the two assays highlight the difficulties in detecting small changes in 
NFKB activity when using less sensitive assays such as the EMSA. Therefore, further 
studies of NFKB activity in the AtT20 D16:16 cells by EMSA were verified by the p65 
TransAMTM assay. 
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Figure 3.18 Effect of CRH (10nM, 30 minutes - 16 hours) on NFicB activity in 
nuclear extracts (10pg) of AtT20 D16:16 cells, detected by (A) electrophoretic 
mobility shift assay (EMSA). (B) Densitometric analysis of the bands representing 
the p65/p50 heterodimer (expressed as percentage of control). (1) p65/p50 
heterodimer; (2) p50/p50 homodimer and (3) non specific binding. (B) The data are 
representative of two separate experiments and the histogram represents the mean 
optical density of the p65/p50 bands, expressed as a percentage of control (0 hours). 
The points on the histogram represent the range values. Competitive reactions were 
included with 100 fold molar excess of the NFKB oligonucleotide (s, specific) and AP-
1 oligonucleotide (AP-1; ns, non-specific). CRH, corticotrophin-releasing hormone; 
NFKB, nuclear factor kappa B; OD, optical density. 
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Figure 3.19 Effect of CRH (10nM, 0-24 hours) stimulation upon NFKB (p65) 
activity in nuclear extracts (2.5µg) of AtT20 D16:16 cells, detected by p65 
TransAMTm assay. The experiment was repeated twice and the data presented is 
the mean optical density for each treatment group [expressed as percentage of 
control (0 hour)]. The points on the histogram represent the range values. ns, non-
specific competitor; s, specific competitor; Jurk, jurkat nuclear extract (positive 
control); NFKB, nuclear factor kappa B; CRH, corticotrophin releasing hormone; OD, 
optical density. 
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3.5.3 Effect of LPS stimulation on ACTH release from AtT20 D16:16 cells 
LPS (10Ong/m1; 30 minutes - 24 hours) did not affect the spontaneous release of 
ACTH from AtT20 D16:16 cells (figure 3.20). 
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Figure 3.20 Effect of LPS (10Ong/ml, 30 minutes — 24 hours) on ACTH release 
from AtT20 D16:16 cells. Control (unstimulated) and stimulated groups are the 
mean of six samples ± SEM. The data are representative of three separate 
experiments. 'p<0.01, 'p<0.001 vs control (0 hour); **p<0.01, ***p<0.001 vs 
preceding time point. Analysis for comparison of time points within each group was 
performed by one-way ANOVA with post hoc comparison using Bonferroni's t-test. 
Analysis for the comparison of LPS vs unstimulated control at each time point was 
performed by two-way ANOVA with post hoc comparison using Bonferroni's t-test 
ACTH, adrenocorticotrophin; LPS, lipopolysaccharide. 
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3.5.4 Effect of LPS stimulation on NFKB activity in AtT20 D16:16 cells 
The constitutive and LPS stimulated activity of NFKB was initially detected by EMSA 
in AtT20 D16:16 cells (30 minutes to 16 hours; figure 3.21A). LPS (10Ong/m1) 
increased basal NFKB (p65/p50) activity 30 minutes after contact, with activity 
decreasing after 2 hours exposure (figure 3.21B). A later increase in NFKB activity 
was evident 4 hours following LPS stimulation, with activity progressively decreasing 
thereafter and returning to basal levels at 16 hours (figure 3.21B). 
140 
4—(1) 
4— (2) 
B 
A 
    
+ LPS 
4 	7 	16 I h 
 
ns s 0.5 2 4 7 16 0.5 2 
200 - 
150 - 
O 	 O 
0 0 
50 - 
0 
0 	0.5 	2 	4 	7 	16 
Time (h) 
Figure 3.21 Time-dependent effect of LPS (10Ong/ml, 30 minutes - 16 hours) 
stimulation upon NFKB activity in nuclear protein extracts (10µg) of AtT20 
D16:16 cells, detected by (A) electrophoretic mobility shift assay. (1), p65/p50 
heterodimer and (2), p50/p50 homodimer. (B) The data are representative of two 
separate experiments and the histogram represents the mean optical density of the 
p65/p50 bands, expressed as a percentage of control (0 hours). The points on the 
histogram represent the range values. Competitive reactions were included with 100 
fold molar excess of the NFKB oligonucleotide (s, specific) and AP-1 oligonucleotide 
(AP-1; ns, non-specific). LPS, lipopolysaccharide; NFKB, nuclear factor kappa B; OD, 
optical density. 
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To verify the EMSA findings, NFKB activity was also measured by the p65 
TransAMTM assay. In contrast to the EMSA results (figure 3.21A and B), whereby 
increased NFKB activity was detected following 30 minutes stimulation with LPS 
(10Ong/m1), increased NFKB activity in the AtT20 D16:16 cells was not detected by 
the TransAMTM assay until 1 hour contact with LPS, with peak activity detected at 7 
hours (figure 3.22). The discrepancies in the time frame of NFKB activation, detected 
by the two assays, is likely to be attributed to the high constitutive activity of AtT20 
D16:16 NFKB, thus making it difficult to discriminate between changes in NFKB 
activity by non-quantitative methods such as the EMSA. 
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Figure 3.22 Time-dependent effect of LPS (10Ong/ml, 15 minutes - 16 hours) 
stimulation upon NFKB activity in nuclear extracts (2.5m) of AtT20 D16:16 
cells, detected by p65 TransAMTM assay. The experiment was repeated twice and 
the data presented is the mean optical density for each treatment group [expressed 
as percentage of control (0 hour)]. The points on the histogram represent the range 
values. Jurk; Jurkat nuclear extract; LPS, lipopolysaccharide; NFic13, nuclear factor 
kappa B; ns, non-specific competitor; OD, optical density; s, specific competitor. 
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3.5.5 Effects of murine recombinant IL-6 upon basal and CRH stimulated 
ACTH release from AtT20 D16:16 cells 
One of the mechanisms through which LPS increases ACTH release is through the 
induction of IL-6 (Bethin et al. 2000; Gloddek et al. 2001). As folliculostellate cells 
reside near corticotrophs and provide a source of IL-6, it was investigated whether 
murine recombinant IL-6 (rIL-6, 1nM, 7 hours) at concentrations comparable to those 
produced by TtT/GF cells following 7 hours stimulation with LPS (10Ong/m1) would 
influence ACTH release from AtT20 D16:16 cells, in the presence and absence of 
graded concentrations of CRH (1-100nM). 
CRH (10 and 100nM, 7 hours) stimulation induced significant increases in ACTH 
release (p<0.001 vs control) from the AtT20 D16:16 cells, but a lower concentration 
of CRH (1nM) was without effect (p=1.00; figure 3.23). Whilst IL-6 alone (1nM, 7 
hours) did not affect ACTH release (p=0.173), when combined with the lower 
concentration of CRH (1nM) it increased basal ACTH release (p<0.01 vs control). In 
contrast, rIL-6 (1nM) did not affect the increase in ACTH release induced by higher 
concentrations (10 and 100nM) of CRH (10nM, p=0.584 and 100nM, p=0.918; figure 
3.23). 
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Figure 3.23 Effects of rIL-6 (1nM, 7 hours) and/or CRH (1-100nM, 7 hours) 
upon ACTH release from AtT20 D16:16 cells. Control (vehicle - 100 ascorbic 
acid) and treated groups are the mean of six samples ± SEM. All samples contained 
vehicle. The data are representative of three separate experiments. 'p<0.01, 
+++p<0.001 vs vehicle, ***p<0.001 vs rIL-6 alone, ttt- p<0.001 vs 1nM CRH alone. 
Analysis was performed by two-way ANOVA with post hoc comparison using 
Bonferroni's t-test. ACTH, adrenocorticotrophin; CRH, corticotrophin releasing 
hormone; rIL-6, recombinant IL-6. 
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3.5.6 Effect of LPS upon CRH stimulated ACTH release from AtT20 D16:16 
cells 
The release of ACTH induced by CRH stimulation was examined in the presence of 
LPS. Whilst LPS (10Ong/ml, 7 hours) challenge alone did not affect the basal ACTH 
release from the AtT20 D16:16 cells (p=0.827), it attenuated the stimulatory effect of 
low CRH (1nM, p<0.01 vs 1nM alone and 10nM, p<0.001 vs 10nM alone) but not 
high (100nM, p=0.169) concentrations of CRH (figure 3.24). 
Figure 3.24 Effects of CRH (1-100nM, 7 hours) and/or LPS (10Ong/ml, 7 hours) 
stimulation on ACTH secretion from AtT20 D16:16 cells. Control (vehicle only —
10µM ascorbic acid) and treated groups are the mean of six samples ± SEM. The 
data are representative of four separate experiments. +++p<0.001 vs vehicle, 
**p<0.01, ***p<0.001 vs 1nM CRH, ttt- p<0.001 vs 10nM CRH. Analysis was 
performed by two-way ANOVA with post hoc comparison using Bonferroni's West. 
ACTH, adrenocorticotrophin; CRH, corticotrophin releasing hormone; LPS, 
lipopolysaccharide. 
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3.5.7 Effect of the IKKO inhibitor, SC-514, on CRH stimulated ACTH release 
from AtT20 D16:16 cells 
Whilst both CRH (10nM) and LPS (10Ong/m1) increased NFKB activity in the AtT20 
D16:16 cells (CRH; figure 3.18 and 3.19 and LPS; figure 3.21 and 3.22), LPS 
attenuated the stimulatory effect of CRH (10nM) upon ACTH secretion from these 
cells (figure 3.24). Therefore, the effect of the NFKB inhibitor, SC-514 (100µM) upon 
AtT20 D16:16-derived ACTH in the presence and absence of CRH (1-10nM) and/or 
LPS (10Ong/m1) was examined (figure 3.25-3.27). 
Primary analysis of the results (performed by 3-way ANOVA), indicated CRH and 
SC-154 induced significant main effects on ACTH release, but that LPS did not 
(figures 3.25-3.27). Significant interactions were also detected between 1) CRH and 
SC-514, 2) CRH and LPS and 3) CRH and SC-514 and LPS. Therefore, further 
analysis of the individual group differences were performed by a second-order one-
way ANOVA with post hoc comparison using Bonferroni's t-test. 
LPS (10Ong/ml, 7 hours) and SC-514 (100µM, 7 hours) alone or in combination had 
no effect on the basal release of ACTH (LPS, p=1.00 and SC-514, p=1.00; figures 
3.25-3.27). CRH (1nM, 7 hours) alone also failed to induce ACTH release (p=1.00, 
figure 3.25). However, when given in combination with SC-514, a significant increase 
(p<0.01 vs control) in peptide release was apparent (figure 3.25). Higher 
concentrations of CRH (10 and 100nM) induced significant increases in ACTH 
release (p<0.001 vs control), which were further increased by SC-514 (10nM, 
p<0.001 vs 10nM CRH alone; figure 3.26 and 100nM, p<0.01 vs 100nM CRH alone; 
figure 3.27). LPS attenuated the stimulatory effect of CRH (10nM, p<0.001 vs CRH 
alone; figure 3.26) upon ACTH secretion and this effect was reversed by SC-514 
(p<0.001 vs CRH + LPS; figure 3.26). 
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Figure 3.25 Effects of the 1KK8 inhibitor, SC-514 (100µM, 8 hours), upon 
ACTH release from AtT20 D16:16 cells in the presence and absence of CRH 
(1nM, 7 hours) and/or LPS (10Ong/ml, 7 hours). The cells were incubated with SC-
514 for 1 hour prior to the addition of CRH and/or LPS and the drug was included 
throughout the incubation period (7 hours). Control (vehicle only - 10µM AA) and 
treated groups are the mean of six samples ± SEM. The data are representative of 
three separate experiments. 'p<0.01, +++p<0.001 vs vehicle (AA). Analysis was 
performed by three-way ANOVA followed by a second order one-way ANOVA with 
post hoc comparison using Bonferroni's t-test. AA, ascorbic acid; ACTH, 
adrenocorticotrophin; CRH, corticotrophin releasing hormone. 
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Figure 3.26 Effects of the IKK13 inhibitor, SC-514 (100µM, 8 hours), upon 
ACTH release from AtT20 D16:16 cells in the presence and absence of CRH 
(10nM, 7 hours) and/or LPS (10Ong/ml, 7 hours). The cells were incubated with 
SC-514 for 1 hour prior to the addition of CRH and/or LPS and the drug was included 
throughout the incubation period (7 hours). Control (vehicle only - 1011M AA) and 
treated groups are the mean of six samples ± SEM. The data are representative of 
three separate experiments. 'p<0.001 vs vehicle (AA), ttt- p<0.001 vs CRH, 
***p<0.001 vs CRH + LPS. Analysis was performed by three-way ANOVA followed 
by a second order one-way ANOVA with post hoc comparison using Bonferroni's t-
test. AA, ascorbic acid; ACTH, adrenocorticotrophin; CRH, corticotrophin releasing 
hormone. 
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Figure 3.27 Effects of the IKKO inhibitor, SC-514 (100µM, 8 hours), upon 
ACTH release from AtT20 D16:16 cells in the presence and absence of CRH 
(100nM, 7 hours) and/or LPS (10Ong/ml, 7 hours). The cells were incubated with 
SC-514 for 1 hour prior to the addition of CRH and/or LPS and the drug was included 
in the medium throughout the incubation period (7 hours). Control (vehicle only -
10µM AA) and treated groups are the mean of six samples ± SEM. The data are 
representative of three separate experiments. 'p<0.001 vs vehicle (AA), ttp<0.01 
vs CRH, ***p<0.001 vs CRH + LPS. Analysis was performed by three-way ANOVA 
followed by a second order one-way ANOVA with post hoc comparison using 
Bonferroni's t-test. AA, ascorbic acid; ACTH, adrenocorticotrophin; CRH, 
corticotrophin releasing hormone. 
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3.5.8 Effects of the IKKf3 inhibitor, SC-514, on CRH and LPS stimulated NFiB 
activity in AtT20 D16:16 cells 
CRH (10nM; figures 3.18 and 3.19) and LPS (10Ong/m1; figures 3.21 and 3.22) were 
previously shown to increase NFKB activity in the AtT20 D16:16 cells after 1 and 7 
hours respectively. Therefore, the effects of 1 and 7 hours stimulation with LPS 
(10Ong/m1) and CRH (10nM), in the presence and absence of SC-514 (100µM) on 
NFKB activity in the AT20 D16:16 cells were examined by p65 TransAMTM assay. 
CRH (10nM, 1 hour) induced a robust increase in NFKB activation (figure 3.28A). 
Similar but less pronounced effects were induced by LPS (10Ong/ml, 1 hour; figure 
3.28A). The effects of CRH and LPS upon NFKB activity appeared to be additive 
(figure 3.28A). SC-514 (10011M, 1 hour) reduced both basal and CRH and/or LPS 
stimulated NFKB activity (figure 3.28A). 
A later increase in activation was evident with LPS (10Ong/ml, 7 hours), whilst the 
stimulatory effect of CRH (10nM) alone was markedly reduced compared to its effect 
after 1 hour stimulation (figure 3.28A). Inclusion of CRH did not affect LPS-induced 
NFKB activity (figure 3.28B). SC-514 (100µM, 7 hours) attenuated LPS and CRH 
induced NFKB activation, to levels comparable to control (figure 3.28B). 
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Figure 3.28 Effects of the IKK(3 inhibitor, SC-514 (100µM), upon CRH (10nM) 
and/or LPS (10Ong/m1) stimulated NFxB activity in nuclear extracts (2.5µg) of 
AtT20 D16:16 cells, detected by p65 TransAMTm assay. Cells were pre-treated for 
1 hour with SC-514 prior to stimulation with CRH and/or LPS for (A) 1 hour and (B) 7 
hours. The drug was included in the medium throughout the incubation periods (1 
and 7 hours). The experiment was performed once and the data are expressed as 
percentage of control (untreated). Con, control; CRH, corticotrophin releasing 
hormone; LPS, lipopolysaccharide; NFKB, nuclear factor kappa B. 
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3.6 Discussion 
3.6.1 Models and methods 
3.6.1.1 	Cell lines 
The current studies utilised the murine TtT/GF and human PDFS cell line as models 
of folliculostellate cells and the murine AtT20 (D1 and D16:16 subclones) cell line as 
a model of corticotrophs. In addition, as folliculostellate cells have been described as 
"glial-like" and show some characteristics similar to that of macrophages (Stokreef et 
al. 1986), initial studies examining LPS signalling in the murine macrophage-like 
RAW 264.7 cell line were also conducted. 
3.6.1.1.1 Folliculostellate cells 
Previous studies examining the function and properties of folliculostellate cells of the 
anterior pituitary have used purified preparations of folliculostellate cells established 
by density gradients (Van Der Schueren et al. 1982; Allaerts & Denef 1989; Hentges 
et al. 2000) or a primary culture system (Ferrara et al. 1986). Although these in vitro 
systems have contributed to the understanding of the function of folliculostellate cells, 
problems using such model systems include unpure preparations and limited viability 
of the cells (Prysor-Jones et aL 1989; Alexander et aL 1991; Alexander et al. 1995). 
The generation of the folliculostellate-like cell lines have omitted these limitations 
(Inoue et al. 1992; Danila et a/. 2000) and have allowed studies of folliculostellate cell 
function to expand considerably (Matsumoto et aL 1993; Traverso et aL 1999; Lohrer 
et aL 2000; Perez Castro et al. 2000; Chapman et aL 2002; Chapman et al. 2003; 
Nagashima et aL 2003; Tierney et aL 2003; Tierney et al. 2005). A well-characterised 
folliculostellate-like cell line is the TtT/GF cell line, which spontaneously developed 
from a murine thyrotrophic tumour (Inoue et al. 1992). This cell line exhibits many of 
the characteristics of primary folliculostellate cells, i.e. they possess many lysosomes 
and numerous intermediate filaments in the cytoplasm, they exhibit phagocytic 
activity and follicle formation and they express the glial and neuronal proteins, GFAP 
and S-100 (Cocchia & Miani 1980; Nakajima et al. 1980; Velasco et al. 1982), as well 
as releasing IL-6 (Inoue et al. 1992). 
More recently, a human derived folliculostellate cell line, designated PDFS, 
developed spontaneously from a clinically non-functioning pituitary macroadenoma, 
(Danila et al. 2000). These cells, which show an epithelial-like morphology with long 
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cytoplasmic processes and stain positively for S-100 protein expression, provide an 
ideal tool for studying folliculostellate cells of human origin (Danila et al. 2000; Solito 
et al. 2003). However, unlike the TtT/GF cell line, it is unclear whether PDFS cells 
release IL-6, particularly in response to endotoxin (LPS), a key feature of 
folliculostellate cells (Inoue et al. 1999; Gloddek et al. 2001; Inoue et at 2002). 
3.6.1.1.2 Corticotrophs 
Due to the low proportion of corticotrophs in the anterior pituitary gland and the 
difficulty in isolating these cells, the current study utilised the AtT20 cell line derived 
from a radiation-induced anterior pituitary tumour (Furth et al. 1953). This cell line 
currently has three known strains (D1, D16v and D16:16). The D1 subclone was first 
derived from the tumour and maintained as a suspension culture (Yasumura 1968), 
the D16v strain was derived from the D1 cells and grows as a monolayer (Yasumura 
1968; Tashjian 1979) and the D16:16 strain was subcloned from the D16v cells on 
the basis of high intracellular 13-endorphin content (Sabol 1980). The AtT20 D16:16 
cell line has maintained many characteristics of the normal corticotroph, such as 
CRH-responsiveness and glucocorticoid suppressibility (Woods et al. 1992) and the 
current study has detected mRNA expression of the LPS signalling receptor toll-like 
receptor 4 (TIr4), another characteristic recently identified in primary corticotrophs 
(Tichomirowa et al. 2005). Therefore, due to their similarity to normal corticotrophs, 
the AtT20 D16:16 cell line was employed as an in vitro model of corticotrophs for 
studying ACTH secretion. AtT20 cells have relatively high rates of basal ACTH 
secretion which is likely to be due to the frequent spontaneous membrane 
depolarisations and neuron-like action potentials observed in electrophysiological 
studies (Surprenant 1982; Adler et a/. 1983; Korn et al. 1991). In concurrence with 
this, the current study identified an accumulation of basal ACTH secretion from the 
AtT20 D16:16 cells. Therefore, to avoid high basal ACTH levels masking any 
alterations in the response of these cells to treatment, maximal incubation times of 7 
hours were used, before significantly elevated levels of basal ACTH were measured. 
3.6.1.1.3 Macrophages 
The RAW 264.7 cell line, a widely used model of macrophages, was established from 
the ascites of a tumour induced in a male mouse by the intraperitoneal injection of 
Abelson leukaemia virus (A-MuLV) (Raschke et al. 1978). Both the LPS signalling 
pathway and NFKB dependent IL-6 synthesis and release have been well 
characterised in these cells, (Le Page et al. 1996; Ishii et al. 2003; Kim et at 2006). 
153 
As such, the RAW 264.7 cells were included in the study as a positive control for 
examining LPS signalling. 
Although studies using transformed cell lines are not without their limitations, they are 
extremely versatile, easily available and do not require the amount of material or time 
required for preparing primary cell populations. Additionally, these cell lines omit the 
problem of heterogeneous populations of cells present in primary cultures, which can 
interfere with the function of the cells of interest, and result in misleading 
interpretations. 
3.6.1.2 	Experimental methods 
3.6.1.2.1 Detection of mRNA for the LPS signalling components by RT-PCR 
To examine whether the TtT/GF, PDFS and AtT20 subclones were appropriate cell 
lines for investigating LPS signalling, the expression of mRNA for the LPS signalling 
components CD14, TIr4 and MD-2 (and the gram positive recognition receptor TIr2) 
were initially examined by RT-PCR. However, the positive expression of such 
components is not necessarily an indication that these cells express the functional 
proteins. Although this problem can be overcome by detecting the protein of interest 
by western blot analysis, specific and reliable antibodies for detecting CD14, MD-2 
and TIr4 protein are not currently available and as such, detection of these 
components was limited to PCR analysis in the study. However, the PCR findings 
complemented the functional studies (NFKB activation), which showed that the 
TtT/GF and AtT20 D16:16 cells were both responsive to LPS stimulation. 
The RT-PCR method does not quantitatively measure changes in mRNA expression. 
However, the purpose of the current study was not to quantify mRNA expression in 
the cells, but to confirm either the presence or absence of the LPS signalling 
components. Several initial studies were required to optimise the PCR conditions, 
such as the number of cycles and annealing temperatures of the oligonucleotides 
and positive and negative controls were included in the study to ensure that amplified 
bands were not representative of non-specific sequences. 
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3.6.1.2.2 Detection of NFiB activity 
3.6.1.2.2.1 Western blot analysis 
In the current study, NFx13 activity was examined using three methods. Initially, the 
expression of the transcriptionally active subunit of NFxB, p65, was detected in 
cytosolic and nuclear cell fractions by western blot analysis. This enabled the 
translocation of p65 from the cytoplasm into the nucleus to be determined. As lxBa 
degradation is associated with increased NFx13 activity, the expression of this protein 
was also examined. Whilst the technique of western blot analysis is a widely utilised 
and accepted method for detecting protein expression, a major draw back to the 
method is the limited power of quantifying protein expression. The majority of the 
western blot studies employed in the current study examined time-dependent 
changes in protein expression in cytosolic and nuclear fractions and due to the 
limited number of samples that can be used for each gel (maximum of nine samples), 
the inclusion of duplicate samples for statistical analysis was not possible. 
Additionally, because comparisons of the density of the bands representing p65 
could not be made on samples from different gels, and cytosol and nuclear fractions 
were loaded on separate gels, direct comparisons in changes in protein expression 
\between the two fractions were limited. However, because only activated and 
unsequestered p65 can translocate to the nucleus, very low levels of p65 protein 
expression were detected in untreated control samples, allowing increases in protein 
levels to be easily detected. Additionally, observed decreases in IxBa protein 
expression in the cytosol are also indicative of NFKB activation. To ensure that the 
changes in protein expression detected by western blot analysis were reproducible, 
the experiments were repeated at least two times. To show the changes in protein 
expression more clearly, densitometric analysis of the bands on the gel were 
performed and the data was expressed as a percentage of control (non-quantitative). 
3.6.1.2.2.2 EMSA analysis 
An important limitation of evaluating NFx13 activation by western blot analysis is that 
this method does not discriminate between non-transcriptional and transcriptionally 
active nuclear NFKB. Therefore, the EMSA method was employed. This assay allows 
the transcriptional activity of NFx13 to be detected by incubating nuclear samples with 
a consensus NFKB sequence. The principal of the assay is based on the observation 
that protein:DNA complexes migrate more slowly than free DNA molecules when 
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subjected to non-denaturing polyacrylamide electrophoresis. If NFKB present in the 
nucleus is transcriptionally active, it will bind to the DNA sequence and the heavier 
complex will be detected as a higher band. Several bands may be detected with this 
method due to the existence of several hetero- or homo-dimers of NFKB. Up to 6 
complexes can be detected although the two predominant ones are the p65/p50 
heterodimer and the p50/p50 homodimer. The other complexes include (in order of 
size, beginning with the largest and thus, the highest bands): p65/p65, p49/p65, 
p52/40 and p49/p49. Increased binding of p65/p65 heterodimers can also be 
observed in vitro in conditions of increased nuclear p65 and multiple complexes 
generally indicate protein degradation or partially pure or crude nuclear extracts. To 
ensure that the detected bands were not due to non-specific binding reactions, 
specific competitive (excess unlabelled NFKB oligonucleotide was added to the 
samples in the presence of the labelled NFKB sequence) and non-specific 
competitive reactions (excess unlabelled AP-1 oligonucleotide was added) were 
included in the assay. Any bands that represent specific NFKB binding would still be 
detected in the non-specific reaction, but not the specific reaction. Similarly to the 
western blot assay, there is a limited power of quantifying DNA-binding activity. 
Multiple samples from the same treatment could not be loaded on the same gel for 
statistical analysis due to the limited number of samples that can be used for each 
gel (maximum of twelve samples). Additionally, comparisons of the density of the 
bands representing NFKB (p65/p50) DNA-binding activity could not be made on 
samples from different gels as they were not normailsed to each other. Therefore, the 
experiments were repeated at least two times to ensure reproducibility and data was 
presented as the mean percentage of control following densitometric analysis, to 
show changes in NFKB DNA-binding activity more clearly (non-quantitative). 
3.6.1.2.2.3 Supershift assay 
Whilst there are characteristic shifts caused by binding of specific protein(s) to the 
target DNA, the change in relative mobility, detected by EMSA, does not identify the 
bound protein. Identification of bound protein is accomplished by including an 
antibody, specific for the DNA-binding protein (e.g. p65), to the reaction. Binding of 
the antibody to the complex will result in either a further shift in the band. In some 
cases, the antibody may disrupt the protein:DNA interaction resulting in the loss of 
the characteristic shift, but no super-shift. A weak shift or a reduction in the intensity 
of the band usually implies the presence of low levels of the protein in the complex. 
The p65 protein is the transcriptionally active subunit of the NFKB dimer and the 
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p65/p50 heterodimer is the most extensively studied form. Therefore, the bands 
representing the p65/p50 heterodimer in nuclear extracts of LPS stimulated TtT/GF 
and AtT20 D16:16 cells were identified by supershift assays (section 2.5.6) and used 
as a reference for further assays. 
Detecting NFKB DNA-binding by EMSA is a lengthy process and requires the use of 
radioactive 32P. As described earlier (3.6.1.2.2.2), this assay has similar limitations to 
the western blot technique, i.e. the inability to compare DNA-binding complexes 
between separate gels and quantifying protein:DNA binding activity for statistical 
analysis. Therefore, the experiments were repeated to ensure the changes in binding 
activity were reproducible and correlated with the western blot findings. 
3.6.1.2.2.4 p65 TransAMTM assay 
Although western blot and EMSA techniques are commonly used for detecting NFKB 
activation, these assays do not provide quantitative results and therefore, unless 
basal NFKB activity is relatively low and there are obvious alterations in observed 
protein expression or binding activity, it is difficult to be sure of any induced changes. 
The ELISA-like p65 TransAMTM assay is a non-radioactive and quantitative method 
of measuring NFKB activity which overcomes the limitations of the western blot and 
EMSA techniques. This assay has been shown to be 10-fold more sensitive than 
EMSA (by tests carried by the manufacturer, Active Motif. U.K.), and can detect 
transcriptionally active NFKB using low nuclear protein concentrations (0.5-2.51.1g), 
compared to the western blot (20µg) and EMSA (10µg) methods, thus reducing 
background levels. Examining NFKB activity by western blot and EMSA in the TtT/GF 
and RAW 264.7 cells was sufficient as both cell lines exhibited low levels of basal 
activity and obvious alterations were detected. However, the basal activity in the 
AtT20 D16:16 cells were much higher and thus, changes in NFKB activity following 
LPS and CRH stimulation were difficult to detect. Therefore, the p65 TransAMTM  
assay was employed for measuring NFKB (p65) DNA-binding activity in these cells. 
However, although the assay can be used to quantitatively measure NFKB DNA-
binding activity, in the current study, the number of samples per treatment group that 
could be included in each assay were limited (n=2) and comparisons between 
separate assays could not be made as they were not standardised. Therefore, 
statistical analysis of the results obtained could not be perfomed. However, where 
possible, the experiements were repeated to ensure reproducibility and the optical 
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density for each treatment group was expressed as the mean percentage of control 
to show changes in activity more clearly (non-quantitative). 
3.6.1.2.3 Measuring IL-6 release by ELISA 
The release of the cytokine IL-6 from primary and transformed cell lines is routinely 
detected by ELISA. The current study employed an ELISA system that utilised a 
primary antibody specific for murine IL-6 for cell lines of a mouse origin (TtT/GF, 
AtT20 D1 and D16:16 subclones and RAW 264.7 cells) or an antibody specific for 
human IL-6 for the detection of IL-6 release from the human derived PDFS cell line. 
The murine ELISA showed no cross-reactivity to either rat, human or porcine IL-6 
and the human ELISA did not cross-react with either rat or mouse IL-6 or the human 
recombinant cytokines IL-11, IL-12, ciliary neurotrophic factor, soluble gp130, LIF 
and oncostatin M (OSM). The measurement of IL-6 by ELISA is advantageous over 
other assays such as western blot analysis and RT-PCR as it quantitatively 
measures the concentrations of secreted IL-6. It also allows high numbers of 
samples to be analysed (approximately 40 per plate) so that appropriate duplicates 
can be included, thus allowing the results to be analysed statistically. The IL-6 
ELISAs used in the current study were also highly sensitive, with detection limits of 
3.9pg/ml and 9.3pg/ml for the mouse and human assays respectively. Each assay 
included positive and negative controls. 
3.6.1.2.4 Measuring ACTH release by RIA 
The concentration of immunoreactive ACTH in the medium of incubated cell lines 
was determined by RIA (section 2.5.11). RIAs are a widely used technique for 
detecting ACTH in vitro due to their high sensitivity and specificity. The RIA used in 
the in vitro studies utilised a primary antibody directed against the 1-39 region of 
ACTH (ACTH1_39), which did not cross react with other molecules that are 
biosynthesised with ACTH, namely CLIP, a-MSH, LH or PRL. However, because the 
RIA only detects molecules of ACTH that are specific to the antibody, a limitation of 
the RIA is that the measurements obtained do not necessarily reflect the amount of 
bioactive ACTH released (due to the presence of fragments of the ACTH1_39 peptide), 
which varies between ACTH precursors (Zehnder et al. 1995). Therefore, caution 
must be applied when interpreting results in regard to bioactivity and hormone 
release. Nevertheless, the current study limited the observations made by the RIA 
results to the effects of CRH and LPS administration upon ACTH secretion, and not 
ACTH bioactivity. The number of samples analysed by the assay were not limited, 
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allowing high sample output, and comparisons could be made between profiles of 
hormone release, with repeated experiments (at least three times) ensuring that 
results were reproducible. 
3.6.1.3 	Compounds for studying NFx13 signalling 
3.6.1.3.1 Synthetic glucocorticoid - dexamethasone 
The synthetic glucocorticoid, dexamethasone, is a readily available compound used 
for the treatment of inflammatory disorders, due to its potent anti-inflammatory 
effects. Dexamethasone is also commonly used in studies of the functions of 
glucocorticoids in modulating the stress response and, as such, was included in the 
current study to investigate the effects of glucocorticoids on NFKB signalling and IL-6 
release from folliculostellate cells. 
3.6.1.3.2 Specific IKKI3 inhibitor - SC-514 
The IKK(3 inhibitor, SC-514, was employed in the study as a specific NFKB inhibitor 
for investigating NFKB signalling in the modulation of IL-6 and ACTH release from 
TtT/GF and AtT20 D16:16 cells respectively. Studies using non-specific NFKB 
inhibitors (Lohrer et al. 2000), such as inhibitors of the p38a mitogen activated kinase 
(MAPK) pathway (e.g. SB203580) or glucocorticoids (e.g. dexamethasone) cannot 
attribute any cellular effects solely to NFKB as such compounds would also interfere 
with other signalling pathways that may not involve NFKB. For example, the p38a 
MAP kinase pathway regulates the activity of other transcription factors involved in 
IL-6 synthesis such as AP-1 (Guha & Mackman 2001; Katsoulidis et aL 2005). The 
SC-514 compound is more applicable to studying NFKB signalling as it specifically 
inhibits activation of the IKKE3 subunit which is responsible for activating NRcB 
(p65/p50) and does not interfere with upstream signalling pathways (Kishore et al. 
2003). However, this compound is not effective in vivo and its use is therefore limited 
to in vitro studies (Kishore et aL 2003). 
3.6.1.3.3 Proteosome inhibitor — Mg132 
For comparative studies of NFKB inhibition, the cells were also treated with the 
proteosome inhibitor, Mg132, which is a non-specific NFKB inhibitor. This compound 
is a useful tool for studying NR(13 signalling as NFKB activation is associated with 
degradation of its inhibitory protein IKBa via the proteosome. However, some studies 
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have found that proteosome inhibitors can also increase NFxB activity by 
phosphorylating the IKKa/13 subunits, leading to degradation of IKBa (Dolcet et al. 
2006). Therefore, using proteosome inhibitors as blockers of NFKB activation is not 
always appropriate. Additionally, the vehicle solution the compound is dissolved in 
(ethanol), can also activate NFKB and induce a pro-inflammatory response (Yuan et 
al. 2006), and as such, vehicle controls were included in the experiments. Although 
Mg132 treatment was effective in inhibiting LPS-induced NFKB activation in the 
TtT/GF cells, the resting levels of NFKB were increased by low concentrations of 
Mg132, which correlates with previous studies that have reported NFKB activating 
properties of Mg132 in other cell systems (Pritts et al. 2002; Dolcet et al. 2006). 
3.6.2 LPS signalling in folliculostellate cells 
3.6.2.1 	Characterisation of folliculostellate cell lines 
The cell lines were initially characterised by RT-PCR for the expression of mRNAs for 
the LPS signalling components, CD14, TIr4 and MD-2. As CD14 signalling also 
occurs through interaction with the receptor involved in recognition of gram-positive 
bacteria, leading to NFKB activation, expression of the mRNA for TIr2 was also 
examined in the cells. Like the RAW 264.7 cells, and in agreement with previous 
studies, the TtT/GF cells expressed mRNA for CD14 and TIr4 (Lohrer et al. 2000). 
Furthermore, mRNAs for the accessory protein, MD-2, and TIr2, were detected in the 
TtT/GF cells, providing evidence for the first time, to our knowledge, of an intact LPS-
signalling system in these cells. 
In contrast, mRNAs for TIr4 and MD-2 were not detectable in the PDFS cells, 
suggesting that these cells do not respond to LPS and therefore, may not be as 
representative of folliculostellate cells as previously believed (Danila et aL 2000). 
However, studies of folliculostellate cells have identified at least five different 
subtypes (see section 1.7.3). It is unclear whether all these subtypes are responsive 
to endotoxin, and as such, it is possible that the PDFS cell line may represent a 
different subtype of folliculostellate cells in comparison to the TtT/GF cell line. 
However, as the current study used LPS as an immunological stimulus, the TtT/GF 
cell line was therefore the appropriate cell line to use as an in vitro model of 
folliculostellate cells. 
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3.6.2.2 	Characterisation of corticotroph cell lines 
Whilst both the AtT20 subclones, D1 and D16:16, expressed mRNAs for TIr4, MD-2 
and TIr2, only the AtT20 D16:16 cells expressed mRNAs for CD14. Although these 
findings do not discount the responsiveness of the AtT20 D1 cells to LPS, as LPS 
signalling can still occur via interaction with the soluble receptor form of CD14 which 
is present in serum, the AtT20 D16:16 cells were employed for further studies of 
corticotrophs as, in addition to being used extensively in other studies (Woods et al. 
1992; Tierney et al. 2003; Tierney et al. 2005), this subclone expressed mRNAs for 
all the LPS signalling components known to be present in primary corticotrophs 
(Tichomirowa et al. 2005). 
3.6.2.3 	Functional consequences of LPS signalling in TtT/GF, PDFS and 
RAW 264.7 cells - NFKB activation and IL-6 release 
In agreement with our suggestion that the PDFS cells would be unresponsive to LPS 
stimulation due to the absence of mRNAs for LPS signalling, the PDFS cells did not 
show an increase in IL-6 release when challenged with LPS. As these cells express 
TIr2, it is possible that they are responsive to gram-positive bacteria or fungal 
stimulation, which activates cellular responses via this receptor. However, as this 
study focused on the use of LPS as the stimulus for NFKB activation, further studies 
of folliculostellate cells were carried out on the TtT/GF cells. These findings highlight 
that initially characterising cell lines is extremely important for determining whether 
they are appropriate models for the intended study. 
In concurrence with the presence of mRNAs for the LPS signalling components, the 
TtT/GF cells readily responded to LPS challenge in a time-dependent manner with 
increased IL-6 release evident within 4 hours of contact. The increase in IL-6 release 
was preceded by activation of NFKB and followed by a secondary decrease in 
cytoplasmic p65 protein expression, detected by western blot analysis after 16 hours 
of LPS exposure. However, the reduction in cytoplasmic p65 was not associated with 
changes in nuclear p65 expression or the transcriptional activity of NFKB activity and 
is therefore likely to be related to its degradation. The subsequent restoration of 
cytoplasmic p65 to control levels at 24 hours may reflect de novo synthesis of the 
protein. 
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The RAW 264.7 cells also responded to LPS stimulation with increases in IL-6 
release which were considerably more pronounced than those observed in the 
TtT/GF cells. The high levels of IL-6 released from the RAW 264.7 cells correlated 
with a rapid and prolonged period of NFKB activation, which persisted up to 24 hours 
after LPS stimulation. These findings are in agreement with previous studies 
reporting NFKB-dependent regulation of IL-6 release from macrophages (Libermann 
& Baltimore 1990; Matsusaka et al. 1993; Deshpande et al. 1997). Because 
macrophages play an important role in mediating an inflammatory response, it is not 
surprising that the RAW 264.7 cells exhibit a sustained period of NFKB activity, with 
high amounts of IL-6 release compared to the TtT/GF cells. In contrast, if comparable 
to primary tissue, the early and rapid response of the TtT/GF cells to LPS may reflect 
the existence of a tightly regulated system within the anterior pituitary gland, which 
ensures appropriate concentrations of IL-6 are produced rapidly to induce ACTH 
release in conditions of endotoxaemia. It is likely that the RAW 264.7 cells release 
high amounts of IL-6 release in response to LPS because, in addition to 
macrophage-derived cytokines being released locally at sites of infection, they are 
also released into the circulation to exert widespread systemic effects. In 
comparison, the low levels of IL-6 produced by the TtT/GF cells compared to the 
RAW 264.7 cells may reflect the fact that folliculostellate cell-derived factors 
generally act locally within the anterior pituitary gland and are not therefore diluted in 
the circulation before reaching their targets (Inoue et al. 1999). 
3.6.2.4 	NFKB dependent IL-6 release from TtT/GF cells 
In conditions of endotoxaemia, evidence supports a paracrine, stimulatory role for 
folliculostellate cell-derived IL-6 on ACTH release from neighbouring corticotrophs, in 
both the presence and absence of hypothalamic CRH (Renner et al. 1998; Bethin et 
al. 2000; Gloddek et al. 2001). IL-6 release from folliculostellate cells may therefore 
present a potential target for the negative feedback actions of glucocorticoids. As 
mentioned previously, in immune cells, such as macrophages and monocytes, IL-6 
synthesis is regulated by NFKB, a transcription factor that is inhibited by 
glucocorticoids (Auphan et al. 1995; Heck et al. 1997; Almawi & Melemedjian 2002). 
Therefore, the mechanism through which glucocorticoids inhibit ACTH release may 
be effected, in part, through the inhibition of NFKB activity in folliculostellate cells. As 
outlined in the sections below, using both non-specific (section 3.6.2.4 and 3.6.2.5) 
and specific (section 3.6.2.6) NFKB inhibitors, the current study has provided firm 
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evidence that an NFKB-dependent pathway is involved in the regulation of IL-6 
release from TtT/GF cells. 
3.6.2.5 	Effects of the proteosome inhibitor, Mg132, on LPS stimulated NFKB 
activity and IL-6 release from TtT/GF cells 
In the current study, treatment with Mg132 inhibited LPS-stimulated NFKB activity 
and IL-6 release from the TtT/GF cells. Interestingly, whilst the vehicle solution in 
which Mg132 was dissolved (ethanol) did not affect basal activity of NFKB in the 
TtT/GF cells, it further increased LPS stimulated NFKB activity. Ethanol is a potent 
stimulator of NFKB (Lee & Rivier 2005) and therefore, it is possible that whilst the 
concentrations (2mM) used in the current study were not sufficient to induce an 
independent increase in NFKB activity, they may have been sufficient to potentiate 
the effects of LPS. 
However, whilst Mg132 was shown to decrease NFKB activity, incubation of the 
TtT/GF cells with lower concentrations of Mg132 (1 and 10p,M) resulted in an 
increase in basal NFKB activity, an effect that cannot be attributed to the vehicle. 
Previous studies have reported increased NFKB activity induced by proteosome 
inhibitors such as Mg132 (Jobin et al. 1998; Lee et al. 2006), which was associated 
with activation of the heat shock response (Jobin et al. 1998). Therefore, in the 
resting state, low concentrations of Mg132, which do not completely block 
proteosome activity, may increase NFKB activity in the TtT/GF cells through the 
activation of heat shock proteins. Concurrent with this, Mg132 treatment also 
increased basal IL-6 release from the TtT/GF cells, an effect which supports previous 
studies demonstrating increased NFKB activity and IL-6 release from other cell types 
following Mg132 treatment (Pritts et al. 2002). 
In LPS stimulated cells, treatment with 25µM Mg132 was more effective at inhibiting 
IL-6 release than a two-fold higher concentration of Mg132 (50µM). As 50µM Mg132 
sufficiently reduced LPS induced NFKB activity, the abrogated inhibitory effect of this 
agent on IL-6 suggests that in response to endotoxin, compensatory mechanisms 
may be activated to facilitate IL-6 release in conditions of repressed NFKB activity, 
such as activation of other IL-6 transcription factors including AP-1, NF-IL6 and 
C/EBP (Akira et al. 1990; Bretz et al. 1994; Galien et al. 1996; Ray et al. 1997; Xiao 
et al. 2004). Screening of the activity of these transcription factors under these 
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conditions is required to confirm whether this is the case. Whether the stimulatory 
effects induced by Mg312 on IL-6 release in the TtT/GF cells involves an 
upregulation in heat shock proteins or other transcription factors involved in IL-6 
synthesis, warrants further investigation and may present an additional signalling 
pathway through which IL-6 release is induced in these cells. However, because 
Mg132 is not a selective inhibitor of NFKB, the inhibitory effects it exerted on IL-6 
release from the TtT/GF cells cannot be assumed to occur through the suppression 
of NFKB alone. Therefore, the effects of the specific NFKB inhibitor, SC-514, on IL-6 
release from LPS-stimulated TtT/GF cells were also examined. 
3.6.2.6 	Effects of the IKKI3 inhibitor, SC-514, on LPS stimulated NFKB 
activation and IL-6 release from TtT/GF cells 
The IKK complex is the convergence point for the activation of NFicB in response to 
LPS. The IKK complex is composed of two catalytic subunits, IKKa and IKK(3, and 
the regulatory subunit IKKy (Didonato et aL 1997; Zandi et al. 1997; Hu & Wang 
1998; Rothwarf et al. 1998; Yamaoka et al. 1998; Karin & Ben-Neriah 2000). Gene 
knockout studies have clearly demonstrated that the IKKE3 and IKKy subunits are both 
required for NFKB activation by most pro-inflammatory stimuli, including LPS (Li et aL 
1999a; Li et al. 1999b). Although NFKB activation is associated with increased IL-6 
release from the TtT/GF cells, the study aimed to investigate the importance of this 
transcription factor in the regulation of IL-6 synthesis, utilising the IKKI3 inhibitor, SC-
514. 
The SC-514 drug, which has been used extensively by others as a selective NFKB 
inhibitor for in vitro studies (Kishore et a/. 2003; Buss et al. 2004; Gomez et al. 2005; 
Jeong et aL 2005; Peng et aL 2005; Hwang et aL 2006), was characterised by 
Kishore et al. and shown to inhibit all forms of recombinant human IKKI3 including the 
recombinant human (rh) IKKf3 homodimer, rhIKKa/IKKO heterodimer, as well as the 
constitutively active form of the rhIKKI3 (Ser177-Glu, Ser181-Glu), with IC50 values in the 
3-12µM range (see figure 3.29A). Furthermore, SC-514 also inhibited the activated, 
native IKK complex immunoprecipitated from IL-1p stimulated rheumatoid arthritis-
derived synovial fibroblasts with similar potency (see figure 3.29B). However, the SC-
514 inhibitor did not interfere with the other IKK isoforms - rhlKKa, rhlKKc or the 
rhTBK-1 or other serine-threonine and tyrosine kinases (see figure 3.29c). 
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The current study showed that inhibition of NFKB resulted in a significant decrease in 
LPS-stimulated IL-6 release from the TtT/GF cells. The inhibitory effect of SC-514 
was no longer apparent at the higher concentration of 300µM, an effect which was 
also observed with increasing concentrations of Mg132. Although this could be due 
to toxic effects of the compound, it is likely that the transcriptional activity of other IL-
6 transcription factors (e.g. NF-IL6 and C/EBP) come into effect in conditions of 
repressed NFKB activity. 
However, these findings provide compelling evidence that, NFKB, which is normally 
associated with immune/inflammatory cells, also plays an important role within the 
anterior pituitary gland, through the regulation of IL-6 release from this folliculostellate 
cell line (figure 3.30). These findings are concurrent with previous studies that have 
demonstrated increased NFKB activity in the TtT/GF cells and pituitary reaggregate 
co-cultures following LPS exposure (Baur et al. 2000; Lohrer et al. 2000) and studies 
that have suggested the involvement of an NFKB-dependent pathway in the 
regulation of IL-6 from LPS-stimulated TtT/GF cells through the use of p38a-
MAPKinase inhibitors, as activation of the p38a-MAPKinase pathway leads to NFKB 
activation (Lohrer et al. 2000). 
C. Kinase 1CmuLADI Kinase IC,,,(uM) Kinase IC(uM) Kinase ICauM) 
JNK1 >200 MK2 >200 MKK7 >200 PKA >100 
JNK2 >200 MK3 >200 GSK3 >100 PKC5 >100 
JNK3 >200 MK3 >200 CDK2/A 61 LYN >100 
P38a >100 PRAK 75 AUR2 71 FGFR1 >100 
P385 >100 RSKB >200 NIM1 >100 EGFR >100 
P38y >100 MSK 123 CHK1 >100 LCK >100 
P388 >100 ERK2 >100 PAK5 >100 cABL >100 
Figure 3.29 
SC-514 drug 
values of SC 
from (Kishore 
SC-514 is a potent and selective inhibitor of IKKI3. (A) structure of 
and (B) IC50 values of SC-514 against IKKI3 and its isoforms. (c) IC50 
-514 against a panel of tyrosine and serine-threonine kinases [Taken 
et al. 2003)]. 
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3.6.2.7 	Inhibitory effects of the synthetic glucocorticoid, dexamethasone, on 
LPS stimulated NFKB activity and IL-6 release from TtT/GF cells 
Glucocorticoids are able to inhibit ACTH release through the upregulation of the 
secondary messenger ANXA1 (Buckingham & Flower 1997; Traverso et al. 1999; 
John et aL 2004) and through binding to glucocorticoid response elements (GREs) 
within the POMC promoter (Keller-Wood & Dallman 1984; Dallman et al. 1987; Nakai 
et al. 1991; De Kloet et al. 1998). In agreement with a previous study (Lohrer et aL 
2000), our data showed for the first time that LPS-stimulated IL-6 release from the 
TtT/GF cells is sensitive to the inhibitory effects of glucocorticoids and this inhibitory 
effect is mediated, at least in part, through the inhibition of NFKB by increasing the 
expression of licBoc, identifying at least one mechanism through which 
dexamethasone inhibits NFKB activity in the TtT/GF cells (Auphan et al. 1995; 
Scheinman et al. 1995a) (figure 3.30). If folliculostellate derived IL-6 is a paracrine 
mediator of ACTH release from corticotrophs, which there is strong evidence for 
(Gloddek et al. 2001), the findings from the current study suggest that NFKB 
signalling in folliculostellate cells is an additional target for glucocorticoid-mediated 
inhibition of ACTH release from the anterior pituitary gland. 
3.6.2.8 	IL-6 response of TtT/GF cells to CRH stimulation 
Previous studies have shown that the TtT/GF-derived factors such as MIF and IL-6 
are not influenced by CRH stimulation (Tichomirowa et aL 2005; Tierney et al. 2005). 
However, to our knowledge, the effects of CRH stimulation on LPS-activated 
folliculostellate cells has not been previously examined and thus, the current study 
addressed this utilising the TtT/GF cell line. In concurrence with previous reports 
(Tichomirowa et al. 2005; Tierney et al. 2005), the TtT/GF cells used in this study did 
not display altered responses to LPS-stimulated IL-6 release in the presence of CRH. 
Classically, CRH stimulates POMC synthesis and ACTH release through its 
interaction with the CRH-R1 subtype expressed by corticotrophs [reviewed by 
(Aguilera et aL 2004)]. To the best of our knowledge, CRH receptor expression has 
not been examined in either primary folliculostellate cells or the TtT/GF cell line and, 
thus, we cannot exclude the possibility that the apparent inactivity of CRH in the 
TtT/GF cells reported here and elsewhere (Tichomirowa et al. 2005; Tierney et al. 
2005) reflects a lack of functional CRH receptors, thus discounting the possibility that 
CRH may also stimulate ACTH release indirectly by acting on TtT/GF cells to 
increase IL-6 release (figure 3.30). 
166 
I 6 
Figure 3.30 Regulation of IL-6 release from TtT/GF cells. Diagrammatic 
representation illustrating the proposed mechanisms by which LPS stimulates IL-6 
synthesis and release from TtT/GF cells. Red arrows indicate pathways leading to 
increased IL-6 release and blue lines indicate inhibitory pathways leading to 
decreased IL-6 production. CD14, cluster of differentiation 14; CRH, corticotrophin 
releasing hormone; GC, glucocorticoid; GR, glucocorticoid receptor; IKE3a, inhibitor of 
kappa B alpha; IL-6; interleukin 6; LPS, lipopolysaccharide; MD-2, myeloid 
differentiation factor 2; NFKB, nuclear factor kappa B; TIr4, toll-like receptor 4. 
3.6.3 LPS signalling in corticotrophs 
3.6.3.1 	Modulation of ACTH release from AtT20 D16:16 cells by CRH and 
LPS 
Although basal ACTH release by AtT20 D16:16 cells is modest, there was an 
accumulation of the ACTH in the medium over the time course studied; with 
significant increases evident after 7 hours incubation in fresh medium. Therefore, 
subsequent studies with the AtT20 D16:16 cells used a maximum incubation time of 
7 hours to prevent high basal amounts of ACTH masking any effects of drug 
treatment. In agreement with previous studies, the AtT20 D16:16 cells readily 
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responded to CRH stimulation in a concentration-dependent manner (Woods et al. 
1992). Despite expressing mRNAs for the LPS signalling components, the cells did 
not exhibit an ACTH response to LPS stimulation alone, which is in agreement with 
previous findings (Tichomirowa et al. 2005). However, in the study by Tichomirowa et 
a!, the effects of LPS were only examined on basal ACTH secretion (Tichomirowa et 
al. 2005). As endotoxin-induced plasma ACTH release is associated with increased 
levels of CRH, which has been detected both in the ME of the hypothalamus and in 
rat brain extracellular fluid (Ma et aL 2000; Beishuizen & Thijs 2003), this suggests 
that the stimulatory effects of LPS on ACTH release from the anterior pituitary 
corticotrophs may also involve CRH. Therefore, the effects of LPS upon CRH 
stimulated ACTH release from the AtT20 D16:16 cells were examined. The current 
study demonstrated an inhibitory effect of LPS on ACTH release in the presence of 
low, but not high, concentrations of CRH, suggesting that the inhibitory effects of LPS 
occur during the initial stages of endotoxaemia, when CRH concentrations are low. 
Furthermore, an indirect mechanism through which LPS inhibits ACTH release has 
been demonstrated recently (Solito et al. 2006). ANXA1, a glucocorticoid-induced 
protein which is released from folliculostellate cells and acts as a paracrine and 
juxtacrine mediator of ACTH release from corticotrophs (Tierney et al. 2003), is 
upregulated in folliculostellate cells by LPS challenge in vitro (Solito et al. 2006). 
Together these findings support the premise that LPS may target corticotrophs in the 
anterior pituitary to inhibit ACTH release as part of the protective mechanism that 
allows the pro-inflammatory host defence response to develop, before it is contained 
within appropriate limits by the hyper-secretion of the anti-inflammatory 
glucocorticoids (Munck & Naray-Fejes-Toth 1994). 
3.6.3.2 	NFiB mediated ACTH release from AtT20 D16:16 cells 
A recent report demonstrated an inhibitory effect of CRH on oxidative stress-induced 
NFKB in corticotrophs in vitro, which was associated with increased POMC synthesis 
(Karalis et al. 2004). However, whilst this study supports the premise that 
corticotroph NFKB is targeted by CRH as part of its stimulatory effect on ACTH 
synthesis, the mechanisms through which this occurs is unclear (Karalis et aL 2004). 
In the current study, LPS challenge attenuated the stimulatory effect of CRH on 
ACTH release from the AtT20 D16:16 cells and this was associated with increased 
NFKB activity. Inhibition of LPS induced NFKB reversed the inhibitory effect of LPS, 
suggesting that inhibition of ACTH release by LPS may occur via an NFKB-mediated 
mechanism. CRH also stimulated NFKB activity in the AtT20 D16:16 cells used in the 
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current study, which conflicts with the inhibitory effects of CRH reported by Karalis et 
al. There are several explanations for the conflicting findings; firstly, the culture 
conditions outlined in the previous study differed from this study — which included the 
absence of serum in the experimental conditions and the absence of proteins such 
as insulin and transferrin in the culture medium. These differences in culture 
conditions can lead to variations in cell phenotype and as such, cells can exhibit 
altered responses. Concurrent with this, previous studies have demonstrated that 
serum in the culture medium is required to effect LPS signalling in vitro (Lohrer et al. 
2000). The study conducted by Karalis et al. did not include serum in the culture 
medium of the AtT20 cells and as LPS (at a concentration 50 times higher than that 
used in the current study) did not induce a noticeable increase in NFKB activation in 
these cells, compared to the AtT20 D16:16 cells used in the current study, this 
response is likely to be attributed to the impaired LPS signalling. However, the 
inhibitory effect of CRH observed upon NFKB activity in the AtT20 cells reported by 
Karalis et al. contradicts the stimulatory effect of CRH observed in the AtT20 
subclone used in the current study. It is therefore possible that the conflicting findings 
are a result of different AtT20 subclones used in these studies. It is likely that the cell 
line used in the study conducted by Karalis et al. was the D1 sub-type which does not 
express the CD14 receptor and, due to the absence of serum in the experimental 
conditions, also lacked the presence of soluble CD14 for effective LPS signalling. 
These observations illustrate the potential difficulties of using different subclones of 
transformed cell lines, as the variations in phenotypes can result in false 
interpretations and comparisons being made between studies, hence the need for 
characterisation of cell lines to investigate their suitability. 
However, both studies have identified an inhibitory effect of NFKB activity on ACTH 
release from corticotrophs in vitro, with the current study showing that inhibition of 
CRH-induced NFKB activity resulted in a potentiation of CRH stimulated ACTH 
release. CRH induced an early increase in resting levels of NFKB activity, with a later 
increase evident at 24 hours, suggesting a bi-phasic effect of CRH upon NFKB 
activation. Immunohistochemical analysis at the electron microscopic level has 
localised MIF to granules in the corticotrophs, with some granules containing MIF 
only, whereas others contain both MIF and ACTH (Nishino et aL 1995). Furthermore, 
functional studies using the AtT20 D16:16 cell line identified a stimulatory role of 
CRH upon MIF release (Nishino et al. 1995). It is therefore possible that the later 
increase in NFKB activity following CRH stimulation is due to autocrine actions of 
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factors such MIF, which both induces, and is induced by, NFKB (Roger et aL 2001; 
Onodera et al. 2004; Cao et al. 2005; Amin et al. 2006; Cao et al. 2006). 
The stimulatory effect of CRH upon NFKB in the current corticotroph model system 
may reflect a counter-regulatory mechanism which is in place to prevent the over-
production of ACTH release and ensure that levels of glucocorticoids produced are 
maintained within appropriate limits (figure 3.31). However, as concentrations of CRH 
increase, this inhibitory effect is less apparent, suggesting that when sufficient 
concentrations of endogenous CRH are released, the inhibitory effects of LPS, via 
NFKB activation, are no longer effective. This effect would initially prevent high levels 
of glucocorticoids, which are potent anti-inflammatory agents, being released 
prematurely, before a sufficient inflammatory/immune response has been mounted. 
The mechanism through which CRH induces NFKB activation in the AtT20 D16:16 
cells is unclear but, in contrast to CRH signalling through CRH-R1 to induce ACTH 
secretion [reviewed in (Aguilera et al. 2004)], CRH-R2 may be involved in CRH-
stimulated NFKB activation. This is supported by studies reporting that the pro-
inflammatory effects exerted by peripherally-acting CRH involves increasing NFKB 
activity in immune cells, via a CRH-R1-independent mechanism (Zhao & Karalis 
2002). Whilst it is understood that the predominant receptor expressed by 
corticotrophs is the CRH-R1 subtype (Perrin & Vale 1999), CRH-R2 mRNA 
expression has been detected in the anterior pituitary gland, albeit at low levels 
(Kageyama et a/. 2003) and it is possible that stimuli such as LPS can increase 
expression of this receptor, as has been reported in mast cells (Papadopoulou et aL 
2005). 
These findings support the premise that in addition to the classically perceived role of 
NFKB in the inflammatory response, this transcription factor is also involved in the 
regulation of ACTH secretion from the anterior pituitary gland, through its activity in 
corticotrophs. However, the mechanisms through which NFic13 inhibits ACTH release 
are unclear, and may involve interference of this transcription factor with other known 
regulators of POMC synthesis, including AP-1 and the orphan nuclear receptor 
Nurr77 (Drouin et al. 1987; Drouin et al. 1989; Drouin et aL 1993; Philips etal. 1997). 
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3.6.3.3 	IL-6 increases CRH stimulated ACTH release from AtT20 D16:16 cells 
The regulation of ACTH secretion from the anterior pituitary gland is complex, and 
the current findings have added to this complexity by showing that LPS differentially 
influences the secretion of IL-6 and ACTH from pituitary derived cell lines, via NFKB-
dependent mechanisms. LPS-induced NFKB activation in the AtT20 D16:16 cells was 
shown to attenuate CRH-stimulated ACTH release. Paradoxically, it has been 
reported that LPS-stimulated IL-6 release from folliculostellate cells, which was 
shown in the current study to also occur via an NFKB-dependent mechanism, 
stimulates ACTH secretion from corticotrophs via paracrine actions (Gloddek et al. 
2001). 
To investigate whether IL-6 stimulates ACTH release from the AtT20 D16:16 cells in 
this study, the effects of murine recombinant IL-6, at concentrations reflecting those 
produced by the TtT/GF cells after LPS stimulation, upon ACTH release were 
examined. Recombinant IL-6 potentiated ACTH release from the AtT20 D16:16 cells 
only in the presence of low concentrations of CRH, with this synergistic effect no 
longer being evident in the presence of increasing concentrations of CRH. This 
supports the premise that, in response to endotoxin exposure, folliculostellate-
derived IL-6 acts to potentiate corticotroph-derived ACTH release in conditions of low 
CRH levels and possibly, to sustain ACTH levels as concentrations of CRH increase 
(figure 3.31). 
3.7 Conclusion 
The findings reported here have provided compelling evidence that the role of 
anterior pituitary-NFKB signalling in the regulation of ACTH release is dependent on 
the cell population it is expressed in. In corticotrophs, NFKB signalling negatively 
regulates ACTH release, whilst a positive effect upon ACTH release is exerted 
through its activity in folliculostellate cells, via the production of IL-6. 
The purpose of this study was to examine the role of NFiB in the regulation of ACTH 
release from the anterior pituitary gland, and whether its inhibition would mimic the 
effects induced by glucocorticoids in regard to attenuating ACTH release. The results 
obtained, using single cell-type cultures of TtT/GF and AtT20 D16:16 cells as models 
of folliculostellate cells and corticotrophs respectively, have shown that NFKB, an 
important regulator of the cellular effects induced by LPS, acts in a cell-specific 
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manner to regulate ACTH release. Whilst its expression in the TtT/GF cells increases 
IL-6 release, which acts synergistically with CRH to further increase ACTH secretion, 
its activation in the AtT20 D16:16 cells has been shown to inhibit CRH-stimulated 
ACTH release. However, the mechanism through which this inhibitory effect occurs —
whether it is directly at the transcriptional level of POMC synthesis or via the 
upregulation of other NFKB-dependent mediators which interfere with ACTH release -
remains unclear. 
Figure 3.28 Regulation of ACTH release from AtT20 016:16 cells. 
Diagrammatic representation illustrating the proposed mechanisms by which LPS 
acts on AtT20 D16:16 cells to inhibit ACTH synthesis and release. Red arrows 
indicate pathways leading to increased ACTH synthesis and release; dotted red lines 
indicate proposed pathways leading to ACTH synthesis and release and blue lines 
indicate inhibitory pathways leading to decreased ACTH synthesis and release. 
ACTH, adrenocorticotrophic hormone; CRH, corticotrophin releasing hormone; CRH-
R, corticotrophin releasing hormone receptor; IL-6, interleukin 6; IL-6Ra, interleukin 6 
receptor alpha; LPS, lipopolysaccharide; NFKB, nuclear factor kappa B; POMC, 
proopiomelanocortin. 
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3.8 Future studies 
The mechanisms involved in CRH-induced activation of NFxB in the AtT20 D16:16 
cells are unclear and warrant further investigation. It has been reported that the pro-
inflammatory effects of CRH occur through the CRH-R2 receptor subtype (Zhao & 
Karalis 2002), whilst ACTH release by CRH is mediated via the CRH-R1 subtype 
(Perrin & Vale 1999). To identify the receptor subtype involved in CRH-mediated 
NFx13 activation, specific CRH-R1 and R2 receptor antagonists can be employed 
(Mousa et aL 2003; Mastorakos et aL 2006). 
Although the current findings have identified a dual role for NFxlii signalling in the 
regulation of ACTH release, these studies were performed in single cell-type cultures 
of folliculostellate cells and corticotrophs. The effects of inhibiting NFKB on IL-6 and 
ACTH release following LPS and/or CRH stimulation when these two cell types are 
cultured together, and thus, able to communicate with one another through direct 
physical contact and exposure to the mediators released by both cell types, needs to 
be addressed. 
Whilst we are aware of the limitations of studying transformed cells, such co-culture 
systems can provide valuable information regarding the interactions between these 
two cell types in conditions of immunological stress and allow the elucidation of the 
molecular mechanisms involved. Co-cultures of transformed cell lines representing 
folliculostellate cells and corticotrophs were used to obtain a clear understanding of 
the interactions between these two cell-types. This approach is advantageous over 
primary pituitary tissue cultures, as the cells would not be exposed to factors 
released from other cell-types of the anterior pituitary, which could also influence 
ACTH secretion. For example, 50% of the cells of the anterior pituitary are 
somatotrophs, which release growth hormones. Growth hormones also stimulate 
ACTH release, through CRH-dependent and independent mechanisms (Ghigo et al. 
1999). Additionally, the incubation times for treatment of the cells were relatively long 
(16 hours for IL-6 release and 7 hours for ACTH release). This may be problematic 
when using primary tissue cultures as their viability is limited and the effects detected 
may be attributed to cell death. As such, the role of NFKB signalling in folliculostellate 
cell and corticotroph co-cultures was examined using the TIT/GF and AtT20 D16:16 
cell lines. 
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4 	Interactions between folliculostellate cells and 
corticotrophs in a co-culture system 
4.1 	Co-cultures of TtT/GF and AtT20 D16:16 cells 
Folliculostellate cells form close connections with corticotrophs in the anterior 
pituitary gland and influence the secretion of ACTH by releasing pro-inflammatory 
cytokines, including IL-6 (Gloddek et al. 2001). The previous chapter focused on the 
responses of the TtT/GF and AtT20 D16:16 cells to LPS and CRH stimulation when 
cultured alone (chapter 3). However, because folliculostellate cells are positioned 
near corticotrophs in the anterior pituitary gland, this chapter examined the 
interactions between these cell types when they were cultured together. Imaging 
studies showed that the morphology of the TtT/GF cells differs from that of the AtT20 
D16:16 cells (figure 4.1A and B), allowing the distinction of the cells when cultured 
together. Figure 4c shows a phase contrast image of the projections from the TtT/GF 
cells forming connections with each other and with the AtT20 D16:16 cells in 
monolayer co-cultures. 
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Figure 4.1 	Phase contrast images of TtT/GF and AtT20 D16:16 cells. (A) 
TtT/GF cells, (e) AtT20 D16:16 cells and (c) monolayer co-cultures of TtT/GF and 
AtT20 D16:16 cells. The co-cultures contained 200, 000 AtT20 D16:16 and 50, 000 
TtT/GF cells. Scale bar is equal to 60[1m. A, AtT20 D16:16 cell; T, TtT/GF cell; P, 
point of contact between a projection from a TtT/GF cell and an AtT20 D16:16 cell. 
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4.2 	LPS and CRH signalling in co-cultures of TtT/GF and AtT20 
D16:16 cells 
The findings described in chapter 3 identified the transcription factor, NFKB, as an 
important mediator of LPS stimulated IL-6 release from TtT/GF cells (section 3.4). In 
contrast, CRH (1, 10 and 100nM) failed to influence either basal or LPS (10Ong/m1) 
stimulated IL-6 release from the TtT/GF cells (section 3.4.4). 
The AtT20 D16:16 cells readily responded to CRH (1, 10 and 100nM) stimulation 
with significant increases in ACTH release (section 3.5.1). Whilst LPS (10Ong/m1) 
failed to affect basal ACTH secretion (section 3.5.3), it attenuated the stimulatory 
effects of CRH (1 and 10nM) via an NFKB dependent mechanism (sections 3.5.6 and 
3.5.7). 
The focus of this chapter was to investigate the IL-6 and ACTH responses of TtT/GF 
and AtT20 D16:16 cells to LPS and CRH when they are cultured together, and thus 
able to communicate which each other, and to examine the effect of the NFKB 
inhibitor, SC-514, on these responses. Because both these cell types adhere to the 
flask wall, a monolayer co-culture system was utilised for these studies. 
4.2.1 Determination of cell numbers of TtT/GF and AtT20 D16:16 cells plated 
in monolayer co-culture for optimal ACTH response to CRH stimulation 
Initially, the optimal number of TtT/GF cells cultured with the AtT20 D16:16 cells was 
determined by culturing different ratios of the two cell-types together and measuring 
their ACTH responses to CRH stimulation. Figure 4.2 shows the effects of CRH 
(10nM) stimulation on ACTH secretion from the AtT20 D16:16 cells, when cultured 
alone (50, 000 or 200, 000 cells) and in the presence of TtT/GF cells at ratios of 1:1 
(50, 000 TtT/GF cells cultured with 50, 000 AtT20 D16:16 cells), 1:4 (50, 000 TtT/GF 
cells cultured with 200, 000 AtT20 D16:16 cells) and 4:1 (200, 000 TtT/GF cells 
cultured with 50, 000 AtT20 D16:16 cells). CRH (10nM, 7 hours) significantly 
increased ACTH release from the AtT20 D16:16 cells (50, 000 cells, p<0.001 vs 
unstimulated AtT20 D16:16 cells and 200, 000 cells, p<0.001 vs unstimulated AtT20 
D16:16 cells) and the co-cultures (1:1, 4:1 and 1:4, p<0.001 vs respective 
unstimulated control; figure 5.2). Both basal [1:1, p<0.001 vs AtT20 D16:16 (50, 000 
cells) control group, 4:1, p<0.01 vs AtT20 D16:16 (50, 000 cells) control group and 
1:4, p<0.001 vs AtT20 D16:16 (200, 000 cells) control group] and CRH-stimulated 
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[1:1 and 4:1, p<0.001 vs AtT20 D16:16 (50, 000 cells) CRH-stimulated group and 
1:4, p<0.001 vs AtT20 D16:16 (200, 000 cells) CRH-stimulated group] ACTH release 
were increased in the presence of the TtT/GF cells compared to the AtT20 D16:16 
single cultures (figure 4.2). CRH stimulation induced the greatest ACTH response 
from the 1:4 co-cultures (p<0.001 vs 4:1 CRH-stimulated group, p<0.01 vs 1:1 CRH-
stimulated group; figure 4.2). These findings concurred with previous studies 
conducted in the laboratory (Tierney et al. 2003) and therefore, all further 
experiments were performed on co-cultures containing 50, 000 TtT/GF cells and 200, 
000 AtT20 D16:16 cells. 
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Figure 4.2 	Effect of CRH (10nM, 7 hours) stimulation on ACTH release from 
AtT20 D16:16 cells and monolayer co-cultures of TtT/GF and AtT20 D16:16 
cells. AtT20 D16:16 cells (50, 000 or 200, 000 cells per well) were cultured alone or 
in the presence of TtT/GF cells (50, 000-200, 000 cells per well). +"p<0.001 vs 
control (within corresponding culture group), Ilp<0.01, Iltp<0.001 vs corresponding 
treatment group of AtT20 D16:16 cells alone (50, 000 cells), $$$p<0.001 vs 
corresponding treatment group of AtT20 D16:16 cells alone (200, 000 cells), 
***p<0.001 vs corresponding treatment group of 200, 000 TtT/GF cells cultured with 
50, 000 AtT20 D16:16 cells (4:1), 1`)14)p<0.01 vs 50, 000 TtT/GF cells cultured with 50, 
000 AtT20 D16:16 cells (1:1) CRH stimulated group. Control groups were incubated 
in medium containing vehicle (10µM ascorbic acid). Each value is a mean ± SEM of 
six samples. Representative example of three separate experiments. Analysis was 
performed by two-way ANOVA with post hoc comparison using Bonferroni's t-test. 
ACTH adrenocorticotrophin; CRH, corticotrophin-releasing hormone. 
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4.2.2 Rate of cell proliferation of single cell and monolayer co-cultures of 
TtT/GF and AtT20 D16:16 cells plated at a ratio of 1:4 
To examine whether the rate of cell proliferation of the TtT/GF and AtT20 D16:16 
cells was changed when the cells were cultured together, the number of TtT/GF and 
AtT20 D16:16 cells cultured alone and together were counted on the day of plating 
(day 1) and the day of stimulation (day 3). The number of AtT20 D16:16 cells in the 
single culture increased by 45% after 3 days in culture, compared to a 39% increase 
in cell growth when they were cultured with the TtT/GF cells (figure 4.3). Overall, the 
number of AtT20 D16:16 cells in the single culture was significantly higher than the 
number of cells in the co-cultures (p<0.001; figure 4.3). The TtT/GF cell number 
increased by 78% when cultured alone, compared to an increase of 54% when 
cultured with the AtT20 D16:16 cells (figure 4.3). Similarly to the AtT20 D16:16 cells, 
the number of TtT/GF cells in the single cultures was significantly higher than in the 
co-cultures (p<0.001; figure 4.3) 
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Figure 4.3 	Cell proliferation of single cultures and monolayer co-cultures of 
TtT/GF and AtT20 D16:16 cells after 3 days in culture. The number of TtT/GF and 
AtT20 D16:16 cells in single and co-cultures was counted on the day of plating (day 
1, D1) and the day of stimulation (day 3, D3). Each value is a mean ± SEM of five 
samples in a single experiment. Analysis was performed by one-way ANOVA with 
post hoc comparison using Bonferroni's West. 
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4.2.3 Effects of CRH on LPS-stimulated IL-6 release from monolayer co-
cultures of TtT/GF and AtT20 cells plated at a ratio of 1:4 
The effect of CRH (1 and 10nM, 16 hours) on basal and LPS (10Ong/ml, 16 hours) 
stimulated IL-6 release from the co-cultures was examined. LPS stimulation induced 
a significant increase (p<0.001 vs control) in IL-6 release (figure 4.4). Whilst CRH 
alone (1 and 10nM) had no effect on basal IL-6 release (p=1.00), it potentiated the 
stimulatory effect of LPS in a concentration-dependent manner (1nM CRH, p<0.05 vs 
LPS and 10nM, p<0.001 vs LPS; figure 4.4). 
Figure 4.4 	Effects of LPS (10Ong/ml, 16 hours) and CRH (1 and 10nM, 16 
hours) on IL-6 release from monolayer co-cultures of TtT/GF and AtT20 D16:16 
cells. Control (10µM ascorbic acid) and treated groups are the mean of six samples 
± SEM. The data are representative of three separate experiments. +++p<0.001 vs 
control (AA), tp<0.05, titp<0.001 vs LPS, ***p<0.001 vs CRH + LPS. Analysis 
performed by two way ANOVA with post hoc comparison using Bonferroni's t-test. 
CRH, corticotrophin releasing hormone; IL-6, interleukin 6; LPS, lipopolysaccharide; 
NS, not significant. 
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4.2.4 Effects of LPS on CRH-stimulated ACTH release from monolayer co-
cultures of TtT/GF and AtT20 D16:16 cells plated at a ratio of 1:4 
The effect of LPS (10Ong/ml, 7 hours) on CRH (1 and 10nM, 7 hours) stimulated 
ACTH release from co-cultures of TtT/GF and AtT20 D16:16 cells were examined. 
Basal ACTH release was significantly increased with 10nM CRH stimulation 
(p<0.001 vs control), but not at the lower concentration of 1nM CRH (p=0.113). 
Although LPS did not affect basal secretion of ACTH (p=0.867), it potentiated the 
stimulatory effects of CRH (p<0.01 vs 1nM CRH alone, p<0.001 vs 10 nM CRH; 
figure 4.5). 
Figure 4.5 	Effects of LPS (10Ong/ml, 7 hours) on CRH (1 and 10nM, 7 hours) 
stimulated ACTH release from monolayer co-cultures of TtT/GF and AtT20 
D16:16 cells. Each value is a mean ± SEM of six samples. Representative example 
of three separate experiments. +++p<0.001 vs control (101uM ascorbic acid), ttp<0.01, 
tttp-<0.001 vs corresponding CRH only stimulated group. Analysis was performed by 
two-way ANOVA with post hoc comparison using Bonferroni's West. AA, ascorbic 
acid; ACTH adrenocorticotrophin; CRH, corticotrophin releasing hormone; LPS, 
lipopolysaccharide. 
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4.3 	Effects of NFiB inhibition upon ACTH and IL-6 release from 
co-cultures of TtT/GF and AtT20 D16:16 cells 
The findings from the single culture studies (chapter 3) support a dual role for NFKB 
signalling in the regulation of ACTH release, exerting a positive effect through its 
activity in the folliculostellate-like ItT/GF cells and an inhibitory effect through its 
activity in the corticotroph-like AtT20 D16:16 cells. To examine to role of NFKB in 
mediating IL-6 and ACTH release when these two cell-types are cultured together, 
the specific NFKB inhibitor, SC-514, was used. 
4.3.1 Effects of the IKKO inhibitor, SC-514, on IL-6 release from monolayer co-
cultures of TtT/GF and AtT20 D16:16 cells 
The release of IL-6 from the co-cultures was significantly increased by treatment with 
LPS (10Ong/ml, p<0.001 vs unstimulated control; figure 4.6A and B). Whilst treatment 
with SC-514 (10011M) alone did not affect basal IL-6 (p=1.00), it significantly 
attenuated the stimulatory effect of LPS (p<0.01 vs LPS; figure 4.6A and B). CRH 
alone (1 and 10nM) did not affect basal IL-6, either in the presence or absence of 
SC-514 (p=1.00; figure 4.6A and B). However, in the presence of LPS, both 
concentrations of CRH potentiated the stimulatory effect of LPS (p<0.001 vs LPS; 
figure 4.6A and B). This increase was attenuated by inclusion of SC-514 in the 
medium (p<0.01 vs LPS + 1nM CRH and p<0.001 vs LPS + 10nM CRH), although 
the amounts of IL-6 released remained significantly higher than the LPS-stimulated 
group (p<0.01 vs LPS and p<0.001 vs LPS; figure 4.6A and B). 
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Figure 4.6 	Effects of SC-514 treatment (100µM, 17 hours) upon LPS 
(10Ong/ml, 16 hours) and (A) 1nM CRH (16 hours) and (B) 10nM CRH (16 hours) 
stimulated IL-6 release from monolayer co-cultures of TtT/GF and AtT20 D16:16 
cells. The cultures were incubated with SC-514 for 1 hour prior to the addition of LPS 
and CRH. Control (10µM ascorbic acid) and treated groups are the mean of six 
samples ± SEM. The data are representative of three separate experiments. 
++p<0.01, +++p<0.001 vs control (AA),ttp<0.01, 	p‹  ttt- 0.001 vs LPS, "p<0.01, 
***p<0.001 vs CRH + LPS. Analysis was performed by three-way ANOVA followed 
by a second order one-way ANOVA with post hoc comparison using Bonferroni's t-
test. AA, ascorbic acid; CRH, corticotrophin releasing hormone; IL-6, interleukin 6; 
LPS, lipopolysaccharide. 
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4.3.2 Effects of the 110(6 inhibitor, SC-514, on ACTH release from monolayer 
co-cultures of TtT/GF and AtT20 D16:16 cells 
The basal release of ACTH from the co-cultures was significantly increased following 
stimulation with CRH for 16 hours (1nM CRH, p<0.01 vs control; figure 4.6A and 10 
and 100nM CRH, p<0.001 vs control; figure 4.7B and c). Although incubation with 
LPS (10Ong/nril, 16 hours) did not affect basal ACTH release (p=1.00), it potentiated 
the stimulatory effect of 1nM CRH (p<0.05 vs 1nM CRH alone; figure 4.7A) and 10nM 
CRH (p<0.01 vs 10nM CRH alone; figure 4.7B), but not 100nM CRH (p=0.093; figure 
4.7c). SC-514 (100µM, 17 hours) treatment also potentiated the stimulatory effect of 
10nM CRH (p<0.01 vs 10nM CRH; figure 4.7B) and 100nM CRH (p<0.01 vs 100nM 
CRH, figure 4.7c), but not of 1nM CRH (p=0.061; figure 4.7A). Treatment with SC-
514, followed by combined stimulation with LPS and 10nM CRH, but not 100nM CRH 
(SC-514 + LPS + 100nM CRH vs SC-514 + 100nM CRH; p=0.130), resulted in a 
further increase in ACTH release (p<0.001 vs CRH + LPS, p<0.01 vs CRH + SC-514; 
figure 4.7B). 
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Figure 4.7 	Effects of the NFKB inhibitor, SC-514 (10011M, 8 hours), on LPS 
(10Ong/m1) and (A) 1nM, (B) 10nM and (c) 10nM CRH stimulated ACTH release 
from monolayer co-cultures of TtT/GF and AtT20 D16:16 cells. Co-cultures were 
incubated with SC-514 1 hour prior to addition of LPS (7 hours) and CRH (7 hours). 
Control (10µM ascorbic acid) and treated groups are the mean of six samples ± 
SEM. The data are representative of three separate experiments. 'p<0.01, 
+++p<0.001 vs control, tp<0.05, ttp<0.01, ttt- p<0.001 vs CRH, "p<0.01, ***p<0.001 vs 
CRH + LPS, up<0.01 vs CRH + SC-514. Analysis was performed by three-way 
ANOVA followed by a second order one-way ANOVA with post hoc comparison 
using Bonferroni's t-test. AA, ascorbic acid; ACTH, adrenocorticotrophin; CRH, 
corticotrophin releasing hormone; LPS, lipopolysaccharide; NS, not significant. 
186 
4.3.3 Effects of the IKKO inhibitor, SC-514, on ACTH release from aggregate 
co-cultures of TtT/GF and AtT20 D16:16 cells 
The aforementioned experiments utilised monolayer co-cultures of TtT/GF and AtT20 
cells D16:16 cells. To examine whether the co-cultures would behave differently if 
cultured as three-dimensional structures, the effects of SC-514 (100µM, 8 hours) 
treatment on LPS (10Ong/ml, 7 hours) and CRH (10nM, 7 hours) stimulated re-
aggregate co-cultures (containing 50, 000 TtT/GF cells cultured with 200, 000 AtT20 
D16:16 cells) was compared. Unlike the monolayer cultures (figure 4.7B), LPS 
induced a small, but significant increase in ACTH release from the aggregate 
cultures (p<0.05 vs control; figure 4.8). LPS exposure also potentiated the 
stimulatory effect of CRH (p<0.001 vs CRH; figure 4.8), similarly to the monolayer 
cultures (figure 4.7B). Incubation of the aggregates with SC-514 and CRH resulted in 
a similar ACTH response to the monolayer cultures (figure 4.7B), with a further 
increase in ACTH release (p<0.001 vs CRH), but this increase was not significantly 
different from that observed with CRH and LPS stimulation (p=1.00; figure 4.8). 
However, incubation with SC-514 and LPS significantly increased CRH-stimulated 
ACTH release compared to the CRH + SC-514 (p<0.001) and CRH + LPS (p<0.001) 
treated groups (figure 4.8), a response which was also seen in the monolayer co-
cultures (figure 4.7B). 
187 
A
C
T
H
 R
el
ea
se
  (
ng
/m
l)  
160 - 
140 -
120 -
100 - 
80 -
60 
40 -
20 - 
0 
AA (10µM) 
CRH (10nM) 
LPS (10Ong/m1) 
SC-514 (100µM) 
$$$ 
*** 
ttt 
+++ 
ttt 
4)4)4) 	ttt 
+++ 	414)4 
+++ 
44) 
+++ 
• 
- 	+ 
Figure 4.8 	Effects of the IKKf3 inhibitor, SC-514 (100p.M, 8 hours), on CRH 
(10nM, 7 hours) and LPS (10Ong/ml, 7 hours) stimulated ACTH release from 
aggregate co-cultures of TtT/GF and AtT20 D16:16 cells. Aggregate cultures, 
which contained 50, 000 TtT/GF cells and 200, 000 AtT20 D16:16 cells, were 
incubated with SC-514 for 1 hour, prior to the addition of LPS and CRH. Control 
(10p.M ascorbic acid) and treated groups are the mean of six samples ± SEM. The 
data are representative of two separate experiments. +p<0.05, +++p<0.001 vs control, 
mp<0.001 vs CRH, 44)p<0.01, (Mp<0.001 vs LPS, "p<0.01, 'p<0.001 vs CRH + 
LPS, $up<0.001 vs CRH + SC-514. Analysis was performed by three-way ANOVA 
followed by a second order one-way ANOVA with post hoc comparison using 
Bonferroni's t-test. AA, ascorbic acid; ACTH, adrenocorticotrophin; CRH, 
corticotrophin releasing hormone. 
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4.3.4 Effects of conditioned medium from TtT/GF cells on the release of ACTH 
from AtT20 D16:16 cells 
To examine whether the synergistic interactions of LPS and CRH upon ACTH 
release from the co-cultures was dependent on cell to cell contact between the 
TtT/GF and AtT20 cells, or whether it was attributed to mediators released from the 
TtT/GF cells acting on the AtT20 D16:16 cells, the effects of incubating the AtT20 
D16:16 cells with conditioned medium, collected from TtT/GF cells stimulated with 
LPS (10Ong/m1) and CRH (10nM), upon ACTH secretion was investigated. As SC-
514 (100µM) treatment potentiated the stimulatory effect of LPS (10Ong/m1) and CRH 
(10nM) on ACTH release from the co-cultures (monolayer co-cultures; figure 4.7B 
and aggregate co-cultures; figure 4.8), the effect of medium collected from TtT/GF 
cells, treated with SC-514 (100µM), on ACTH release from AtT20 D16:16 cells was 
further explored. 
The TtT/GF cells were stimulated with LPS (10Ong/m1) in the presence and absence 
of CRH (10nM) and/or SC-514 (100µM: pre-incubation of 1 hour prior to addition of 
LPS and/or CRH stimulation) for 7 hours. The AtT20 D16:16 cells were incubated 
with the conditioned medium collected from the TtT/GF cells for a further 7 hours. For 
comparison, the AtT20 D16:16 cells were incubated for 7 hours with unconditioned 
medium, which had been treated under the same conditions as the TtT/GF cells. 
The conditioned medium had no effect on the basal release of ACTH from the AtT20 
D16:16 cells (p=1.00; figure 4.9). The basal release of ACTH from the AtT20 D16:16 
cells incubated with conditioned or unconditioned medium was also unaffected by 
inclusion of LPS in the medium (unconditioned medium, p=0.885 and conditioned 
medium, p=0.771) and (unconditioned medium, p=0.624 and conditioned p=0.493) 
/or (unconditioned medium, p=0.239 and conditioned p=0.874) SC-514 (figure 4.9). 
The release of ACTH from the AtT20 D16:16 cells incubated in conditioned and 
unconditioned medium was increased to the same degree by CRH (p<0.001 vs 
basal) and the effects of the peptide were potentiated by SC-514 in both conditions 
(p<0.01 vs CRH alone; figure 4.9). In the unconditioned medium, LPS attenuated 
CRH-stimulated ACTH release (p<0.01 vs CRH) and this effect was overcome in the 
presence of SC-514 (p<0.01 vs LPS and CRH; figure 4.9). In contrast, the 
attenuating effect of unconditioned medium containing LPS upon ACTH release was 
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reversed when the cells were incubated with conditioned medium containing LPS 
(p<0.01 vs unconditioned medium containing LPS and CRH; figure 4.9). 
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Figure 4.9 	Effects of conditioned medium collected from TtT/GF cells 
following LPS (10Ong/ml, 7 hours), CRH (10nM, 7 hours) and SC-514 (10001, 8 
hours) stimulation upon ACTH release from AtT20 D16:16 cells. TtT/GF cells 
(50, 000) were pre-incubated with SC-514 for 1 hour prior to the addition of LPS 
and/or CRH (7 hours). Following incubation, the medium from the TtT/GF cells was 
collected (medium still contained LPS, CRH and/or SC-514) and added to AtT20 
D16:16 (200, 000) cells. The AtT20 D16:16 cells were then incubated with the 
TtT/GF cell-conditioned medium for a further 7 hours. The ACTH response of the 
AtT20 D16:16 cells to conditioned medium were compared to their response to 
unconditioned medium (AtT20 D16:16 cells were incubated for 7 hours in 
unconditioned medium). The unconditioned medium was treated under the same 
conditions as the conditioned medium, i.e. the unconditioned medium, containing 
LPS and/or CRH and SC-514 were placed in empty wells and incubated for 7 hours 
under the same conditions as the TtT/GF cells prior to addition to the AtT20 D16:16 
cells. Control (10µM ascorbic acid) and treated groups are the mean of six samples ± 
SEM. 'p<0.001 vs control, ttp<0.01 vs unconditioned medium (within the same 
treatment group), "p<0.01 vs CRH stimulated conditioned medium group), 44p<0.01 
vs CRH + LPS. Analysis was performed by three-way ANOVA followed by a second 
order two-way ANOVA with post hoc comparison using Bonferroni's t-test. AA, 
ascorbic acid; ACTH, adrenocorticotrophin; CRH, corticotrophin releasing hormone; 
LPS, lipopolysaccharide; NS, not significant. 
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4.4 Discussion 
4.4.1 Monolayer co-cultures of TtT/GF and AtT20 D16:16 cells 
Given the complexity of intra-pituitary signalling, direct investigation of 
communication between two specific cell types is not possible in an in vivo model. 
Similarly, studies on primary pituitary tissue in vitro are limited in this regard because 
of the presence of multiple cell types. Several workers have attempted to purify 
specific pituitary cell populations to address these problems and whilst the 
preparations of enriched cell populations of a variety of pituitary types, including 
folliculostellate cells and corticotrophs, have met with some success, the cell 
populations are not homogenous and, thus, the results cannot be attributed solely to 
the cell types under investigation (Prysor-Jones et al. 1989; Alexander et aL 1991; 
Alexander et al. 1995; Gloddek et al. 2001). Furthermore, these preparations require 
the use of large numbers of animals and have limited viability in vitro (Alexander et 
al. 1991; Alexander et al. 1995). An alternative approach is to use cell lines as 
models. Accordingly, in the present study we used two pituitary cell lines, the murine 
folliculostellate-like TtT/GF cell line (Inoue et al. 1992; Lohrer et al. 2000; Gloddek et 
al. 2001) and the murine corticotroph-like AtT20 D16:16 cell line (Woods et al. 1992), 
to model interactions between folliculostellate cells and corticotrophs. 
4.4.1.1 	Increased basal ACTH release from AtT20 D16:16 cells in the 
presence of the TtT/GF cells 
The current study showed that both basal and CRH-stimulated ACTH release from 
the AtT20 D16:16 cells are significantly enhanced in the presence of TtT/GF cells, 
thus confirming a previous report from our laboratory (Tierney et aL 2003). Since 
TtT/GF cells produce growth factors which are known to increase corticotroph 
proliferation, e.g. bFGF (Ferrara et al. 1987; Amano et aL 1993; Van Wijk et al. 
1995), we hypothesised that this differential effect may reflect increased proliferation 
of the AtT20 D16:16 cells. However, our data showed that, when grown in the 
presence of TtT/GF cells, the rate of proliferation of the AtT20 D16:16 cells was 
reduced, as indeed was that of the TtT/GF cells. This surprising finding may be 
attributed to the relative decrease in the surface area available for cell adhesion in 
the co-cultures vs. single cell cultures, as the total number of cells in the co-culture 
(5x104 TtT/GF cells cultured with 2x105 AtT20 D16:16 cells) was greater compared to 
the total number of cells in the single cultures (5x104 TtT/GF cells cultured alone and 
2x105 AtT20 D16:16 cells cultured alone). To examine this, further studies are 
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required using varied culture conditions and more precise measurements of 
proliferation, e.g. [3H]-thymidine uptake or measures of DNA content. 
Several factors released from folliculostellate cells are known to exert a positive 
effect on ACTH secretion from corticotrophs and, in particular, to enhance the 
response to CRH (Auernhammer & Melmed 1999). Of particular importance are IL-6 
and other cytokines such as LIF, which act via gp130 receptors (Ferrara et al. 1992; 
Gearing 1993; Bousquet et aL 1997). Although measurements of cytokine release 
were not made in the study in which we compared single cell cultures and co-cultures 
directly, it is feasible that the increased ACTH release observed in the presence of 
TtT/GF cells reflects the actions of these agents (Chesnokova et al. 1998; 
Chesnokova & Melmed 2000) which may accumulate at the junctions between 
TtT/GF and AtT20 D16:16 cells at high concentrations. 
4.4.1.2 	Increased ACTH response of monolayer co-cultures of TtT/GF and 
AtT20 D16:16 cells to LPS and CRH stimulation 
In contrast to the attenuating effect of LPS upon CRH-induced ACTH release from 
the AtT20 D16:16 cells (section 3.5.6), the current study has provided evidence that 
the ACTH-stimulating effects of LPS at the anterior pituitary level are mediated 
through its actions on folliculostellate cells, with LPS potentiating CRH-induced 
ACTH secretion. Our previous studies on single cell cultures (section 3.5.5) indicated 
that at concentrations akin to those found in medium from TtT/GF cells challenged 
with LPS, IL-6 alone does not increase ACTH per se from AtT20 D16:16 cells, 
although it potentiates the stimulatory effect of low concentrations of CRH, 
suggesting that this cytokine is important in the ACTH response during the early 
stages of endotoxaemia, when CRH concentrations are low. Therefore, unless the 
concentration of IL-6 increases in the intercellular spaces between the TtT/GF and 
AtT20 D16:16 cells to amounts sufficient to stimulate ACTH release, the potentiating 
effects of LPS observed in the current study are likely to involve other TtT/GF cell-
derived mediators induced by LPS, e.g. LIF (Wang et al. 1996). The section below 
discusses such potential TtT/GF cell-derived factors. 
4.4.1.3 	Potential ACTH-stimulating cytokines released from folliculostellate 
cells 
In vivo studies show that peripherally administered LPS rapidly and massively 
activates NFKB transcriptional activity in cells throughout the anterior and posterior 
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pituitary lobes (Quan et al. 1998; Whiteside et al. 1999). In addition, mRNAs for 
cytokines such as IL-1j3 and TNFa are more discretely induced in both lobes, with 
separate induction time courses for each lobe and cytokine (Whiteside et al. 1999). 
The phenotypes of the expressing cells are not known, but, on the basis of their 
widespread and scattered locations (Quan et al. 1998; Whiteside et al. 1999), it 
appears that a portion of them could be folliculostellate cells (Herkenham 2005). 
Therefore, in addition to LPS-induced IL-6 production, other cytokines produced by 
these cells could be involved in the increased ACTH response to LPS observed in 
the current study (Kobayashi et al. 1997). Furthermore, folliculostellate cells produce 
LIF (Inoue et aL 2002), which potently induces POMC gene transcription and ACTH 
secretion (Auernhammer et al. 1998; Butzkueven et al. 2002; Mynard et al. 2002) 
and potentiates CRH induction of POMC gene expression in vitro (Bousquet et aL 
1997; Bousquet et aL 2000). Moreover, LIF is strongly induced in the anterior 
pituitary gland in response to inflammation in vivo (Wang et al. 1996; Chesnokova & 
Melmed 2000; Chesnokova et al. 2002). Thus, it is possible that the increased effects 
of LPS upon ACTH release measured in the current study may also be attributed to 
TtT/GF cell-derived LIF release. Furthermore, LIF production is regulated by NFKB 
signalling in human endometrial cells (Laird et al. 2000) and LIF also induces IL-6 
gene expression in mononuclear phagocytes through transcriptional activation of 
NFKB (Gruss et aL 1992). Therefore, in addition to the direct stimulatory effect of LIF 
upon ACTH release, which occurs via the same signalling pathway as IL-6 (Mynard 
et aL 2002), it is possible that this cytokine is also involved in increasing ACTH 
release by acting in an autocrine manner to activate NFKB, subsequently leading to 
increased IL-6 release from folliculostellate cells. 
4.4.2 Aggregate co-cultures of TtTIGF and AtT20 D16:16 cells 
The effective actions of the aforementioned folliculostellate cell-derived mediators 
upon corticotrophs may be enhanced by the increased cell to cell contacts which 
form in the three-dimensional structure of re-aggregate cultures. In view of this, a 
previous study identified discrepancies between the ACTH responses of primary 
pituitary cells grown as monolayer and re-aggregate cultures (Gloddek et al. 2001). 
These findings suggest that the multiple cell to cell contacts formed in the re-
aggregates may allow relatively high concentration of mediators to accumulate in the 
intracellular spaces, thus permitting effective paracrine or juxtacrine communication 
between the cells. In monolayer co-cultures, cell to cell contacts are inevitably more 
limited and the concentration of mediators may be insufficient to affect hormone 
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release. In the present study, we therefore compared the ACTH responses of 
monolayer co-cultures of TtT/GF and AtT20 D16:16 cells to aggregate co-cultures of 
TtT/GF and AtT20 D16:16 cells. 
4.4.2.1 	Increased ACTH response of aggregate co-cultures of TtT/GF and 
AtT20 D16:16 cells to LPS 
In accordance with the studies by Gloddek et al., LPS alone increased ACTH release 
from the AtT20 D16:16 cells in the presence of TtT/GF cells in the aggregate co-
cultures, but not in the monolayer co-cultures (Gloddek et al. 2001). The different 
responses elicited by these co-culture models therefore support the premise that a 
three-dimensional structure optimises the communication between folliculostellate 
cells and corticotrophs in conditions of endotoxaemia. These findings raise the 
possibility that single cell type cultures grown as a monolayer may also behave 
differently when cultured as aggregates. For example, the previous single culture 
studies used monolayer cultures of TtT/GF or AtT20 D16:16 cells to examine the 
effects of LPS and CRH upon IL-6 and ACTH release (chapter 3). As these cell types 
also form connections when they are cultured separately (see section 4.1), it is 
possible that altered responses to LPS may be elicited from these cells when 
cultured as aggregates. However, our studies indicate that only the LPS 
responsiveness of these cells is enhanced, as the response to combined CRH and 
LPS stimulation were similar in both models. As such, monolayer co-cultures of 
TtT/GF and AtT20 D16:16 cells is a valid model for investigating the role of NFKB 
signalling in the interactions between these two cell types. 
4.4.3 Role of NFKB signalling in the ACTH response to LPS 
A dual role for NFKB signalling in the regulation of ACTH release was suggested in 
the previous chapter, with a potentiating effect exerted through TtT/GF cell-derived 
IL-6 (section 3.5.5) and an inhibitory effect exerted through its activity in the AtT20 
D16:16 cells (section 3.5.7). To examine this further, the effects of NFKB blockade, 
using the specific NFKB inhibitor, SC-514, upon the ACTH responses of monolayer 
and aggregate co-cultures of TtT/GF and AtT20 D16:16 cells to LPS and CRH 
stimulation was investigated; the responses were qualitatively similar in both culture 
conditions. 
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In the presence of the TtT/GF cells, NFKB blockade continued to augment the ACTH 
response to lower concentrations of CRH, despite reduced IL-6 production. This 
suggests that the stimulatory effect of CRH upon the AtT20 D16:16 cells is partially 
masked by a paradoxical NFKB-dependent inhibitory effect of the peptide on ACTH 
release, as was seen in the AtT20 D16:16 cells alone (section 3.5.7). Alternatively, 
NFKB activity may be involved in repressing the synthesis and/or release of an AtT20 
D16:16 cell-derived mediator(s) involved in increasing ACTH release from 
corticotrophs and/or IL-6 release from folliculostellate cells. Both mechanisms would 
explain the effects of the NFKB inhibitor on the response to LPS although the latter 
would predict that the inhibitor would augment the release of IL-6, which was not 
shown in the current study. Furthermore, the responses to the NFKB inhibitor suggest 
that the NFKB-dependent inhibitory actions of LPS and CRH on ACTH release may 
be of considerable importance in tempering the neuroendocrine responses to LPS 
and thus, this may represent an important mechanism by which ACTH release is 
limited during endotoxaemia to facilitate an effective inflammatory response. 
However, LPS stimulation further potentiated CRH-induced ACTH release in 
conditions of suppressed NFKB activity. Initially these findings appear to contradict 
the premise that reduced NFKB-dependent IL-6 release from the TtT/GF cells would 
result in a reduction, or complete removal, of the stimulatory effect of LPS. However, 
upon further investigation, it was shown that in the presence of AtT20 D16:16 cells, 
LPS-induced IL-6 release from the TtT/GF cells was potentiated further by CRH 
stimulation, with the concentration of IL-6, even after SC-514 treatment, remaining 
significantly higher than that induced by LPS alone. Therefore, in line with the current 
findings, the concentration of IL-6 under these conditions may have remained 
sufficient to augment ACTH secretion, thus accounting for the potentiating effect of 
LPS, even after NFKB blockade. Furthermore, these findings have provided evidence 
for the first time, to our knowledge, that a CRH-induced mediator(s) released from 
AtT20 D16:16 cells may act on the TtT/GF cells to augment LPS-stimulated IL-6 
release. The co-operative interactions between these two cell types to augment 
ACTH release, as part of the neuroendocrine response to bacterial LPS, may 
therefore be attributed to the paracrine/juxtacrine actions of released mediators from 
both cell types. The sections below consider potential corticotroph-derived factors 
effecting communication between these two cell types to enhance ACTH release. 
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4.4.4 Potential IL-6 secretagogues released from AtT20 D16:16 cells 
A potential IL-6 secretagogue is the pro-inflammatory cytokine, MIF, which has been 
localised to secretory granules in corticotrophs (Nishino et al. 1995) and is released 
from AtT20 D16:16 cells in response to CRH and LPS stimulation (Nishino et al. 
1995; Tierney et al. 2005). MIF stimulates IL-6 release from human monocytes, 
dendritic cells and fibroblast-like synoviocytes (Murakami et al. 2002; Santos et al. 
2004), whilst macrophages from MIF knockout mice exhibit decreased IL-6 
production in response to LPS (Bozza et al. 1999). Thus it is possible that the 
paracrine actions of CRH-induced MIF release from corticotrophs may increase IL-6 
production from folliculostellate cells (figure 4.10). MIF exerts some of its biological 
effects through binding to its cognate receptor, CD74 (Renner et al. 2005), but it is 
not known whether the TtT/GF cells express this receptor. However, MIF may also 
signal via a nonclassical endocytic pathway in the absence of CD74 (Renner et al. 
2005). MIF signalling is associated with activation of the extracellular signal-regulated 
kinase 1/2 (ERK-1/2), promoting cell growth and activating Ets transcription factors 
which are critical for the expression of TIr4 (Mitchell et al. 1999; Roger et aL 2001; 
Renner et al. 2005).(Renner et al. 2005). Therefore, MIF may also increase the 
responsiveness of folliculostellate cells to LPS and thus, CRH-induced MIF release 
from corticotrophs may present an additional mechanism through which the ACTH 
response to endotoxin is enhanced. The mechanism(s) through which CRH induces 
MIF release is unclear, although NFKB signalling may be involved as the mif 
promoter region contains an NFKB DNA-binding site (Renner et al. 2005). However, 
since the concentrations of CRH required to induce MIF release are well below those 
required for maximal release of ACTH (Calandra et al. 1994; Nishino et al. 1995; 
Tierney et al. 2005), and as the affinity of CRH for CRH-R2, the receptor implicated 
in NFKB activation (Zhao & Karalis 2002), is lower than that for CRH-R1 (Kishimoto 
et al. 1995; Chalmers et al. 1996; Perrin & Vale 1999), direct activation of NFKB by 
CRH is unlikely to be involved. 
The expression of urocortin, a mammalian member of the CRH family, has been 
detected in the mouse (Chen et aL 2003) and rat pituitary gland (Wong et al. 1996a; 
Oki et al. 1998) and is released from rat primary pituitary cultures in response to CRH 
(Nemoto et al. 2007). Urocortin exhibits a high affinity for CRH-R2 (Vaughan et al. 
1995) and therefore, CRH may increase NFKB-mediated MIF release indirectly 
through the upregulation of urocortin. Furthermore, the function of urocortin in the 
anterior pituitary gland is unclear, since it does not appear to affect POMC synthesis 
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or ACTH release (Nemoto et al. 2007). Thus it is possible that CRH-induced urocortin 
may act via CRH-R2 to activate NFKB and increase MIF synthesis in our system. 
However, the receptor involved in CRH-induced urocortin release has not yet been 
determined (Nemoto et al. 2007) and it remains to be investigated whether CRH 
stimulates urocortin release from AtT20 D16:16 cells at concentrations sufficient to 
stimulate MIF release. 
In addition to NFKB, MIF is regulated by other CRH-induced transcription factors, 
namely AP-1 and CREB (Boutillier et al. 1995; Waeber et al. 1998; Becquet et al. 
2001; Kasagi et al. 2002; Kasckow et al. 2003; Mynard et al. 2004; Renner et al. 
2005), and activation of CREB by CRH has previously been shown to occur through 
the CRH-R1 subtype (McEvoy et al. 2002; Kasckow et al. 2003). Moreover, a 
previous study has demonstrated impaired CRH-induced MIF release from AtT20 
cells containing a mutated CRE site within the mif promoter region (Waeber et aL 
1998). It is therefore plausible that CRH-induced MIF release from the AtT20 D16:16 
cells is regulated by transcription factors such as CREB, at least during early 
endotoxaemia when CRH concentrations are low. During later stages of immune 
stimulation, when concentrations of CRH increase, MIF regulation by NFKB via CRH-
R2 may come into effect, possibly via the induction of urocortin. This is supported by 
the finding that whilst LPS-stimulated IL-6 release from the TtT/GF cells is mediated 
by NFKB (see section 3.4.1), inhibition of NFKB only partially attenuated the 
synergistic effects of CRH and LPS upon IL-6 release, with the percentage reduction 
in IL-6 release being similar in both the presence and absence of CRH. Together, 
these findings support the premise that the attenuating effect of the NFKB inhibitor 
upon IL-6 release can be attributed to its direct effects on the TtT/GF cells, whilst the 
potentiating effect of CRH occurs predominantly via an NFKB-independent 
mechanism. 
4.4.4.1 Eicosanoids as potential AtT20 D16:16 cell-derived IL-6 
secretagogues 
Eicosanoids have been implicated in the regulation of ACTH secretion, exerting both 
inhibitory and stimulatory effects, depending on both the locus of action and the 
species of eicosanoid. At the hypothalamic level, prostanoids (e.g. PGA,, PG131  and 
PGE1) increase CRH release (Hedge 1972; Hedge 1976; Navarra etal. 1991), whilst, 
conversely, in the pituitary gland prostanoids are inhibitory to ACTH release. For 
example, stimulation of primary pituitary tissue with PGA,, PGB1, PGE, and PGE2 
depresses ACTH release, whilst treatment with the non-selective COX inhibitor, 
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indomethacin, reverses this inhibitory effect (Hedge 1977; Vlaskovska et al. 1984; 
Cowell et al. 1991; Wilson & Guild 2002). However, PGE2, which is formed in the rat 
anterior pituitary gland in response to CRH and AVP stimulation (Vlaskovska et al. 
1984; Knepel et al. 1985), stimulates the release of IL-6 from primary pituitary cells 
(Spangelo et al. 1990a). As corticotrophs are the primary target of CRH, it is possible 
that CRH-induced PGE2 originates from this cell type, possibly through NRc13-
mediated synthesis of COX-2, the enzyme responsible for prostaglandin synthesis 
(Bukata et al. 2004) (figure 4.10), and acts on folliculostellate cells to induce IL-6 
release. Furthermore, PGE2 also increases CD14 gene expression and activates AP-
1, a regulator of IL-6 transcription in murine macrophages (lwahashi et al. 2000). 
Therefore, if PGE2 exerts similar effects on folliculostellate cells, this may present a 
potential mechanism through which CRH indirectly increases IL-6 production in the 
anterior pituitary gland. 
Whilst studies using both the AtT20 D16:16 cell line and dispersed rat pituitary cells 
have demonstrated an inhibitory effect of PGE2 upon ACTH release (Vlaskovska et 
al. 1984; Wilson & Guild 2002), the preparation of dispersed anterior pituitary cells 
would result in the loss of folliculostellate cells and of the three-dimensional cell 
network, which in turn may impair their function (Christian et al. 1997). Therefore, 
such studies may not be a reliable representation of the true effects of PGE2 on the 
anterior pituitary gland (Vlaskovska et al. 1984). However, these studies have 
demonstrated a direct inhibitory effect of PGE2 at the corticotroph level and thus, in 
combination with its stimulatory effects upon folliculostellate cell-derived IL-6, the 
actions of PGE2 within the anterior pituitary gland may represent a regulatory 
mechanism through which exacerbated ACTH release in response to endotoxin is 
prevented. Furthermore, NFKB-dependent PGE2 synthesis in corticotrophs may 
represent a mechanism through which NFKB activity in corticotrophs inhibits ACTH 
release (figure 4.10). 
In addition to prostaglandins, potential corticotroph-derived mediators include other 
metabolites of arachidonic acid, which are generated via the cytochrome P450 and 
lipoxygenase pathways, such as 12(S)-hydroxyeicosatetra-enoic acid [12(S)-HETE]. 
These metabolites increase ACTH release from primary pituitary cells (Luini & 
Axelrod 1985; Cowell & Buckingham 1989; Cowell et al. 1991), and inhibition of the 
lipoxygenase pathway impairs CRH-induced ACTH release from AtT20 cells (Luini & 
Axelrod 1985). Furthermore, 12(S)-HETE also increases ACTH secretion in vivo 
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(Won & Orth 1994) and is one of the major lipoxygenase metabolites identified in the 
rat anterior pituitary gland, although it is not known whether it is produced by 
corticotrophs. 12(S)-HETE increases both the mRNA and protein expression of IL-6 
and TNFa in macrophages via PKC, p38 MAP Kinase and JNK signalling pathways 
(Wen et al. 2006) and stimulates LIF release from human bone marrow stromal cells 
(Denizot et al. 1998). Therefore, if products of the lipoxygenase pathway originating 
in corticotrophs act via a similar mechanism in folliculostellate cells to augment 
cytokine generation, they could indirectly potentiate CRH-induced ACTH secretion 
(figure 4.10). 
4.4.5 Effects of conditioned medium from TtT/GF cells on the ACTH 
responses of the AtT20 D16:16 cells 
Our findings have provided novel evidence for reciprocal communication between the 
TtT/GF and AtT20 D16:16 cells via the actions of released mediators. To examine 
whether these mediators exert their effects through a paracrine and/or juxtacrine 
manner, we examined the effects of TtT/GF cell-conditioned medium upon the ACTH 
response of the AtT20 D16:16 cells. The conditioned medium did not affect the ability 
of the NFKB inhibitor to potentiate the response to CRH, thus supporting the view 
that CRH exerts two opposing actions directly on the AtT20 D16:16 cells to regulate 
ACTH release. The conditioned medium did, however, overcome the inhibitory 
effects of LPS upon CRH-driven ACTH release from the AtT20 D16:16 cells, thus 
supporting the premise that the synergistic effects of LPS and CRH in the co-cultures 
are dependent upon the release of a TtT/GF-derived mediator(s), which could be IL-
6, LIF or a combined effect of the two cytokines, although the concentration of these 
cytokines and other potential mediators (i.e. IL-10, TNFa, IL-11 and OSM) need to be 
measured in the conditioned medium to confirm this. Although the conditioned 
medium overcame the direct inhibitory effect of LPS upon ACTH release, it did not 
further potentiate the effects of CRH. This is likely to be because the conditioned 
medium was obtained from TtT/GF cells that were not cultured in the presence of the 
AtT20 D16:16 cells, which have been shown to cause increased TtT/GF cell-derived 
IL-6 release, possibly via a CRH-induced mediator(s), even in the presence of the 
NFKB inhibitor. Therefore, the concentration of IL-6 in the conditioned medium may 
have been too low to potentiate CRH-induced ACTH release, supporting the premise 
that bi-directional communication between the two cell types is an important requisite 
for the ACTH response to endotoxin. Moreover, although LPS potentiated CRH-
stimulated ACTH release from the AtT20 D16:16 cells when co-cultured with the 
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TtT/GF cells, the conditioned medium from LPS-stimulated TtT/GF cells wherein 
NFKB activity was inhibited failed to have an effect, providing further evidence that 
the actions of TtT/GF cell-derived mediators induced by LPS are dependent on NFKB 
activation. 
Whilst these findings support the involvement of paracrine-acting mediators in 
regulating the IL-6 and ACTH responses to LPS and CRH stimulation, the close 
contact the cells have when they are cultured together is also likely to be of 
importance. As the TtT/GF cell-conditioned medium, containing LPS-induced factors 
which stimulate ACTH release, was incubated for 7 hours prior to its addition to the 
AtT20 D16:16 cells, it is possible that such mediators were degraded, as cytokines 
have a relatively short half-life (Noguchi et al. 1996). In contrast, the AtT20 D16:16 
cells were exposed to TtT/GF cell-derived mediators rapidly, i.e. upon release, and 
they were situated close to the TtT/GF cells so that the mediators were not diluted in 
the medium before reaching the AtT20 D16:16 cells. This problem can be avoided 
with the use of Transwell® cell culture inserts which allows two cell types to be 
cultured separately but in the same culture medium. The use of such a system would 
allow the reciprocal communication between the two cell types to be further 
investigated and provide valuable information as to the importance of cell to cell 
contact between the TtT/GF and AtT20 D16:16 cells. 
Together, these findings support the premise that both folliculostellate cells and 
corticotrophs interact with one another in response to endotoxin, to increase ACTH 
release. Moreover, in addition to the classical actions of CRH on corticotrophs to 
increase ACTH secretion, CRH also indirectly increases ACTH release through the 
up-regulation of IL-6 release from folliculostellate cells. This is the first time, to our 
knowledge, that corticotrophs have been implicated in the modulation of 
folliculostellate cell-derived mediators (figure 4.10). 
4.5 Conclusion 
It is understood that LPS acts directly at the pituitary level to induce ACTH release, 
as well as acting indirectly via the induction of pro-inflammatory cytokines released 
from immune/inflammatory cells (Haddad et aL 2002). However, the mechanisms 
governing this response are unclear, although a role for folliculostellate cells has 
been identified (Gloddek et al. 2001). The current study has provided novel evidence 
that LPS-induced ACTH release, through its direct actions on the anterior pituitary 
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gland, involves interactions between the TtT/GF and AtT20 D16:16 cells and these 
interactions are modulated, at least in part, through paracrine-acting mediators. 
Potential mediators released from the TtT/GF and AtT20 D16:16 cells, and the 
pathways through which they act, are summarised in figure 4.10. 
The study has provided conclusive evidence that the potentiating effect of LPS upon 
ACTH release is mediated by NFKB-dependent factors released from the TtT/GF 
cells. We have also shown for the first time, to our knowledge, an additional pathway 
through which CRH increases ACTH release, i.e. through the production of 
corticotroph-derived mediators which, in turn, act on neighbouring folliculostellate 
cells to increase IL-6 production. The potentiating effects of IL-6 upon ACTH release 
in the presence of low concentrations of CRH suggest that this cytokine is important 
in activating the HPA axis during early endotoxaernia. However, the inhibitory effect 
of CRH upon ACTH release, via activation of corticotroph-NFKB, may occur to 
ensure the ACTH response is contained, allowing an effective pro-inflammatory 
response to be mounted prior to increased glucocorticoid release. Together, these 
findings have provided further information as to how the extremely complex 
interactions that occur at the level of the anterior pituitary ensure the HPA response 
to endotoxin is tightly regulated. 
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Figure 4.10 Diagrammatic 	representation 	illustrating the 	proposed 
mechanisms by which LPS and CRH act on TtT/GF and AtT20 D16:16 cells to 
regulate IL-6 and ACTH synthesis and release. Red arrows indicate stimulatory 
pathways, blue arrows indicate inhibitory pathways and dotted lines indicate 
proposed pathways. Pathway (1) illustrates LPS stimulated NFKB activity in TtT/GF 
cells, leading to IL-6 synthesis and release (which is sensitive to the inhibitory effects 
of glucocorticoids), which in turn acts on neighbouring AtT20 D16:16 cells to 
stimulate POMC synthesis and ACTH release via the IL-Ra/gp130 receptor complex. 
Pathways (2) and (3) show LPS and CRH/urocortin stimulated NFKB activity in AtT20 
D16:16 cells respectively, leading to both the inhibition of ACTH synthesis and 
release and COX-2 mediated PGE2 synthesis, which in turn acts on the TtT/GF cells 
to increase IL-6 release and on AtT20 D16:16 cells to inhibit ACTH release. CRH 
stimulated ACTH secretion from AtT20 D16:16 cells through CRH-R1 is illustrated in 
pathway (4), and pathway (5) shows CRH-induced AtT20 D16:16 derived 
mediator(s), such as 12(S)-HETE and MIF acting on neighbouring TtT/GF cells to 
stimulate IL-6 release. MIF may increase IL-6 release either through interaction with 
its receptor, CD74, or through endocytosis. 12(S)-HETE, 12(S)-
hydroxyeicosatetraenoic acid; ACTH, adrenocorticotrophic hormone; COX-2, 
cyclooxygenase 2; CRH, corticotrophin-releasing hormone; CRH-R, corticotrophin-
releasing hormone receptor; GC, glucocorticoid; IL-6, interleukin 6; IL-6Ra, 
interleukin 6 receptor alpha; LPS, lipopolysaccharide; MIF, macrophage inhibitory 
factor; NFKB, nuclear factor kappa B; PGE2, prostaglandin E2; POMC, 
proopiomelanocortin; TIr4, toll-like receptor 4; Ucn, urocortin. 
203 
4.6 Future studies 
Although an important role for folliculostellate cell-derived IL-6 in mediating the ACTH 
response to endotoxin has been demonstrated, the studies indicate the involvement 
of other mediators, possibly including LIF and other gp130 cytokines. Further work is 
required to ascertain whether LPS induces LIF release from the TtT/GF cells and 
whether LIF, alone and in combination with IL-6, potentiates CRH-induced ACTH 
release in the current model. Further work is also required to identify potential 
corticotroph-derived mediator(s) (which may include MIF) that are involved in 
increasing LPS-stimulated IL-6 release from folliculostellate cells. Although studies of 
immune cells in vitro have demonstrated that CRH induces NFKB activation through 
CRH-R2 (Zhao & Karalis 2002), it is unclear whether the signalling mechanism is the 
same in corticotrophs. Therefore more work is required to identify the receptor 
through which CRH activates NFKB in the AtT20 D16:16 cells (see section 3.8), 
which can be achieved using specific CRH-R inhibitors [reviewed in (Hillhouse & 
Grammatopoulos 2006)]. The premise that urocortin, which preferentially binds to 
CRH-R2, may activate NFKB in corticotrophs to induce potential IL-6 secretagogues 
e.g. via COX-2 dependent prostaglandin synthesis or MIF (section 4.4.4), warrants 
further investigation to further our understanding into the mechanisms through which 
NFKB is activated in corticotrophs. 
Within the AtT20 D16:16 cells, NFKB signalling has been shown to play an inhibitory 
role in CRH stimulated ACTH release. Thus, targeting NFKB for therapeutic 
treatment of inflammatory disorders may lead to increased levels of ACTH release 
and thus, a hyper-active HPA response if the individual is under immunological 
stress. Furthermore, treatment with NFKB inhibitors may impair the negative 
feedback actions of glucocorticoids, leading to prolonged hypercortisolemia and 
dysregulation of the HPA axis which in turn can lead to an array of diseases, 
including severe forms of depression (Gibbons & Mc 1962; Carpenter & Bunney 
1971; Gillespie & Nemeroff 2005), type II diabetes and cardiovascular disease 
(Bjorntorp et al. 1999). It is clear from these findings that NFKB is involved 
modulating the HPA response to immunological stress, providing a link between the 
interactions between the endocrine and immune systems, at least at the level of the 
anterior pituitary gland. Additionally, NFKB signalling has been demonstrated 
throughout the brain, specifically in limbic regions, hypothalamic nuclei and within 
brain stem nuclei associated with cranial nerves (Joseph et al. 1996; Lee & Rivier 
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2005). Therefore, the effects of NFKB blockade upon the HPA response to 
immunological stress need to be investigated, using in vivo models, to further 
understand the extend to which this transcription factor is involved in regulating the 
HPA response to stress. 
Although activation of the HPA axis in response to psychological stress does not 
involve an immune component, restraint stress, which is regarded as a form of 
psychological stress (Pare & Glavin 1986; Glavin et al. 1994), increases NFKB 
activity in the rat brain (Garcia-Bueno et al. 2005). Furthermore, activation of NFKB in 
human PBMCs in response to psychosocial stress, which may occur through 
interactions of noradrenaline with al- and p-adrenergic receptors, leads to activation 
of the MAPKinase pathway and subsequent NFKB nuclear translocation (Bierhaus et 
al. 2003). Therefore, in addition to investigating the role of NFKB in the HPA 
response to immunological stress, its role in psychological stress warrants further 
investigation. To this end, the following chapter examines the effects of inhibiting 
NFKB upon ACTH, corticosterone and pro-inflammatory cytokine release (IL-6 and 
TNFa) from rat models subjected to either immunological (LPS) or psychological 
(restraint) stress. 
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5 	Role of NFxB in the regulation of the HPA axis 
5.1 Introduction 
Immunological stress is a potent activator of the HPA axis, ultimately leading to 
restoration of physiological homeostasis through the anti-inflammatory actions of 
released glucocorticoids [reviewed by (Buckingham 1996)]. The mechanisms 
underlying the interplay between the immune system and the HPA axis are now 
understood to involve the actions of pro-inflammatory cytokines, in particular IL-6. 
Injection of the endotoxin LPS, in vivo increases the plasma concentrations of IL-6 
(Kakizaki et al. 1999) which, in turn, stimulate the release of ACTH (Fukata et aL 
1989; Bethin et al. 2000). In addition to the stimulatory effect of IL-6 released from 
activated immune cells into the systemic circulation, IL-6 is also produced within the 
anterior pituitary gland by folliculostellate cells. Transcriptional regulation of the IL-6 
gene in many cell types (e.g. macrophages, endothelial cells, microglial cells, 
dendritic cells) is dependent in part on NFKB signalling (Takatsuna et al. 2005). Thus, 
the activation of the HPA axis by immunological stress may be, at least in part, 
dependent on NFKB (Ji et al. 2004). 
The previous chapters have provided evidence that LPS-induced ACTH release is 
positively regulated by NFKB signalling in folliculostellate cells and negatively 
regulated by NFKB signalling in corticotrophs (chapters 3 and 4). However, the 
involvement of NFKB in activating the HPA axis may not be confined to conditions of 
immunological stress. Indirect evidence for a role of NFKB in mediating cellular 
effects in response to psychological stress stems from animal studies describing 
stress-induced NFKB activation and subsequent NFKB-dependent gene expression 
in the brain cortex of rats exposed to immobilisation stress (Madrigal et al. 2002). 
Increased NFKB activity has also been detected in blood lymphocytes of females 
stressed by the experience of breast biopsy (Nagabhushan et al. 2001). Furthermore, 
in vivo studies have described increased plasma concentrations of IL-6 in response 
to psychological stress such as footshock and immobilisation stress, which may be 
attributed to activation of NFKB (Zhou et al. 1993). These findings provide strong 
evidence of a role for NFKB in modulating HPA responses to both immunological and 
psychological stress. 
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NFKB is an important mediator of the immune response to stress, and its activation 
results in increased expression of many genes involved in the inflammatory response 
[reviewed in (Ozato et al. 2002)]. Therefore drugs, which target NFxB activation in 
patients with chronic inflammatory disorders, such as rheumatoid arthritis, could 
provide potential therapeutic treatment (Carlsen et al. 2004; Kulms & Schwarz 2006). 
However, whilst such compounds may be effective in treating such disorders, the 
additional side effects NFKB inhibition may have upon the HPA axis have not been 
addressed. Therefore, the aim of this study was to investigate the effects of NFKB 
inhibition upon the HPA responses to both immunological and psychological stress. 
5.2 	Experimental design 
5.2.1 Immunological stress — LPS 
For the immunological stress model (section 2.4.3), male Sprague-Dawley rats 
(section 2.1) were injected with either vehicle (4001.11 i.p., sterile physiological saline) 
or LPS (5mg/kg i.p., Escherichia coli serotype 055:B5). Control animals were not 
subjected to any treatment. Initial time course studies were performed to examine the 
optimal time for ACTH (IRMA; section 2.4.17) and corticosterone (RIA; section 
2.4.18) responses following LPS challenge. Plasma IL-6 and TNFa concentrations 
(ELISA; section 2.4.15) were measured as a marker of immunological activation and 
the effects LPS on NRc6 activity in the anterior pituitary gland were examined by 
EMSA (section 2.4.12). For comparison, DNA binding activity of NFKB was also 
examined in thymic tissue. 
5.2.2 Effects of the IKK8 inhibitor, PHA781535E, on LPS-induced HPA 
activation 
Following the determination of the optimal time point for immunological (IL-6; figure 
5.2) and HPA (ACTH and corticosterone; figure 5.1A and B) activation in response to 
LPS, the effects of suppressing LPS induced NFKB activation upon these parameters 
were examined (section 2.4.4). Rats were treated with either the NFKB inhibitor, 
PHA781535E (25 or 50mg/kg, p.o.), or the vehicle solution [400µI, methylcellulose 
(0.5% w/v) tween (0.1% w/v) p.o.] orally, 2 hours prior to injection of LPS (5mg/kg, 
i.p., Escherichia coli serotype 055:65) or saline (400111 i.p., physiological saline). 
Blood and tissues were collected 2 hours later for analysis. The control animals were 
not subjected to any treatment. Elevated concentrations of the pro-inflammatory 
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cytokine TNFa (which is both regulated by, and stimulates, NFKB activation) have 
been reported in models of endotoxaemia (Kakizaki et al. 1999) and therefore, 
plasma TNFa concentrations were also examined (ELISA; section 2.4.16) as an 
indicator of immunological stress induced by LPS, and NFKB inhibition by 
PHA781535E administration. 
5.2.3 Psychological stress — restraint 
For the psychological stress model, male Sprague-Dawley rats were subjected to 
restraint stress (section 2.4.1). Initial studies examined the optimal time point for HPA 
activation by measuring ACTH (IRMA; section 2.4.17) and corticosterone (RIA; 
section 2.4.18) plasma concentrations at intervals after stress. Rats were restrained 
either for (a) 15 or 30 minutes and killed immediately or for (b) 30 minutes followed 
by either a 30 or 60 minute recovery period (rodents were returned to their housing 
cage for the recovery period). For the assessment of cytokine activation, plasma IL-6 
concentrations (ELISA; section 2.4.15) were measured. Although NFKB activation 
following psychological stress has been reported in the brain cortex (Madrigal et al. 
2002) and PBMCs (Nagabhushan et al. 2001), to our knowledge, its activity in the 
anterior pituitary gland under these conditions has not. Therefore, the effect of 
restraint stress upon NFKB activity in the anterior pituitary gland were assessed 
(EMSA; section 2.4.12). For a comparison of NFKB activity in distal organs, NFKB 
DNA-binding activity was also examined in thymic and adrenal tissue. 
5.2.4 Effects of the IKK8 inhibitor, PHA781535E, on restraint stress-induced 
HPA activation 
Following the determination of the optimal time point for HPA activation in response 
to restraint stress, the effects of NFKB inhibition upon these parameters were 
examined (section 2.4.2). Male adult rats were treated either with the vehicle solution 
(400111, methylcellulose-tween, p.o.) or with PHA781535E (25 or 50mg/kg, p.o.) 2 
hours prior to being subjected to 15 minutes of restraint stress, the optimal time of 
restraint exposure where both ACTH and corticosterone concentrations were 
significantly elevated (figure 5.17A and B). Psychological stress exposure has also 
been associated with increased plasma TNFa concentrations (Yamasu et al. 1992; 
Nukina et al. 1998), and therefore, the effects of restraint stress, in the presence and 
absence of PHA781353E, upon plasma TNFa concentrations (ELISA; section 2.4.16) 
were also included in the study. 
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5.3 	Results — Immunological stress (LPS) 
5.3.1 Effects of LPS upon the plasma ACTH and corticosterone 
concentrations 
The LPS vehicle (saline; 400µ1, i.p.) did not affect basal plasma concentrations of 
ACTH (2 and 4 hours, p=0.966), but LPS (5mg/kg, i.p.) challenge resulted in a 
significant increase in plasma ACTH concentration (2 hours, p<0.001 vs untreated 
control; figure 5.1A). Four hours after the injection, the plasma ACTH concentration 
had declined (p<0.01 vs 2 hours), although it remained higher than the basal 
concentration (p<0.001; figure 5.1A). 
The basal plasma concentration of corticosterone was unaffected by injection of 
saline (4000, i.p.) 2 or 4 hours (p=0.899; figure 5.1B) previously. LPS (5mg/kg, i.p.) 
administration induced a significant increase in plasma corticosterone concentration 
within 2 hours (p<0.001; figure 5.1B) which was maintained for at least a further 2 
hours (2 hours LPS vs 4 hours LPS, p=0.110; figure 5.1B). 
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Figure 5.1 	Time-dependent effects of LPS (5mg/kg i.p.) on the plasma (A) 
ACTH and (B) corticosterone concentrations. Rats in the untreated group 
remained in their housing cages until collection and vehicle treated groups were 
injected with saline (400µI i.p.) for 2 or 4 hours. Untreated (control) and treated 
groups are the mean of five samples ± SEM. "p<0.001 vs untreated control, 
mp<0.001 vs 2 hour saline, ***p<0.001 vs 4 hour saline, #4p<0.01 vs 2 hour LPS. 
Analysis was performed by two-way ANOVA with post hoc comparison using 
Bonferroni's t-test. ACTH, adrenocorticotrophin; LPS, lipopolysaccharide. 
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5.3.2 Effect of LPS upon the plasma IL-6 concentration 
IL-6 was undetectable by ELISA in the plasma collected from untreated rats or rats 
treated with saline 2 or 4 hours previously (figure 5.2). By contrast, IL-6 was readily 
detectable in the plasma of rats challenged with LPS (figure 5.2). Marked elevations 
in the plasma IL-6 concentration were thus evident with 2 hours of the injection 
(p<0.001 vs control; figure 5.2). These declined over the next 2 hours (2 hours LPS 
vs 4 hours LPS, p<0.01), but remained significantly higher than basal (p<0.001; 
figure 5.2). 
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Figure 5.2 	Time-dependent effects of LPS (5mg/kg, i.p.) on the plasma IL-6 
concentration. Rats in the untreated group remained in their housing cages until 
collection. Blood was collected 2 or 4 hours after the injection of saline (4000) or 
LPS (5mg/kg). Untreated (control) and treated groups are the mean of five samples ± 
SEM. 'p<0.001 vs untreated control, ttt- p<0.001 vs 2 hour saline, ***p<0.001 vs 4 
hour saline, tmp<0.01 vs 2 hour LPS. Analysis was performed by two-way ANOVA 
with post hoc comparison using Bonferroni's t-test. IL-6, interleukin 6; LPS, 
lipopolysaccharide; ND, not detectable. 
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5.3.3 Effect of LPS treatment in vivo, on NFKB activity in rat anterior pituitary 
tissue 
Basal DNA-binding activity of NFKB was low in pituitary tissue extracted from 
untreated rats (lanes 1-4; figure 5.3A and 5.4A). There was no detectable change in 
NFKB activity 2 hours (lanes 5-8; figure 5.3A) or 4 hours (lanes 5-8; figure 5.4A) after 
the injection of saline. By contrast, LPS (5mg/kg) caused a marked increase in NFKB 
DNA-binding at 2 hours (p<0.05 vs control and 2 hour saline; 2 hour LPS - lanes 9-
12, untreated control - lanes 1-4 and saline-injected control - lanes 5-8; figure 5.3A 
and B) and 4 hours (p<0.05 vs control and 4 hour saline; 4 hour LPS - lanes 9-12, 
untreated control - lanes 1-4 and saline-injected control - lanes 5-8; figure 5.4A and 
B). 
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Figure 5.3 	Detection of NFKB DNA-binding activity in anterior pituitary 
tissue extracted from LPS (5mg/kg, i.p., 2 hours) and saline (4000, i.p., 2 hours) 
treated rats by (A) electrophoretic mobility shift assay (EMSA). (a) Densitometric 
analysis of the bands representing the p65/p50 heterodimer [each group represents 
the mean optical density of four samples ± SEM and is expressed as percentage of 
control (untreated)]. Lanes 1-4, untreated; lanes 5-8, saline; lanes 9-12, LPS. 
+p<0.05 vs untreated control, tp<0.05 vs 2 hour saline. Analysis of densitometric 
results was performed by Kruskal-Wallis one-way ANOVA on ranks with the Student-
Newman-Keuls post hoc method. Con, untreated control; LPS, lipopolysaccharide; 
NFKB, nuclear factor kappa B; ns, non-specific binding reaction (AP-1); OD, optical 
density; s, specific binding reaction (NFKB). 
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Figure 5.4 	Detection of NFicB DNA-binding activity in anterior pituitary 
tissue extracted from LPS (5mg/kg, i.p., 4 hours) and saline (400µ1, i.p., 4 hours) 
treated rats by (A) electrophoretic mobility shift assay (EMSA). (B) Densitometric 
analysis of the bands representing the p65/p50 heterodimer [each group represents 
the mean optical density of four samples ± SEM and is expressed as percentage of 
control (untreated)]. Lanes 1-4, untreated; lanes 5-8, saline; lanes 9-12, LPS. 
+p<0.05 vs untreated control, tp<0.05 vs 4 hour saline. Analysis of densitometric 
results was performed by Kruskal-Wallis one-way ANOVA on ranks with the Student-
Newman-Keuls post hoc method. Con, untreated control; LPS, lipopolysaccharide; 
NFKB, nuclear factor kappa B; ns, non-specific binding reaction (AP-1); OD, optical 
density; s, specific binding reaction (NFKB). 
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5.3.4 Effect of LPS treatment in vivo, on NFKB activity in rat thymic tissue 
The basal NFKB DNA-binding activity (lanes 1-4; figure 5.5A and 5.6A) was 
unchanged 2 hours (p>0.05, lanes 5-8; figure 5.5A and B) and 4 hours after saline 
injection (p>0.05, lanes 5-8; figure 5.6A and B). LPS injection increased NFKB activity 
(lanes 9-12) in the thymus gland at both 2 and 4 hours (2 hours, p<0.05 vs untreated 
control and p<0.05 vs saline control and 4 hours, p<0.05 vs saline control; figure 5.5A 
and B and 5.6A and B). 
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Figure 5.5 	Detection of NFKB DNA-binding activity in thymic tissue 
extracted from LPS (5mg/kg, i.p., 2 hours) and saline (400µI, i.p., 2 hours) 
treated rats by (A) electrophoretic mobility shift assay (EMSA). (B) Densitometric 
analysis of the bands representing the p65/p50 heterodimer [each group represents 
the mean optical density of four samples ± SEM and is expressed as percentage of 
control (untreated)]. Lanes 1-4, untreated; lanes 5-8, saline; lanes 9-12, LPS. 
+p<0.05 vs untreated control, tp<0.05 vs 2 hour saline. Analysis of densitometric 
results was performed by Kruskal-Wallis one-way ANOVA on ranks with the Student-
Newman-Keuls post hoc method. Con, untreated control; LPS, lipopolysaccharide; 
NFKB, nuclear factor kappa B; NS, not significant; ns, non-specific binding reaction 
(AP-1); OD, optical density; s, specific binding reaction (NFKB). 
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Figure 5.6 	Detection of NFx13 DNA-binding activity in thymic tissue 
extracted from LPS (5mg/kg, i.p., 4 hours) and saline (4000, i.p., 4 hours) 
treated rats by (A) electrophoretic mobility shift assay (EMSA). (B) Densitometric 
analysis of the bands representing the p65/p50 heterodimer [each group represents 
the mean optical density of four samples ± SEM and is expressed as percentage of 
control (untreated)]. Lanes 1-4, untreated; lanes 5-8, saline; lanes 9-12, LPS. 
tp<0.05 vs 4 hour saline. Analysis of densitometric results was performed by Kruskal-
Wallis one-way ANOVA on ranks with the Student-Newman-Keuls post hoc method. 
Con, untreated control; LPS, lipopolysaccharide; NFKB, nuclear factor kappa B; NS, 
not significant; ns, non-specific binding reaction (AP-1); OD, optical density; s, 
specific binding reaction (NFKB). 
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5.3.5 Effects of LPS treatment in vivo, on NFKB activity in rat adrenal tissue 
The basal DNA-binding activity of NFKB in adrenal tissue extracted from rats was not 
affected by saline treatment at 2 hours (p>0.05, lanes 9-12, figure 5.7A and B) or at 4 
hours (p>0.05, lanes 5-8, figure 5.8A and B). In contrast, LPS exposure for 2 hours 
(lanes 5-8; figure 5.7A), but not 4 hours (lanes 9-12; figure 5.8A), resulted in an 
increase in NFKB activity compared to basal activity (p<0.05 vs control, lanes 1-4; 
figure 5.7B). 
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Figure 5.7 	Detection of NFKB DNA-binding activity in adrenal tissue 
extracted from LPS (5mg/kg, i.p., 2 hours) and saline (400µ1, i.p., 2 hours) 
treated rats by (A) electrophoretic mobility shift assay (EMSA). (B) Densitometric 
analysis of the bands representing the p65/p50 heterodimer [each group represents 
the mean optical density of four samples ± SEM and is expressed as percentage of 
control (untreated)]. Lanes 1-4, untreated; lanes 5-8, saline; lanes 9-12, LPS. 
+p<0.05 vs untreated control, tp<0.05 vs 2 hour saline. Analysis of densitometric 
results was performed by Kruskal-Wallis one-way ANOVA on ranks with the Student-
Newman-Keuls post hoc method. Con, untreated control; LPS, lipopolysaccharide; 
NFKB, nuclear factor kappa B; ns, non-specific binding reaction (AP-1); OD, optical 
density; s, specific binding reaction (NFKB). 
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Figure 5.8 	Detection of NFx13 DNA-binding activity in adrenal tissue 
extracted from LPS (5mg/kg, i.p., 4 hours) and saline (400µI, i.p., 4 hours) 
treated rats by (A) electrophoretic mobility shift assay (EMSA). (B) Densitometric 
analysis of the bands representing the p65/p50 heterodimer [each group represents 
the mean optical density of four samples ± SEM and is expressed as percentage of 
control (untreated)]. Lanes 1-4, untreated; lanes 5-8, saline; lanes 9-12, LPS. 
Analysis of densitometric results was performed by Kruskal-Wallis one-way ANOVA 
on ranks with the Student-Newman-Keuls post hoc method. Con, untreated control; 
LPS, lipopolysaccharide; NFKB, nuclear factor kappa B; NS, not significant; NS, not 
significant; ns, non-specific binding reaction (AP-1); OD, optical density; s, specific 
binding reaction (NFKB). 
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5.3.6 Effects of the IKKI3 inhibitor, PHA781353E, on LPS stimulated plasma 
ACTH and corticosterone concentrations 
The findings outlined in sections 5.3.1 and 5.3.2 showed the optimal time point for 
increased plasma concentrations of ACTH (figure 5.1A), corticosterone (figure 5.1B) 
and IL-6 (figure 5.2) following LPS (5mg/kg, i.p.) injection was 2 hours. LPS (5mg/kg, 
i.p.) also induced, within 2 hours, an increase in NFKB activity in the anterior pituitary 
(figure 5.3), thymus (figure 5.5) and adrenal glands (figure 5.7). Therefore, the effects 
of the NFKB inhibitor, PHA781535E (25 and 50mg/kg, p.o.), upon these parameters 
was investigated in rats challenged with LPS (5mg/kg, i.p.) for 2 hours (see section 
3.4.3). 
	
5.3.6.1 	Effects of treatment with PHA781535E and LPS vehicles on the 
plasma ACTH and corticosterone concentrations 
Administration of the PHA781353E vehicle, methylcellulose-tween (400µI, p.o.), 2 
hours prior to administration of the LPS vehicle (physiological saline, 400111, i.p.) had 
no significant effect on the plasma ACTH or corticosterone concentrations (ACTH, 
p=0.319 vs saline; corticosterone, p=0.663 vs saline; figure 5.9A and B). Therefore, 
any changes in ACTH and corticosterone concentrations following treatment with 
PHA781353E and/or LPS could not be attributed to the effects of either vehicle. 
5.3.6.2 	Effect of PHA781535E treatment upon LPS-induced plasma ACTH 
concentrations 
LPS caused a highly significant increase in plasma ACTH concentration (p<0.001 vs 
basal; figure 5.9A). Whilst PHA781535E treatment alone did not affect the resting 
plasma concentration of ACTH (25mg/kg, p=1.00; 50mg/kg, p=1.00) at both doses 
tested, 25mg/kg (p<0.001) and 50mg/kg (p<0.001), it attenuated the stimulatory 
effect of LPS on ACTH release (figure 5.9A). 
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5.3.6.3 Effect of PHA781535E treatment upon LPS-induced plasma 
corticosterone concentrations 
LPS caused a highly significant increase in the plasma concentration of 
corticosterone (p<0.001 vs basal; figure 5.9B) which was unaffected by PHA781535E 
treatment at both doses tested (25mg/kg, p=1.00; 50mg/kg, p=0.780; figure 5.9B). 
However, whilst treatment with the lower dose of 25mg/kg PHA781535E alone did 
not alter the basal plasma corticosterone concentration (p=1.00 vs basal), treatment 
with the higher dose (50mg/kg) significantly increased the basal corticosterone 
concentration (p<0.01 vs basal; figure 5.9B). 
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Figure 5.9 	Effects of the IKKO inhibitor, PHA781535E (25 and 50mg/kg, p.o., 
4 hours), on plasma (A) ACTH and (B) corticosterone concentrations in LPS 
(5mg/kg, i.p., 2 hours) treated rats. Rats were treated with either PHA781535E or 
the vehicle (methylcellulose-tween; 4000, p.o.) for 2 hours prior to LPS or saline 
(400µI; i.p.) administration. Untreated (control) and treated groups are the mean of 
five samples ± SEM. 'p<0.01, 'p<0.001 vs methylcellulose-tween + saline treated 
controls, tttp<0.001 vs methylcellulose-tween + LPS, ***p<0.001 vs 25mg/kg 
PHA781535E + saline. Analysis was performed by two-way ANOVA with post hoc 
comparison using Bonferroni's t-test. ACTH, adrenocorticotrophin; LPS, 
lipopolysaccharide; met, methylcellulose-tween; PHA, PHA781353E; Sal, saline. 
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5.3.7 Effects of the IKK6 inhibitor, PHA781353E, on plasma IL-6 and TNFa 
concentrations in LPS treated rats 
The concentrations of IL-6 and TNFa in the plasma of untreated and vehicle treated 
groups (methylcellulose tween and/or saline) were below the detection limit of the 
ELISA assays, but treatment with LPS for 2 hours induced a significant increase in 
the plasma concentrations of IL-6 (p<0.001 vs control; figure 5.10A) and TNFa 
(p<0.001 vs control; figure 5.10B). Treatment with PHA781353E dose-dependently 
inhibited the LPS-induced increase in plasma TNFa concentration (25mg/kg, p<0.01 
vs LPS and 50mg/kg, p<0.001 vs LPS; figure 5.10B). Similarly, the higher (50mg/kg, 
p<0.01 vs LPS), but not the lower (25mg/kg, p=0.885) dose of PHA781353E 
attenuated the increase in plasma IL-6 concentration induced by LPS (figure 5.10A). 
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Figure 5.10 Effects of the IKKO inhibitor, PHA781535E (25 and 50mg/kg, p.o., 
4 hours), on the plasma concentrations of (A) IL-6 and (B) TNFa in LPS (5mg/kg, 
i.p., 2 hours) treated rats. Rats were treated with either PHA781535E or the vehicle 
(methylcellulose-tween; 400µ1, p.o.) for 2 hours prior to LPS or saline (400111, i.p.) 
administration. Untreated (control) and treated groups are the mean of five samples ± 
SEM. IL-6 and TNFa concentrations were undetectable in control, vehicle treated 
and PHA781353E treated groups. +++p<0.001 vs methylcellulose-tween + saline 
treated control, ttp<0.01, ttt- p<0.001 vs methylcellulose-tween + LPS. Analysis was 
performed by two-way ANOVA with post hoc comparison using Bonferroni's t-test. IL-
6, interleukin 6; LPS, lipopolysaccharide; ND, not detected; PHA, PHA781353E; 
TNFa, tumour necrosis factor alpha. 
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5.3.8 Effect of the IKKr3 inhibitor, PHA781353E, on NFicB activity in anterior 
pituitary tissue extracted from LPS treated rats 
The activity of NFKB in nuclear extracts of pituitary tissue from rats that were pre-
treated with either vehicle (methylcellulose-tween, 400µ1, p.o.) or the NFKB inhibitor, 
PHA781535E (25 and 50mg/kg, p.o.) 2 hours prior to saline (4000, i.p.) or LPS 
(5mg/kg, i.p.) injection was investigated 2 hours after the final injection. 
Pituitary tissue from rats treated with either the vehicle (methylcellulose-tween, lanes 
1-2; figure 5.11A and B) or PHA781535E, followed by saline injection (lanes 6-8; 
25mg/kg: figure 5.11A and 50mg/kg; figure 5.12A), exhibited a decrease in basal 
NFKB DNA-binding activity (figure 5.11A and B and 5.12A and B). LPS injection 
increased NFKB activity (lanes 3-5; figure 5.11A and B and 5.12A and B) compared to 
the untreated (lane c) and vehicle treated groups (lanes 1-2; figure 5.11A and B and 
5.12A and B). Pre-treatment with PHA781353E reduced LPS-stimulated NFKB activity 
(lanes 9-11; 25mg/kg; figure 5.11A and B and 50mg/kg; figure 5.12 A and B). 
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Figure 5.11 Effect of the IKKI3 inhibitor, PHA781353E (25mg/kg, p.o., 4 hours), 
on LPS (5mg/kg, i.p., 2 hours) stimulated NFKB activity in anterior pituitary 
tissue, detected by (A) electrophoretic mobility shift assay (EMSA). (B) 
Densitometric analysis of the bands representing the p65/p50 homodimer [control is 
based on the optical density of 1 sample, vehicle + saline group represent the mean 
optical density of 2 samples and LPS and PHA781535E treated groups represent the 
mean optical density of 3 samples. Data are expressed as percentage of control 
(untreated)]. The points on the histogram represent the range values. Rats were 
treated with either PHA781535E or the vehicle (methylcellulose-tween; 400111, p.o.) 2 
hours prior to LPS or saline (400µ1, i.p.) injection. Lane c, untreated control; lanes 1-
2, methylcellulose-tween + saline; lanes 3-5, methylcellulose-tween + LPS; lanes 6-8, 
PHA781353E + saline; lanes 9-11, PHA781353E + LPS. LPS, lipopolysaccharide; 
NFKB, nuclear factor kappa B; ns, non-specific binding reaction (AP-1); OD, optical 
density; PHA, PHA781535E; s, specific binding reaction (NFKB); Sal, saline; V, 
vehicle (methylcellulose-tween-saline. 
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Figure 5.12 Effect of the IKKi3 inhibitor, PHA781353E (50mg/kg, p.o., 4 hours), 
on LPS (5mg/kg, i.p., 2 hours) stimulated NFKB activity in anterior pituitary 
tissue, detected by (A) electrophoretic mobility shift assay (EMSA). (B) 
Densitometric analysis of the bands representing the p65/p50 homodimer [control 
group is based on the optical density of 1 sample, vehicle + saline group represent 
the mean optical density of 2 samples and LPS and PHA781535E treated groups 
represent the mean optical density of 3 samples. Data are expressed as percentage 
of control (untreated)]. The points on the histogram represent the range values. Rats 
were treated with either PHA781535E or the vehicle (methylcellulose-tween; 404.1, 
p.o.) 2 hours prior to LPS or saline (400111, i.p.) injection. Lane c, untreated control; 
lanes 1-2, methylcellulose-tween + saline; lanes 3-5, methylcellulose-tween + LPS; 
lanes 6-8, PHA781353E + saline; lanes 9-11, PHA781353E + LPS. LPS, 
lipopolysaccharide; NFKB, nuclear factor kappa B; ns, non-specific binding reaction 
(AP-1); OD, optical density; PHA, PHA781535E; s, specific binding reaction (NFKB); 
Sal, saline; V, vehicle (methylcellulose-tween-saline. 
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5.3.9 Effect of the IKK8 inhibitor, PHA781353E, on NFKB activity in thymic 
tissue extracted from LPS treated rats 
The effects of PHA781535E (25 and 50mg/kg, p.o.) treatment on LPS (5mg/kg, i.p., 2 
hours) induced NFKB activity in excised thymic tissue was also investigated. 
Administration of methylcellulose-tween (4000, p.o.) or saline (4000, i.p.) increased 
thymic NFKB activity (lanes 1-2; figure 5.13A and B and 5.14A and B) compared to the 
untreated control (lane c; figure 5.13A and B and 5.14A and B). LPS failed to cause a 
further increase in NFKB activity (lanes 3-6; figure 5.13A and B and lanes 3-5; figure 
5.14A and B compared to the vehicle and saline treated groups, lanes 1-2; figure 
5.13A and B and 5.14A and B). However, PHA781535E (25mg/kg PHA781535E + 
saline, lanes 7-9 and 25mg/kg PHA781535E + LPS, lanes 10-12; figure 5.13A and B 
and 50mg/kg PHA781535E + saline, lanes 6-8 and 50mg/kg PHA781535E + LPS, 
lanes 9-11; figure 5.14A and B) reduced NFKB activity to levels comparable to the 
control in both LPS and saline-treated animals (figure 5.13A and B and 5.14A and B). 
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Figure 5.13 Effect of the IKK13 inhibitor, PHA781353E (25mg/kg, p.o., 4 hours), 
on LPS (5mg/kg, i.p., 2 hours) stimulated NFKB activity in thymic tissue, 
detected by (A) electrophoretic mobility shift assay (EMSA). (B) Densitometric 
analysis of the bands representing the p65/p50 homodimer [control group is based 
on the optical density of 1 sample, vehicle + saline group represent the mean optical 
density of 2 samples and LPS and PHA781535E treated groups represent the mean 
optical density of 3 samples. Data are expressed as percentage of control 
(untreated)]. The points on the histogram represent the range values. Rats were 
treated with either PHA781535E or the vehicle (methylcellulose-tween; 4000, p.o.) 2 
hours prior to LPS or saline (4000, i.p.) injection. Lane c, untreated control; lanes 1-
2, methylcellulose-tween + saline; lanes 3-5, methylcellulose-tween + LPS; lanes 6-8, 
PHA781353E + saline; lanes 9-11, PHA781353E + LPS. LPS, lipopolysaccharide; 
NFKB, nuclear factor kappa B; ns, non-specific binding reaction (AP-1); OD, optical 
density; PHA, PHA781535E; s, specific binding reaction (NFKB); Sal, saline; V, 
vehicle (methylcellulose-tween-saline. 
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Figure 5.14 Effect of the IKKI3 inhibitor, PHA781353E (50mg/kg, p.o., 4 hours), 
on LPS (5mg/kg, i.p., 2 hours) stimulated NFKB activity in thymic tissue, 
detected by (A) electrophoretic mobility shift assay (EMSA). (B) Densitometric 
analysis of the bands representing the p65/p50 homodimer [control group is based 
on the optical density of 1 sample, vehicle + saline group represent the mean optical 
density of 2 samples and LPS and PHA781535E treated groups represent the mean 
optical density of 3 samples. Data are expressed as percentage of control 
(untreated)]. The points on the histogram represent the range values. Rats were 
treated with either PHA781535E or vehicle (methylcellulose-tween; 4001,11, p.o.) 2 
hours prior to LPS or saline (4000, i.p.) injection. Lane c, untreated control; lanes 1-
2, methylcellulose-tween + saline; lanes 3-5, methylcellulose-tween + LPS; lanes 6-8, 
PHA781353E + saline; lanes 9-11, PHA781353E + LPS. LPS, lipopolysaccharide; 
NFKB, nuclear factor kappa B; ns, non-specific binding reaction (AP-1); OD, optical 
density; PHA, PHA781535E; s, specific binding reaction (NFKB); Sal, saline; V, 
vehicle (methylcellulose-tween-saline. 
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5.3.10 Effect of the IKK0 inhibitor, PHA781353E, on NFKB activity in adrenal 
tissue extracted from LPS treated rats 
NFKB DNA-binding activity in the adrenal tissue extracted from untreated (lane c), or 
vehicle treated groups (lanes 1-2) was barely detectable (figure 5.15A and B and 
5.16A and B). Both PHA781535E and saline (lanes 1-2) and vehicle and LPS (lanes 
3-4; figure 5.15A and lanes 3-5; figure 5.16A) increased basal NFKB activity to the 
same degree (figures 5.15B and 5.16B), but pre-treatment of LPS-injected rats with 
25mg/kg PHA781535E resulted in a slight reduction in NFKB activity (lanes 8-10; 
figure 5.15A and B), whilst 50mg/kg PHA781535E failed to have an effect (lanes 8-
10; figure 5.16A and B). 
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Figure 5.15 Effect of the IKKf3 inhibitor, PHA781353E (25mg/kg, p.o., 4 hours), 
on LPS (5mg/kg, i.p., 2 hours) stimulated NFKB activity in adrenal tissue, 
detected by (A) electrophoretic mobility shift assay (EMSA). (B) Densitometric 
analysis of the bands representing the p65/p50 homodimer [control group is based 
on the optical density of 1 sample, vehicle + saline group represent the mean optical 
density of 2 samples and LPS and PHA781535E treated groups represent the mean 
optical density of 3 samples. Data are expressed as percentage of control 
(untreated)]. The points on the histogram represent the range values. Rats were 
treated with either PHA781535E or the vehicle (methylcellulose-tween; 4000, p.o.) 2 
hours prior to LPS or saline (4000, i.p.) injection. Lane c, untreated control; lanes 1-
2, methylcellulose-tween + saline; lanes 3-4, methylcellulose-tween + LPS; lanes 5-7, 
PHA781353E + saline; lanes 8-10, PHA781353E + LPS. LPS, lipopolysaccharide; 
NFKB, nuclear factor kappa B; ns, non-specific binding reaction (AP-1); OD, optical 
density; PHA, PHA781535E; s, specific binding reaction (NFKB); Sal, saline; V, 
vehicle (methylcellulose-tween-saline. 
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Figure 5.16 Effect of the IKKO inhibitor, PHA781353E (50mg/kg, p.o.), on LPS 
(5mg/kg, i.p., 2 hours) stimulated NFKB activity in adrenal tissue, detected by 
(A) electrophoretic mobility shift assay (EMSA). (B) Densitometric analysis of the 
bands representing the p65/p50 homodimer [control group is based on the optical 
density of 1 sample, vehicle + saline group represent the mean optical density of 2 
samples and LPS and PHA781535E treated groups represent the mean optical 
density of 3 samples. Data are expressed as percentage of control (untreated)]. The 
points on the histogram represent the range values. Rats were treated with either 
PHA781535E or the vehicle (methylcellulose-tween; 4001u,l, p.o.) 2 hours prior to LPS 
or saline (400111, i.p.) injection. Lane c, untreated control; lanes 1-2, methylcellulose-
tween + saline; lanes 3-4, methylcellulose-tween + LPS; lanes 5-7, PHA781353E + 
saline; lanes 8-10, PHA781353E + LPS. LPS, lipopolysaccharide; NFKB, nuclear 
factor kappa B; ns, non-specific binding reaction (AP-1); OD, optical density; 
PHA781535E; s, specific binding reaction (NFKB); Sal, saline; V, vehicle 
(methylcellulose-tween-saline). 
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5.4 	Results - Psychological stress (restraint) 
5.4.1 Effects of restraint stress upon plasma ACTH and corticosterone 
concentrations 
The effects of the mild psychological stressor, restraint stress, upon the plasma 
ACTH and corticosterone concentrations were examined to elucidate the optimal 
time point for maximal HPA axis activation. Following 15 minutes of restraint stress, 
plasma ACTH concentrations were significantly and maximally elevated compared to 
basal levels (p<0.001; figure 5.17A). After 30 minutes of restraint stress, plasma 
ACTH concentrations were not significant from control levels (p=0.449; figure 5.17A). 
The plasma concentrations of ACTH from rats that were restrained for 30 minutes 
followed by a 30 minute and 60 minute recovery period were also comparable to 
basal (30 minutes recovery, p=1.00 and 60 minutes recover, p=1.00; figure 5.17A). 
The plasma corticosterone concentration was increased in rats that had been 
restrained for 15 minutes (p<0.01 vs control) and maximal after 30 minutes restraint 
stress (p<0.001 vs control; figure 5.17B). The plasma corticosterone concentration in 
rats that were allowed a recovery period after 30 minutes restraint stress were 
significantly reduced and comparable to the unrestrained control group (30 minutes 
recovery, p=1.00 and 60 minutes recovery, p=1.00; figure 5.17B). 
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Figure 5.17 Time-dependent effects of restraint stress on the plasma (A) 
ACTH and (B) corticosterone concentrations. Male adult rats were restrained for 
15 or 30 minutes followed by a recovery period of 0, 30 or 60 minutes. Each group is 
a mean of five animals ± sem. **p<0.01, ***p<0.001 vs control (0 min), ### p <0 .00 1 vs 
30 min restraint + 30 min recovery, $$$p<0.001 vs 30 min restraint + 60 min recovery. 
Analysis was performed by one way ANOVA followed by Bonferroni's post hoc t-test. 
ACTH, adrenocorticotrophin. 
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5.4.2 Effects of restraint stress on the plasma IL-6 concentration 
Previous studies have reported that rats exposed to psychological stressors, such as 
immobilization stress and footshock, exhibit elevated concentrations of plasma IL-6. 
However, rats exposed to restraint stress in this study did not have detectable 
concentrations of plasma IL-6 (Table 5.1). 
Table 5.1 	Detection of plasma IL-6 concentration from rats subjected to 15 
or 30 minutes restraint stress or 30 minutes restraint stress followed by a 30 or 
60 minute recovery period by enzyme linked immunosorbant assay (ELISA). 
The detection limit of the rat IL-6 ELISA was 31.25pg/ml. IL-6, interleukin 6. 
Sample IL-6 (pg/ml) 
Unrestrained Undetectable 
15 minutes restraint Undetectable 
30 minutes restraint Undetectable 
30 minutes restraint + 30 minutes 
recovery 
Undetectable 
30 minutes restraint + 60 minutes 
recovery 
Undetectable 
Known standard (1000pg/m1) 1168.46±267 
5.4.3 Effects of restraint stress on NFKB activity in rat anterior pituitary tissue 
In the pituitary nuclear extracts, 15 minutes restraint stress induced an increase in 
NFKB DNA-binding activity (p<0.05 vs control, lanes 6-10; figure 5.18A and B) 
compared to the unrestrained control samples (lanes 1-5; figure 5.18A and B). The 
increase in NFKB DNA-binding activity was still evident after 30 minutes restraint 
stress (p<0.05 vs control; lanes 5-10; figure 5.19A and B) and after 30 minutes 
restraint stress followed by a 30 minute recovery period (p<0.05 vs control; lanes 6-
10; figure 5.20A and B). The activity of NFKB was not examined in the anterior 
pituitary tissue of rats subjected to 30 minutes restraint stress followed by a 60 
minute recovery period. 
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Figure 5.18 Effect of restraint stress (15 minutes) on NFIcI3 activity in anterior 
pituitary tissue, detected by (A) electrophoretic mobility shift assay (EMSA). (B) 
Densitometric analysis of the bands representing the p65/p50 heterodimer [optical 
density values are the mean of 5 samples ± SEM and expressed as percentage of 
control (untreated)]. Lanes 1-5; unrestrained control samples; lanes 6-10, restrained 
samples. +p<0.05 vs control. Analysis of densitometric results was performed by 
Mann-Whitney rank sum test. NFKB, nuclear factor kappa B; ns, non-specific binding 
reaction (AP-1); OD, optical density; s, specific binding reaction (NFKB). 
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Figure 5.19 Effect of restraint stress (30 minutes) on NFKB activity in anterior 
pituitary tissue, detected by (A) electrophoretic mobility shift assay (EMSA). (B) 
Densitometric analysis of the bands representing the p65/p50 heterodimer [optical 
density values are the mean of 5 samples ± SEM and expressed as percentage of 
control (untreated)]. Lanes 1-5; unrestrained control samples; lanes 6-10, restrained 
samples. +p<0.05 vs control. Analysis of densitometric results was performed by 
Mann-Whitney rank sum test. NFKB, nuclear factor kappa B; ns, non-specific binding 
reaction (AP-1); OD, optical density; s, specific binding reaction (NFKB). 
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Figure 5.20 Effect of restraint stress (30 minutes restraint followed by a 30 
minute recovery period) on NFKB activity in anterior pituitary tissue, detected 
by (A) electrophoretic mobility shift assay (EMSA). (B) Densitometric analysis of 
the bands representing the p65/p50 heterodimer [optical density values are the mean 
of 5 samples ± SEM and expressed as percentage of control (untreated)]. For the 
recovery period, rats were returned to their housing cages. Lanes 1-5; unrestrained 
control samples; lanes 6-10, restrained samples. +p<0.05 vs control. Analysis of 
densitometric results was performed by Mann-Whitney rank sum test. NFKB, nuclear 
factor kappa B; ns, non-specific binding reaction (AP-1); OD, optical density; s, 
specific binding reaction (NFKB). 
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5.4.4 NFxB activity in thymic tissue extracted from restraint stressed rats 
The profile of NFKB DNA-binding activity in thymic tissue extracted from restraint 
stressed rats was examined. An increase in NFKB DNA-binding activity was not 
detected until 30 minutes restraint stress (lanes 6-8; figure 5.21A and B), compared to 
the control group (lanes 1-2; figure 5.21A and B). This increase was still evident after 
30 minute restraint stress and the rats were allowed to recover for a further 30 
minutes (lanes 9-10) and 60 minutes (lane 11; figure 5.21A and B) in their housing 
cages. 
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Figure 5.21 Effects of restraint stress (15 - 30 minutes, followed by 30 - 60 
minutes recovery period) on NFKB activity in thymic tissue, detected by (A) 
electrophoretic mobility shift assay (EMSA). (B) Densitometric analysis of the 
bands representing the p65/p50 heterodimer [control and 30 minutes restraint + 30 
minutes recovery group represent the mean optical density of 2 samples, 15 and 30 
minute restraint group represent the mean optical density of 3 samples and 30 
minutes restraint + 60 minutes recovery group is based on the optical density of 1 
sample. Data are expressed as percentage of control (unrestrained)]. The points on 
the histogram represent the range values. Lanes 1-2, unrestrained control samples; 
lanes 3-5, 15 minutes restraint stress; lanes 6-8, 30 minutes restraint stress; lanes 9-
10, 30 minutes restraint stress followed by 30 minutes recovery period and lane 11, 
30 minutes restraint stress followed by 60 minutes recovery. NFKB, nuclear factor 
kappa B; ns, non-specific binding reaction (AP-1); OD, optical density; s, specific 
binding reaction (NFKB). 
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5.4.5 Effects of the IKKr3 inhibitor, PHA781535E, on plasma ACTH and 
corticosterone concentrations in restraint stressed rats 
Significantly elevated plasma ACTH and corticosterone concentrations were 
measured in rats exposed to 15 minutes restraint stress (section 5.4.1). Similarly, 
increased NFKB activity was detected in anterior pituitary tissue after 15 minutes 
restraint stress (section 5.4.3). Therefore, the effects of treatment with the NFKB 
inhibitor, PHA781535E on these parameters were investigated in rats exposed to 15 
minutes restraint stress. 
	
5.4.5.1 	Effects of PHA781535E treatment on restraint stress-induced plasma 
ACTH concentrations 
Pre-treatment with the PHA781353E vehicle, methylcellulose-tween (4000; p.o.), did 
not affect basal (p=0.081) or restraint induced plasma ACTH concentrations 
(p=0.203; figure 5.22A). Whilst treatment with PHA781353E alone (25mg/kg, p=1.00 
and 50mg/kg, p=1.00) had no affect on basal plasma concentrations of ACTH, the 
NFKB inhibitor significantly attenuated the elevated plasma ACTH concentrations 
induced by restraint stress (25 and 50mg/kg PHA781535E, p<0.01 vs restraint), with 
no significant difference in the inhibitory effect induced by 25mg/kg and 50mg/kg 
PHA781353E (p=0.901; figure 5.22A). 
5.4.5.2 	Effects of PHA781535E treatment on restraint stress-induced plasma 
corticosterone concentrations 
Similarly to the ACTH response, the vehicle (methylcellulose-tween) did not affect 
basal (p=0.645) or restraint induced plasma corticosterone concentrations (p=288; 
figure 5.22B). Exposure to 15 minutes restraint significantly increased concentrations 
of plasma corticosterone compared to the unrestrained control (p<0.001) and pre-
treatment with both doses of PHA781535E attenuated this increase (p<0.001 vs 
restraint), with there being no significant difference in the effect induced by 25mg/kg 
and 50mg/kg PHA781353E (p=1.00; figure 5.22B). However, whilst treatment with 
25mg/kg PHA781535E alone did not affect basal corticosterone concentrations 
(p=1.00), 50mg/kg PHA781535E significantly increased the basal plasma 
corticosterone concentration (p<0.01 vs unrestrained control; figure 5.22B). 
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Figure 5.22 Effects of the IKK8 inhibitor, PHA781353E (25 and 50mg/kg, p.o.), 
on plasma (A) ACTH and (B) corticosterone concentrations in rats subjected to 
15 minutes restraint stress. Rats were treated with PHA781535E or vehicle 
(methylcellulose-tween; 4000, p.o.) 2 hours prior to restraint stress. Control 
(untreated/unrestrained) and treated/restrained groups are the mean of five samples 
± SEM. ++p<0.01, +++p<0.001 vs untreated control, ttp<0.01, tttp<0.001 vs 15 
minutes restraints stress. Analysis was performed by two-way ANOVA with post hoc 
comparison using Bonferroni's t-test. ACTH, adrenocorticotrophin; PHA, 
PHA781353E; Met methylcellulose-tween. 
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5.4.6 Effects of the IKK8 inhibitor, PHA781353E, on plasma IL-6 and TNFa 
concentrations from rats subjected to restraint stress 
The concentrations of IL-6 and TNFa were undetectable in the plasma collected from 
both the control and restrained groups (Table 5.2 and 5.3). Treatment with 
methylcellulose-tween or PHA781353E alone or prior to restraint stress also failed to 
induce detectable concentrations of these cytokines (Table 5.2 and 5.3). 
Table 5.2 	Detection of the plasma IL-6 concentration. Rats were treated with 
either vehicle (methylcellulose-tween; 400µI, p.o.) or the NFKB inhibitor, 
PHA781535E (25 and 50mg/kg, p.o.), 2 hours prior to 15 minutes restraint stress by 
enzyme linked immunosorbant assay (ELISA). The detection limit of the rat IL-6 
ELISA was 31.25pg/ml. IL-6, interleukin 6; vehicle, methylcellulose-tween. 
Sample IL-6 (pg/ml) 
Control Undetectable 
Vehicle Undetectable 
PHA781535E (25mg/kg) Undetectable 
PHA781535E (50mg/kg Undetectable 
15 minutes restraint + vehicle Undetectable 
15 minutes restraint + PHA781535E 
(25mg/kg) 
Undetectable 
15 minutes restraint + PHA781535E 
(50mg/kg) 
Undetectable 
Known standard (500pg/ml) 775.07±110.24 
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Table 5.3 	Detection of the plasma TNFa concentration. Rats were treated 
with either vehicle (methylcellulose-tween; 400111, p.o.) or the NFKB inhibitor, 
PHA781535E (25 and 50mg/kg, p.o.), 2 hours prior to 15 minutes restraint stress by 
enzyme linked immunosorbant assay (ELISA). The detection limit of the rat TNFa 
ELISA was 31.25pg/ml. TNFa, tumour necrosis factor alpha; vehicle, 
methylcellulose-tween. 
Sample TNFa (pg/ml) 
Control Undetectable 
Vehicle Undetectable 
PHA781535E (25mg/kg) Undetectable 
PHA781535E (50mg/kg Undetectable 
15 minutes restraint + vehicle Undetectable 
15 minutes restraint + PHA781535E 
(25mg/kg) 
Undetectable 
15 minutes restraint + PHA781535E 
(50mg/kg) 
Undetectable 
Known standard (125pg/m1) 136.47±15.66 
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5.4.7 Effect of the IKK8 inhibitor, PHA781353E, on restraint stress-induced 
NFicB activity in anterior pituitary tissue 
Restraint stress (15 minutes) increased basal NFKB activity in pituitary tissue nuclear 
extracts (lanes 1-3; figure 5.23A and B and figure 5.24A and B). Treatment with the 
vehicle (methylcellulose-tween, 400µI, p.o.) slightly reduced basal NFKB (lane V; 
figure 5.23A and B and figure 5.24A and B) and administration of 25mg/kg 
PHA781353E induced a further reduction (lanes 4-5; figure 5.23A and B). The higher 
dose of 50mg/kg PHA781535E did not have an observable effect on basal NFKB 
activity (lanes 5-6; figure 5.24A and B). However, pre-treatment with PHA781535E 
(lanes 7-10; 25mg/kg PHA781535E + restraint; figure 5.23A and B and 50mg/kg 
PHA781535E + restraint; figure 5.24A and B) resulted in a decrease in restraint 
stress-induced NFKB activation. 
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Figure 5.23 Effect of the IKKO inhibitor, PHA781353E (25mg/kg, p.o.), on 
NFxB activity in anterior pituitary tissue extracted from rats subjected to 
restraint stress (15 minutes), detected by (A) electrophoretic mobility shift 
assay (EMSA). (B) Densitometric analysis of the bands representing the p65/p50 
heterodimer [control and vehicle groups are based on the optical density of 1 sample, 
PHA781353E only treated and restraint only groups represent the mean optical 
density of 3 samples and restraint + PHA781535E treated group represent the mean 
optical density of 4 samples. Data are expressed as percentage of control 
(untreated)]. The points on the histogram represent the range values. Rats were 
treated with either PHA781353E or vehicle (methylcellulose-tween; 4000, p.o.) 2 
hours prior to restraint stress. Lane c, unrestrained control; lane V, vehicle 
(methylcellulose-tween); lanes 1-3, restraint stress; lanes 4-6, PHA781353E 
treatment; lanes 7-10; PHA781535E treatment + restraint stress. NFKB, nuclear 
factor kappa B; ns, non-specific binding reaction (AP-1); OD, optical density; PHA, 
PHA781535E; rest, restraint; s, specific binding reaction (NFKB); V, vehicle 
(methylcellulose-tween). 
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Figure 5.24 Effect of the IKKO inhibitor, PHA781353E (50mg/kg, p.o.), on 
NFxB activity in anterior pituitary tissue extracted from rats subjected to 
restraint stress (15 minutes), detected by (A) electrophoretic mobility shift 
assay (EMSA). (B) Densitometric analysis of the bands representing the p65/p50 
heterodimer [control and vehicle treated groups are based on the optical density of 1 
sample, PHA781353E only treated and restraint only groups represent the mean 
optical density of 3 samples and restraint + PHA781535E treated group represent the 
mean optical density of 4 samples. Data are expressed as percentage of control 
(untreated)]. The points on the histogram represent the range values. Rats were 
treated with either PHA781353E or vehicle (methylcellulose-tween; 400)11, p.o.) 2 
hours prior to restraint stress. Lane c, unrestrained control; lane V, vehicle 
(methylcellulose-tween); lanes 1-3, restraint stress; lanes 4-6, PHA781353E 
treatment; lanes 7-10; PHA781535E treatment + restraint stress. NFxB, nuclear 
factor kappa B; ns, non-specific binding reaction (AP-1); OD, optical density; PHA, 
PHA781535E; rest, restraint; s, specific binding reaction (NFKB); V, vehicle 
(methylcellulose-tween). 
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5.4.8 Effect of the IKKO inhibitor, PHA781353E, on restraint stress-induced 
NFKB activity in thymic tissue 
The PHA781535E vehicle (methylcellulose-tween, 400µ1, p.o.) increased basal 
activity (lane c, control and lane V, vehicle) of NFKB in thymic tissue extracted from 
unrestrained rats (figure 5.25A and B and 5.26A and B). However, treatment with 
PHA781535E did not induce an observable effect on basal NFKB activity (lanes 4-6; 
25mg/kg; figure 5.25A and B and 50mg/kg; figure 5.26A and B). Restraint stress 
increased NFKB DNA-binding activity compared to both unrestrained and vehicle 
induced levels (lanes 1-3; figure 5.25A and B and 5.26A and B) and pre-treatment with 
25mg/kg PHA781535E attenuated this increase to levels comparable to control 
(lanes 7-10; figure 5.25A and B). Treatment with 50mg/kg did not affect increased 
NFKB induced activity by restraint stress (lanes 7-10; 50mg/kg; figure 5.26A and B). 
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Figure 5.25 Effect of the IKKO inhibitor, PHA781353E (25mg/kg, p.o.), on 
NFKB activity in thymic tissue extracted from rats subjected to restraint stress 
(15 minutes), detected by (A) electrophoretic mobility shift assay (EMSA). (B) 
Densitometric analysis of the bands representing the p65/p50 heterodimer [control 
and vehicle treated groups are based on the optical density of 1 sample, 
PHA781353E only treated and restraint only groups represent the mean optical 
density of 3 samples and restraint + PHA781535E treated group represent the mean 
optical density of 4 samples. Data are expressed as percentage of control 
(untreated)]. The points on the histogram represent the range values. Rats were 
treated with either PHA781353E or vehicle (methylcellulose-tween; 4001.11, p.o.) 2 
hours prior to restraint stress. Lane c, unrestrained control; lane V, vehicle 
(methylcellulose-tween); lanes 1-3, restraint stress; lanes 4-6, PHA781353E 
treatment; lanes 7-10; PHA781535E treatment + restraint stress. NFKB, nuclear 
factor kappa B; ns, non-specific binding reaction (AP-1); OD, optical density; PHA, 
PHA781535E; rest, restraint; s, specific binding reaction (NFKB); V, vehicle 
(methylcellulose-tween). 
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Figure 5.26 Effect of the IKKI3 inhibitor, PHA781353E (50mg/kg, p.o.) on NFKB 
activity in thymic tissue extracted from rats subjected to restraint stress (15 
minutes), detected by (A) electrophoretic mobility shift assay (EMSA). (B) 
Densitometric analysis of the bands representing the p65/p50 heterodimer [optical 
density for the control and vehicle treated groups are representative of 1 sample, 
PHA781535E only treated and restraint only groups represent the mean optical 
density of 3 samples and PHA781535E + restraint group represent the mean optical 
density for 4 samples. Data are expressed as percentage of control (untreated)]. The 
points on the histogram represent the range values. Rats were treated with either 
PHA781353E or vehicle (methylcellulose-tween; 400,11, p.o.) 2 hours prior to restraint 
stress. Lane c, unrestrained control; lane V, vehicle (methylcellulose-tween); lanes 1-
3, restraint stress; lanes 4-6, PHA781353E treatment; lanes 7-10; PHA781535E 
treatment + restraint stress. NFKB, nuclear factor kappa B; ns, non-specific binding 
reaction (AP-1); OD, optical density; PHA, PHA781535E; rest, restraint; s, specific 
binding reaction (NFKB); V, vehicle (methylcellulose-tween). 
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5.4.9 Effect of the IKKI3 inhibitor, PHA781353E, on restraint stress-induced 
NFKB activity in rat adrenal tissue 
In adrenal tissue, NFKB activity appeared to be reduced by both vehicle 
(methylcellulose-tween, 4000, p.o., lane V; figure 5.27A and B and 5.28A and B) and 
PHA781353 treatment (lanes 4-6; 25mg/kg; figure 5.27A and B and 50mg/kg; figure 
5.28A and B). NFKB activity also appeared to be attenuated by restraint stress 
samples (lanes 1-3; figure 5.27A and B and figure 5.28A and B). Treatment with 
25mg/kg PHA781535E following restraint stress increased NFKB activity (lanes 7-10; 
figure 5.25A and B) compared to the restraint group (lanes 1-3; figure 5.27A and B) 
but DNA-binding activity was still less than control levels (lane c; figure 5.27A and B). 
Treatment with the higher dose of 50mg/kg PHA781535E prior to restraint stress did 
not have an observable effect on NFKB activity (lanes 7-10; figure 5.28A and B) 
compared to the restraint group (lanes 1-3; figure 5.28A and B). 
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Figure 5.27 Effect of the IKKO inhibitor, PHA781353E (25mg/kg, p.o.), on 
NFx13 activity in adrenal tissue extracted from rats subjected to restraint stress 
(15 minutes), detected by (A) electrophoretic mobility shift assay (EMSA). (B) 
Densitometric analysis of the bands representing the p65/p50 heterodimer [control 
and vehicle treated groups are based on the optical density of 1 sample, 
PHA781353E only treated and restraint only groups represent the mean optical 
density of 3 samples and restraint + PHA781535E treated group represent the mean 
optical density of 4 samples. Data are expressed as percentage of control 
(untreated)]. The points on the histogram represent the range values. Rats were 
treated with either PHA781353E or vehicle (methylcellulose-tween; 4004 p.o.) 2 
hours prior to restraint stress. Lane c, unrestrained control; lane V, vehicle 
(methylcellulose-tween); lanes 1-3, restraint stress; lanes 4-6, PHA781353E 
treatment; lanes 7-10; PHA781535E treatment + restraint stress. NFKB, nuclear 
factor kappa B; ns, non-specific binding reaction (AP-1); OD, optical density; PHA, 
PHA781535E; rest, restraint; s, specific binding reaction (NFKB); V, vehicle 
(methylcellulose-tween). 
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Figure 5.28 Effect of the IKKO inhibitor, PHA781353E (50mg/kg, p.o.), on 
NFKB activity in adrenal tissue extracted from rats subjected to restraint stress 
(15 minutes), detected by (A) electrophoretic mobility shift assay (EMSA). (B) 
Densitometry analysis of the bands representing the p65/p50 heterodimer (control 
and vehicle treated groups are based on the optical density of 1 sample, 
PHA781353E only treated and restraint only groups represent the optical density of 3 
samples and restraint + PHA781535E treated group represent the mean optical 
density of 4 samples. Data are expressed as percentage of control (untreated)]. The 
points on the histogram represent the range values. Rats were treated with either 
PHA781353E or vehicle (methylcellulose-tween; 400111, p.o.) 2 hours prior to restraint 
stress. Lane c, unrestrained control; lane V, vehicle (methylcellulose-tween); lanes 1-
3, restraint stress; lanes 4-6, PHA781353E treatment; lanes 7-10; PHA781535E 
treatment + restraint stress. NFKB, nuclear factor kappa B; ns, non-specific binding 
reaction (AP-1); OD, optical density; PHA, PHA781535E; rest, restraint; s, specific 
binding reaction (NFKB); V, vehicle (methylcellulose-tween). 
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5.5 Discussion 
The HPA axis is readily activated by immunological or psychological stress. ACTH 
release from the anterior pituitary gland is thus increased, as too is the synthesis and 
release of glucocorticoids (cortisol in humans and corticosterone in rodents) from the 
adrenal cortex (section 1.2). The HPA axis plays a key role in regulating the body's 
response to stress and restoring homeostasis. Its activity is normally maintained 
within limits by the negative feedback actions of glucocorticoids (see section 1.3), but 
perturbations of cortisol secretion are not uncommon in clinical medicine and are now 
thought to be a major contributing factor to the pathogenesis of a variety of diseases. 
The pro-inflammatory transcription factor, NFKB, is an important mediator of the 
inflammatory response and regulates the gene expression of a variety of pro-
inflammatory enzymes and mediators, including the inducible enzymes NOS-2 and 
COX-2 and the pro-inflammatory cytokines TNFa and IL-6 (see section 1.6). 
Therefore, targeting NFKB may provide potential therapy for the treatment of chronic 
inflammatory disorders such as rheumatoid arthritis. However, our studies (see 
chapter 3 and 4) and those of others (Lohrer et al. 2000) have identified a role for 
pituitary-derived NFKB in mediating the release of ACTH induced by endotoxin. 
Therefore, inhibition of NFKB in patients with chronic inflammatory disorders as a 
form of treatment may result in adverse side effects such as impaired HPA 
responses to immunological stress. Furthermore, as NFKB is also activated in human 
PBMCs and rodent brain cortex tissue by psychological stress (see section 1.6.3), 
NFKB blockade may also affect the HPA responses to psychological stress. 
5.5.1 Models and methods 
5.5.1.1 	Animal model for immune stress (LPS) 
To study the effects of a novel NFKB inhibitor (PHA818535E; section 5.5.3.1) upon 
the rat HPA responses to immunological stress, adult male Sprague-Dawley rats 
were injected intraperinatally (i.p.) with the bacterial endotoxin, LPS. LPS, a major 
component of the outer surface membrane of almost all gram-negative bacteria, acts 
as a powerful stimulator of innate or natural immunity and is commonly used 
experimentally to induce immunological responses in vivo [reviewed in (Beishuizen & 
Thijs 2003)]. However, as high doses of LPS can lead to severe pathological 
reactions such as the induction of septic shock (Beishuizen & Thijs 2003), care must 
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be taken in selecting the dose. Previous studies have shown that i.p. administration 
of 5mg/kg LPS (Escherichia coli; serotype 055:B5) in adult male Sprague-Dawley 
rats induces an immunological response with increased plasma TNFa and IL-6 
concentrations, without causing lethality, and an associated increase in HPA activity 
(Fernandez-Martinez et al. 2004). Therefore, the current study used this dose of LPS 
for the model of immunological stress. 
Recent studies have demonstrated that, in addition to stimulating the HPA axis 
indirectly through the release of pro-inflammatory cytokines from immune cells (e.g. 
macrophages), LPS also acts directly at the level of the anterior pituitary gland to 
stimulate ACTH release (Lohrer et al. 2000; Gloddek et al. 2001). The in vitro 
experiments conducted in the current study (chapters 3 and 4) provide evidence that 
this effect is mediated by NFKB. Therefore, the effects of LPS injection upon NFKB 
activity in the anterior pituitary gland were examined by EMSA. For a comparison, 
NFKB activity was also examined in distal organs (thymus and adrenal glands) after 
LPS injection. 
Initially, the profiles of NFKB activity in anterior pituitary tissue and the plasma ACTH 
and corticosterone concentrations were examined in rats 2 or 4 hours after treatment 
with LPS. We found robust increases in plasma ACTH and corticosterone 
concentrations 2 hours after LPS injection, together with increases in plasma IL-6 
and TNFa (which were measured to determine activation of the immune system) and 
anterior pituitary NFKB activity. Therefore, we selected this time point to investigate 
the effects of the NFKB inhibitor, PHA781535E, upon the HPA responses to LPS. 
Vehicle-treated and untreated control groups were included to ensure that the effects 
induced by LPS could be distinguished from the stress of injecting the rats with a 
needle and from the vehicle. The untreated control groups were left in their housing 
cage on the day of the study until tissue collection and vehicle-treated controls 
received an equivalent volume of the vehicle solution (sterile physiological saline; 
400µI, i.p.) in place of LPS. For the NFKB inhibition studies, the control groups 
included rats treated with the PHA781535E vehicle (methylcellulose-tween, 4000, 
p.o.) and the LPS vehicle (physiological saline, 400411, i.p.) and rats treated with 
PHA781535E (25 or 50mg/kg, p.o.) and the LPS vehicle (physiological saline, 4001.11, 
i.p.) so as to ensure that any effects were attributed to PHA781535E and not the 
vehicles or the stress of oral dosing or i.p. injection. 
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5.5.1.2 	Animal model for psychological stress (restraint) 
The current study aimed to investigate the role NFKB in mediating the HPA response 
to stress. Emerging evidence suggests that in addition to contributing to the 
responses to immunological stress [reviewed in (Liou 2002)], NFKB also has a role in 
effecting the responses to psychological stress (Bierhaus et al. 2003; Garcia-Bueno 
et al. 2005). Therefore, we examined the effects of psychological stress upon the 
HPA axis (plasma ACTH and corticosterone concentrations) and the immune system 
(plasma IL-6 and TNFa concentrations and NF-KB activity in anterior pituitary, thymic 
and adrenal tissues) and explored how these effects were modified by NFKB 
blockade. Restraint stress is widely accepted as a model of psychological stress 
(Pare & Glavin 1986; Glavin et al. 1994). The procedure involves confining the rat in 
a cylindrical plastic tube for periods ranging from 5 minutes to several hours. The 
restraint tubes used in the present study were sized according to the weight of the 
rats to ensure that the animals were unable to move once placed inside the tube. 
Other models used for the study of psychological stress include immobilisation stress 
(which involves restraining the rat on a board in a supine position by taping the limbs 
to holders without anaesthesia), water immersion, conditioned fear responses, 
whole-body vibration, loud noise, foot-shock and forced swimming. Unlike restraint, 
these are considered intense forms of psychological stress (Pare & Glavin 1986; 
Glavin et aL 1994). Restraint stress was used in the current study because, in 
addition to this technique being less severe than the immobilisation method, its 
effects upon the HPA axis are well documented (Seltzer et al. 1986; Tan & Nagata 
2002). Furthermore, restraint stress also increases plasma IL-6 concentrations in the 
rat (Zhou et al. 1993; Nukina et al. 1998) and mouse (Nukina et al. 2001; Huang et 
aL 2003). The source IL-6 in the plasma of restraint stressed rats is unclear and does 
not appear to be attributable to secretion by splenic cells or PBMCs (Zhou et al. 
1993). As explanted adrenal cells release IL-6 in vitro and ACTH can stimulate IL-6 
release from cultured adrenal zonal glomerulosa cells (Judd & Macleod 1992; Judd & 
Macleod 1995), it is possible that the adrenal glands provide an important source of 
IL-6 during restraint stress. 
Increased NFKB activity has been reported in rat brain cortex tissue following 
restraint stress, possibly as a consequence of activation of glutamate receptors 
following the release of excitatory amino acids during stress (Guerrini et al. 1995; 
Kaltschmidt et al. 1995; Madrigal et al. 2003). These findings led us to hypothesise 
that NFKB is an important effector of the HPA response to restraint stress. To explore 
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this hypothesis, we examined the effects of NFKB blockade on the responses to 
restraint stress. Initial studies were designed to optimise the period of restraint stress 
required to increase plasma ACTH and corticosterone concentrations. In light of 
reports that restraint stress increases IL-6 release (Zhou et al. 1993; Nukina et al. 
1998), plasma IL-6 concentrations were also determined. As detailed in chapters 3 
and 4, LPS-induced NFKB signalling plays a role in regulating corticotroph-derived 
ACTH release. To our knowledge, the effects of psychological stress upon NFKB 
activity in the anterior pituitary gland have not been investigated and thus, the 
present study examined the effects of restraint stress upon anterior pituitary NFKB 
activity. For comparison, NFKB activity was also examined in the thymus and adrenal 
glands. 
5.5.2 Experimental methods 
5.5.2.1 	Detection of plasma ACTH by IRMA 
The concentration of ACTH in the plasma collected from the trunk blood of the rats 
was determined in triplicate by an immunoradiometric assay (IRMA; section 2.5.12). 
ACTH is a single chain polypeptide consisting of 39 amino acids. The first 24 N-
terminal amino acids are essential for its biological activity and are identical in many 
mammalian species (White & Gibson 1998). The IRMA used in the in vivo studies is 
designed for quantitative determination of intact ACTH (ACTH1_39) in plasma and 
uses two polyclonal antibodies recognising different binding sites on the antigen. The 
first antibody is a highly purified monospecific radioionated sheep IgG and 
recognises the N-terminus of the ACTH molecule and the second antibody reacts 
non-competitively with the C-terminal region of the ACTH molecule and is 
immobilised and coupled to primary sheep anti-rabbit coated tubes. During the 
incubation step, both antibodies react with the molecules of the sample and a 
sandwich-type complex is formed. 
The IRMA assay is specific for the ACTI-11_39 peptide and does not detect ACTH1_24, 
ACTH18-39, ACTF122-39, ACTI-134-39, CLIP, a-MSH, 13-MSH and 13-endorphin. The 
quantification of ACTH by IRMA is advantageous over more conventional RIAs as 
the use of monoclonal antibodies increases the sensitivity of the assay (3pg/m1) and 
avoids cross-reaction with metabolites and related peptides. However, because most 
anti-ACTH antibodies currently available have slow association kinetics and poor 
affinity constants, this level of sensitivity is often achieved after an incubation of 20 
hours. Despite this, the incubation period of the samples in the IRMA assay is faster 
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than that required for RIAs (four days) (Kertesz et al. 1998). The IRMA assay also 
has increased reproducibility compared to RIAs and the number of samples analysed 
per assay are not limited, thus allowing a high sample output. 
5.5.2.2 	Detection of plasma corticosterone by RIA 
The concentration of corticosterone (4-pregnen-11, 21-diol-3, 20-dione) in the plasma 
collected from the trunk blood of the rats was determined by RIA (section 2.5.13). As 
described previously (section 3.6.1.2.4), RIAs are routinely used for measuring 
plasma concentrations of hormones, including corticosterone, due to their high 
sensitivity and specificity and the corticosterone assay used in the current study had 
a detection limit of 0.39ng/ml. The assay employed is based on the ability of a limited 
quantity of antibody to bind to a fixed amount of radiolabelled antigen. The 
percentage of bound radiolabelled antigen decreases as a function of increasing 
concentration of unlabelled antigen in the test sample. The relative percent of cross-
reactivities of the assay are outlined in table 5.4. The RIA employed is designed to 
measure corticosterone concentrations in plasma samples (plasma is the virtually 
cell-free supernatant of blood containing anticoagulant obtained after centrifugation) 
unlike most other assays which require serum (serum is the undiluted, extracellular 
portion of blood after adequate coagulation is complete). Several stages are required 
for the collection of serum samples, which include incubating whole blood samples 
for up to 30 minutes to allow for coagulation. In contrast, plasma samples are 
collected in the presence of an anti-coagulant, such as EDTA, and can be separated 
immediately from whole blood by centrifugation. This process is more efficient in 
comparison to serum collection and also results in larger volumes of plasma, 
compared to serum, collected from the same volume of blood. Additionally, the use of 
plasma samples omits coagulation-induced changes which can arise from serum 
samples. These include changes in the concentration of numerous constituents of 
the extra-cellular fluid which can be induced by the following mechanisms: (a) 
increase in the concentrations of platelet components in serum as compared to 
plasma (e.g. potassium, phosphate, magnesium, aspartate aminotransferase, lactate 
dehydrogenase, serotonin, neurone-specific enolase, zinc), (b) decrease in the 
concentration of constituents in serum as a result of cellular metabolism and the 
coagulation process (e.g. glucose, total protein, platelets) and (c) activation of the cell 
lysis of erythrocytes and leukocytes in non-coagulated blood (e.g. cell-free 
haemoglobin, cytokines, receptors) (Uges 1988). Although the disadvantages of 
using plasma samples in some assay systems include the unknown influence of the 
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anticoagulant on the assay system, on the protein binding and on the stability of the 
sample, the RIA employed in the current study was designed specifically for plasma 
samples. Furthermore, the current study also measured ACTH concentrations in the 
plasma (section 5.5.2.1) and therefore, the samples collected could be used for both 
assays. 
5.5.2.3 	Detection of plasma IL-6 and TNFa by ELISA 
Plasma concentrations of IL-6 and TNFa are routinely measured by ELISA. The 
ELISAs used in the present study utilised primary antibodies specific for rat IL-6 and 
TNFa respectively. The rat anti-IL-6 antibody showed no cross-reactivity with human 
or porcine recombinant IL-6 or with recombinant ciliary neutrophic factor (CNTF), but 
weak (0.7%) cross reactivity with mouse recombinant IL-6. The anti-TNFa antibody 
showed no cross-reactivity with either human recombinant TNFa or TNFI3 or porcine 
recombinant TNFa, but moderate (2.4%) cross reactivity with mouse recombinant 
TNFa. The measurement of IL-6 and TNFa by ELISA is quantitative and thus has 
advantages over qualitative methods such as western blot analysis. It also allows a 
high number of samples to be analysed (approximately 40 per plate) in parallel so 
that appropriate duplicates can be included, thus allowing the results to be analysed 
statistically. The ELISAs used in the current study were also highly sensitive, with a 
detection limit of 31.25pg/ml. Each assay included positive and negative controls to 
ensure the assays were working correctly. 
261 
Table 5.4 	The relative percentage of cross-reactivity of the anti- 
corticosterone antibody with other hormones. The relative percentage of cross-
reactivity by weight of highly purified corticosterone and various other hormones was 
determined from the amount of purified corticosterone required to reduce the binding 
of 125 1 corticosterone by 50%, relative to the amount of steroid being tested that is 
required to do the same. Specificity of the assay was performed by IDS Ltd, UK. 
Analyte % Cross reactivity 
Aldosterone 0.20 
Cortisol 0.40 
Cortisone <0.10 
Deoxycorticosterone 3.30 
Deoxycortisol <0.10 
Dexamethasone 0.05 
DHEA 0.03 
Oestradiol 0.01 
Oestriol 0.01 
Oestrone 0.03 
1 7alpha-hydroxypregnenolone 0.01 
17a/pha-hydroxyprogesterone 0.20 
20a/pha-hydroxyprogesterone 0.20 
20beta-hydroxyprogesterone 0.20 
Prednisone 0.04 
Prednisolone 0.20 
Pregnanediol <0.01 
5alpha-pregnanedione 0.40 
5beta-pregnanedione 1.00 
Pregnanetriol 0.01 
Pregnolone 0.04 
Progesterone 0.60 
Testosterone 0.10 
Tetrahyd rocortisol 0.09 
Tetrahydrocortisone 0.02 
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5.5.2.4 	Detection of NFKB DNA-binding activity in animal tissue 
5.5.2.4.1 EMSA analysis 
The DNA-binding activity of NFKB in nuclear extracts (5µg) of anterior pituitary, 
thymic and adrenal tissue extracted from the rats was examined by EMSA. As 
described previously (see section 3.6.1.2.2.2), EMSA is an ideal method for detecting 
NFKB DNA-binding activity because, unlike western blot analysis, the EMSA method 
discriminates between non-transcriptional and transcriptionally active nuclear NFKB. 
Several bands may be detected by this method due to the existence of several 
hetero- or homo-dimers of NFxB, although the two predominant ones are the 
p65/p50 heterodimer and the p50/p50 homodimer. To ensure that the detected 
bands were not due to non-specific binding reactions, competitive (excess unlabelled 
NFKB oligonucleotide was added to the samples in the presence of the labelled 
NFKB sequence) and non-competitive (excess unlabelled AP-1 oligonucleotide was 
added to the samples in the presence of the labelled NFKB sequence) reactions were 
included in the assay. Bands that represent NFKB binding would be detected in the 
non-specific reaction, but not the specific reaction. The limitations of the EMSA 
include the length of time required for the assay to be completed and the requisite for 
radioactive 32P. Additionally, this method does not allow direct comparisons of the 
DNA-binding complexes between separate gels and quantifying protein:DNA binding 
activity on each gel is difficult due to the limited number of samples that can be used 
for each gel (maximum of 12) so that duplicate samples could not always be assayed 
together. However, most assays were conducted with at least 2 samples per group 
assayed together and the mean optical density of the bands per treatment group 
were expressed as a percentage of control to show changes in NFKB DNA-binding 
activity more clearly (non-quantitative). Where four or five samples per treatment 
group were loaded on the same gel, non-parametric statistical analysis was 
perfomed (semi-quantitative; see section 2.5.13). 
It has been noted that in some cases the variability between samples within a 
treatment group was high. This could be attributed to several factors, for example the 
tissues used in the current study (anterior pituitary gland, thymus and adrenal glands) 
are highly vascularised and it is possible that blood-borne cells which express NFKB 
activity may have contributed to the overall activity detected by EMSA. Although this 
could be avoided by using perfused tissue, the aim of the current study was to 
investigate the HPA response to stress (immunological and psychological) and the 
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consequences of inhibiting NFKB upon these parameters. Furthermore, the in vitro 
findings described earlier (chapters 3 and 4) support the premise that NFKB 
signalling in folliculostellate cells and corticotrophs of the anterior pituitary gland is 
important in mediating the ACTH response to LPS. Because these tissues are 
vascularised, it is possible that NFKB activity in cells from the blood may in turn 
influence the secretion of factors from these glands. As such, removal of the blood 
from the tissues may result in reduced NFKB activity detected by EMSA and thus 
misleading interpretations into the importance of NFKB signalling in the stress 
response. 
A more likely explanation for the variability in the NFKB DNA-binding activity detected 
in the tissues is variations in the nuclear protein concentrations used in the assay, 
since the method for measuring the nuclear protein concentrations (Bradford assay; 
section 2.5.4.1) is an estimation. Unlike western blot analysis, whereby detection of a 
house-keeping gene can be used to ensure consistent protein concentrations 
between the samples, this can not be applied to the EMSA. Therefore, as described 
above, where possible, three or more samples from each group were assayed on the 
same gel to reduce the risk of large variations in protein concentrations causing 
ambiguous results. However, the main drawback to this method is the limited power 
of quantification as direct comparisons between the absolute values obtained for 
each sample by densitometric analysis can only be made on the same gel. Together, 
these features inherent to EMSA present problems for statistical analysis. Therefore 
non-parametric tests were adopted where four or more samples within each group 
were used on the same gel. For a comparison of two groups (i.e. control vs restraint 
stress), the Mann-Whitney rank sum test was employed and for comparisons of three 
groups (control vs vehicle vs LPS), the Kruskal-Wallis one-way ANOVA on ranks 
followed by the Student-Newman-Keuls post hoc method was used. 
5.5.2.4.2 Supershift assay 
Whilst there are characteristic shifts caused by binding of specific protein(s) to the 
target DNA, the change in relative mobility detected by EMSA does not identify the 
bound protein. Identification of bound protein is accomplished by including an 
antibody specific for the DNA-binding protein (e.g. p65) to the reaction. Binding of the 
antibody to the complex results in a further shift in the band, although in some cases 
the antibody may disrupt the protein:DNA interaction resulting in the loss of the 
characteristic shift, but no super-shift. A weak shift or a reduction in the intensity of 
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the band usually implies the presence of low levels of the protein in the complex. The 
p65 protein is the transcriptionally active subunit of the NFKB dimer and the p65/p50 
heterodimer is the most extensively studied form. Therefore, the bands representing 
the p65/p50 heterodimer in nuclear extracts of anterior pituitary and adrenal tissues 
were identified by supershift assays (section 2.5.6) and used as a reference for 
further assays. 
5.5.3 Compounds for studying NFiB signalling 
5.5.3.1 	PHA781535E 
The IKK13 inhibitor, PHA781535E (2-amino-[6-[2-hydroxy-6-(2-methylpropoxy) 
phenyl]-4-(3-piperidinyl)]-3-pyridinecarbonitrile), was employed in the study to 
investigate the importance of NFKB signalling in mediating the rat HPA responses to 
immunological (LPS) and psychological (restraint) stress. Studies using non-specific 
NFKB inhibitors, such as inhibitors of the p38a MAPKinase pathway (e.g. SB203580) 
(Dong et al. 2006) or glucocorticoids (e.g. dexamethasone) (Unlap & Jope 1997) 
cannot attribute any cellular effects solely to NFKB as such compounds would also 
interfere with other signalling pathways that may not involve NFKB. For example, the 
p38a MAPKinase pathway regulates the transcriptional activity of other transcription 
factors involved in IL-6 synthesis such as AP-1 (Guha & Mackman 2001; Katsoulidis 
et al. 2005). 
Other methods for inhibiting NFKB include (a) targeting NFKB protein expression by 
siRNA (Guo et al. 2004; Kalota et al. 2004), (b) interference with NFKB nuclear 
translocation and DNA-binding using NFKB decoys or proteosome inhibitors 
[reviewed in (Montagut et al. 2006)], (c) interference with IKK complex formation 
using specific IKK inhibitors (Hideshima et al. 2006) or vectors encoding a 
superrepressor form of licBa (Batra et al. 1999; Widera et al. 2006; Tamura et aL 
2007), (d) blockade of upstream activators and (e) inhibition of NFKB transcriptional 
activity (p65 kinases) [reviewed in (Burke 2003)]. Inhibition of NFKB by siRNA has 
been demonstrated in tumour cells in vivo (Guo et aL 2004). However, despite these 
promising findings, gene-specific knockdown at the RNA level is a relatively new 
technology and requires significant refinement. The disadvantages to this technique 
include difficulties in the efficiency of delivery, duration of action, improved specificity, 
and establishment of safety (Kalota et al. 2004). Although interference with the 
degradation of IKB through the use of proteosome inhibitors, such as Mg132, is an 
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effective way to inhibit NFKB [reviewed in (Montagut et aL 2006)], the proteosome is 
involved in the degradation of all poly-ubiquitinated proteins. As such, proteosome 
inhibition impacts many signalling pathways and thus, the specificity of the response 
is unclear. Furthermore, there are reports that Mg132 can also activate NFKB by 
inducing the heat shock response, suggesting that such compounds may not be 
reliable NFKB inhibitors (Jobin et al. 1998; Lee etal. 2006). 
Inhibitors of the NFKB pathway are being developed by the pharmaceutical industry 
for potential therapeutic use and much effort is focused on the discovery of selective 
small molecule inhibitors of IKK(3 [reviewed in (Karin et al. 2004)], such as SC-514 
(Kishore et aL 2003). However, SC-514, which was used for the in vitro studies (see 
chapters 3 and 4), is not effective in vivo due to its limited bioavailability (2%) and 
poor half-life (0.2 hours) (Kishore et al. 2003). PHA781535E, which was generously 
provided by Pfizer Ltd, is a small molecule which effectively inhibits NFKB in vivo 
(Murata et aL 2004) (see figure 5.29). This compound is more applicable to studying 
NFKB signalling as it specifically inhibits activation of the IKKI3 subunit which is 
responsible for activating NFKB (p65/p50) and thus, does not interfere with upstream 
signalling pathways (see table 5.5) (Murata et aL 2004). 
Figure 5.29 Structure of PHA781535E (2-amino-[6-[2-hydroxy-6-(2-methyl 
propoxy)pheny1]-4-(3-piperidiny1)]-3-pyridinecarbonitrile). [Taken from (Murata et 
al. 2004)]. 
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Table 5.5 	Pharmacokinetics of the specific IKKO inhibitor, PHA781535E. 
The compound was generously provided by Pfizer Ltd (unpublished data). IL-113, 
interleukin 1 beta; IL-8, interleukin 8; IKK13, inhibitor of kappa B Kinase beta; LPS, 
lipopolysaccharide; PBMC, peripheral blood mononuclear cells; TNFa, tumour 
necrosis factor alpha. 
IC50 (1.M) 
IKKI3 (Resin Assay) 0.031 
IL-1(3 stimulated synovial fibroblasts (IL-8) 0.576 
IKKI3 alamar blue (synovial fibroblasts) >30 
IKK(3 LPS treated PBMC TNFa release assay 0.021 
IKK0 alamar blue (PBMC) >1.0 
LPS stimulated human whole blood (TNFa) 1.5 
Acute rat i.p. LPS model — 98.4% inhibition of TNFa at 100mg/kg 
Acute rat i.p. LPS model — 95.3% inhibition of TNFa at 10mg/kg 
Protein binding — 97% 
Tmax — 0.44 hours 
Cmax — 20.911g/ill/kg 
Oral bio-availability — 99.3% 
5.5.4 Effects of LPS on the HPA axis 
5.5.4.1 	ACTH and corticosterone responses to LPS 
The current study confirmed reports that LPS activates the HPA axis, inducing 
robust increases in the plasma concentrations of ACTH and corticosterone within 2 
hours of treatment (Besedovsky et al. 1975; Lenczowski et aL 1997; Takemura et al. 
1997; Conde et al. 1998; Whiteside et al. 1999; Dunn 2000). The finding that the 
ACTH concentration had declined, albeit not to basal, 4 hours after LPS injection but 
that the increase in plasma corticosterone concentration was sustained may reflect a 
reduction in the intensity of the stress, with corticosterone taking longer to return to 
basal due to the time required for corticosterone synthesis and the different half lives 
of the two hormones (Cook et al. 1972; Keller-Wood et al. 1983; Lu et aL 1983; 
Sainio et al. 1988). Alternatively, it may be explained by the negative feedback 
actions of corticosterone upon ACTH release being effective at this time. Previous 
studies have documented that corticosterone typically returns to baseline 
concentrations 8 hours after LPS challenge in rats (Givalois et al. 1994). However, as 
the aim of this study was to determine the optimal time point for HPA activation to 
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examine the effects of NFKB inhibition on this system, time points exceeding 4 hours 
were not examined. As such, the length of time required for plasma corticosterone 
concentrations to return to basal was not determined in the current LPS model. 
5.5.4.2 	Role for NFKB signalling in the HPA response to LPS 
The plasma concentrations of the pro-inflammatory cytokines TNFa and IL-6, which 
act at all levels of the HPA axis including the anterior pituitary gland to stimulate 
ACTH release (Arzt et al. 1999; Bethin et al. 2000), were increased 2 hours after 
treatment with LPS. These findings agree with previous reports documenting the 
temporal profile of TNFa and IL-6 release in rats and other species, with an early 
phase (90 minutes after LPS treatment) characterised by increased plasma TNFa, 
rising plasma IL-6 (Givalois et al. 1994; Kakizaki et al. 1999) and peak ACTH 
secretion (Kakizaki et al. 1999), and the later phase characterised by maximal levels 
of IL-6 (Givalois et al. 1994; Kakizaki et al. 1999). IL-1p is also released in response 
to LPS and reaches maximum plasma concentrations after TNFa, but before IL-6 
(Givalois et al. 1994; Kakizaki et aL 1999). In the current model, the increase in the 
plasma concentration of ACTH in LPS treated rats is likely to be attributable, at least 
in part, to the direct and indirect stimulatory actions of systemic TNFa, IL-113 and IL-6 
on the release of CRH, and possibly also AVP, from the hypothalamus (Navarra et al. 
1991; Spinedi et al. 1992; Beishuizen & Thijs 2003). The ME of the rat hypothalamus 
expresses the receptors involved in LPS signalling, namely CD14 and TIr4 
(Laflamme & Rivest 2001) and thus LPS itself may directly act at the hypothalamic 
level to augment the secretion of the releasing factors. 
The anterior pituitary gland also expresses CD14 and TIr4 (Gloddek et al. 2001; 
Breuel et aL 2004; Tichomirowa et al. 2005) and may therefore also be targeted 
directly by LPS as indicated by our in vitro studies (chapter 4) which show that 
pituitary cell lines respond to LPS with increases in NFKB activity. In accordance with 
these findings, our in vivo study showed that the LPS-induced rise in plasma ACTH 
concentration is paralleled by an increase in NFKB DNA-binding activity in the 
anterior pituitary gland. These data concur with previous reports of LPS-induced 
increases in NFKB activity in the mouse (Parnet et aL 2003) and rat (Yang et aL 
2002) pituitary gland. Together these findings provide evidence that, in addition to the 
stimulatory effects of circulating pro-inflammatory cytokines on the release of CRH 
and AVP in vivo, LPS-induced NFKB activity within the anterior pituitary gland may be 
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involved in mediating the hypersecretion of ACTH in conditions of endotoxaemia. 
Therefore, to determine the importance of NFKB signalling in the ACTH response to 
LPS treatment, we examined the effects of a novel NFKB inhibitor, PHA781535E, on 
the HPA responses to the toxin (see section 5.5.3.1). 
5.5.4.3 	Evidence of PHA781535E as an effective NFiB inhibitor 
As we have had no previous experience of using this compound, we included 
measures to verify the effectiveness of PHA781535E as an NFKB inhibitor. In accord 
with reports that LPS-induced IL-6 and TNFa release from immune cells such as 
macrophages is mediated by NFKB (Libermann & Baltimore 1990; Laird et al. 2000; 
Corsini et al. 2006; Kim et al. 2006; Martin et al. 2006), the present data show that 
NFKB blockade attenuates the LPS-induced increases in the plasma concentrations 
of both cytokines. Interestingly, the reduction in plasma IL-6 was less pronounced 
than that of TNFa and was evident only with the higher dose of PHA781535E tested, 
perhaps because transcription factors other than NFiB which are involved in the 
regulation of IL-6 synthesis (e.g. AP-1, CREB, C/EBP(3 and NF-IL6) come into effect 
to compensate for the repression of NFKB activity (Ray et al. 1988; Tanabe et al. 
1988; Akira et al. 1990). 
Since previous studies using molecular imaging techniques have demonstrated a 
robust increase in NFKB activity in the thymus gland within 2 hours of LPS treatment 
(Carlsen et al. 2004), we also examined the effects of PHA781535E treatment upon 
NFKB activity in this organ. NFKB activity was readily detected in the thymus gland of 
untreated rats by the EMSA in our study. This was not surprising as NFKB plays an 
important role in thymocyte development and activation, with impaired NFKB activity 
resulting in a reduction in T cell numbers in peripheral tissue and increased apoptosis 
of thymocytes (Liu et al. 2006). We also observed an increase in NFKB DNA-binding 
activity in thymic tissue 2 and 4 hours after LPS treatment compared to the untreated 
and saline treated controls. Importantly, the effect of LPS on thymic NFKB activity 
was attenuated by PHA781535E. These findings, together with the evidence that the 
increases in plasma IL-6 and TNFa concentrations induced by LPS were decreased 
by PHA781535E treatment, support the premise that this compound is an effective 
NFKB inhibitor in vivo (Murata et al. 2004). 
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5.5.4.4 	Potential NFKB-dependent mechanism mediating LPS-stimulated 
ACTH secretion from the anterior pituitary gland 
In accordance with the premise that NFKB drives the ACTH response to LPS, 
treatment with the NFiB inhibitor attenuated LPS-stimulated ACTH release. The 
inhibitor did not however completely abolish the adrenocorticotrophic response to the 
toxin, even at the higher dose tested, raising the possibility that, in addition to NFKB, 
other factors contribute to the increase in ACTH release. 
The role of circulating cytokines in mediating the hypothalamo-anterior pituitary 
response to LPS is well documented (Martin et al. 2006) and one possible 
explanation for the inhibitory effects of PHA781535E on LPS-induced ACTH 
secretion would be blockade of the release of TNFa, IL-6 and possibly IL-1p into the 
systemic circulation. Surprisingly however, PHA781535E had only a very small effect 
on the plasma IL-6 concentration in comparison to its effects on ACTH, suggesting 
that reduced availability of circulating cytokines does not account entirely for the 
inhibition of ACTH secretion. A further possibility is that PHA781535E acts within the 
brain to attenuate the stimulatory actions of NFKB-dependent cytokines on the 
release of CRH and AVP, possibly by suppressing the induction of COX-2 or NOS-2, 
and hence, the generation of prostaglandins and NO in the hypothalamus (Gadek-
Michalska & Bugajski 2004; Lee et al. 1999; Uribe et al. 1999). In support of this, a 
growing body of data suggests that NFKB signalling contributes to the hypothalamic 
response to stress. For example, NFKB activity in the rat hypothalamus is increased 
by oxidative stress (Lezoualc'h et al. 2000) and alcohol vapour exposure (Lee & 
Rivier 2005), whilst inhibition of hypothalamic NFKB attenuates alcohol-induced 
ACTH release (Lee & Rivier 2005). Whether PHA781535E crosses the BBB to reach 
potential targets such as the perikarya of the CRH/AVP cells is unknown, although it 
is possible that the inhibitor may attenuate CRH and AVP release by acting on 
structures of the hypothalamus that are exposed to the blood stream (e.g. the axon 
terminals of the PVN neurones that project into the ME) or cross the BBB at sites of 
increased permeability induced by LPS (Banks et al. 1994; Gutierrez et al. 1994; 
Boje 1995; De Vries et al. 1996; Banks et al. 2001). 
As the reduction in ACTH release effected by NFiB blockade was also paralleled 
with a decrease in NFKB activity in the anterior pituitary gland, it seems likely that 
intra-pituitary NFiB signalling is involved in mediating the ACTH response to 
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endotoxin in vivo. Furthermore, the data correlate with the findings obtained from the 
co-culture studies (chapter 4) which suggest an important role for NFx13 in mediating 
the ACTH response to LPS. Therefore, it is likely that the inhibition of LPS-induced 
ACTH release in PHA781535E treated rats is attributable to the combined effects of 
blocking intra-pituitary NFKB signalling and the inhibition of the release of immune 
derived cytokines, including TNFa and IL-6, into the systemic circulation. 
Although the current findings support the hypothesis that the stimulatory effect of 
LPS upon ACTH secretion in vivo is mediated, at least in part, by its direct actions on 
the anterior pituitary gland, the mechanisms governing this response are unclear. 
The previous chapters provided evidence for both direct inhibitory (in corticotrophs) 
and indirect stimulatory (in folliculostellate cells) effects of NFKB-signalling in the 
regulation of ACTH release in vitro (chapters 3 and 4). Therefore, as folliculostellate 
cells and corticotrophs predominantly reside within the anterior portion of the pituitary 
gland (Rennels & Herbert 1979; Matsumoto et al. 1993), the current study examined 
NFKB DNA-binding activity in this region. As the measurements were made in tissue 
extracts, we were not able to distinguish differences between the anterior pituitary 
cell-types in the activation of NFxB. However, it is possible that, in accordance with 
the in vitro findings, the effects of NFKB upon ACTH release are cell-specific in vivo. 
Hence, activation of NFx13 in corticotrophs by CRH may exert an inhibitory effect 
upon ACTH release, whilst its activation in folliculostellate cells by LPS may increase 
ACTH release via a paracrine mechanism involving the release of IL-6 and possibly 
other cytokines. If, as published evidence suggests, CRH is released much more 
rapidly than IL-6 in response to LPS (Naitoh et al. 1988; Kakizaki et al. 1999), the 
effects of LPS at the pituitary level on ACTH release would be phasic with an initial 
inhibition and subsequent rise in secretion. Such a mechanism would temper 
glucocorticoid release in the early phase of infection, thus allowing an effective pro-
inflammatory response to be mounted, but subsequently induce a rise in 
glucocorticoids to contain the inflammatory response and thus restore homeostasis 
(Munck & Naray-Fejes-Toth 1994). The notion that glucocorticoid release is initially 
inhibited in response to immunological stress, to allow an inflammatory response to 
be mounted to fight the infection, is further supported by a recent study from our 
laboratory on folliculostellate cells, which demonstrated a rapid and transient 
increase in the release from folliculostellate cells of ANXA1 (Solito et al. 2006), a 
protein which is known to be a powerful inhibitor of ACTH release (Taylor et al. 
1993). To explore further the possibility of cell-specific NFKB activation in vivo, 
271 
nuclear translocation of NFKB (p65 subunit) in the folliculostellate cells and 
corticotrophs could be identified at different time points after the administration of 
LPS, using immunohistochemical techniques [i.e. co-staining anterior pituitary tissue 
from LPS-treated rats with antibodies specific for NFKB (p65) and specific markers 
for folliculostellate cells (S100) and corticotrophs (ACTH or POMC)] and the 
functional effects of NFKB signalling in each cell type could be identified using a 
transgenic approach (e.g. by targeted deletion of the NFxB or IxBa genes or by 
generation of mice which overexpress NFKB or licEla in a cell-specific manner). 
5.5.4.5 	Role of NF-K13 in mediating the corticosterone response to LPS 
As ACTH is the primary stimulus for corticosterone release and the increase in the 
plasma corticosterone concentration induced by LPS treatment is associated with a 
marked increase in ACTH release, it would appear that the adrenocortical response 
to LPS is secondary to the rise in ACTH. However, there is evidence that LPS acts 
directly at the level of the adrenal glands, which express the LPS signalling receptor 
TIr4 (Vakharia et al. 2002; Bornstein et al. 2004a; Zacharowski et al. 2006), to 
stimulate cortisol release (Vakharia et al. 2002) and, as our data demonstrate, the 
LPS-induced increase in corticosterone release was also associated with a rise in 
adrenal NFKB activity. Together, these data raise the possibility that LPS acts at the 
adrenal level to modulate corticosterone release via an NR(B-dependent 
mechanism. Our studies in animals treated with PHA781535E do not however 
support this premise and are difficult to interpret for several reasons. Firstly, at both 
doses tested, PHA781535E itself increased NFKB activity in the adrenal gland and 
failed to modify the response to LPS; it thus failed to act as a NFx13 inhibitor in this 
tissue. Secondly, while at the lower dose tested, the inhibitor effectively attenuated 
the ACTH response to LPS, it failed to modify the LPS-induced rise the 
corticosterone. Although it can be argued that, despite the inhibitory effects of 
PHA781535E on the LPS-induced release of ACTH, the plasma ACTH levels 
attained may still be sufficient to cause maximal steroidogenesis, an alternative 
explanation is that PHA781535E activates NFx13 at the adrenal level and thereby 
augments corticosterone secretion. Such an argument is supported by our 
observation that the higher dose of PHA781535E augmented the basal plasma 
corticosterone concentration. Furthermore, although this dose reduced the LPS-
induced increment in plasma corticosterone, the absolute levels of corticosterone 
attained after LPS treatment were unaffected by the higher dose of PHA781535E. 
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As PHA781535E treatment did not affect the basal plasma concentrations of IL-6, 
TNFa and ACTH or basal pituitary NFKB activity, the unusual effects of the drug do 
not appear to be systemic, but rather due to direct actions on the adrenal glands. 
However, the underlying mechanism(s) by which PHA781535E increases adrenal 
NFKB activity and corticosterone release is unclear. Although PHA781535E was 
shown to inhibit NFKB-dependent signalling pathways in the current study (see 
section 5.5.4.3), there is limited information available on the effects of this compound 
upon other signalling pathways. Studies by Pfizer Ltd have demonstrated lethality in 
rats treated with doses above 50mg/kg (unpublished observations, Pfizer Ltd). 
Therefore it is possible that, whilst the highest dose tested in the present study was 
not lethal, this dose may activate NFKB in the adrenal glands through the local 
production of inducers of NFKB, such as NO, heat shock proteins (Schreck et al. 
1992) or the pro-inflammatory cytokines TNFa, IL-1 and IL-6, thus resulting in the 
subsequent release of corticosterone (Judd & Macleod 1995; Swain & Maric 1996; 
Judd 1998; Wang etal. 2003). 
5.5.4.6 Possible NFxB-dependent mechanisms involved in mediating 
corticosterone synthesis and release 
The current findings suggest that adrenal NFKB is involved in the control of 
corticosterone secretion. Previous reports have provided indirect evidence of a 
potential role for NFKB in the pathways leading to corticosterone biosynthesis, 
including the detection of increased mRNA expression of the NFKB-dependent 
enzyme COX-2 in the adrenal glands of LPS-treated rats (Cover et al. 2001). COX-2 
is an important regulator of prostaglandin synthesis [reviewed in (Simmons et al. 
2004)] including the prostaglandin, PGE2, which is released from the adrenal glands 
in response to LPS (Vakharia & Hinson 2005). Interestingly, in conditions of 
endotoxaemia, PGE2 release precedes the increase in cortisol secretion, with COX-2 
inhibition attenuating the concentrations of both PGE2 and cortisol. These findings 
suggest that the formation of prostaglandins is an important step in the adrenal 
response to LPS (Vakharia & Hinson 2005) (figure 5.30). 
In addition to the stimulatory effects of IL-6 upon glucocorticoid release from the 
adrenal glands (Path et al. 1997), which express the IL-6 signalling receptor, IL-6Ra 
(Zubelewicz et al. 1999; Willenberg et al. 2002), the adrenal glands also provide a 
source of IL-6 (Judd & Macleod 1992; Judd & Macleod 1995; Judd 1998). Therefore 
increased adrenal NFKB activity induced by PHA781535E treatment may result in the 
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local synthesis and release of IL-6, which in turn acts in an autocrine manner to 
further stimulate corticosterone release (Path et aL 1997) (see figure 5.30). 
Figure 5.30 Hypothetical representation of the stimulatory effects of LPS 
upon corticosterone synthesis/release from the adrenal gland. LPS-induced 
NFKB-mediated COX-2 expression in the adrenal gland increases prostaglandin 
synthesis (e.g. PGE2), which in turn stimulates corticosterone release. LPS-induced 
NFKB activity increases adrenal-derived IL-6 release which acts in an autocrine 
manner to stimulate corticosterone release, in addition to the effects of IL-6 produced 
by immune cells (e.g. macrophages). Red arrows depict activation pathways and 
dashed blue lines represent inhibitory pathways. ACTH, adrenocorticotrophin; ACTH-
R, adrenocorticotrophin receptor; CORT, corticosterone; COX-2, cyclooxygenase 2; 
IL-6, interleukin 6; IL-6Ra, interleukin 6 receptor alpha; LPS, lipopolysaccharide; 
NFKB, nuclear factor kappa B; PGE2, prostaglandin E2; TIr4, toll-like receptor 4. 
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5.5.5 Role of NFKB in the HPA response to psychological stress 
In addition to the systemic effects of NFKB signalling (i.e. increased production of 
circulating pro-inflammatory cytokines), the current study has identified an important 
role for NFKB signalling within the anterior pituitary, and possibly the adrenal glands, 
in mediating the HPA response to immunological stress. However, whilst NFKB 
activation is normally associated with immunological stress, recent studies show that 
NFKB activity in the rat cerebral cortex (Garcia-Bueno et al. 2005) and human 
PBMCs (Bierhaus et aL 2003) is increased by psychological stress. Therefore, we 
also examined the effects of NFKB blockade upon the rat HPA responses to restraint 
stress, using PHA781535E. 
5.5.5.1 	ACTH and corticosterone responses to restraint stress 
In accordance with previous reports (Seltzer et al. 1986; Ginsberg et al. 2003; 
Bomholt et al. 2005; Hesketh et al. 2005) and similarly to the effects of LPS, restraint 
stress induced robust increases in the plasma concentrations of ACTH and 
corticosterone. Whereas the increase in ACTH was transient (maximal after 15 
minutes stress), the rise in corticosterone was maintained throughout the period of 
the restraint stress (15 to 30 minutes) and declined when the animal was returned to 
its home cage. The decline in the plasma ACTH concentration at 30 minutes restraint 
may reflect a reduction in the intensity of the stress to the rat and thus, reduced 
sensory input to the hypothalamus. As corticosterone has a longer half-life than 
ACTH (Cook et al. 1972; Keller-Wood et al. 1983; Lu et al. 1983; Sainio et al. 1988), 
it is not unusual that the corticosterone concentration remained elevated when the 
ACTH concentration had declined. Alternatively, the temporal profile of ACTH and 
corticosterone release may be attributable to the effective negative feedback actions 
of corticosterone at this time. 
Elevated cytokine concentrations have been reported in animals subjected to severe 
forms of psychological stress (see section 1.6.3), such as prolonged (3-4 hours) 
immobilisation (Zhou et al. 1993; Nukina et al. 1998; Nukina et al. 2001; Merlot et al. 
2002). However, in contrast to these findings and to our studies in which LPS was 
used as a stress, the plasma concentrations of IL-6 and TNFa remained 
undetectable in rats subjected to restraint stress. As the short period of restraint (30 
minutes) used in the current study is a less intense form of psychological stress than 
3-4 hours immobilisation, this suggests that the activation of the immune system by 
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psychological stress is dependent on the severity and duration of the stressor (Li et 
al. 2000). Furthermore, IL-6 released in response to chronic stress may be an 
important factor in sustaining corticosterone release as administration of recombinant 
IL-6 prolongs the elevation in plasma corticosterone induced by restraint (Zhou et al. 
1996). 
5.5.5.2 	Role of anterior pituitary NFKB signalling in mediating the ACTH 
response to restraint stress 
Activation of the HPA axis during psychological stress involves input from several 
CNS regions, including the hippocampus, the medial prefrontal cortex and the 
amygdala which converge on the hypothalamus to regulate CRH and AVP release 
(see section 1.2.5). In the present study we did not explore the potential role for 
NFKB signalling in the brain in mediating the release of these neuropeptides. Hence, 
we cannot exclude the possibility that the inhibitory effects of the NFKB-inhibitor, 
PHA781535E, on ACTH release reported here are exerted, at least in part, in the 
brain. Indeed, evidence that psychological stress increases NFKB activity (Garcia-
Bueno et al. 2005) and the expression of the NFKB-dependent proteins, NOS-2 and 
TNFa, in the cerebral cortex of adult male rats (Madrigal et al. 2002) would favour 
such an action. However, the present data suggest that NFKB signalling in the 
anterior pituitary gland is also important in this regard. Certainly, NFKB activity in the 
anterior pituitary gland was increased by restraint stress, and remained so 30 
minutes after the removal of the stressor. Furthermore, the stress-induced 
increments in anterior pituitary NFKB activity and plasma ACTH concentration were 
effectively inhibited by treatment with the NFKB inhibitor. Although psychological 
stress increases NFKB activity in the rat cerebral cortex (Garcia-Bueno et al. 2005), 
to our knowledge this is the first time that activation of this transcription factor has 
been detected in the anterior pituitary gland of rats subjected to a psychological 
stress or implicated in mediating the associated increase in ACTH release. 
The mechanisms through which psychological stress induces NFKB activity are 
unclear, since this transcription factor is normally activated by immunological 
stimulants. Furthermore, as the plasma concentrations of IL-6 and TNFa remained 
undetectable after restraint, the activation of anterior pituitary NFKB could not be 
attributed to the stimulatory effects of these circulating cytokines. Previous studies 
have shown that CRH activates NFKB in macrophages (Agelaki et al. 2002), as also 
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did our in vitro studies on AtT20 D16:16 cells (chapter 3). However, CRH-induced 
NFKB activation would be unlikely to increase ACTH release because, as our in vitro 
data demonstrate, CRH-driven NFKB activation in corticotrophs inhibits ACTH 
release. A more likely explanation is that psychological stress activates NFKB in the 
folliculostellate cells, promoting the release of factors such as IL-6 which augment 
ACTH release via a paracrine mechanism. How this is triggered requires further 
investigation. 
5.5.5.3 	Role of adrenal NFKB signalling in mediating the corticosterone 
response to restraint stress 
Although restraint stress did not affect NFKB activity in the adrenal glands, treatment 
with PHA781535E significantly attenuated the stress-induced increase in 
corticosterone release. From these findings, it appears that the effects of the drug 
upon corticosterone release are likely to be due to attenuated ACTH release. 
However, as in our previous study in which LPS was used as a stressor, the higher 
dose of PHA781535E caused a significant increase in the basal corticosterone 
concentration without affecting ACTH release. Together these findings suggest that 
PHA781535E may also exert a direct action at the adrenal level, although the 
underlying mechanism is unknown. In contrast to our study with LPS which 
demonstrated a positive effect of PHA781535E on NFKB activity in the adrenal gland, 
in our study on restraint stress, PHA781535E appeared to depress basal adrenal 
NFKB activity. This discrepancy may reflect small differences in the experimental 
conditions and/or the small sample size (n=3-4). However, our studies on the thymus 
also suggest that the actions of the higher dose of PHA781153E may be non-
specific. Thus, while restraint stress increased NFKB activity in the thymus gland and 
this activity was attenuated by the lower dose of PHA781535E (25mg/kg), the higher 
dose of the inhibitor (50mg/kg) was ineffective in this regard. As described earlier, 
(section 5.5.4.5), high doses of PHA781535E may activate the heat shock response 
or ROS formation, both of which induce NFKB activation (Tacchini et al. 1995; Kurata 
et al. 1996; Basu et aL 2000). Therefore, whilst the effects of PHA781535E at the 
lower dose tested may be attributable to blockade of NFKB activation, interpretation 
of the responses to the higher dose may be confounded by non-specific actions, 
which include increased NFKB activity. 
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5.6 Conclusion 
The purpose of this study was to examine the role of NFKB in mediating the HPA 
responses to two different types of stressors — immunological and psychological. The 
data show that inhibition of NFKB at the anterior pituitary level suppresses stress-
induced ACTH release. In the case of psychological stress, the adrenocortical 
response is also inhibited. However, the adrenocortical response to LPS was 
retained in rats treated with PHA781535E and, at the higher dose tested, the inhibitor 
also increased the basal corticosterone concentration. Further studies are necessary 
to determine the potential relevance of these findings to the proposed clinical usage 
of NFKB inhibitors as anti-inflammatory drugs. As discussed earlier, it seems likely 
that the elevation in basal corticosterone induced by the higher dose of PHA781535E 
reflects non-specific action. However, if it extends to drugs used in clinical practice, 
then patients may be at risk of developing an array of disorders associated with 
hypercortisolemia, including type II diabetes mellitus, hypertension, coronary heart 
disease, osteoporosis and depression. Conversely, the suppression of the HPA 
responses to acute psychological stress may precipitate a potentially fatal adrenal 
crisis. 
5.7 Future studies 
Although the current study has demonstrated that NFKB plays an important in 
mediating the HPA response to immunological and psychological stress, it is unclear 
whether adrenal NFKB signalling is involved in these responses. To explore this 
possibility, studies on the effects of NFKB blockade upon resting and ACTH-
stimulated corticosterone release from primary adrenal tissue, in the presence and 
absence of LPS, are required. In the current study, changes in NFiB activity in the 
adrenal and thymus tissue were difficult to detect by EMSA as the sample numbers 
were small, and thus statistical analysis was limited. Therefore, more quantitative 
methods of measuring NFKB activity need to be employed, such as the p65 
TransAMTm assay which also allows a high sample output, to confirm whether high 
doses of PHA781535E stimulate NFKB activity. It is also possible that the non-
specific effects of the high dose of PHA781535E used in the current study activate 
pathways involved in corticosterone biosynthesis and release (see section 5.1.4.8). 
To examine this possibility, further studies are required to investigate the effects of 
this compound upon mediators involved in steroidogenesis, which include NO, COX-
2 and PGE2. 
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The current findings support the premise that anterior pituitary-derived NFKB is 
involved in mediating stress-induced ACTH release, and subsequent corticosterone 
release. However, the cell-types within the anterior pituitary that are involved in this 
regulation need to be identified to corroborate the in vitro findings of a dual-role for 
NFKB signalling in the regulation of ACTH release. The overall decrease in ACTH 
release induced by the NFKB inhibitor may also be attributable in part to effects of the 
compound at the hypothalamic level, possibly by impairing CRH and AVP secretion. 
As such, the effects of the NFKB inhibitor at the hypothalamic level could be 
determined by measuring CRH and AVP mRNA expression (rat brains were also 
collected in the study and are currently stored, awaiting analysis). In addition, 
previous studies have demonstrated elevated pro-inflammatory cytokine release in 
response to severe and prolonged psychological stress, which may involve action of 
NFKB (see section 1.4.1). Thus while the relative mild restraint stress employed in 
the present study did not increase plasma IL-6 or TNFa release, it did increase NFKB 
activity in the anterior pituitary and thymus glands, suggesting the immune system is 
activated by psychological stressors and that more severe stressors may evoke 
systemic immunological responses. Therefore, there would be merit in examining the 
effects of NFKB inhibition upon the HPA responses to more severe psychological 
stressors (e.g. immobilisation stress, foot shock, water immersion), to provide further 
insight to the role of NFKB signalling in the activation of the immune system by 
psychological stressors. 
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6 General discussion 
The HPA axis is activated by immunological stress (e.g. endotoxaemia), with 
consequent release of glucocorticoids from the adrenal cortex. Glucocorticoid 
synthesis and release are largely dependent on the stimulatory actions of ACTH, 
which is secreted from the anterior pituitary gland in response to the hypothalamic 
neuropeptides CRH and AVP. LPS, a component of gram negative bacteria, 
activates the HPA axis through the actions of circulating immune-derived mediators, 
which include the pro-inflammatory cytokines, TNFa, IL-18 and IL-6 (Navarra et al. 
1991; Besedovsky & Del Rey 1996; Vallieres & Rivest 1997; Beishuizen & Thijs 
2003). However, recent studies suggest that LPS also acts directly on the anterior 
pituitary gland to stimulate the secretion of ACTH, and subsequent glucocorticoid 
release, independently of the actions of CRH (Elenkov et aL 1992a; Elenkov et al. 
1992b; Yang et al. 2002). Although the mechanisms governing the effects of LPS 
upon ACTH release are unclear, a key role has been identified for the paracrine 
actions of IL-6 (Gloddek et al. 2001), which is synthesised and released from anterior 
pituitary-derived folliculostellate cells (Vankelecom et al. 1989; Vankelecom et aL 
1993). The pro-inflammatory transcription factor NFKB, which is activated by LPS, is 
an important regulator of IL-6 gene transcription in immune cells, such as 
macrophages, and its activity is inhibited by glucocorticoids (Ray & Prefontaine 1994; 
Auphan et al. 1995; Scheinman et al. 1995a; De Bosscher et a/. 1997). As 
folliculostellate cells exhibit similar characteristics to macrophages, NFKB may also 
regulate the synthesis and release of IL-6 from these pituitary-derived cells. 
Therefore folliculostellate cell-derived NFKB signalling could be both potentially 
important in mediating the ACTH response to LPS and an additional target for the 
negative feedback actions of glucocorticoids. If this premise is true, the utilisation of 
specific NFKB inhibitors, which are currently being developed by the pharmaceutical 
industry to treat chronic inflammatory diseases such as rheumatoid arthritis, may 
induce adverse side effects associated with impaired HPA activity, by mimicking the 
negative feedback actions of glucocorticoids. 
Therefore, the current study examined the importance of NFKB signalling in 
mediating the ACTH response to LPS in vitro, using transformed murine cell lines as 
models of folliculostellate cells (TtT/GF cells) and corticotrophs (AtT20 D16:16 cells). 
Both the TtT/GF and AtT20 D16:16 cells expressed the LPS signalling components 
CD14, TIr4 and MD-2 and responded to LPS stimulation with increased NFKB 
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activity. Within the TtT/GF cells, LPS-induced IL-6 release was dependent on NFKB 
activation and this cytokine, at concentrations reflecting those released from the 
TtT/GF cells, potentiated the stimulatory effect of low concentrations of CRH upon 
ACTH release from the AtT20 D16:16 cells. Taken together, these findings support 
the premise that folliculostellate cell-derived IL-6 increases ACTH secretion when 
CRH concentrations are low, and possibly sustains ACTH release as CRH 
concentrations increase. Furthermore, NFKB-dependent IL-6 release from the TtT/GF 
cells was inhibited by the synthetic glucocorticoid, dexamethasone, which concurs 
with the hypothesis that NFx13 activity in folliculostellate cells is a target for the 
negative feedback actions of glucocorticoids. 
LPS and CRH stimulated NFx13 activity in the AtT20 D16:16, with inhibition of NFxB 
paradoxically potentiating the stimulatory effects of low concentrations of CRH upon 
ACTH secretion. Although the in vitro studies indicate that the inhibitory effects of 
LPS upon ACTH release occur when CRH concentrations are low, CRH release is an 
immediate response, occurring within minutes following stressful exposure. Thus it 
appears unlikely that the inhibitory effects of LPS at the anterior pituitary level would 
be as rapid in vivo. However, the current in vivo studies demonstrated increased 
NFKB activity in the anterior pituitary gland at 2 hours following LPS injection 
(although its is unknown whether activation may occur earlier since the earliest time 
point examined in the current study was 2 hours) and previous studies have 
demonstrated increased CRH mRNA expression at 6 hours following LPS injection 
(Grinevich et al. 2001). Thus, if the in vitro studies are translated to the in vivo model, 
it is possible that within the first few hours of endotoxaemia, LPS may exert a partial 
inhibitory effect upon CRH-induced ACTH release at the corticotroph level as part of 
a mechanism through which the hyper-secretion of ACTH is prevented, thus allowing 
a sufficient immune response to be mounted. However, as the response develops 
and the concentration of CRH increases, the inhibitory actions of LPS may no longer 
be effective, to allow restoration of homeostasis. 
To investigate further a potential dual-role for intra-pituitary NFKB signalling in 
mediating LPS and CRH induced ACTH release, co-cultures of TtT/GF and AtT20 
D16:16 cells were used to mimic the interactions between folliculostellate cells and 
corticotrophs. In agreement with previous work (Gloddek et aL 2001) and the data 
from the current single cell culture studies (chapter 3), the co-culture studies 
demonstrated a potentiating effect for LPS-induced folliculostellate cell-derived IL-6 
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upon CRH-induced ACTH release. Furthermore, the study also provided novel 
evidence that CRH-induced mediator(s) released from corticotrophs act on 
folliculostellate cells to potentiate LPS-induced IL-6 release. Therefore, in addition to 
the direct actions of CRH on corticotrophs, the paracrine effects of corticotroph-
derived mediator(s) may present an additional pathway through which CRH 
increases ACTH release in conditions of immunological stress. Although NFKB 
blockade enhanced the stimulatory effects of CRH upon ACTH release, the 
concentrations of IL-6 in the medium of cells treated with LPS, CRH and the NFKB 
inhibitor were higher than those induced by LPS alone. This implies that the 
synthesis of corticotroph-derived IL-6 secretagogues is mediated through NFKB-
independent mechanisms. Together these findings have provided novel evidence 
that NFKB signalling plays an important role in regulating the ACTH response to LPS, 
with a positive effect exerted through its activity in folliculostellate cells, and a 
negative effect exerted through its expression in corticotrophs. 
Although the in vitro studies demonstrated blockade of NFKB within the anterior 
pituitary gland alters the ACTH response to CRH and LPS stimulation, to address the 
issue of whether inhibition of NFKB alters the stress response in an intact HPA 
system, the study in chapter 5 utilised in vivo models. In addition to immunological 
stress, the study also addressed the role of NFKB in the HPA response to 
psychological stress through the use of two stress models - LPS (immunological) and 
restraint (psychological) stress. Inhibition of NFKB in vivo attenuated the ACTH 
response to LPS treatment and restraint, thus mimicking the actions of 
glucocorticoids. Furthermore, the decrease in ACTH release correlated with reduced 
NFKB activity in the anterior pituitary gland in both models, supporting the premise 
that intra-pituitary NFKB is important in mediating ACTH secretion. The partial 
reduction in ACTH release in conditions of suppressed NFKB activity, 2 hours after 
LPS injection, is in agreement with the in vitro findings; folliculostellate cell-derived 
NFKB increases ACTH secretion, whilst in corticotrophs NFKB inhibits ACTH release. 
Alternatively, it may reflect the fact that LPS also acts via NFKB-independent 
mechanisms to augment ACTH release. As the NFKB inhibitor did not affect the 
corticosterone response to LPS, it is likely that NFKB is primarily important in 
mediating the HPA response to LPS at the anterior pituitary level. Surprisingly, NFKB 
blockade exerted a powerful effect upon the HPA response to psychological stress, 
decreasing both ACTH and corticosterone to near basal concentrations. 
Psychological stress is modulated by the higher brain centres that converge on the 
282 
hypothalamus (see section 1.2.5), and although the effects of the NFKB inhibitor 
focused on the anterior pituitary and adrenal glands in the current study, it is possible 
that the reduced ACTH and corticosterone plasma concentrations are attributable to 
impaired NFx13 signalling in the hypothalamus and possibly in the higher brain 
structures. 
Together these findings have identified, for the first time, that in addition to its role in 
the inflammatory response, NFx13 signalling in the anterior pituitary gland is also 
important in mediating the HPA response to stress. As such, the use of NFKB 
inhibitors for the treatment of chronic inflammatory disorders may impair the 
individual's ability to cope with stress, whether it is immunological or psychological in 
nature. Further to this, the NFKB inhibitor used in the study increased the plasma 
concentration of basal corticosterone, but not that of ACTH. Although the site(s) of 
action and the mechanisms involved in this response are unclear, these findings 
suggest that, in addition to impairing the HPA responses to stress, NFKB inhibitors 
may also alter basal corticosterone release in the absence of stress, thus increasing 
susceptibility to disorders associated with hypercortisolemia. 
In conclusion, this thesis has provided evidence for the first time that NFKB is 
involved in the bi-directional communication between folliculostellate cells and 
corticotrophs in regulating IL-6 and ACTH release. Furthermore, NFxB signalling has 
been identified as an important mediator in the HPA responses to both 
immunological and psychological stress. 
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